Pharmaceutical Management Agency

New Zealand Pharmaceutical Schedule

Section H for Hospital Pharmaceuticals

November 2019
Introducing PHARMAC

Part I
General Rules 4

Part II
Alimentary Tract and Metabolism 5
Blood and Blood Forming Organs 24
Cardiovascular System 38
Dermatologicals 52
Genito-Urinary System 58
Hormone Preparations 62
Infections 72
Musculoskeletal System 94
Nervous System 103
Oncology Agents and Immunosuppressants 128
Respiratory System and Allergies 193
Sensory Organs 201
Various 208
Extemporaneous Compounds (ECPs) 216
Special Foods 219
Vaccines 234

Part III
Optional Pharmaceuticals 244

Index 245
Introducing PHARMAC

The Pharmaceutical Management Agency (PHARMAC) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. PHARMAC negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The funding for pharmaceuticals comes from District Health Boards.

PHARMAC’s role:

“If eligible for people in need of pharmaceuticals, the best health outcomes that can reasonably be achieved, and from within the amount of funding provided.”

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures. Further information about PHARMAC and the way we make funding decisions can be found on the PHARMAC website at http://www.pharmac.health.nz/about.

Glossary

Units of Measure

<table>
<thead>
<tr>
<th>Unit</th>
<th>Abbreviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>gram</td>
<td>g</td>
</tr>
<tr>
<td>kilogram</td>
<td>kg</td>
</tr>
<tr>
<td>international unit</td>
<td>iu</td>
</tr>
<tr>
<td>microgram</td>
<td>mcg</td>
</tr>
<tr>
<td>milligram</td>
<td>mg</td>
</tr>
<tr>
<td>millilitre</td>
<td>ml</td>
</tr>
<tr>
<td>millimole</td>
<td>mmol</td>
</tr>
<tr>
<td>unit</td>
<td>u</td>
</tr>
</tbody>
</table>

Abbreviations

<table>
<thead>
<tr>
<th>Term</th>
<th>Abbreviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>application</td>
<td>app</td>
</tr>
<tr>
<td>capsule</td>
<td>cap</td>
</tr>
<tr>
<td>cream</td>
<td>crm</td>
</tr>
<tr>
<td>dispersible</td>
<td>disp</td>
</tr>
<tr>
<td>effervescent</td>
<td>eff</td>
</tr>
<tr>
<td>emulsion</td>
<td>emul</td>
</tr>
<tr>
<td>enteric coated</td>
<td>EC</td>
</tr>
<tr>
<td>granules</td>
<td>grans</td>
</tr>
<tr>
<td>injection</td>
<td>inj</td>
</tr>
<tr>
<td>liquid</td>
<td>liq</td>
</tr>
<tr>
<td>lotion</td>
<td>lotn</td>
</tr>
<tr>
<td>ointment</td>
<td>oint</td>
</tr>
<tr>
<td>solution</td>
<td>soln</td>
</tr>
<tr>
<td>suppository</td>
<td>suppos</td>
</tr>
<tr>
<td>tablet</td>
<td>tab</td>
</tr>
<tr>
<td>tincture</td>
<td>tinc</td>
</tr>
</tbody>
</table>

HSS Hospital Supply Status
## Guide to Section H listings

### Example

<table>
<thead>
<tr>
<th>THERAPEUTIC HEADING</th>
<th>CHEMICAL A</th>
<th>Restricted see terms below</th>
<th>Price</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CHEMICAL A</td>
<td>Presentation A</td>
<td>10.00</td>
<td>100</td>
<td>Brand A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Restricted</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CHEMICAL B</td>
<td>Some items restricted</td>
<td>1,589.00</td>
<td>1</td>
<td>Brand B1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Presentation B1</td>
<td></td>
<td></td>
<td>e.g. Brand B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Presentation B2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CHEMICAL C</td>
<td>Restricted</td>
<td>15.00</td>
<td>28</td>
<td>Brand C</td>
</tr>
<tr>
<td></td>
<td>CHEMICAL D</td>
<td>Restricted</td>
<td>38.65</td>
<td>500</td>
<td>Brand D</td>
</tr>
<tr>
<td></td>
<td>CHEMICAL E</td>
<td>Limited to five weeks' treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Product with Hospital Supply Status (HSS) are in **bold**
- Indicators: 
  - **Restricted**: Indicates only presentation B1 is Restricted
  - **Restricted**: From 1 January 2012 to 30 June 2014, at least 99% of the total volume of this item purchased must be Brand C
  - **Restricted**: Limited to five weeks' treatment
  - **-1% DV Limit Jan-12**: Standard national price excluding GST
  - **-1% DV Limit Mar-13**: Form and strength
  - **Item restricted (see above); Item restricted (see below)**

Products with Hospital Supply Status (HSS) are in **bold**

- Oncologist or haematologist
- Only for use in children under 12 years of age
- Oncologist or haematologist
- Limited to five weeks' treatment
- 1 For the prophylaxis of venous thromboembolism following a total hip replacement; or
- 2 For the prophylaxis of venous thromboembolism following a total knee replacement.
General Rules for Section H of the Pharmaceutical Schedule are included in Section A General Rules and are located on the PHARMAC website.
PART II: ALIMENTARY TRACT AND METABOLISM

Antacids and Antiflatulents

Antacids and Reflux Barrier Agents

ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETICONE
- Tab 200 mg with magnesium hydroxide 200 mg and simeticone 20 mg e.g. Mylanta
- Oral liq 400 mg with magnesium hydroxide 400 mg and simeticone 30 mg per 5 ml e.g. Mylanta Double Strength

SIMETICONE
- Oral drops 100 mg per ml
- Oral drops 20 mg per 0.3 ml

SODIUM ALGINATE WITH MAGNESIUM ALGINATE
- Powder for oral soln 225 mg with magnesium alginate 87.5 mg, sachet e.g. Gaviscon Infant

SODIUM ALGINATE WITH SODIUM BICARBONATE AND CALCIUM CARBONATE
- Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg e.g. Gaviscon Double Strength
- Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml 4.95 500 ml Acidex

SODIUM CITRATE
- Oral liq 8.8% (300 mmol/l)

Phosphate Binding Agents

ALUMINIUM HYDROXIDE
- Tab 600 mg

CALCIUM CARBONATE – Restricted see terms below
- Oral liq 250 mg per ml (100 mg elemental per ml) 39.00 500 ml Roxane

→ Restricted (RS1698)
Initiation
Only when prescribed for patients unable to swallow calcium carbonate tablets or where calcium carbonate tablets are inappropriate..

Antidiarrhoeals and Intestinal Anti-Inflammatory Agents

Antipropulsives

DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHATE
- Tab 2.5 mg with atropine sulphate 25 mcg

LOPERAMIDE HYDROCHLORIDE
- Tab 2 mg 10.75 400 Nodia
- Cap 2 mg – 1% DV Oct-19 to 2022 6.25 400 Diamide Relief

Rectal and Colonic Anti-Inflammatories

BUDESONIDE – Restricted see terms on the next page
- Cap 3 mg

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

- **Restricted (RS1026)**

  **Initiation – Crohn's disease**
  Both:
  1. Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and
  2. Any of the following:
     2.1 Diabetes; or
     2.2 Cushingoid habitus; or
     2.3 Osteoporosis where there is significant risk of fracture; or
     2.4 Severe acne following treatment with conventional corticosteroid therapy; or
     2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
     2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
     2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

- **Initiation – Collagenous and lymphocytic colitis (microscopic colitis)**

  Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

- **Initiation – Gut Graft versus Host disease**

  Patient has gut Graft versus Host disease following allogenic bone marrow transplantation.

- **HYDROCORTISONE ACETATE**
  Rectal foam 10%, CFC free (14 applications) ................................................. 26.55 21.1 g Colifoam

- **HYDROCORTISONE ACETATE WITH PRAMOXINE HYDROCHLORIDE**
  Topical Aerosol foam, 1% with pramoxine hydrochloride 1%

- **MESALAZINE**
  Tab EC 400 mg ................................................................. 49.50 100 Asacol
  Tab EC 500 mg ................................................................. 49.50 100 Asamax
  Tab long-acting 500 mg ............................................................ 59.05 100 Pentasa
  Tab 800 mg ................................................................. 85.50 90 Asacol
  Modified release granules 1 g ...................................................... 141.72 120 g Pentasa
  Suppos 500 mg ................................................................. 22.80 20 Asacol
  Suppos 1 g ................................................................. 54.60 30 Pentasa
  Enema 1 g per 100 ml ............................................................. 41.30 7 Pentasa

- **OLSALAZINE**
  Tab 500 mg ................................................................. 93.37 100 Dipentum
  Cap 250 mg ................................................................. 53.00 100 Dipentum

- **SODIUM CromOGLICATE**
  Cap 100 mg

- **SULFASALAZINE**
  Tab 500 mg ................................................................. 14.00 100 Salazopyrin
  Tab EC 500 mg – 1% DV Dec-19 to 2022 ........................................ 15.53 100 Salazopyrin EN

**Local Preparations for Anal and Rectal Disorders**

**Antihaeorrhoidal Preparations**

- **CINCHOCAINE HYDROCHLORIDE WITH HYDROCORTISONE**
  Oint 5 mg with hydrocortisone 5 mg per g ........................................ 15.00 30 g Proctosedyl
  Suppos 5 mg with hydrocortisone 5 mg per g ...................................... 9.90 12 Proctosedyl

---

- Item restricted (see ➥ above);
- Item restricted (see ➥ below)

e.g. Brand indicates brand example only. It is not a contracted product.
FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAIN

Oint 950 mcg with fluocortolone pivalate 920 mcg and cinchocaine hydrochloride 5 mg per g ................................................................. 6.35 30 g Ultraproct
Suppos 630 mcg with fluocortolone pivalate 610 mcg and cinchocaine hydrochloride 1 mg ................................................................. 2.66 12 Ultraproct

Management of Anal Fissures

GLYCERYL TRINITRATE
Oint 0.2% ........................................................................................................ 22.00 30 g Rectogesic

Rectal Sclerosants

OILY PHENOL [PHENOL OILY]
Inj 5%, 5 ml vial

Antispasmodics and Other Agents Altering Gut Motility

GLYCOPYRRONIUM BROMIDE
Inj 200 mcg per ml, 1 ml ampoule ................................................................. 17.14 10 Max Health

HYOSCINE BUTYLBROMIDE
Tab 10 mg – 1% DV Dec-17 to 2020 ............................................................... 8.75 100 Buscopan
Inj 20 mg, 1 ml ampoule .............................................................................. 9.57 5 Buscopan

MEBEVERINE HYDROCHLORIDE
Tab 135 mg ..................................................................................................... 18.00 90 Colofac

Antiulcerants

Antisecretory and Cytoprotective

MISOPROSTOL
Tab 200 mcg .................................................................................................... 41.50 120 Cytotec

H2 Antagonists

CIMETIDINE
Tab 200 mg
Tab 400 mg

FAMOTIDINE
Tab 20 mg
Tab 40 mg
Inj 10 mg per ml, 4 ml vial

RANITIDINE – Restricted see terms below

Tab 150 mg – 1% DV Oct-17 to 2020............................................................ 12.91 500 Ranitidine Relief
Tab 300 mg – 1% DV Oct-17 to 2020............................................................ 18.21 500 Ranitidine Relief
Oral liq 150 mg per 10 ml – 1% DV Oct-17 to 2020 .................................... 5.14 300 ml Peptisoothe
Inj 25 mg per ml, 2 ml ampoule ................................................................. 13.40 5 Zantac

Initiation
Either:
1. For continuation use; or
2. Routine prevention of allergic reactions.
## ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

### Proton Pump Inhibitors

**LANSOPRAZOLE**
- Cap 15 mg – 1% DV Sep-18 to 2021................................................. 4.58 100 Lanzol Relief
- Cap 30 mg – 1% DV Sep-18 to 2021................................................. 5.41 100 Lanzol Relief

**OMEPRAZOLE**
- Tab dispersible 20 mg
  - Restricted (RS1027)

**Initiation**
Only for use in tube-fed patients.
- Cap 10 mg – 1% DV Mar-18 to 2020............................................... 1.98 90 Omeprazole actavis 10
- Cap 20 mg – 1% DV Mar-18 to 2020............................................... 1.96 90 Omeprazole actavis 20
- Cap 40 mg – 1% DV Mar-18 to 2020............................................... 3.12 90 Omeprazole actavis 40
- Powder for oral liq................................................................. 42.50 5g Midwest
- Inj 40 mg ampoule with diluent – 1% DV Oct-19 to 2022.................. 33.98 5 Dr Reddy's Omeprazole
- Inj 40 mg vial – 1% DV Oct-19 to 2022....................................... 11.46 5 Omezol IV

**PANTOPRAZOLE**
- Tab EC 20 mg – 1% DV Oct-19 to 2022........................................... 2.02 100 Panzop Relief
- Tab EC 40 mg – 1% DV Oct-19 to 2022........................................... 2.85 100 Panzop Relief
- Inj 40 mg vial

### Site Protective Agents

**COLLOIDAL BISMUTH SUBCITRATE**
- Tab 120 mg ................................................................. 14.51 50 Gastrodenol

**SUCRALFATE**
- Tab 1 g

### Bile and Liver Therapy

**L-ORNITHINE L-ASPARTATE** – Restricted see terms below
- Grans for oral liquid 3 g
  - Restricted (RS1261)

**Initiation**
For patients with chronic hepatic encephalopathy who have not responded to treatment with, or are intolerant to lactulose, or where lactulose is contraindicated.

**RIFAXIMIN** – Restricted see terms below
- Tab 550 mg – 1% DV Sep-17 to 2020.............................................. 625.00 56 Xifaxan
  - Restricted (RS1416)

**Initiation**
For patients with hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

### Diabetes

#### Alpha Glucosidase Inhibitors

**ACARBOSE**
- Tab 50 mg – 1% DV Sep-18 to 2021............................................. 3.50 90 Glucobay
- Tab 100 mg – 1% DV Sep-18 to 2021........................................... 6.40 90 Glucobay

---

*Item restricted (see above); Item restricted (see below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
Hyperglycaemic Agents

DIAZOXIDE – Restricted see terms below
- Cap 25 mg...............................................................110.00 100 Proglucom
- Cap 100 mg..............................................................280.00 100 Proglucom
- Oral liq 50 mg per ml..................................................620.00 30 ml Proglycem

Initiation
For patients with confirmed hypoglycaemia caused by hyperinsulinism.

GLUCAGON HYDROCHLORIDE
- Inj 1 mg syringe kit......................................................32.00 1 Glucagen Hypokit

GLUCOSE [DEXTROSE]
- Tab 1.5 g
- Tab 3.1 g
- Tab 4 g
- Gel 40%

GLUCOSE WITH SUCROSE AND FRUCTOSE
- Gel 19.7% with sucrose 35% and fructose 19.7%, 18 g sachet

Insulin - Intermediate-Acting Preparations

INSULIN ASPART WITH INSULIN ASPART PROTAMINE
- Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml, 3 ml prefilled pen...........................................52.15 5 NovoMix 30 FlexPen

INSULIN ISOPHANE
- Inj insulin human 100 u per ml, 10 ml vial
- Inj insulin human 100 u per ml, 3 ml cartridge

INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE
- Inj insulin lispro 25% with insulin lispro protamine 75%, 100 u per ml, 3 ml cartridge............................................................42.66 5 Humalog Mix 25
- Inj insulin lispro 50% with insulin lispro protamine 50%, 100 u per ml, 3 ml cartridge............................................................42.66 5 Humalog Mix 50

INSULIN NEUTRAL WITH INSULIN ISOPHANE
- Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 10 ml vial
- Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 3 ml cartridge
- Inj insulin neutral 40% with insulin isophane 60%, 100 u per ml, 3 ml cartridge
- Inj insulin neutral 50% with insulin isophane 50%, 100 u per ml, 3 ml cartridge

Insulin - Long-Acting Preparations

INSULIN GLARGINE
- Inj 100 u per ml, 3 ml disposable pen...................................94.50 5 Lantus SoloStar
- Inj 100 u per ml, 3 ml cartridge..........................................94.50 5 Lantus
- Inj 100 u per ml, 10 ml vial...............................................63.00 1 Lantus
# Insulin - Rapid-Acting Preparations

<table>
<thead>
<tr>
<th>Insulin - Rapid-Acting Preparations</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INSULIN ASPART</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml syringe</td>
<td></td>
<td>51.19</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>NovoRapid FlexPen</strong></td>
</tr>
<tr>
<td><strong>INSULIN GLULISINE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 10 ml vial</td>
<td></td>
<td>27.03</td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td></td>
<td>46.07</td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml disposable pen</td>
<td></td>
<td>46.07</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Apidra Solostar</strong></td>
</tr>
<tr>
<td><strong>INSULIN LISPRO</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

# Insulin - Short-Acting Preparations

<table>
<thead>
<tr>
<th>Insulin - Short-Acting Preparations</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INSULIN NEUTRAL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj human 100 u per ml, 10 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj human 100 u per ml, 3 ml cartridge</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Oral Hypoglycaemic Agents

<table>
<thead>
<tr>
<th>Oral Hypoglycaemic Agents</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GLIBENCLAMIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Oct-18 to 2021</td>
<td></td>
<td>6.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Daonil</strong></td>
</tr>
<tr>
<td><strong>GLICLAZIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 80 mg – 1% DV Sep-17 to 2020</td>
<td></td>
<td>10.29</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Glizide</strong></td>
</tr>
<tr>
<td><strong>GLIPIZIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Dec-18 to 2021</td>
<td></td>
<td>3.27</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Minidiab</strong></td>
</tr>
<tr>
<td><strong>METFORMIN HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab immediate-release 500 mg – 1% DV Feb-19 to 2021</td>
<td>8.63</td>
<td>1,000</td>
</tr>
<tr>
<td>Tab immediate-release 850 mg – 1% DV Feb-19 to 2021</td>
<td>7.04</td>
<td>500</td>
</tr>
<tr>
<td><strong>PIOGLITAZONE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 15 mg – 1% DV Oct-18 to 2021</td>
<td></td>
<td>3.47</td>
</tr>
<tr>
<td>Tab 30 mg – 1% DV Oct-18 to 2021</td>
<td></td>
<td>5.06</td>
</tr>
<tr>
<td>Tab 45 mg – 1% DV Oct-18 to 2021</td>
<td></td>
<td>7.10</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Vexazone</strong></td>
</tr>
<tr>
<td><strong>VILDAGLIPTIN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg</td>
<td></td>
<td>40.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Galvus</strong></td>
</tr>
<tr>
<td><strong>VILDAGLIPTIN WITH METFORMIN HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg with 1,000 mg metformin hydrochloride</td>
<td>40.00</td>
<td>60</td>
</tr>
<tr>
<td>Tab 50 mg with 850 mg metformin hydrochloride</td>
<td>40.00</td>
<td>60</td>
</tr>
<tr>
<td>Price (ex man. excl. GST)</td>
<td>Brand or Generic Manufacturer</td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------------------------</td>
<td></td>
</tr>
<tr>
<td>Per</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Digestives Including Enzymes**

**PANCREATIC ENZYME**

- Cap pancreatin (175 mg (25,000 U lipase, 22,500 U amylase, 1,250 U protease))
  - Cap pancreatin 150 mg (amylase 8,000 Ph Eur U, lipase 10,000 Ph Eur U, total protease 600 Ph Eur U) – 1% DV Sep-18 to 2021..........................34.93 100 Creon 10000
- Cap pancreatin 300 mg (amylase 18,000 Ph Eur U, lipase 25,000 Ph Eur U, total protease 1,000 Ph Eur U) – 1% DV Sep-18 to 2021 ..............94.38 100 Creon 25000
- Powder pancreatin 60.12 mg (3,600 Ph. Eur. u/amylase, 5,000 Ph. Eur. u/lipase and 200 Ph. Eur. u/protease)

**URSODEOXYCHOLIC ACID** – Restricted see terms below

- Cap 250 mg – 1% DV Sep-17 to 2020...........................................................37.95 100 Ursosan
  - Restricted (RS1647)

**Initiation – Alagille syndrome or progressive familial intrahepatic cholestasis**

Either:
1. Patient has been diagnosed with Alagille syndrome; or
2. Patient has progressive familial intrahepatic cholestasis.

**Initiation – Chronic severe drug induced cholestatic liver injury**

All of the following:
1. Patient has chronic severe drug induced cholestatic liver injury; and
2. Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
3. Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

**Initiation – Primary biliary cholangitis**

Both:
1. Primary biliary cholangitis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy; and
2. Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis.

**Initiation – Pregnancy**

Patient diagnosed with cholestasis of pregnancy.

**Initiation – Haematological transplant**

Both:
1. Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
2. Treatment for up to 13 weeks.

**Initiation – Total parenteral nutrition induced cholestasis**

Both:
1. Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by TPN; and
2. Liver function has not improved with modifying the TPN composition.

**Laxatives**

**Bowel-Cleansing Preparations**

**CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE**

- Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet
  - e.g. PicoPrep

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE
Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet
  e.g. Glycoprep-C

MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE AND SODIUM SULPHATE
Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet – 1% DV Aug-19 to 2022
  .........................................14.31 4
  Klean Prep

ISPAGHULA (PSYLLIUM) HUSK
Powder for oral soln – 1% DV Oct-17 to 2020
  .................................................6.05 500 g
  Konsyl-D

STERCULIA WITH FRANGULA – Restricted: For continuation only
  Powder for oral soln

DOCUSATE SODIUM
Tab 50 mg – 1% DV Sep-17 to 2020
  ...............................................................2.31 100
  Coloxyl

DOCUSATE SODIUM WITH SENNOSIDES
Tab 50 mg with sennosides 8 mg – 1% DV Jun-18 to 2021
  .............................................................3.10 200
  Laxsol

PARAFFIN
Oral liquid 1 mg per ml
Enema 133 ml

POLOXAMER
Oral drops 10% – 1% DV Sep-17 to 2020
  .......................................................3.78 30 ml

METHYLNALTREXONE BROMIDE – Restricted see terms below
  ▼ Inj 12 mg per 0.6 ml vial………………………………………………..36.00 1
  246.00 7
  Relistor

▼ Restricted (RS1601)
Initiation – Opioid induced constipation
Both:
  1 The patient is receiving palliative care; and
  2 Either:
     2.1 Oral and rectal treatments for opioid induced constipation are ineffective; or
     2.2 Oral and rectal treatments for opioid induced constipation are unable to be tolerated.

GLYCEROL
Suppos 1.27 g
Suppos 2.55 g
Suppos 3.6 g – 1% DV Oct-18 to 2021
  ............................................................9.25 20
  PSM
LACTULOSE
Oral liq 10 g per 15 ml – 1% DV Nov-19 to 2022.........................................................3.33 500 ml Laevolac

MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE
Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg
Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – 1% DV
Feb-18 to 2020..................................................................................................................6.78 30 Molaxole

SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml – 1%
DV Nov-19 to 2022.............................................................................................................29.98 50 Micolette

SODIUM PHOSPHATE WITH PHOSPHORIC ACID
Oral liq 16.4% with phosphoric acid 25.14%
Enema 10% with phosphoric acid 6.58%...........................................................................2.50 1 Fleet Phosphate Enema

Stimulant Laxatives

BISACODYL
Tab 5 mg – 1% DV Sep-18 to 2021.................................................................5.99 200 Lax-Tabs
Suppos 10 mg – 1% DV Sep-18 to 2021.........................................................3.74 10 Lax-Suppositories

SENNOSIDES
Tab 7.5 mg

Metabolic Disorder Agents

ALGLUCOSIDASE ALFA – Restricted see terms below
↓ Inj 50 mg vial............................................................................................................1,142.60 1 Myozyme
→ Restricted (RS1545)

Initiation
Metabolic physician
Re-assessment required after 12 months

All of the following:

1 The patient is aged up to 24 months at the time of initial application and has been diagnosed with infantile Pompe disease; and
2 Any of the following:
   2.1 Diagnosis confirmed by documented deficiency of acid alpha-glucosidase by prenatal diagnosis using chorionic villus biopsies and/or cultured amniotic cells; or
   2.2 Documented deficiency of acid alpha-glucosidase, and urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides; or
   2.3 Documented deficiency of acid alpha-glucosidase, and documented molecular genetic testing indicating a disease-causing mutation in the acid alpha-glucosidase gene (GAA gene); or
   2.4 Documented urinary tetrasaccharide testing indicating a diagnostic elevation of glucose tetrasaccharides, and molecular genetic testing indicating a disease-causing mutation in the GAA gene; and
3 Patient has not required long-term invasive ventilation for respiratory failure prior to starting enzyme replacement therapy (ERT); and
4 Patient does not have another life-threatening or severe disease where the prognosis is unlikely to be influenced by ERT or might be reasonably expected to compromise a response to ERT; and
5 Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks.

continued…
Continuation

Metabolic physician

Re-assessment required after 12 months

All of the following:

1. The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
2. Alglucosidase alfa to be administered at doses no greater than 20 mg/kg every 2 weeks; and
3. Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
4. Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by ERT; and
5. Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT; and
6. There is no evidence of life threatening progression of respiratory disease as evidenced by the needed for > 14 days of invasive ventilation; and
7. There is no evidence of new or progressive cardiomyopathy.

ARGinine

Powder

Inj 600 mg per ml, 25 ml vial

BETaine – Restricted see terms below

$ Powder for oral soln..........................................................................................575.00 180 g Cystadane

Initiation

Metabolic physician

Re-assessment required after 12 months

All of the following:

1. The patient has a confirmed diagnosis of homocystinuria; and
2. Any of the following:
   2.1 A cystathionine beta-synthase (CBS) deficiency; or
   2.2 A 5,10-methylene-tetrahydrofolate reductase (MTHFR) deficiency; or
   2.3 A disorder of intracellular cobalamin metabolism; and
3. An appropriate homocysteine level has not been achieved despite a sufficient trial of appropriate vitamin supplementation.

Continuation

Metabolic physician

Re-assessment required after 12 months

The treatment remains appropriate and the patient is benefiting from treatment.

BIOTIN – Restricted see terms below

$ Cap 50 mg
$ Cap 100 mg
$ Inj 10 mg per ml, 5 ml vial

Initiation

Metabolic physician or metabolic disorders dietitian

GALSULFASE – Restricted see terms below

$ Inj 1 mg per ml, 5 ml vial.............................................................................2,234.00 1 Naglazyme

Initiation

Metabolic physician

Re-assessment required after 12 months

Both:

continued…
continued...

1. The patient has been diagnosed with mucopolysaccharidosis VI; and
2. Either:
   2.1 Diagnosis confirmed by demonstration of N-acetyl-galactosamine-4-sulfatase (arylsulfatase B) deficiency confirmed by either enzyme activity assay in leukocytes or skin fibroblasts; or
   2.2 Detection of two disease causing mutations and patient has a sibling who is known to have mucopolysaccharidosis VI.

Continuation

Metabolic physician

Re-assessment required after 12 months

All of the following:

1. The treatment remains appropriate for the patient and the patient is benefiting from treatment; and
2. Patient has not had severe infusion-related adverse reactions which were not preventable by appropriate pre-medication and/or adjustment of infusion rates; and
3. Patient has not developed another life threatening or severe disease where the long term prognosis is unlikely to be influenced by Enzyme Replacement Therapy (ERT); and
4. Patient has not developed another medical condition that might reasonably be expected to compromise a response to ERT.

HAEM ARGINATE

Inj 25 mg per ml, 10 ml ampoule

IDURSULFASE – Restricted see terms below

- Inj 2 mg per ml, 3 ml vial..........................................................4,608.30 1 Elaprase

- Restricted (RS1546)

Initiation

Metabolic physician

Limited to 24 weeks treatment

All of the following:

1. The patient has been diagnosed with Hunter Syndrome (mucopolysaccharidosis II); and
2. Either:
   2.1 Diagnosis confirmed by demonstration of iduronate 2-sulfatase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or
   2.2 Detection of a disease causing mutation in the iduronate 2-sulfatase gene; and
3. Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with idursulfase would be bridging treatment to transplant; and
4. Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and
5. Idursulfase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 weeks post-HSCT) at doses no greater than 0.5 mg/kg every week.

LARONIDASE – Restricted see terms below

- Inj 100 U per ml, 5 ml vial.......................................................1,335.16 1 Aldurazyme

- Restricted (RS1607)

Initiation

Metabolic physician

Limited to 24 weeks treatment

All of the following:

1. The patient has been diagnosed with Hurler Syndrome (mucopolysaccharidosis I-H); and
2. Either:

continued…
continued...

2.1 Diagnosis confirmed by demonstration of alpha-L-iduronidase deficiency in white blood cells by either enzyme assay in cultured skin fibroblasts; or

2.2 Detection of two disease causing mutations in the alpha-L-iduronidase gene and patient has a sibling who is known to have Hurler syndrome; and

3 Patient is going to proceed with a haematopoietic stem cell transplant (HSCT) within the next 3 months and treatment with laronidase would be bridging treatment to transplant; and

4 Patient has not required long-term invasive ventilation for respiratory failure prior to starting Enzyme Replacement Therapy (ERT); and

5 Laronidase to be administered for a total of 24 weeks (equivalent to 12 weeks pre- and 12 post-HSCT) at doses no greater than 100 units/kg every week.

LEVOCARNITINE – Restricted see terms below

- Cap 500 mg
- Oral soln 1,000 mg per 10 ml
- Inj 200 mg per ml, 5 ml vial

→ Restricted (RS1035)

Neurologist, metabolic physician or metabolic disorders dietitian

PYRIDOXAL-5-PHOSPHATE – Restricted see terms below

- Tab 50 mg

→ Restricted (RS1331)

Neurologist, metabolic physician or metabolic disorders dietitian

SAPROPTERIN DIHYDROCHLORIDE – Restricted see terms below

- Tab soluble 100 mg ....................................................................................1,452.70 30 Kuvan

→ Restricted (RS1656)

Initiation

Metabolic physician

Re-assessment required after 1 month

All of the following:

1 Patient has phenylketonuria (PKU) and is pregnant or actively planning to become pregnant; and

2 Treatment with sapropterin is required to support management of PKU during pregnancy; and

3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and

4 Sapropterin to be used alone or in combination with PKU dietary management; and

5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

Continuation

Metabolic physician or any relevant practitioner on the recommendation of a metabolic physician

Re-assessment required after 12 months

All of the following:

1 Either:

1.1 Following the initial one-month approval, the patient has demonstrated an adequate response to a 2 to 4 week trial of sapropterin with a clinically appropriate reduction in phenylalanine levels to support management of PKU during pregnancy; or

1.2 On subsequent renewal applications, the patient has previously demonstrated response to treatment with sapropterin and maintained adequate phenylalanine levels to support management of PKU during pregnancy; and

2 Any of the following:

2.1 Patient continues to be pregnant and treatment with sapropterin will not continue after delivery; or

2.2 Patient is actively planning a pregnancy and this is the first renewal for treatment with sapropterin; or

continued…
continued...

2.3 Treatment with sapropterin is required for a second or subsequent pregnancy to support management of their PKU during pregnancy; and

3 Sapropterin to be administered at doses no greater than a total daily dose of 20 mg/kg; and

4 Sapropterin to be used alone or in combination with PKU dietary management; and

5 Total treatment duration with sapropterin will not exceed 22 months for each pregnancy (includes time for planning and becoming pregnant) and treatment will be stopped after delivery.

SODIUM BENZOATE
- Cap 500 mg
- Powder
- Soln 100 mg per ml
- Inj 20%, 10 ml ampoule

SODIUM PHENYLButYRATE – Some items restricted see terms below
- Tab 500 mg
  - Grans 483 mg per g ................................................................. 1,920.00 174 g Pheburane
  - Oral liq 250 mg per ml
  - Inj 200 mg per ml, 10 ml ampoule

- Restricted (RS1526)

Initiation
Metabolic physician
Re-assessment required after 12 months
For the chronic management of a urea cycle disorder involving a deficiency of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase.

Continuation
Metabolic physician
Re-assessment required after 12 months
The treatment remains appropriate and the patient is benefiting from treatment.

TALIGLUCERASE ALFA – Restricted see terms below
- Inj 200 unit vial ................................................................. 1,072.00 1 Elelyso

- Restricted (RS1034)

Initiation
Only for use in patients with approval by the Gaucher Treatment Panel.

TRIENTINE DIHYDROCHLORIDE
- Cap 300 mg

Minerals

Calcium

CALCIUM CARBONATE
- Tab 1.25 g (500 mg elemental) – 1% DV Mar-18 to 2020 ................. 7.52 250 Arrow-Calcium
- Tab eff 1.75 g (1 g elemental)

Fluoride

SODIUM FLUORIDE
- Tab 1.1 mg (0.5 mg elemental)

Iodine

POTASSIUM IODATE
- Tab 253 mcg (150 mcg elemental iodine) – 1% DV Mar-19 to 2020 .......... 4.69 90 NeuroTabs

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
**POTASSIUM IODATE WITH IODINE**  
Oral liq 10% with iodine 5%

### Iron

**FERRIC CARBOXYMALTOSE – Restricted see terms below**
- Inj 50 mg per ml, 10 ml vial

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$150.00</td>
<td>Ferinject</td>
</tr>
</tbody>
</table>

**Iron**

**FERRIC CARBOXYMALTOSE – Restricted (RS1417)**

Initiation  
Treatment with oral iron has proven ineffective or is clinically inappropriate.

**FERROUS FUMARATE**
- Tab 200 mg (65 mg elemental) – 1% DV Jan-19 to 2021

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$3.09</td>
<td>Ferro-tab</td>
</tr>
</tbody>
</table>

**FERROUS FUMARATE WITH FOLIC ACID**
- Tab 310 mg (100 mg elemental) with folic acid 350 mcg – 1% DV (Jun-18 to 2021)

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4.68</td>
<td>Ferro-F-Tabs</td>
</tr>
</tbody>
</table>

**FERROUS GLUCONATE WITH ASCORBIC ACID**
- Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg

**FERROUS SULFATE**
- Oral liq 30 mg (6 mg elemental) per ml – 1% DV Nov-19 to 2022

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$12.08</td>
<td>Ferodan</td>
</tr>
</tbody>
</table>

**FERROUS SULFATE**
- Tab long-acting 325 mg (105 mg elemental) – 1% DV (Jun-18 to 2021)

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2.06</td>
<td>Ferrograd</td>
</tr>
</tbody>
</table>

**FERROUS SULFATE WITH ASCORBIC ACID**
- Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg

**IRON POLYMALTOSE**
- Inj 50 mg per ml, 2 ml ampoule

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$34.50</td>
<td>Ferrosig</td>
</tr>
</tbody>
</table>

**IRON SUCROSE**
- Inj 20 mg per ml, 5 ml ampoule

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100.00</td>
<td>Venofer</td>
</tr>
</tbody>
</table>

**Magnesium**

**MAGNESIUM AMINO ACID CHELATE**
- Cap 750 mg (150 mg elemental)

**MAGNESIUM CHLORIDE**
- Inj 1 mmol per 1 ml, 100 ml bag

**MAGNESIUM HYDROXIDE**
- Tab 311 mg (130 mg elemental)

**MAGNESIUM OXIDE**
- Cap 663 mg (400 mg elemental)
- Cap 696 mg (420 mg elemental)

**MAGNESIUM OXIDE WITH MAGNESIUM ASPARTATE, MAGNESIUM AMINO ACID CHELATE AND MAGNESIUM CITRATE**
- Cap 500 mg with magnesium aspartate 100 mg, magnesium amino acid chelate 100 mg and magnesium citrate 100 mg (360 mg elemental magnesium)

**MAGNESIUM SULPHATE**
- Inj 0.4 mmol per ml, 250 ml bag
- Inj 2 mmol per ml, 5 ml ampoule – 1% DV Sep-17 to 2020

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$10.21</td>
<td>DBL</td>
</tr>
</tbody>
</table>

---

*Item restricted (see above); Item restricted (see below)*  
e.g. *Brand* indicates brand example only. It is not a contracted product.
### Zinc

<table>
<thead>
<tr>
<th>Product</th>
<th>Concentration</th>
<th>Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zinc</td>
<td>Oral liq 5 mg per 5 drops</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zinc Chloride</td>
<td>Inj 5.3 mg per ml (5.1 mg per ml elemental), 2 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zinc Sulphate</td>
<td>Cap 137.4 mg (50 mg elemental) – 1% DV Dec-19 to 2022</td>
<td>100 Zincaps</td>
<td>11.00</td>
</tr>
</tbody>
</table>

### Mouth and Throat

#### Agents Used in Mouth Ulceration

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzydamine Hydrochloride</td>
<td>Soln 0.15%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzydamine Hydrochloride with Cetylpyridinium Chloride</td>
<td>Lozenge 3 mg with cetylpyridinium chloride</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carboxymethylcellulose</td>
<td>Oral spray</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carmellose Sodium with Pectin and Gelatine</td>
<td>Paste, Powder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlormhexidine Gluconate</td>
<td>Mouthwash 0.2%</td>
<td></td>
<td>2.57</td>
</tr>
<tr>
<td>Choline Salicylate with Cetalkonium Chloride</td>
<td>Adhesive gel 8.7% with cetalkonium chloride 0.01%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dichlorobenzyl Alcohol with Amylmetacresol</td>
<td>Lozenge 1.2 mg with amylmetacresol 0.6 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triamcinolone Acetonide</td>
<td>Paste 0.1% – 1% DV Sep-17 to 2020</td>
<td></td>
<td>5.33</td>
</tr>
</tbody>
</table>

#### Oropharyngeal Anti-Infectives

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Manufacturer</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphotericin B</td>
<td>Lozenge 10 mg</td>
<td></td>
<td>5.86</td>
</tr>
<tr>
<td>Miconazole</td>
<td>Oral gel 20 mg per g – 1% DV Sep-18 to 2021</td>
<td></td>
<td>4.74</td>
</tr>
<tr>
<td>Nystatin</td>
<td>Oral liquid 100,000 u per ml – 1% DV Oct-17 to 2020</td>
<td></td>
<td>1.95</td>
</tr>
</tbody>
</table>

#### Other Oral Agents

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyaluronic Acid with Lidocaine [Lignocaine]</td>
<td>Inj 20 mg per ml</td>
<td></td>
</tr>
<tr>
<td>SODIUM HYALURONATE [HYALURONIC ACID] – Restricted</td>
<td>See terms below</td>
<td></td>
</tr>
</tbody>
</table>

Otolaryngologist

---

1. Products with Hospital Supply Status (HSS) are in **bold**
2. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
THYMOL GLYCERIN Compound, BPC ........................................................................................................... 9.15 500 ml PSM

Vitamins

Multivitamin Preparations

MULTIVITAMIN AND MINERAL SUPPLEMENT – Restricted see terms below

Cap.................................................................................................................................................. 23.35 180 Clinicians Multivit & Mineral Boost

→ Restricted (RS1498)

Initiation

Limited to 3 months treatment

Both:

1. Patient was admitted to hospital with burns; and
2. Any of the following:
   2.1 Burn size is greater than 15% of total body surface area (BSA) for all types of burns; or
   2.2 Burn size is greater than 10% of BSA for mid-dermal or deep dermal burns; or
   2.3 Nutritional status prior to admission or dietary intake is poor.

MULTIVITAMIN RENAL – Restricted see terms below

Cap........................................................................................................................................... 6.49 30 Clinicians Renal Vit

→ Restricted (RS1499)

Initiation

Either:

1. The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or
2. The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of < 15 ml/min/1.73m² body surface area (BSA).

MULTIVITAMINS

Tab (BPC cap strength).............................................................................................................. 10.50 1,000 Mvite

↓ cap vitamin A 2500 u, betacarotene 3 mg, cholecalciferol 11 mcg, alpha tocopherol 150 u, phytomenadione 150 mcg, folic acid 0.2 mg, ascorbic acid 100 mg, thiamine 1.5 mg, pantothenic acid 12 mg, riboflavin 1.7 mg, niacin 20 mg, pyridoxine hydrochloride 1.9 mg, cyanocobalamin 3 mcg, zinc 7.5 mg and biotin 100 mcg
e.g. Vitabdeck

→ Restricted (RS1620)

Initiation

Any of the following:

1. Patient has cystic fibrosis with pancreatic insufficiency; or
2. Patient is an infant or child with liver disease or short gut syndrome; or
3. Patient has severe malabsorption syndrome.

↓ Powder vitamin A 4200 mcg with vitamin D 155.5 mcg, vitamin E 21.4 mg, vitamin C 400 mg, vitamin K1 166 mcg thiamine 3.2 mg, riboflavin 4.4 mg, niacin 35 mg, vitamin B6 3.4 mg, folic acid 303 mcg, vitamin B12 8.6 mcg, biotin 214 mcg, pantothenic acid 17 mg, choline 350 mg and inositol 700 mg
e.g. Paediatric Seravit

→ Restricted (RS1178)

Initiation

Patient has inborn errors of metabolism.
VITAMIN A WITH VITAMINS D AND C
- Soln 1,000 u with vitamin D 400 u and ascorbic acid 30 mg per 10 drops
e.g. Vitadol C
*(e.g. Vitadol C Soln 1,000 u with vitamin D 400 u and ascorbic acid 30 mg per 10 drops to be delisted 1 December 2019)*

**Vitamin A**

**RETINOL**
- Tab 10,000 iu
- Cap 25,000 iu
- Oral liq 150,000 iu per ml
- Oral liq 5,000 iu per drop, 30 ml

**Vitamin B**

**HYDROXOCOBALAMIN**
- Inj 1 mg per ml, 1 ml ampoule – 1% DV Sep-18 to 2021
  - 1.89 3 Neo-B12

**PYRIDOXINE HYDROCHLORIDE**
- Tab 25 mg – 1% DV Jan-18 to 2020
  - 2.70 90 Vitamin B6 25
- Tab 50 mg – 1% DV Oct-17 to 2020
  - 13.63 500 Apo-Pyridoxine
- Inj 100 mg per ml, 2 ml vial
- Inj 100 mg per ml, 1 ml ampoule
- Inj 100 mg per ml, 30 ml vial

**THIAMINE HYDROCHLORIDE**
- Tab 50 mg – 1% DV Nov-18 to 2020
  - 4.89 100 Max Health
- Tab 100 mg
- Inj 100 mg per ml, 1 ml vial
- Inj 100 mg per ml, 2 ml vial

**VITAMIN B COMPLEX**
- Tab strong, BPC
  - 7.15 500 Bplex

**Vitamin C**

**ASCORBIC ACID**
- Tab 100 mg
  - 8.10 500 Cvite
- Tab chewable 250 mg

**Vitamin D**

**ALFACALCIDOL**
- Cap 0.25 mcg – 1% DV Aug-17 to 2020
  - 26.32 100 One-Alpha
- Cap 1 mcg – 1% DV Aug-17 to 2020
  - 87.98 100 One-Alpha
- Oral drops 2 mcg per ml – 1% DV Aug-17 to 2020
  - 60.68 20 ml One-Alpha

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
ALIMENTARY TRACT AND METABOLISM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic</td>
<td></td>
</tr>
</tbody>
</table>

**CALCITRIOL**

- Cap 0.25 mcg – 1% DV Oct-19 to 2022 .................................................. 7.95 100 Calcitriol-AFT
- Cap 0.5 mcg – 1% DV Oct-19 to 2022 .................................................. 13.75 100 Calcitriol-AFT
- Oral liq 1 mcg per ml
- Inj 1 mcg per ml, 1 ml ampoule

**COLECALCIFEROL**

- Cap 1.25 mg (50,000 iu) – 1% DV Oct-17 to 2020 ........................................ 2.50 12 Vit.D3
- Oral liq 188 mcg per ml (7,500 iu per ml) ............................................. 9.00 4.8 ml Puria

**Vitamin E**

**ALPHA TOCOPHERYL** – Restricted see terms below

- Oral liq 156 u per ml
- → Restricted (RS1632)

Initiation – Cystic fibrosis

Both:
1. Cystic fibrosis patient; and
2. Either:
   2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
   2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

Initiation – Osteoradionecrosis

For the treatment of osteoradionecrosis.

Initiation – Other indications

All of the following:
1. Infant or child with liver disease or short gut syndrome; and
2. Requires vitamin supplementation; and
3. Either:
   3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
   3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

**ALPHA TOCOPHERYL ACETATE** – Restricted see terms below

- Cap 100 u
- Cap 500 u
- Oral liq 156 u per ml
- → Restricted (RS1176)

Initiation – Cystic fibrosis

Both:
1. Cystic fibrosis patient; and
2. Either:
   2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
   2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

Initiation – Osteoradionecrosis

For the treatment of osteoradionecrosis.

Initiation – Other indications

All of the following:
1. Infant or child with liver disease or short gut syndrome; and

continued…
continued...

2 Requires vitamin supplementation; and

3 Either:
   3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
   3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.
### Antianaemics

#### Hypoplastic and Haemolytic

**EPOETIN ALFA** – *Restricted* see terms below

- **Inj 1,000 iu in 0.5 ml syringe – 1% DV Apr-19 to 2022** ................................250.00 6 *Binocrit*
- **Inj 2,000 iu in 1 ml syringe – 1% DV Apr-19 to 2022** ................................100.00 6 *Binocrit*
- **Inj 3,000 iu in 0.3 ml syringe – 1% DV Apr-19 to 2022** ................................150.00 6 *Binocrit*
- **Inj 4,000 iu in 0.4 ml syringe – 1% DV Apr-19 to 2022** ................................96.50 6 *Binocrit*
- **Inj 5,000 iu in 0.5 ml syringe – 1% DV Apr-19 to 2022** ................................125.00 6 *Binocrit*
- **Inj 6,000 iu in 0.6 ml syringe – 1% DV Apr-19 to 2022** ................................145.00 6 *Binocrit*
- **Inj 8,000 iu in 0.8 ml syringe – 1% DV Apr-19 to 2022** ................................175.00 6 *Binocrit*
- **Inj 10,000 iu in 1 ml syringe – 1% DV Apr-19 to 2022** .................................197.50 6 *Binocrit*
- **Inj 40,000 iu in 1 ml syringe – 1% DV Apr-19 to 2022** .................................250.00 1 *Binocrit*

* Restricted (RS1660)

**Initiation – chronic renal failure**

All of the following:

1. Patient in chronic renal failure; and
2. Haemoglobin is less than or equal to 100g/L; and
3. Either:
   3.1 Both:
      3.1.1 Patient does not have diabetes mellitus; and
      3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
   3.2 Both:
      3.2.1 Patient has diabetes mellitus; and
      3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; and
4. Patient is on haemodialysis or peritoneal dialysis.

**Initiation – myelodysplasia**

*Re-assessment required after 2 months*

All of the following:

1. Patient has a confirmed diagnosis of myelodysplasia (MDS); and
2. Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
3. Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
4. Other causes of anaemia such as B12 and folate deficiency have been excluded; and
5. Patient has a serum epoetin level of < 500 IU/L; and
6. The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

**Continuation – myelodysplasia**

*Re-assessment required after 12 months*

All of the following:

1. The patient's transfusion requirement continues to be reduced with epoetin treatment; and
2. Transformation to acute myeloid leukaemia has not occurred; and
3. The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

**Initiation – all other indications**

Haematologist

For use in patients where blood transfusion is not a viable treatment alternative.

Note: Indications marked with * are unapproved indications
EPOETIN BETA – Restricted see terms below

Note: Epoetin beta is considered a Discretionary Variance Pharmaceutical for epoetin alfa.

- Inj 2,000 iu in 0.3 ml syringe
- Inj 3,000 iu in 0.3 ml syringe
- Inj 4,000 iu in 0.3 ml syringe
- Inj 5,000 iu in 0.3 ml syringe
- Inj 6,000 iu in 0.3 ml syringe
- Inj 10,000 iu in 0.6 ml syringe

Initiation – chronic renal failure
All of the following:
1. Patient in chronic renal failure; and
2. Haemoglobin is less than or equal to 100g/L; and
3. Either:
   3.1 Both:
      3.1.1 Patient does not have diabetes mellitus; and
      3.1.2 Glomerular filtration rate is less than or equal to 30ml/min; or
   3.2 Both:
      3.2.1 Patient has diabetes mellitus; and
      3.2.2 Glomerular filtration rate is less than or equal to 45ml/min; and
4. Patient is on haemodialysis or peritoneal dialysis.

Initiation – myelodysplasia*
Re-assessment required after 12 months
All of the following:
1. Patient has a confirmed diagnosis of myelodysplasia (MDS); and
2. Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
3. Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
4. Other causes of anaemia such as B12 and folate deficiency have been excluded; and
5. Patient has a serum epoetin level of < 500 IU/L; and
6. The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Continuation – myelodysplasia*
Re-assessment required after 2 months
All of the following:
1. The patient's transfusion requirement continues to be reduced with epoetin treatment; and
2. Transformation to acute myeloid leukaemia has not occurred; and
3. The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week.

Initiation – all other indications
Haematologist.
For use in patients where blood transfusion is not a viable treatment alternative.
*Note: Indications marked with * are unapproved indications.

Megaloblastic

FOLIC ACID

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 0.8 mg – 1% DV Oct-18 to 2021</td>
<td>21.84</td>
<td>Apo-Folic Acid</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Oct-18 to 2021</td>
<td>12.12</td>
<td>Apo-Folic Acid</td>
</tr>
<tr>
<td>Oral liq 50 mcg per ml</td>
<td>26.00</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 10 ml vial</td>
<td>25 ml</td>
<td>Biomed</td>
</tr>
</tbody>
</table>
Antifibrinolytics, Haemostatics and Local Sclerosants

ALUMINIUM CHLORIDE – Restricted see terms below

*Topical soln 20% w/v*  
*Restricted (RS1500)*

Initiation
For use as a haemostatis agent.

APROTININ – Restricted see terms below

*Inj 10,000 kIU per ml (equivalent to 200 mg per ml), 50 ml vial*  
*Restricted (RS1332)*

Initiation
Cardiac anaesthetist
Either:
1. Paediatric patient undergoing cardiopulmonary bypass procedure; or
2. Adult patient undergoing cardiac surgical procedure where the significant risk of massive bleeding outweighs the potential adverse effects of the drug.

ELTROMBOPAG – Restricted see terms below

*Tab 25 mg*  
*1,550.00 28 Revolade*  
*Tab 50 mg*  
*3,100.00 28 Revolade*  
*Restricted (RS1648)*

Initiation – idiopathic thrombocytopenic purpura - post-splenectomy
Haematologist
*Re-assessment required after 6 weeks*
All of the following:
1. Patient has had a splenectomy; and
2. Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
3. Any of the following:
   3.1. Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
   3.2. Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding; or
   3.3. Patient has a platelet count of less than or equal to 10,000 platelets per microlitre.

Initiation – idiopathic thrombocytopenic purpura - preparation for splenectomy
Haematologist
*Limited to 6 weeks treatment*
The patient requires eltrombopag treatment as preparation for splenectomy.

Continuation – idiopathic thrombocytopenic purpura - post-splenectomy
Haematologist
*Re-assessment required after 12 months*
The patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre

Initiation – idiopathic thrombocytopenic purpura contraindicated to splenectomy
Haematologist
*Re-assessment required after 3 months*
All of the following:
1. Patient has a significant and well-documented contraindication to splenectomy for clinical reasons; and

continued…
Continuation – idiopathic thrombocytopenic purpura contraindicated to splenectomy
Haematologist
*Re-assessment required after 12 months*

All of the following:
1. The patient’s significant contraindication to splenectomy remains; and
2. The patient has obtained a response from treatment during the initial approval period; and
3. Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment; and
4. Further treatment with eltrombopag is required to maintain response.

Initiation – severe aplastic anaemia
Haematologist
*Re-assessment required after 3 months*

Both:
1. Two immunosuppressive therapies have been trialled and failed after therapy of at least 3 months duration; and
2. Either:
   2.1 Patient has severe aplastic anaemia with a platelet count of less than or equal to 20,000 platelets per microlitre; or
   2.2 Patient has severe aplastic anaemia with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding.

Continuation – severe aplastic anaemia
Haematologist
*Re-assessment required after 12 months*

Both:
1. The patient has obtained a response from treatment of at least 20,000 platelets per microlitre above baseline during the initial approval period; and
2. Platelet transfusion independence for a minimum of 8 weeks during the initial approval period.

**FERRIC SUBSULFATE**

- Gel 25.9%
- Soln 500 ml

**POLIDOCANOL**

- Inj 0.5%, 30 ml vial

**SODIUM TETRADECYL SULPHATE**

- Inj 3%, 2 ml ampoule

**THROMBIN**

- Powder

**TRANEXAMIC ACID**

- Tab 500 mg .................................................................20.67 100 Cyklokapron
- Inj 100 mg per ml, 5 ml ampoule – 1% DV Sep-18 to 2021…………………………………….6.95 5 Tranexamic-AFT
- Inj 100 mg per ml, 10 ml ampoule – 1% DV Sep-18 to 2021……………………………………10.95 5 Tranexamic-AFT

**Anticoagulant Reversal Agents**

**IDARUCIZUMAB – Restricted** see terms on the next page

- Inj 50 mg per ml, 50 ml vial…………………………………………………………….4,250.00 2 Praxbind

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
**Blood Factors**

**EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] – Restricted see terms below**

- **Inj 250 iu vial** ................................................................. 612.50 1 Alprolix
- **Inj 500 iu vial** ................................................................. 1,225.00 1 Alprolix
- **Inj 1,000 iu vial** ............................................................... 2,450.00 1 Alprolix
- **Inj 2,000 iu vial** ............................................................... 4,900.00 1 Alprolix
- **Inj 3,000 iu vial** ............................................................... 7,350.00 1 Alprolix

**EPTACOG ALFA [RECOMBINANT FACTOR VIIA] – Restricted see terms below**

- **Inj 1 mg syringe** .......................................................... 1,178.30 1 NovoSeven RT
- **Inj 2 mg syringe** .......................................................... 2,356.60 1 NovoSeven RT
- **Inj 5 mg syringe** .......................................................... 5,891.50 1 NovoSeven RT
- **Inj 8 mg syringe** .......................................................... 9,426.40 1 NovoSeven RT

**FACTOR EIGHT INHIBITOR BYPASSING FRACTION – Restricted see terms below**

- **Inj 500 U** ................................................................. 1,315.00 1 FEIBA NF
- **Inj 1,000 U** ................................................................. 2,630.00 1 FEIBA NF
- **Inj 2,500 U** ................................................................. 6,575.00 1 FEIBA NF

**MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] – Restricted see terms below**

- **Inj 250 iu prefilled syringe** ............................................. 287.50 1 Xyntha
- **Inj 500 iu prefilled syringe** ........................................... 575.00 1 Xyntha
- **Inj 1,000 iu prefilled syringe** ....................................... 1,150.00 1 Xyntha
- **Inj 2,000 iu prefilled syringe** ....................................... 2,300.00 1 Xyntha
- **Inj 3,000 iu prefilled syringe** ....................................... 3,450.00 1 Xyntha

**NONACOG GAMMA, [RECOMBINANT FACTOR IX] – Restricted see terms on the next page**

- **Inj 500 iu vial** ........................................................... 435.00 1 RIXUBIS
- **Inj 1,000 iu vial** ........................................................... 870.00 1 RIXUBIS
- **Inj 2,000 iu vial** ........................................................... 1,740.00 1 RIXUBIS
- **Inj 3,000 iu vial** ........................................................... 2,610.00 1 RIXUBIS

**Initiation**

For the reversal of the anticoagulant effects of dabigatran when required in situations of life-threatening or uncontrolled bleeding, or for emergency surgery or urgent procedures.
For patients with haemophilia. Access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (ADVATE) – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Volume (iu)</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>250</td>
<td>$210.00</td>
<td>Advate</td>
</tr>
<tr>
<td>500</td>
<td>$420.00</td>
<td>Advate</td>
</tr>
<tr>
<td>1,000</td>
<td>$840.00</td>
<td>Advate</td>
</tr>
<tr>
<td>1,500</td>
<td>$1,260.00</td>
<td>Advate</td>
</tr>
<tr>
<td>2,000</td>
<td>$1,680.00</td>
<td>Advate</td>
</tr>
<tr>
<td>3,000</td>
<td>$2,520.00</td>
<td>Advate</td>
</tr>
</tbody>
</table>

OCTOCOG ALFA [RECOMBINANT FACTOR VIII] (KOGENATE FS) – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Volume (iu)</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>250</td>
<td>$237.50</td>
<td>Kogenate FS</td>
</tr>
<tr>
<td>500</td>
<td>$475.00</td>
<td>Kogenate FS</td>
</tr>
<tr>
<td>1,000</td>
<td>$950.00</td>
<td>Kogenate FS</td>
</tr>
<tr>
<td>2,000</td>
<td>$1,900.00</td>
<td>Kogenate FS</td>
</tr>
<tr>
<td>3,000</td>
<td>$2,850.00</td>
<td>Kogenate FS</td>
</tr>
</tbody>
</table>

RURIOCTOCOG ALFA PEGOL [RECOMBINANT FACTOR VIII] – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Volume (iu)</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>250</td>
<td>$300.00</td>
<td>Adynovate</td>
</tr>
<tr>
<td>500</td>
<td>$600.00</td>
<td>Adynovate</td>
</tr>
<tr>
<td>1,000</td>
<td>$1,200.00</td>
<td>Adynovate</td>
</tr>
<tr>
<td>2,000</td>
<td>$2,400.00</td>
<td>Adynovate</td>
</tr>
</tbody>
</table>

Vitamin K

**PHYTOMENADIONE**

- Inj 2 mg in 0.2 ml ampoule ...................................................... $8.00  5 Konakion MM
- Inj 10 mg per ml, 1 ml ampoule ...................................................... $9.21  5 Konakion MM

Antithrombotics

**Anticoagulants**

**BIVALIRUDIN** – **Restricted** see terms below

- Inj 250 mg vial

Initiation

Either:
continued...

1 For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance; or
2 For use in patients undergoing endovascular procedures.

CITRATE SODIUM

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 4% (200 mg per 5 ml), 5 ml ampoule</td>
<td>$76.36</td>
<td>60 Pradaxa</td>
</tr>
<tr>
<td>Inj 46.7% (1.4 g per 3 ml), 3 ml syringe</td>
<td>$76.36</td>
<td>60 Pradaxa</td>
</tr>
<tr>
<td>Inj 46.7% (2.36 g per 5 ml), 5 ml ampoule</td>
<td>$76.36</td>
<td>60 Pradaxa</td>
</tr>
</tbody>
</table>

DABIGATRAN

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 75 mg</td>
<td>$76.36</td>
<td>60 Pradaxa</td>
</tr>
<tr>
<td>Cap 110 mg</td>
<td>$76.36</td>
<td>60 Pradaxa</td>
</tr>
<tr>
<td>Cap 150 mg</td>
<td>$76.36</td>
<td>60 Pradaxa</td>
</tr>
</tbody>
</table>

DALTEPARIN

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2,500 iu in 0.2 ml syringe</td>
<td>$19.97</td>
<td>10 Fragmin</td>
</tr>
<tr>
<td>Inj 5,000 iu in 0.2 ml syringe</td>
<td>$39.94</td>
<td>10 Fragmin</td>
</tr>
<tr>
<td>Inj 7,500 iu in 0.75 ml syringe</td>
<td>$60.03</td>
<td>10 Fragmin</td>
</tr>
<tr>
<td>Inj 10,000 iu in 1 ml syringe</td>
<td>$77.55</td>
<td>10 Fragmin</td>
</tr>
<tr>
<td>Inj 12,500 iu in 0.5 ml syringe</td>
<td>$99.96</td>
<td>10 Fragmin</td>
</tr>
<tr>
<td>Inj 15,000 iu in 0.6 ml syringe</td>
<td>$120.05</td>
<td>10 Fragmin</td>
</tr>
<tr>
<td>Inj 18,000 iu in 0.72 ml syringe</td>
<td>$158.47</td>
<td>10 Fragmin</td>
</tr>
</tbody>
</table>

(Dalteparin Inj 2,500 iu in 0.2 ml syringe to be delisted 1 April 2020)
(Dalteparin Inj 5,000 iu in 0.2 ml syringe to be delisted 1 April 2020)
(Dalteparin Inj 7,500 iu in 0.75 ml syringe to be delisted 1 April 2020)
(Dalteparin Inj 10,000 iu in 1 ml syringe to be delisted 1 January 2020)
(Dalteparin Inj 12,500 iu in 0.5 ml syringe to be delisted 1 January 2020)
(Dalteparin Inj 15,000 iu in 0.6 ml syringe to be delisted 1 January 2020)
(Dalteparin Inj 18,000 iu in 0.72 ml syringe to be delisted 1 January 2020)

DANAPAROID – Restricted see terms below

- Restricted (RS1182)

Initiation

For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance.

DEFIBROTIDE – Restricted see terms below

- Restricted (RS1183)

Initiation

Haematologist

Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities.

DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A]

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag</td>
<td>$27.93</td>
<td>10 Clexane</td>
</tr>
</tbody>
</table>

ENOXAPARIN SODIUM

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 20 mg in 0.2 ml syringe</td>
<td>$27.93</td>
<td>10 Clexane</td>
</tr>
<tr>
<td>Inj 40 mg in 0.4 ml ampoule</td>
<td>$37.27</td>
<td>10 Clexane</td>
</tr>
<tr>
<td>Inj 60 mg in 0.6 ml syringe</td>
<td>$56.18</td>
<td>10 Clexane</td>
</tr>
<tr>
<td>Inj 80 mg in 0.8 ml syringe</td>
<td>$74.90</td>
<td>10 Clexane</td>
</tr>
<tr>
<td>Inj 100 mg in 1 ml syringe</td>
<td>$93.80</td>
<td>10 Clexane</td>
</tr>
<tr>
<td>Inj 120 mg in 0.8 ml syringe</td>
<td>$116.55</td>
<td>10 Clexane</td>
</tr>
<tr>
<td>Inj 150 mg in 1 ml syringe</td>
<td>$133.20</td>
<td>10 Clexane</td>
</tr>
</tbody>
</table>

- Item restricted (see ➥ above); ➥ Item restricted (see ➥ below)
e.g. Brand indicates brand example only. It is not a contracted product.
### Blood and Blood Forming Organs

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per</td>
<td></td>
</tr>
</tbody>
</table>

#### FONDAPARINUX SODIUM – Restricted see terms below
- Inj 2.5 mg in 0.5 ml syringe
- Inj 7.5 mg in 0.6 ml syringe

**Initiation**
For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance.

**HEPARIN SODIUM**
- Inj 100 iu per ml, 250 ml bag
- Inj 1,000 iu per ml, 1 ml ampoule
- Inj 1,000 iu per ml, 5 ml ampoule – 1% DV Nov-18 to 2021
- Inj 5,000 iu in 0.2 ml ampoule
- Inj 5,000 iu per ml, 1 ml ampoule
- Inj 5,000 iu per ml, 5 ml ampoule – 1% DV Nov-18 to 2021

**HEPARINISED SALINE**
- Inj 10 iu per ml, 5 ml ampoule
- Inj 100 iu per ml, 2 ml ampoule
- Inj 100 iu per ml, 5 ml ampoule

**PHENINDIONE**

<table>
<thead>
<tr>
<th>Tab 10 mg</th>
<th>Tab 25 mg</th>
<th>Tab 50 mg</th>
</tr>
</thead>
</table>

**PROTAMINE SULPHATE**
- Inj 10 mg per ml, 5 ml ampoule

**RIVAROXABAN**
- Tab 10 mg
- Tab 15 mg
- Tab 20 mg

**SODIUM CITRATE WITH SODIUM CHLORIDE AND POTASSIUM CHLORIDE**
- Inj 4.2 mg with sodium chloride 5.7 mg and potassium chloride 74.6 mcg per ml, 5,000 ml bag

**WARFARIN SODIUM**
- Tab 1 mg
- Tab 2 mg
- Tab 3 mg
- Tab 5 mg

### Antiplatelets

**ASPIRIN**
- Tab 100 mg – 10% DV Nov-19 to 2022
- Suppos 300 mg

**CLOPIDOGREL**
- Tab 75 mg

**DIPYRIDAMOLE**
- Tab 25 mg
- Tab long-acting 150 mg – 1% DV Oct-19 to 2022
- Inj 5 mg per ml, 2 ml ampoule

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiration date of HSS period is 30 June of the year indicated unless otherwise stated.
EPTIFIBATIDE – Restricted see terms below

- Inj 2 mg per ml, 10 ml vial – 1% DV Nov-18 to 2021 ...................................138.75 1 Integrilin
- Inj 750 mcg per ml, 100 ml vial – 1% DV Nov-18 to 2021 .........................405.00 1 Integrilin

Initiation
Either:
1. For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or
2. For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography.

LYSINE ACETYLSALICYLATE [LYSINE ASPRIN] – Restricted see terms below

- Inj 500 mg

Initiation
Both:
1. For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventional cardiology procedure; and
2. Administration of oral aspirin would delay the procedure.

PRASUGREL – Restricted see terms below

- Tab 5 mg .................................................................108.00 28 Effient
- Tab 10 mg .............................................................120.00 28 Effient

Initiation – Bare metal stents
Limited to 6 months treatment
Patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic.

Initiation – Drug-eluting stents
Limited to 12 months treatment
Patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic.

Initiation – Stent thrombosis
Patient has experienced cardiac stent thrombosis whilst on clopidogrel.

Initiation – Myocardial infarction
Limited to 1 week treatment
For short term use while in hospital following ST-elevated myocardial infarction.

Note: Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment

TICAGRELOR – Restricted see terms below

- Tab 90 mg ..............................................................90.00 56 Brilinta

Initiation
Restricted to treatment of acute coronary syndromes specifically for patients who have recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome, and in whom fibrinolytic therapy has not been given in the last 24 hours and is not planned.

TICLOPIDINE

- Tab 250 mg

Fibrinolytic Agents

ALTEPLASE
- Inj 2 mg vial
- Inj 10 mg vial
- Inj 50 mg vial
BLOOD AND BLOOD FORMING ORGANS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**TENECTEPLASE**
- Inj 50 mg vial

**UROKINASE**
- Inj 5,000 iu vial
- Inj 10,000 iu vial
- Inj 50,000 iu vial
- Inj 100,000 iu vial
- Inj 500,000 iu vial

### Colony-Stimulating Factors

#### Drugs Used to Mobilise Stem Cells

**PLERIXAFOR – Restricted** see terms below
- Inj 20 mg per ml, 1.2 ml vial
  - Restricted (RS1536)
  - Initiation – Autologous stem cell transplant
    - Haematologist
    - Limited to 3 days treatment

All of the following:
1. Patient is to undergo stem cell transplantation; and
2. Patient has not had a previous unsuccessful mobilisation attempt with plerixafor; and
3. Any of the following:
   3.1 Both:
      - 3.1.1 Patient is undergoing G-CSF mobilisation; and
      - 3.1.2 Either:
        - 3.1.2.1 Has a suboptimal peripheral blood CD34 count of less than or equal to $10 \times 10^6$/L on day 5 after 4 days of G-CSF treatment; or
        - 3.1.2.2 Efforts to collect $> 1 \times 10^6$ CD34 cells/kg have failed after one apheresis procedure; or
   3.2 Both:
      - 3.2.1 Patient is undergoing chemotherapy and G-CSF mobilisation; and
      - 3.2.2 Any of the following:
        - 3.2.2.1 Both:
          - 3.2.2.1.1 Has rising white blood cell counts of $> 5 \times 10^9$/L; and
          - 3.2.2.1.2 Has a suboptimal peripheral blood CD34 count of less than or equal to $10 \times 10^9$/L; or
        - 3.2.2.2 Efforts to collect $> 1 \times 10^6$ CD34 cells/kg have failed after one apheresis procedure; or
        - 3.2.2.3 The peripheral blood CD34 cell counts are decreasing before the target has been received; or
   3.3 A previous mobilisation attempt with G-CSF or G-CSF plus chemotherapy has failed.

**Granulocyte Colony-Stimulating Factors**

**FILGRASTIM – Restricted** see terms below
- Inj 300 mcg in 0.5 ml prefilled syringe – 1% DV May-19 to 2021
  - Restricted (RS1188)
  - Haematologist or oncologist

**PEGFILGRASTIM – Restricted** see terms on the next page
- Inj 6 mg per 0.6 ml syringe

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
BLOOD AND BLOOD FORMING ORGANS

Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer

Restricted (RS1262)
Initiation
For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk greater than or equal to 20%).
Note: *Febrile neutropenia risk greater than or equal to 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines

Fluids and Electrolytes

Intravenous Administration

CALCIUM CHLORIDE
Inj 100 mg per ml, 10 ml vial
Inj 100 mg per ml, 50 ml syringe e.g. Baxter

CALCIUM GLUCONATE
Inj 10%, 10 ml ampoule e.g. Max Health

COMPOUND ELECTROLYTES
Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 500 ml bag – 1% DV Jun-18 to 2021 .................................................. 44.10 18 Plasma-Lyte 148
Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 1,000 ml bag – 1% DV Jun-18 to 2021 .................................................. 27.24 12 Plasma-Lyte 148

COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]
Inj sodium 140 mmol/l, 5 mmol/l potassium, 1.5 mmol/l magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, glucose 23 mmol/l (5%), 1,000 ml bag – 1% DV Jun-18 to 2021 .......... 211.92 12 Plasma-Lyte 148 & 5% Glucose

COMPOUND SODIUM LACTATE [HARTMANN’S SOLUTION]
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 500 ml bag – 1% DV Jun-18 to 2021 .................................................. 23.40 18 Baxter
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 1,000 ml bag – 1% DV Jun-18 to 2021 .................................................. 15.72 12 Baxter

GLUCOSE [DEXTROSE]
Inj 5%, 1,000 ml bag – 1% DV Aug-18 to 2021 .................................................. 16.80 10 Fresenius Kabi
Inj 5%, 100 ml bag – 1% DV Aug-18 to 2021 .................................................. 77.50 50 Fresenius Kabi
Inj 5%, 250 ml bag – 1% DV Aug-18 to 2021 .................................................. 52.50 30 Fresenius Kabi
Inj 5%, 50 ml bag – 1% DV Jun-18 to 2021 .................................................. 143.40 60 Baxter Glucose 5%
Inj 5%, 500 ml bag – 1% DV Aug-18 to 2021 .................................................. 24.00 20 Fresenius Kabi
Inj 10%, 1,000 ml bag – 1% DV Jun-18 to 2021 .................................................. 111.96 12 Baxter Glucose 10%
Inj 10%, 500 ml bag – 1% DV Jun-18 to 2021 .................................................. 109.98 18 Baxter Glucose 10%
Inj 50%, 10 ml ampoule – 1% DV Oct-17 to 2020 .................................................. 29.50 5 Biomed
Inj 50%, 500 ml bag – 1% DV Jun-18 to 2021 .................................................. 337.32 18 Baxter Glucose 50%
Inj 50%, 90 ml bottle – 1% DV Oct-17 to 2020 .................................................. 14.50 1 Biomed

GLUCOSE WITH POTASSIUM CHLORIDE
Inj 10% glucose with 20 mmol/l potassium chloride, 500 ml bag

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)
e.g. Brand indicates brand example only. It is not a contracted product.
### GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Brand</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2.5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 3,000 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10% glucose with potassium chloride 10 mmol/l and sodium chloride 15 mmol/l, 500 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride 0.18%, 1,000 ml bag</td>
<td>1% DV Jun-18 to 2021</td>
<td>203.40 12</td>
<td></td>
</tr>
<tr>
<td>Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 1,000 ml bag</td>
<td>1% DV Jun-18 to 2021</td>
<td>159.96 12</td>
<td></td>
</tr>
</tbody>
</table>

### GLUCOSE WITH SODIUM CHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Brand</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj glucose 2.5% with sodium chloride 0.45%, 500 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 4% glucose and sodium chloride 0.18%, 1,000 ml bag – 1% DV Jun-18 to 2021</td>
<td>12</td>
<td>163.32 12</td>
<td></td>
</tr>
<tr>
<td>Inj 5% glucose and sodium chloride 0.45%, 1,000 ml bag – 1% DV Jun-18 to 2021</td>
<td>12</td>
<td>163.20 12</td>
<td></td>
</tr>
</tbody>
</table>

### POTASSIUM CHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Brand</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 75 mg (1 mmol) per ml, 10 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 225 mg (3 mmol) per ml, 20 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### POTASSIUM CHLORIDE WITH SODIUM CHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Brand</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag</td>
<td>1% DV Jun-18 to 2021</td>
<td>476.64 48</td>
<td></td>
</tr>
<tr>
<td>Inj 20 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag</td>
<td>1% DV Jun-18 to 2021</td>
<td>163.08 12</td>
<td></td>
</tr>
<tr>
<td>Inj 40 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag</td>
<td>1% DV Jun-18 to 2021</td>
<td>253.32 12</td>
<td></td>
</tr>
</tbody>
</table>

### POTASSIUM DIHYDROGEN PHOSPHATE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Brand</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mmol per ml, 10 ml ampoule</td>
<td></td>
<td>151.80 10 Hospira</td>
<td></td>
</tr>
</tbody>
</table>

### RINGER'S SOLUTION

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Brand</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>chloride 156 mmol/l, 1,000 ml bag</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SODIUM ACETATE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Brand</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 4 mmol per ml, 20 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SODIUM BICARBONATE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Brand</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 8.4%, 10 ml vial</td>
<td></td>
<td>19.95 1 Biomed</td>
<td></td>
</tr>
<tr>
<td>Inj 8.4%, 50 ml vial</td>
<td></td>
<td>19.95 1 Biomed</td>
<td></td>
</tr>
<tr>
<td>Inj 8.4%, 100 ml vial</td>
<td></td>
<td>20.50 1 Biomed</td>
<td></td>
</tr>
</tbody>
</table>
SODIUM CHLORIDE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 0.9%, 5 ml ampoule – 1% DV Dec-19 to 2022</td>
<td>$2.80</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 0.9%, 10 ml ampoule – 1% DV Dec-19 to 2022</td>
<td>$7.00</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 0.9%, 3 ml syringe, non-sterile pack – 1% DV Sep-18 to 2021</td>
<td>$6.63</td>
<td>BD PosiFlush</td>
</tr>
<tr>
<td><strong>Restricted (RS1297)</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Initiation

For use in flushing of in-situ vascular access devices only.

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 0.9%, 5 ml syringe, non-sterile pack – 1% DV Sep-18 to 2021</td>
<td>$162.91</td>
<td>BD PosiFlush</td>
</tr>
<tr>
<td><strong>Restricted (RS1297)</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Initiation

For use in flushing of in-situ vascular access devices only.

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 0.9%, 10 ml syringe, non-sterile pack – 1% DV Sep-18 to 2021</td>
<td>$170.35</td>
<td>BD PosiFlush</td>
</tr>
<tr>
<td><strong>Restricted (RS1297)</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Initiation

For use in flushing of in-situ vascular access devices only.

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 0.9%, 20 ml ampoule – 1% DV Dec-19 to 2022</td>
<td>$5.00</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 23.4% (4 mmol/ml), 20 ml ampoule</td>
<td>$33.00</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 0.45%, 500 ml bag</td>
<td>$71.28</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 3%, 1,000 ml bag</td>
<td>$91.20</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 0.9%, 50 ml bag</td>
<td>$109.80</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 0.9%, 100 ml bag</td>
<td>$78.24</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 0.9%, 250 ml bag</td>
<td>$44.64</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 0.9%, 500 ml bag</td>
<td>$22.14</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 0.9%, 1,000 ml bag</td>
<td>$15.12</td>
<td>Baxter</td>
</tr>
<tr>
<td>Inj 1.8%, 500 ml bottle</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(InterPharma Inj 0.9%, 5 ml ampoule to be delisted 1 December 2019)
(Pfizer Inj 0.9%, 10 ml ampoule to be delisted 1 December 2019)
(Multichem Inj 0.9%, 20 ml ampoule to be delisted 1 December 2019)

SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE]

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mmol per ml, 20 ml ampoule – 1% DV Oct-18 to 2021</td>
<td>$48.70</td>
<td>Biomed</td>
</tr>
</tbody>
</table>

WATER

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 5 ml ampoule</td>
<td>$7.00</td>
<td>InterPharma</td>
</tr>
<tr>
<td>Inj 10 ml ampoule</td>
<td>$6.63</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Inj 20 ml ampoule</td>
<td>$5.00</td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td>Inj 250 ml bag</td>
<td>$7.50</td>
<td>InterPharma</td>
</tr>
<tr>
<td>Inj 500 ml bag</td>
<td>$5.00</td>
<td>Multichem</td>
</tr>
<tr>
<td>Inj, 1,000 ml bag</td>
<td>$19.08</td>
<td>Baxter</td>
</tr>
</tbody>
</table>

Oral Administration

CALCIUM POLYSTYRENE SULPHONATE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder</td>
<td>$169.85</td>
<td>Calcium Resonium</td>
</tr>
</tbody>
</table>
### COMPOUND ELECTROLYTES

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Expiry Date</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder for oral soln – 1% DV</td>
<td>Apr-20 to 2022</td>
<td>9.77 $</td>
<td>Electrolyte</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.30 $</td>
<td>Enerlyte</td>
</tr>
</tbody>
</table>

*(Enerlyte Powder for oral soln to be delisted 1 April 2020)*

### COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE]

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Expiry Date</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soln with electrolytes (2 x 500 ml) – 1% DV</td>
<td>Nov-18 to 2021</td>
<td>6.55 $</td>
<td>Pedialyte - Bubblegum</td>
</tr>
</tbody>
</table>

### PHOSPHORUS

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab eff 500 mg (16 mmol)</td>
<td>8.90 $</td>
<td>Span-K</td>
</tr>
</tbody>
</table>

### POTASSIUM CHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)</td>
<td>8.52 $</td>
<td>Sodibic</td>
</tr>
<tr>
<td>Tab long-acting 600 mg (8 mmol) – 1% DV</td>
<td>Oct-18 to 2021</td>
<td>8.90 $</td>
</tr>
<tr>
<td>Oral liq 2 mmol per ml</td>
<td>200</td>
<td></td>
</tr>
</tbody>
</table>

### SODIUM BICARBONATE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 840 mg</td>
<td>8.52 $</td>
<td>Sodibic</td>
</tr>
</tbody>
</table>

### SODIUM CHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 600 mg</td>
<td>8.52 $</td>
<td>Sodibic</td>
</tr>
<tr>
<td>Oral liq 2 mmol/ml</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SODIUM POLYSTYRENE SULPHONATE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder – 1% DV</td>
<td>Sep-18 to 2021</td>
<td>84.65 $</td>
</tr>
</tbody>
</table>

### Plasma Volume Expanders

### GELATINE, SUCCINYLATED

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 4%, 500 ml bag – 1% DV</td>
<td>Jun-18 to 2021</td>
<td>120.00 $</td>
</tr>
</tbody>
</table>
## Agents Affecting the Renin-Angiotensin System

### ACE Inhibitors

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CAPTOPRIL</strong></td>
<td>Oral liq 5 mg per ml</td>
<td>$94.99/95 ml</td>
<td>Capoten</td>
</tr>
</tbody>
</table>

- **Restricted (RS1263)**

**Initiation**
Any of the following:
1. For use in children under 12 years of age; or
2. For use in tube-fed patients; or
3. For management of rebound transient hypertension following cardiac surgery.

**CILAZAPRIL**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 0.5 mg – 1% DV Sep-19 to 2022</td>
<td>$2.09/90</td>
<td>Zapril</td>
</tr>
<tr>
<td>Tab 2.5 mg – 1% DV Feb-20 to 2022</td>
<td>$7.20/200</td>
<td>Apo-Cilazapril</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Feb-20 to 2022</td>
<td>$12.00/200</td>
<td>Apo-Cilazapril</td>
</tr>
</tbody>
</table>

(Apo-Cilazapril Tab 2.5 mg to be delisted 1 February 2020)
(Apo-Cilazapril Tab 5 mg to be delisted 1 February 2020)

**ENALAPRIL MALEATE**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg</td>
<td>$3.84/100</td>
<td>Ethics Enalapril</td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>$4.96/100</td>
<td>Ethics Enalapril</td>
</tr>
<tr>
<td>Tab 20 mg</td>
<td>$7.12/100</td>
<td>Ethics Enalapril</td>
</tr>
</tbody>
</table>

**LISINOPRIL**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg – 1% DV Dec-18 to 2021</td>
<td>$2.07/90</td>
<td>Ethics Lisinopril</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Dec-18 to 2021</td>
<td>$2.36/90</td>
<td>Ethics Lisinopril</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Dec-18 to 2021</td>
<td>$3.17/90</td>
<td>Ethics Lisinopril</td>
</tr>
</tbody>
</table>

**PERINDOPRIL**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2 mg – 1% DV Sep-17 to 2020</td>
<td>$3.75/30</td>
<td>Apo-Perindopril</td>
</tr>
<tr>
<td>Tab 4 mg – 1% DV Sep-17 to 2020</td>
<td>$4.80/30</td>
<td>Apo-Perindopril</td>
</tr>
</tbody>
</table>

**QUINAPRIL**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg – 1% DV Nov-18 to 2021</td>
<td>$6.01/90</td>
<td>Arrow-Quinapril 5</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Nov-18 to 2021</td>
<td>$3.16/90</td>
<td>Arrow-Quinapril 10</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Nov-18 to 2021</td>
<td>$4.89/90</td>
<td>Arrow-Quinapril 20</td>
</tr>
</tbody>
</table>

### ACE Inhibitors with Diuretics

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CILAZAPRIL WITH HYDROCHLOROTHIAZIDE</strong></td>
<td>Tab 5 mg with hydrochlorothiazide 12.5 mg</td>
<td>$10.18/100</td>
<td>Apo-Cilazapril/Hydrochlorothiazide</td>
</tr>
</tbody>
</table>

**QUINAPRIL WITH HYDROCHLOROTHIAZIDE**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg with hydrochlorothiazide 12.5 mg – 1% DV Dec-18 to 2021</td>
<td>$3.83/30</td>
<td>Accuretic 10</td>
</tr>
<tr>
<td>Tab 20 mg with hydrochlorothiazide 12.5 mg – 1% DV Dec-18 to 2021</td>
<td>$4.92/30</td>
<td>Accuretic 20</td>
</tr>
</tbody>
</table>
### Angiotensin II Antagonists

**CANDESARTAN CILEXETIL**

<table>
<thead>
<tr>
<th>Size</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 4 mg – 1% DV Sep-18 to 2021</td>
<td>1.90 90</td>
<td>Candestar</td>
</tr>
<tr>
<td>Tab 8 mg – 1% DV Sep-18 to 2021</td>
<td>2.28 90</td>
<td>Candestar</td>
</tr>
<tr>
<td>Tab 16 mg – 1% DV Sep-18 to 2021</td>
<td>3.67 90</td>
<td>Candestar</td>
</tr>
<tr>
<td>Tab 32 mg – 1% DV Sep-18 to 2021</td>
<td>6.39 90</td>
<td>Candestar</td>
</tr>
</tbody>
</table>

**LOSARTAN POTASSIUM**

<table>
<thead>
<tr>
<th>Size</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 12.5 mg – 1% DV Nov-17 to 2020</td>
<td>1.39 84</td>
<td>Losartan Actavis</td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Nov-17 to 2020</td>
<td>1.63 84</td>
<td>Losartan Actavis</td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Nov-17 to 2020</td>
<td>2.00 84</td>
<td>Losartan Actavis</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Nov-17 to 2020</td>
<td>2.31 84</td>
<td>Losartan Actavis</td>
</tr>
</tbody>
</table>

### Angiotensin II Antagonists with Diuretics

**LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE**

<table>
<thead>
<tr>
<th>Size</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg with hydrochlorothiazide 12.5 mg – 1% DV Jan-19 to 2021</td>
<td>1.88 30</td>
<td>Arrow-Losartan &amp; Hydrochlorothiazide</td>
</tr>
</tbody>
</table>

### Angiotensin II Antagonists with Neprilysin Inhibitors

**SACUBITRIL WITH VALSARTAN** – Restricted see terms below

- Tab 24.3 mg with valsartan 25.7 mg ................................................................. 190.00 56 | Entresto 24/26
- Tab 48.6 mg with valsartan 51.4 mg ................................................................. 190.00 56 | Entresto 49/51
- Tab 97.2 mg with valsartan 102.8 mg ................................................................. 190.00 56 | Entresto 97/103

**Restricted (RS1649)**

**Initiation**

*Re-assessment required after 12 months*

All of the following:

1. Patient has heart failure; and
2. Any of the following:
   1. Patient is in NYHA/WHO functional class II; or
   2. Patient is in NYHA/WHO functional class III; or
   3. Patient is in NYHA/WHO functional class IV; and
3. Patient has a documented left ventricular ejection fraction (LVEF) of less than or equal to 35%; and
4. Patient is receiving concomitant optimal standard chronic heart failure treatments.

**Continuation**

*Re-assessment required after 12 months*

The treatment remains appropriate and the patient is benefiting from treatment.

Note: Due to the angiotensin II receptor blocking activity of sacubitril with valsartan it should not be co-administered with an ACE inhibitor or another ARB.

### Alpha-Adrenoceptor Blockers

**DOXAZOSIN**

<table>
<thead>
<tr>
<th>Size</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 2 mg – 1% DV Sep-17 to 2020</td>
<td>6.75 500</td>
<td>Apo-Doxazosin</td>
</tr>
<tr>
<td>Tab 4 mg – 1% DV Sep-17 to 2020</td>
<td>9.09 500</td>
<td>Apo-Doxazosin</td>
</tr>
</tbody>
</table>

**PHENOXYBENZAMINE HYDROCHLORIDE**

<table>
<thead>
<tr>
<th>Size</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 10 mg</td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule</td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 2 ml ampoule</td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
# CARDIOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

## PHENTOLAMINE MESYLATED
- **Inj 5 mg per ml, 1 ml ampoule**
- **Inj 10 mg per ml, 1 ml ampoule**

## PRAZOSIN
- **Tab 1 mg**
- **Tab 2 mg**
- **Tab 5 mg**

## TERAZOSIN
- **Tab 1 mg**
- **Tab 2 mg**
- **Tab 5 mg**

### Antiarrhythmics

#### ADENOSINE
- **Inj 3 mg per ml, 2 ml vial**
  - 1% DV Feb-20 to 2022
  - 62.73 6 Adenocor
- **Inj 3 mg per ml, 10 ml vial**
  - Restricted (RS1266)
- **Inj 3 mg per ml, 10 ml vial**
  - Restricted (RS1266)

#### AJMALINE
- **Inj 5 mg per ml, 10 ml ampoule**
  - Restricted (RS1001)

#### AMIODARONE HYDROCHLORIDE
- **Tab 100 mg**
  - 1% DV Dec-19 to 2022
  - 3.80 30 Aratac
- **Tab 200 mg**
  - 1% DV Dec-19 to 2022
  - 4.66 30 Aratac
- **Inj 50 mg per ml, 3 ml ampoule**
  - 1% DV Feb-20 to 2022
  - 11.98 6 Cordarone-X
  - 9.98 5 Lodi
  - 16.37 10 Max Health

(Cordarone-X Tab 100 mg to be delisted 1 December 2019)
(Cordarone-X Tab 200 mg to be delisted 1 December 2019)
(Cordarone-X Inj 50 mg per ml, 3 ml ampoule to be delisted 1 February 2020)
(Lodi Inj 50 mg per ml, 3 ml ampoule to be delisted 1 February 2020)

#### ATROPINE SULPHATE
- **Inj 600 mcg per ml, 1 ml ampoule**
  - 1% DV Oct-18 to 2021
  - 12.07 10 Martindale

#### DIGOXIN
- **Tab 62.5 mcg**
  - 1% DV Nov-19 to 2022
  - 7.00 240 Lanoxin PG
- **Tab 250 mcg**
  - 1% DV Nov-19 to 2022
  - 15.20 240 Lanoxin
- **Oral liq 50 mcg per ml**
- **Inj 250 mcg per ml, 2 ml vial**

#### DISOPYRAMIDE PHOSPHATE
- **Cap 100 mg**

---

*Item restricted (see ➞ above); Item restricted (see ➞ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
FLECAINIDE ACETATE

Tab 50 mg – 1% DV Feb-20 to 2022 ................................................................. 19.95 60 Flecainide BNM Tambocor

38.95 30

Cap long-acting 100 mg – 1% DV Dec-19 to 2022 ............................................39.51 90 Flecainide Controlled Release Teva Tambocor CR

38.95 30

Flecainide BNM

Cap long-acting 200 mg – 1% DV Dec-19 to 2022 ............................................61.06 90 Flecainide Controlled Release Teva Tambocor CR

Flecainide Controlled Release Teva

Inj 10 mg per ml, 15 ml ampoule .......................................................................52.45 5 Tambocor

(Tambocor Tab 50 mg to be delisted 1 February 2020)

(Tambocor CR Cap long-acting 100 mg to be delisted 1 December 2019)

(Tambocor CR Cap long-acting 200 mg to be delisted 1 December 2019)

IVABRADINE – Restricted see terms below

Tab 5 mg

MEXILETINE HYDROCHLORIDE

Cap 150 mg ...................................................................................................162.00 100 Mexiletine Hydrochloride USP

Cap 250 mg ...................................................................................................202.00 100 Mexiletine Hydrochloride USP

PROPAFENONE HYDROCHLORIDE

Tab 150 mg

Antihypotensives

MIDODRINE – Restricted see terms below

Tab 2.5 mg

Tab 5 mg

MIDODRINE

BISOPROLOL FUMARATE

Tab 2.5 mg – 1% DV Dec-17 to 2020 ............................................................... 3.53 90 Bosvate

Tab 5 mg – 1% DV Dec-17 to 2020 ................................................................. 5.15 90 Bosvate

Tab 10 mg – 1% DV Dec-17 to 2020 ................................................................. 9.40 90 Bosvate

Beta-Adrenoceptor Blockers

ATENOLOL

Tab 50 mg – 1% DV Sep-18 to 2021 ................................................................. 4.26 500 Mylan Atenolol

Tab 100 mg – 1% DV Sep-18 to 2021 ............................................................... 7.30 500 Mylan Atenolol

Oral liq 5 mg per ml ............................................................... 21.25 300 ml Atenolol-AFT

BISOPROLOL FUMARATE

Tab 2.5 mg – 1% DV Dec-17 to 2020 ............................................................... 3.53 90 Bosvate

Tab 5 mg – 1% DV Dec-17 to 2020 ................................................................. 5.15 90 Bosvate

Tab 10 mg – 1% DV Dec-17 to 2020 ................................................................. 9.40 90 Bosvate

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARVEDILOL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 6.25 mg – 1% DV Dec-17 to 2020</td>
<td>2.24</td>
<td>60</td>
<td>Carvedilol Sandoz</td>
</tr>
<tr>
<td>Tab 12.5 mg – 1% DV Dec-17 to 2020</td>
<td>2.30</td>
<td>60</td>
<td>Carvedilol Sandoz</td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Dec-17 to 2020</td>
<td>2.95</td>
<td>60</td>
<td>Carvedilol Sandoz</td>
</tr>
<tr>
<td>CELIPROLOL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>21.40</td>
<td>180</td>
<td>Celol</td>
</tr>
<tr>
<td>ESMOLOL HYDROCHLORIDE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml vial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labetalol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td>11.36</td>
<td>100</td>
<td>Hybloc Presolol</td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td>29.74</td>
<td>100</td>
<td>Hybloc Presolol</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 20 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Hybloc Tab 100 mg to be delisted 1 December 2019)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Hybloc Tab 200 mg to be delisted 1 February 2020)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>METOPROLOL SUCCINATE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab long-acting 23.75 mg – 1% DV Mar-18 to 2020</td>
<td>1.03</td>
<td>30</td>
<td>Betaloc CR</td>
</tr>
<tr>
<td>Tab long-acting 47.5 mg – 1% DV Mar-18 to 2020</td>
<td>1.25</td>
<td>30</td>
<td>Betaloc CR</td>
</tr>
<tr>
<td>Tab long-acting 95 mg – 1% DV Mar-18 to 2020</td>
<td>1.99</td>
<td>30</td>
<td>Betaloc CR</td>
</tr>
<tr>
<td>Tab long-acting 190 mg – 1% DV Mar-18 to 2020</td>
<td>3.00</td>
<td>30</td>
<td>Betaloc CR</td>
</tr>
<tr>
<td>METOPROLOL TARTRATE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Oct-18 to 2021</td>
<td>5.66</td>
<td>100</td>
<td>Apo-Metoprolol</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Oct-18 to 2021</td>
<td>7.55</td>
<td>60</td>
<td>Apo-Metoprolol</td>
</tr>
<tr>
<td>Tab long-acting 200 mg</td>
<td>23.40</td>
<td>28</td>
<td>Slow-Lopresor</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 5 ml vial – 1% DV Feb-19 to 31 Jan 2022</td>
<td>29.50</td>
<td>5</td>
<td>Metroprolol IV Mylan</td>
</tr>
<tr>
<td>NADOLOL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 40 mg – 1% DV Oct-18 to 2021</td>
<td>16.69</td>
<td>100</td>
<td>Apo-Nadolol</td>
</tr>
<tr>
<td>Tab 80 mg – 1% DV Oct-18 to 2021</td>
<td>26.43</td>
<td>100</td>
<td>Apo-Nadolol</td>
</tr>
<tr>
<td>PINDOLOL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Oct-18 to 2021</td>
<td>13.22</td>
<td>100</td>
<td>Apo-Pindolol</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Oct-18 to 2021</td>
<td>23.12</td>
<td>100</td>
<td>Apo-Pindolol</td>
</tr>
<tr>
<td>Tab 15 mg – 1% DV Oct-18 to 2021</td>
<td>33.31</td>
<td>100</td>
<td>Apo-Pindolol</td>
</tr>
<tr>
<td>PROPRANOLOL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Oct-18 to 2021</td>
<td>4.64</td>
<td>100</td>
<td>Apo-Propranolol</td>
</tr>
<tr>
<td>Tab 40 mg – 1% DV Oct-18 to 2021</td>
<td>5.72</td>
<td>100</td>
<td>Apo-Propranolol</td>
</tr>
<tr>
<td>Cap long-acting 160 mg</td>
<td>18.17</td>
<td>100</td>
<td>Cardinol LA</td>
</tr>
<tr>
<td>Oral liq 4 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOTALOL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 80 mg – 1% DV Oct-19 to 2022</td>
<td>32.58</td>
<td>500</td>
<td>Mylan</td>
</tr>
<tr>
<td>Tab 160 mg – 1% DV Oct-19 to 2022</td>
<td>10.98</td>
<td>100</td>
<td>Mylan</td>
</tr>
<tr>
<td>TIMOLOL MALEATE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Calcium Channel Blockers

### Dihydropyridine Calcium Channel Blockers

#### AMLODIPINE
- Tab 2.5 mg – 1% DV Sep-17 to 2020 .................................................. 1.72 100 Apo-Amlodipine
- Tab 5 mg – 1% DV Sep-17 to 2020 .................................................. 3.33 250 Apo-Amlodipine
- Tab 10 mg – 1% DV Sep-17 to 2020 ............................................... 4.40 250 Apo-Amlodipine

#### FELODIPINE
- Tab long-acting 2.5 mg – 1% DV Sep-18 to 2021 ....................... 1.45 30 Plendil ER
- Tab long-acting 5 mg – 1% DV Dec-18 to 2021 ................. 3.93 90 Felo 5 ER
- Tab long-acting 10 mg – 1% DV Dec-18 to 2021 .............. 4.32 90 Felo 10 ER

#### ISRADIPINE
- Tab 2.5 mg
- Cap 2.5 mg

#### NICARDIPINE HYDROCHLORIDE – Restricted see terms below

- Inj 2.5 mg per ml, 10 ml vial
- Restricted (RS1699)

**Initiation**

Anaesthetist, intensivist, cardiologist or paediatric cardiologist

Any of the following:
- 1 Patient has hypertension requiring urgent treatment with an intravenous agent; or
- 2 Patient has excessive ventricular afterload; or
- 3 Patient is awaiting or undergoing cardiac surgery using cardiopulmonary bypass.

#### NIFEDIPINE
- Tab long-acting 10 mg – 1% DV Aug-17 to 2020 ....................... 10.63 60 Adalat 10
- Tab long-acting 20 mg................................................................. 9.59 100 Nyefax Retard
- Tab long-acting 30 mg................................................................. 3.14 30 Adalat Oros
- Tab long-acting 60 mg – 1% DV Dec-17 to 2020 .............. 5.67 30 Adalat Oros
- Cap 5 mg

#### NIMODIPINE
- Tab 30 mg
- Inj 200 mcg per ml, 50 ml vial

### Other Calcium Channel Blockers

#### DILTIAZEM HYDROCHLORIDE
- Tab 30 mg .................................................................................. 4.60 100 Dilzem
- Tab 60 mg .................................................................................. 8.50 100 Dilzem
- Cap long-acting 120 mg – 1% DV Oct-18 to 2021 ............... 33.42 500 Apo-Diltiazem CD
- Cap long-acting 180 mg – 1% DV Oct-18 to 2021 ............... 50.05 500 Apo-Diltiazem CD
- Cap long-acting 240 mg – 1% DV Oct-18 to 2021 ............... 66.76 500 Apo-Diltiazem CD
- Inj 5 mg per ml, 5 ml vial

#### PERHEXILINE MALEATE
- Tab 100 mg – 1% DV Oct-19 to 2022 ................................................. 62.90 100 Pexsig
CARDIOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

VERAPAMIL HYDROCHLORIDE

Tab 40 mg .......................................................... 7.01 100 Isoptin
Tab 80 mg .......................................................... 11.74 100 Isoptin
Tab long-acting 120 mg ........................................ 36.02 100 Isoptin SR
Tab long-acting 240 mg ........................................ 25.00 250 Verpamil SR
Inj 2.5 mg per ml, 2 ml ampoule .................................. 25.00 5 Isoptin

(Verpamil SR Tab long-acting 120 mg to be delisted 1 May 2020)

Centrally-Acting Agents

CLONIDINE

Patch 2.5 mg, 100 mcg per day – 1% DV Sep-17 to 2020 ......................... 7.40 4 Mylan
Patch 5 mg, 200 mcg per day – 1% DV Sep-17 to 2020 ......................... 10.04 4 Mylan
Patch 7.5 mg, 300 mcg per day – 1% DV Sep-17 to 2020 ......................... 12.34 4 Mylan

CLONIDINE HYDROCHLORIDE

Tab 25 mcg – 1% DV Oct-18 to 2021 ............................................ 8.75 112 Clonidine BNM
Tab 150 mcg ............................................................... 34.32 100 Catapres
Inj 150 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021 ................. 25.96 10 Medsurge

METHYLDOPA

Tab 250 mg ............................................................... 15.10 100 Methyldopa Mylan

Diuretics

Loop Diuretics

BUMETANIDE

Tab 1 mg ............................................................... 16.36 100 Burinex
Inj 500 mcg per ml, 4 ml vial

FUROSEMIDE [FRUSEMIDE]

Tab 40 mg – 1% DV Dec-19 to 2022 ............................................ 7.24 1,000 Apo-Furosemide
Tab 500 mg – 1% DV Mar-19 to 2021 ........................................... 8.00 Diurin 40
Oral liq 10 mg per ml – 1% DV Jan-20 to 2022 ............................... 25.00 50 Urex Forte
Inj 10 mg per ml, 2 ml ampoule – 1% DV Oct-19 to 2022 ................. 11.20 30 ml Lasix
Inj 10 mg per ml, 25 ml ampoule – 1% DV Jan-20 to 2022 ................. 60.65 6 Lasix

(Diurin 40 Tab 40 mg to be delisted 1 December 2019)

Osmotic Diuretics

MANNITOL

Inj 10%, 1,000 ml bag – 1% DV Jun-18 to 2021 ............................. 747.24 12 Baxter
Inj 20%, 500 ml bag – 1% DV Jun-18 to 2021 ............................. 1,096.92 18 Baxter

Potassium Sparing Combination Diuretics

AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE
Tab 5 mg with furosemide 40 mg

AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE
Tab 5 mg with hydrochlorothiazide 50 mg
# Potassium Sparing Diuretics

**AMILORIDE HYDROCHLORIDE**

- **Tab 5 mg**
  - Oral liq 1 mg per ml .......................................................... 30.00 25 ml Biomed

**EPLERENONE** – **Restricted** see terms below

- **Tab 25 mg** – 1% DV Sep-18 to 2021 .............................................. 11.87 30 Inspra
- **Tab 50 mg** – 1% DV Dec-18 to 2021 .............................................. 17.00 30 Inspra

- **Restrict**ed (RS1640)

**Initiation**

Both:

1. Patient has heart failure with ejection fraction less than 40%; and
2. Either:
   1. Patient is intolerant to optimal dosing of spironolactone; or
   2. Patient has experienced a clinically significant adverse effect while on optimal dosing of spironolactone.

**SPIRONOLACTONE**

- **Tab 25 mg** .................................................................................. 4.38 100 Spiractin
- **Tab 100 mg** ............................................................................... 11.80 100 Spiractin
- **Oral liq 5 mg per ml** – 1% DV Nov-19 to 2022 ................................ 30.60 25 ml Biomed

## Thiazide and Related Diuretics

**BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]**

- **Tab 2.5 mg** – 1% DV Mar-18 to 2020 ............................................... 12.50 500 Arrow-Bendrofluazide
- **Tab 5 mg** – 1% DV Mar-18 to 2020 ............................................... 20.42 500 Arrow-Bendrofluazide

**CHLOROTHIAZIDE**

- **Oral liq 50 mg per ml** .................................................................. 26.00 25 ml Biomed

**CHLORTALIDONE [CHLORTHALIDONE]**

- **Tab 25 mg** – 1% DV Dec-19 to 2022 .............................................. 6.50 50 Hygroton

**INDAPAMIDE**

- **Tab 2.5 mg** ................................................................................ 2.60 90 Dapa-Tabs

**METOLAZONE**

- **Tab 5 mg**

## Lipid-Modifying Agents

### Fibrates

**BEZAFIBRATE**

- **Tab 200 mg** – 1% DV Dec-18 to 2021 ........................................... 19.01 90 Bezalip
- **Tab long-acting 400 mg** – 1% DV Dec-18 to 2021 ..................... 12.89 30 Bezalip Retard

**GEMFIBROZIL**

- **Tab 600 mg** .................................................................................. 19.56 60 Lipazil

## HMG CoA Reductase Inhibitors (Statins)

**ATORVASTATIN**

- **Tab 10 mg** – 1% DV Sep-18 to 2021 ............................................... 6.96 500 Lorstat
- **Tab 20 mg** – 1% DV Sep-18 to 2021 ............................................... 9.99 500 Lorstat
- **Tab 40 mg** – 1% DV Sep-18 to 2021 ............................................... 15.93 500 Lorstat
- **Tab 80 mg** – 1% DV Sep-18 to 2021 ............................................... 27.19 500 Lorstat

*Products with Hospital Supply Status (HSS) are in bold*  
*Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.*
### CARDIOVASCULAR SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

**PRAVASTATIN**

<table>
<thead>
<tr>
<th>Item</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Mar-18 to 2020</td>
<td>4.72</td>
<td>Apo-Pravastatin</td>
</tr>
<tr>
<td>Tab 40 mg – 1% DV Mar-18 to 2020</td>
<td>8.06</td>
<td>Apo-Pravastatin</td>
</tr>
</tbody>
</table>

**SIMVASTATIN**

<table>
<thead>
<tr>
<th>Item</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Mar-18 to 2020</td>
<td>0.95</td>
<td>Simvastatin Mylan</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Mar-18 to 2020</td>
<td>1.52</td>
<td>Simvastatin Mylan</td>
</tr>
<tr>
<td>Tab 40 mg – 1% DV Mar-18 to 2020</td>
<td>2.63</td>
<td>Simvastatin Mylan</td>
</tr>
<tr>
<td>Tab 80 mg – 1% DV Mar-18 to 2020</td>
<td>6.00</td>
<td>Simvastatin Mylan</td>
</tr>
</tbody>
</table>

**Resins**

- **CHOLESTYRAMINE**
  - Powder for oral liq 4 g
- **COLESTIPOL HYDROCHLORIDE**
  - Grans for oral liq 5 g

**Selective Cholesterol Absorption Inhibitors**

**EZETIMIBE**

- **Restricted** see terms below
- Tab 10 mg – 1% DV Mar-18 to 2020
  - 2.00

**EZETIMIBE WITH SIMVASTATIN**

- **Restricted** see terms below
- Tab 10 mg with simvastatin 10 mg
  - 5.15
- Tab 10 mg with simvastatin 20 mg
  - 6.15
- Tab 10 mg with simvastatin 40 mg
  - 7.15
- Tab 10 mg with simvastatin 80 mg
  - 8.15

**Other Lipid-Modifying Agents**

- **ACIPIMOX**
  - Cap 250 mg
- **NICOTINIC ACID**
  - Tab 50 mg – 1% DV Oct-17 to 2020
    - 4.12
  - Tab 500 mg – 1% DV Oct-17 to 2020
    - 17.89

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
### Nitrates

**GLYCERYL TRINITRATE**
- **Inj 1 mg per ml, 5 ml ampoule**
- **Inj 1 mg per ml, 10 ml ampoule**
- **Inj 1 mg per ml, 50 ml vial**
- **Inj 5 mg per ml, 10 ml ampoule** ................................................................. 100.00  
- **Oral pump spray, 400 mcg per dose** ......................................................... 4.45  
- **Oral spray, 400 mcg per dose** ................................................................. 4.45  
- **Patch 25 mg, 5 mg per day** ..................................................................... 15.73  
- **Patch 50 mg, 10 mg per day** ..................................................................... 18.62  

*(Glyrin Oral spray, 400 mcg per dose to be delisted 1 May 2020)*

**ISOSORBIDE MONONITRATE**
- **Tab 20 mg – 1% DV Oct-17 to 2020** ......................................................... 18.80  
- **Tab long-acting 40 mg** ............................................................................. 7.50  
- **Tab long-acting 60 mg – 1% DV Sep-17 to 2020** ........................................ 8.29  

*(Glybin Oral spray, 400 mcg per dose to be delisted 1 May 2020)*

### Other Cardiac Agents

**LEVOSIMENDAN** – **Restricted** see terms below
- **Inj 2.5 mg per ml, 5 ml vial**
- **Inj 2.5 mg per ml, 10 ml vial**
- **Restricted (RS1007)**

**Initiation – Heart transplant**
Either:
1. For use as a bridge to heart transplant, in patients who have been accepted for transplant; or
2. For the treatment of heart failure following heart transplant.

**Initiation – Heart failure**
Cardiologist or intensivist
For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine.

### Sympathomimetics

**ADRENALINE**
- **Inj 1 in 1,000, 1 ml ampoule** ................................................................. 4.98  
- **Inj 1 in 1,000, 30 ml vial** ........................................................................ 5.25  
- **Inj 1 in 10,000, 10 ml ampoule** ............................................................... 49.00  
- **Inj 1 in 10,000, 10 ml syringe** ................................................................. 27.00  

**DOBUTAMINE**
- **Inj 12.5 mg per ml, 20 ml ampoule – 1% DV Jan-19 to 2021** .................... 61.13  

**DOPAMINE HYDROCHLORIDE**
- **Inj 40 mg per ml, 5 ml ampoule – 1% DV Sep-18 to 2021** ......................... 29.73  

**EPHEDRINE**
- **Inj 3 mg per ml, 10 ml syringe**
- **Inj 30 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020** ......................... 36.04  

**ISOPRENALENE [ISOPROTERENOL]**
- **Inj 200 mcg per ml, 1 ml ampoule**
- **Inj 200 mcg per ml, 5 ml ampoule**

---

Products with Hospital Supply Status (HSS) are in **bold**

Expriy date of HSS period is 30 June of the year indicated unless otherwise stated.
METARAMINOL
- Inj 0.5 mg per ml, 10 ml syringe
- Inj 0.5 mg per ml, 20 ml syringe
- Inj 0.5 mg per ml, 5 ml syringe
- Inj 1 mg per ml, 1 ml ampoule
- Inj 1 mg per ml, 10 ml syringe
- Inj 10 mg per ml, 1 ml ampoule

NORADRENALINE
- Inj 0.06 mg per ml, 100 ml bag
- Inj 0.06 mg per ml, 50 ml syringe
- Inj 0.1 mg per ml, 100 ml bag
- Inj 0.1 mg per ml, 50 ml syringe
- Inj 0.12 mg per ml, 100 ml bag
- Inj 0.12 mg per ml, 50 ml syringe
- Inj 0.16 mg per ml, 50 ml syringe
- Inj 1 mg per ml, 100 ml bag
- Inj 1 mg per ml, 4 ml ampoule – 1% DV Oct-19 to 2022 ......................... 45.00 10 Noradrenaline BNM

PHENYLEPHRINE HYDROCHLORIDE
- Inj 10 mg per ml, 1 ml ampoule ................................................................. 115.50 25 Neosynephrine HCL

Vasodilators

ALPROSTADIL HYDROCHLORIDE
- Inj 500 mcg per ml, 1 ml ampoule – 1% DV Dec-18 to 2021 ................. 1,765.50 5 Prostin VR

DIAZOXIDE
- Inj 15 mg per ml, 20 ml ampoule

HYDRALAZINE HYDROCHLORIDE
- Tab 25 mg
  - Restricted (RS1008)
Initiation
Either:
1. For the treatment of refractory hypertension; or
2. For the treatment of heart failure, in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.

- Inj 20 mg ampoule ....................................................................................... 25.90 5 Apresoline

MILRINONE
- Inj 1 mg per ml, 10 ml ampoule – 1% DV Sep-18 to 2021 ..................... 99.00 10 Primacor

MINOXIDIL
- Tab 10 mg ................................................................................................. 70.00 100 Loniten

NICORANDIL
- Tab 10 mg – 1% DV Dec-19 to 2022 .......................................................... 25.57 60 Ikorel
- Tab 20 mg – 1% DV Dec-19 to 2022 ......................................................... 32.28 60 Ikorel

PAPAVERINE HYDROCHLORIDE
- Inj 30 mg per ml, 1 ml vial
- Inj 12 mg per ml, 10 ml ampoule ............................................................ 217.90 5 Hospira

PENTOXIFYLLINE [OXPENTIFYLLINE]
- Tab 400 mg

SODIUM NITROPRUSSIDE
- Inj 50 mg vial
## Endothelin Receptor Antagonists

### AMBRISENTAN – Restricted see terms below

- **Tab 5 mg** ................................................................. $4,585.00 30 Volibris
- **Tab 10 mg** ................................................................. $4,585.00 30 Volibris

**Initiation**

Either:

1. For use in patients with a valid Special Authority approval for ambrisentan by the Pulmonary Arterial Hypertension Panel; or
2. In-hospital stabilisations in emergency situations.

### BOSENTAN – Restricted see terms below

- **Tab 62.5 mg** – 1% DV Dec-18 to 2021 ........................................................ $141.00 60 Bosentan Dr Reddy's
- **Tab 125 mg** – 1% DV Dec-18 to 2021 ......................................................... $141.00 60 Bosentan Dr Reddy's

**Initiation – Pulmonary arterial hypertension**

*Re-assessment required after 6 months*

Either:

1. All of the following:
   1.1 Patient has pulmonary arterial hypertension (PAH); and
   1.2 PAH is in Group 1, 4 or 5 of the WHO (Venice) clinical classifications; and
   1.3 PAH is at NYHA/WHO functional class II, III, or IV; and
   1.4 Any of the following:
      1.4.1 Both:
         1.4.1.1 Bosentan is to be used as PAH monotherapy; and
         1.4.1.2 Either:
            1.4.1.2.1 Patient is intolerant or contraindicated to sildenafil; or
            1.4.1.2.2 Patient is a child with idiopathic PAH or PAH secondary to congenital heart disease; or
      1.4.2 Both:
         1.4.2.1 Bosentan is to be used as PAH dual therapy; and
         1.4.2.2 Either:
            1.4.2.2.1 Patient has tried a PAH monotherapy for at least three months and failed to respond; or
            1.4.2.2.2 Patient deteriorated while on a PAH monotherapy; or
      1.4.3 Both:
         1.4.3.1 Bosentan is to be used as PAH triple therapy; and
         1.4.3.2 Any of the following:
            1.4.3.2.1 Patient is on the lung transplant list; or
            1.4.3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
            1.4.3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
            1.4.3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHS) who have no major morbidities and are deteriorating despite combination therapy; or

2. In-hospital stabilisation in emergency situations.

### Continuation – Pulmonary arterial hypertension

*Re-assessment required after 6 months*

Any of the following:

continued…
continued...

1 Both:
   1.1 Bosentan is to be used as PAH monotherapy; and
   1.2 Patient is stable or has improved while on bosentan; or

2 Both:
   2.1 Bosentan is to be used as PAH dual therapy; and
   2.2 Patient has tried a PAH monotherapy for at least three months and either failed to respond or later deteriorated; or

3 Both:
   3.1 Bosentan is to be used as PAH triple therapy; and
   3.2 Any of the following:
      3.2.1 Patient is on the lung transplant list; or
      3.2.2 Patient is presenting acutely with idiopathic pulmonary arterial hypertension (IPAH) in New York Heart Association/World Health Organization (NYHA/WHO) Functional Class IV; or
      3.2.3 Patient is deteriorating rapidly to NYHA/WHO Functional Class IV who may be lung transplant recipients in the future, if their disease is stabilised; or
      3.2.4 Patient has PAH associated with the scleroderma spectrum of diseases (APAHSSD) who have no major morbidities and are deteriorating despite combination therapy.

**Phosphodiesterase Type 5 Inhibitors**

**SILDENAFIL** – **Restricted** see terms below

- Tab 25 mg – 1% DV Sep-18 to 2021 ......................................................0.64 4 Vedafil
- Tab 50 mg – 1% DV Sep-18 to 2021 ......................................................0.64 4 Vedafil
- Tab 100 mg – 1% DV Sep-18 to 2021 .................................................6.60 12 Vedafil
- Inj 0.8 mg per ml, 12.5 ml vial

**Initiation – tablets Raynaud’s Phenomenon**

All of the following:

1 Patient has Raynaud’s phenomenon; and
2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
3 Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and
4 Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).

**Initiation – tablets Pulmonary arterial hypertension**

Any of the following:

1 All of the following:
   1.1 Patient has pulmonary arterial hypertension (PAH); and
   1.2 Any of the following:
      1.2.1 PAH is in Group 1 of the WHO (Venice) clinical classifications; or
      1.2.2 PAH is in Group 4 of the WHO (Venice) clinical classifications; or
      1.2.3 PAH is in Group 5 of the WHO (Venice) clinical classifications; and
   1.3 Any of the following:
      1.3.1 PAH is in NYHA/WHO functional class II; or
      1.3.2 PAH is in NYHA/WHO functional class III; or
      1.3.3 PAH is in NYHA/WHO functional class IV; and
   1.4 Either:

continued…
continued...

1.4.1 All of the following:
   1.4.1.1 Patient has a pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg; and
   1.4.1.2 Either:
      1.4.1.2.1 Patient has a mean pulmonary artery pressure (PAPm) > 25 mmHg; or
      1.4.1.2.2 Patient is peri Fontan repair; and
   1.4.1.3 Patient has a pulmonary vascular resistance (PVR) of at least 3 Wood Units or at least 240 International Units (dyn s cm⁻⁵); or

1.4.2 Testing for PCWP, PAPm, or PVR cannot be performed due to the patient’s young age; or

  2 For use in neonatal units for persistent pulmonary hypertension of the newborn (PPHN); or
  3 In-hospital stabilisation in emergency situations.

Initiation – tablets other conditions

Any of the following:

  1 For use in weaning patients from inhaled nitric oxide; or
  2 For perioperative use in cardiac surgery patients; or
  3 For use in intensive care as an alternative to nitric oxide; or
  4 For use in the treatment of erectile dysfunction secondary to spinal cord injury in patients being treated in a spinal unit.

Initiation – injection

Both:

  1 For use in the treatment of pulmonary hypertension in infants or children being treated in paediatric intensive care units and neonatal intensive care units when the enteral route is not accessible; and
  2 Any of the following:
     2.1 For perioperative use following cardiac surgery; or
     2.2 For use in persistent pulmonary hypertension of the newborn (PPHN); or
     2.3 For use in congenital diaphragmatic hernia.

### Prostacyclin Analogues

**EPOPROSTENOL** – **Restricted** see terms below

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 500 mcg vial</td>
<td>Veletri</td>
</tr>
<tr>
<td>Inj 1.5 mg vial</td>
<td>Veletri</td>
</tr>
</tbody>
</table>

**ILOPROST**

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 50 mcg in 0.5 ml ampoule – 1% DV Jan-20 to 2022</td>
<td>Clinect</td>
</tr>
<tr>
<td>Nebuliser soln 10 mcg per ml, 2 ml – 1% DV Jan-20 to 2022</td>
<td>Ventavis</td>
</tr>
</tbody>
</table>

**Ilomedin Inj 50 mcg in 0.5 ml ampoule to be delisted 1 January 2020**

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Anti-Infective Preparations

#### Antibacterials

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crystaderm</td>
<td>$8.56 15 g</td>
</tr>
<tr>
<td>Pharmacy Health</td>
<td>$1.40 100 ml</td>
</tr>
</tbody>
</table>

**HYDROGEN PEROXIDE**
- Crm 1%........................................ 8.56 15 g
- Soln 3% (10 vol)...................... 1.40 100 ml

(Pharmacy Health Soln 3% (10 vol) to be delisted 1 July 2020)

**MAFENIDE ACETATE** – **Restricted** see terms below
- Powder 50 g sachet
- Restricted (RS1299)

Initiation
For the treatment of burns patients.

**MUPIROCIN**
- Oint 2%

**SODIUM FUSIDATE [FUSIDIC ACID]**
- Crm 2% – 1% DV May-19 to 2021........ 1.59 5 g
- Oint 2% – 1% DV May-19 to 2021........ 1.59 5 g

**SULFADIAZINE SILVER**
- Crm 1% – 1% DV Aug-17 to 2020......... 10.80 50 g

#### Antifungals

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>MycoNail</td>
<td>$15.95 5 ml</td>
</tr>
<tr>
<td>Apo-Ciclopirox</td>
<td>$5.72 7 ml</td>
</tr>
<tr>
<td>Clomazol</td>
<td>$0.70 20 g</td>
</tr>
<tr>
<td>Sebizole</td>
<td>$2.99 100 ml</td>
</tr>
<tr>
<td>healthE Dimethicone</td>
<td>$4.98 200 ml</td>
</tr>
</tbody>
</table>

**AMOROLFINE**
- Nail soln 5% – 1% DV Sep-17 to 2020................. 15.95 5 ml

**CICLOPIROX OLAMINE**
- Nail soln 8% – 1% DV Sep-18 to 2021................. 5.72 7 ml
- Soln 1% – Restricted: For continuation only

**CLOTRIMAZOLE**
- Crm 1% – 1% DV Jan-18 to 2020................. 0.70 20 g
- Soln 1% – Restricted: For continuation only

**ECONAZOLE NITRATE**
- Crm 1% – Restricted: For continuation only
- Foaming soln 1%

**KETOCONAZOLE**
- Shampoo 2% – 1% DV Sep-17 to 2020................. 2.99 100 ml

**METRONIDAZOLE**
- Gel 0.75%

**MICONAZOLE NITRATE**
- Crm 2% – 1% DV Jan-18 to 2020................. 0.74 15 g
- Lotn 2% – Restricted: For continuation only
- Tinc 2%

**NYSTATIN**
- Crm 100,000 u per g

#### Antiparasitics

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>healthE Dimethicone 4% Lotion</td>
<td>$4.98 200 ml</td>
</tr>
</tbody>
</table>
### MALATHION [MALDISON]
- Shampoo 0.5%
  - Lotn 0.5%
- Permethrin
  - Crm 5% – 1% DV Dec-17 to 2020: $4.95 30 g Lyderm
  - Lotn 5% – 1% DV Oct-17 to 2020: $3.69 30 ml A-Scabies

### PHENOTHRIN
- Shampoo 0.5%

### Antiacne Preparations
#### ADAPALENE
- Crm 0.1%
- Gel 0.1%

#### BENZOYL PEROXIDE
- Soln 5%

### ISOTRETINOIN
- Cap 5 mg – 1% DV Oct-18 to 2021: $8.14 60 Oratane
- Cap 10 mg – 1% DV Oct-18 to 2021: $13.34 120 Oratane
- Cap 20 mg – 1% DV Oct-18 to 2021: $20.49 120 Oratane

### TRETINOIN
- Crm 0.05% – 1% DV Jun-18 to 2021: $13.90 50 g ReTrieve

### Antipruritic Preparations
#### CALAMINE
- Crm, aqueous, BP – 1% DV Nov-18 to 2021: $1.26 100 g healthE Calamine
  - Aqueous Cream BP
- Lotn, BP: $12.94 2,000 ml PSM
  (PSM Lotn, BP to be delisted 1 July 2020)

#### CROTAMITON
- Crm 10% – 1% DV Sep-18 to 2021: $3.29 20 g Itch-Soothe

### Barrier Creams and Emollients
#### Barrier Creams

### DIMETHICONE
- Crm 5% tube – 1% DV Oct-19 to 2022: $1.53 100 g healthE Dimethicone
- Crm 5% pump bottle: $4.48 500 ml healthE Dimethicone 5%
- Crm 10% pump bottle – 1% DV Sep-18 to 2021: $4.52 500 ml healthE Dimethicone 10%

#### ZINC
- Crm
- Oint
  - Paste
e.g. Zinc Cream (Orion-)
; Zinc Cream (PSM)
e.g. Zinc oxide (PSM)

### Notes
- Products with Hospital Supply Status (HSS) are in **bold**
- Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
ZINC AND CASTOR OIL

Crm ................................................................. 1.63 20 g Orion
Oint – 1% DV Jul-18 to 2020 ............................... 4.25 500 g Boucher
Oint, BP – 1% DV Nov-17 to 2020 ....................... 1.26 20 g healthE

Note: DV limit applies to the pack sizes of greater than 30 g.

Note: DV limit applies to the pack sizes of 30 g or less.

ZINC WITH WOOL FAT

Crm zinc 15.25% with wool fat 4% e.g. Sudocrem

Emollients

AQUEOUS CREAM

Crm 100 g – 1% DV Oct-18 to 2021 ........................ 1.05 100 g Pharmacy Health SLS-free
Crm 500 g – 1% DV Dec-18 to 2021 ....................... 1.92 500 g Boucher

Note: DV limit applies to the pack sizes of 100 g or less.

Note: DV limit applies to the pack sizes of greater than 100 g.

CETOMACROGOL

Crm BP, 500 g – 1% DV Sep-18 to 2021 .................. 2.48 500 g healthE
Crm BP, 100 g – 1% DV Sep-18 to 2021 .................. 1.42 1 healthE

CETOMACROGOL WITH GLYCEROL

Crm 90% with glycerol 10%, – 1% DV Dec-19 to 2022 1.65 100 g healthE
Crm 90% with glycerol 10% – 1% DV Mar-20 to 2022 3.35 1,000 ml Boucher
Note: DV limit applies to the pack sizes of 100 g or less.

Note: DV limit applies to the pack sizes of greater than 100 g.

(Pharmacy Health Sorbolene with Glycerin Crm 90% with glycerol 10% to be delisted 1 March 2020)

EMULSIFYING OINTMENT

Oint BP – 1% DV Oct-17 to 2020 .......................... 1.84 100 g Jaychem
Note: DV limit applies to pack sizes of less than 200 g.

Oint BP, 500 g – 1% DV Oct-17 to 2020 .................. 3.59 500 g AFT
Note: DV limit applies to pack sizes of greater than 200 g.

GLYCEROL WITH PARAFFIN

Crm glycerol 10% with white soft paraffin 5% and liquid paraffin 10% e.g. QV cream

OIL IN WATER EMULSION

Crm, 500 g – 1% DV Jan-19 to 2021 ....................... 2.19 500 g O/W Fatty Emulsion Cream
Note: DV limit applies to the pack sizes of greater than 100 g.

Crm, 100 g – 1% DV Dec-18 to 2021 ....................... 1.44 1 healthE Fatty Cream

PARAFFIN

Oint liquid paraffin 50% with white soft paraffin 50% – 1% DV Jan-19 to 2021 .......................... 1.97 100 g healthE
Note: DV limit applies to the pack sizes of 100 g or greater.

White soft – 1% DV Sep-18 to 2021 ....................... 0.79 10 g healthE
Note: DV limit applies to pack sizes of 30 g or less, and to both white soft paraffin and yellow soft paraffin.

White soft, – 1% DV Apr-20 to 2022 ....................... 4.99 450 g healthE
Yellow soft
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Manufacturer/Brand</th>
<th>Price</th>
<th>Expiry Date</th>
<th>Pack Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARAFFIN WITH WOOL FAT</td>
<td>e.g. AlphaKeri: BK; DP; Hydroderm Lotn</td>
<td>$1.37</td>
<td>50 g</td>
<td>healthE Urea Cream</td>
</tr>
<tr>
<td>UREA</td>
<td>e.g. Alpha Keri Bath Oil</td>
<td>$1.11</td>
<td>30 g</td>
<td>DermAssist</td>
</tr>
<tr>
<td>WOOL FAT</td>
<td></td>
<td>$1.11</td>
<td>30 g</td>
<td>AFT</td>
</tr>
<tr>
<td>CORTICOSTEROIDS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BETAMETHASONE DIPROPIONATE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 0.05%</td>
<td></td>
<td>$3.45</td>
<td>50 g</td>
<td>Beta Cream</td>
</tr>
<tr>
<td>Oint 0.05%</td>
<td></td>
<td>$3.45</td>
<td>50 g</td>
<td>Beta Ointment</td>
</tr>
<tr>
<td>BETAMETHASONE VALERATE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 0.1% – 1% DV Oct-18 to 2021</td>
<td></td>
<td>$3.45</td>
<td>50 g</td>
<td>Beta Cream</td>
</tr>
<tr>
<td>Oint 0.1% – 1% DV Oct-18 to 2021</td>
<td></td>
<td>$3.45</td>
<td>50 g</td>
<td>Beta Ointment</td>
</tr>
<tr>
<td>Lotn 0.1% – 1% DV Dec-18 to 2021</td>
<td></td>
<td>$18.00</td>
<td>50 ml</td>
<td>Betnovate</td>
</tr>
<tr>
<td>CLOBETASOL PROPIONATE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 0.05%</td>
<td></td>
<td>$2.18</td>
<td>30 g</td>
<td>Dermol</td>
</tr>
<tr>
<td>Oint 0.05%</td>
<td></td>
<td>$2.12</td>
<td>30 g</td>
<td>Dermol</td>
</tr>
<tr>
<td>CLOBETASONE BUTYRATE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 0.05%</td>
<td></td>
<td>$3.42</td>
<td>30 g</td>
<td>Advantan</td>
</tr>
<tr>
<td>DIFLUCORTOLONE VALERATE</td>
<td>Restricted: For continuation only</td>
<td>$1.11</td>
<td>30 g</td>
<td>DermAssist</td>
</tr>
<tr>
<td>➝ Crm 0.1%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>➝ Fatty oint 0.1%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYDROCORTISONE</td>
<td></td>
<td>$1.11</td>
<td>30 g</td>
<td>DermAssist</td>
</tr>
<tr>
<td>Crm 1%, 30 g</td>
<td></td>
<td>$16.25</td>
<td>500 g</td>
<td>Pharmacy Health</td>
</tr>
<tr>
<td>Note: DV limit applies to the pack sizes of less than or equal to 100 g.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crm 1%, 500 g</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYDROCORTISONE ACETATE</td>
<td></td>
<td>$2.48</td>
<td>14.2 g</td>
<td>AFT</td>
</tr>
<tr>
<td>Crm 1%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN</td>
<td></td>
<td>$10.57</td>
<td>250 ml</td>
<td>DP Lotn HC</td>
</tr>
<tr>
<td>Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% – 1% DV Sep-17 to 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYDROCORTISONE BUTYRATE</td>
<td></td>
<td>$3.42</td>
<td>30 g</td>
<td>Locoid Lipocream</td>
</tr>
<tr>
<td>Crm 0.1%</td>
<td></td>
<td>$6.85</td>
<td>100 g</td>
<td>Locoid Lipocream</td>
</tr>
<tr>
<td>Oint 0.1% – 1% DV Mar-19 to 2021</td>
<td></td>
<td>$13.70</td>
<td>100 g</td>
<td>Locoid</td>
</tr>
<tr>
<td>Milky emul 0.1% – 1% DV Mar-19 to 2021</td>
<td></td>
<td>$13.70</td>
<td>100 ml</td>
<td>Locoid Crelo</td>
</tr>
<tr>
<td>METHYLPREDNISOLONE ACPONATE</td>
<td></td>
<td>$4.95</td>
<td>15 g</td>
<td>Advantan</td>
</tr>
<tr>
<td>Crm 0.1%</td>
<td></td>
<td>$4.95</td>
<td>15 g</td>
<td>Advantan</td>
</tr>
<tr>
<td>MOMETASONE FURATE</td>
<td></td>
<td>$1.51</td>
<td>15 g</td>
<td>Elocon Alcohol Free</td>
</tr>
<tr>
<td>Crm 0.1% – 1% DV Nov-18 to 2021</td>
<td></td>
<td>$2.50</td>
<td>50 g</td>
<td>Elocon Alcohol Free</td>
</tr>
<tr>
<td>Oint 0.1% – 1% DV Nov-18 to 2021</td>
<td></td>
<td>$1.51</td>
<td>15 g</td>
<td>Elocon</td>
</tr>
<tr>
<td>Lotn 0.1% – 1% DV Nov-18 to 2021</td>
<td></td>
<td>$2.90</td>
<td>50 g</td>
<td>Elocon</td>
</tr>
<tr>
<td>Products with Hospital Supply Status (HSS) are in <strong>bold</strong></td>
<td></td>
<td>$6.30</td>
<td>30 ml</td>
<td>Elocon</td>
</tr>
<tr>
<td>Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
DERMATOLOGICALS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**TRIAMCINOLONE ACETONIDE**

- Crm 0.02% – 1% DV Sep-17 to 2020 ...................................................... 6.30 100 g Aristocort
- Oint 0.02% – 1% DV Sep-17 to 2020 ...................................................... 6.35 100 g Aristocort

**Corticosteroids with Anti-Infective Agents**

**BETAMETHASONE VALERATE WITH CLIOQUINOL** – Restricted see terms below

- Crm 0.1% with clioquinol 3%
- Restricted (RS1125)

**Initiation**

Either:
1. For the treatment of intertrigo; or
2. For continuation use.

**BETAMETHASONE VALERATE WITH SODIUM FUSIDATE [FUSIDIC ACID]**

- Crm 0.1% with sodium fusidate (fusidic acid) 2%

**HYDROCORTISONE WITH MICONAZOLE**

- Crm 1% with miconazole nitrate 2% – 1% DV Sep-18 to 2021 ................. 2.00 15 g Micreme H

**HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN**

- Crm 1% with natamycin 1% and neomycin sulphate 0.5% .............................. 3.35 15 g Pimafucort
- Oint 1% with natamycin 1% and neomycin sulphate 0.5% .............................. 3.35 15 g Pimafucort

**TRIAMCINOLONE ACETONIDE WITH NEOMYCIN SULPHATE, GRAMICIDIN AND NYSTATIN**

- Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g

**Psoriasis and Eczema Preparations**

**ACITRETIN**

- Cap 10 mg – 1% DV Sep-17 to 2020 ...................................................... 17.86 60 Novatretin
- Cap 25 mg – 1% DV Sep-17 to 2020 ...................................................... 41.36 60 Novatretin

**BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL**

- Gel 500 mcg with calcipotriol 50 mcg per g – 1% DV Dec-18 to 2021 .......... 52.24 60 g Daivobet
- Oint 500 mcg with calcipotriol 50 mcg per g – 1% DV Dec-18 to 2021 .......... 19.95 30 g Daivobet

**CALCIPOTRIOL**

- Oint 50 mcg per g – 1% DV Jul-17 to 2020 .................................................. 45.00 100 g Daivonex

**COAL TAR WITH SALICYLIC ACID AND SULPHUR**

- Oint 12% with salicylic acid 2% and sulphur 4%

**METHOXSALEN [8-METHOXYPSORALEN]**

- Tab 10 mg
- Lotn 1.2%

**PINE TAR WITH TROLAMINE LAURILSULFATE AND FLUORESCIN**

- Soln 2.3% with trolamine laurilsulfate and fluorescein sodium – 1% DV Oct-17 to 2020 .................................................. 3.86 500 ml Pinetarsol

**POTASSIUM PERMANGANATE**

- Tab 400 mg
- Crystals

**Scalp Preparations**

**BETAMETHASONE VALERATE**

- Scalp app 0.1% – 1% DV Oct-18 to 2021 ...................................................... 7.75 100 ml Beta Scalp
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLOBETASOL PROPIONATE</td>
<td>$5.69</td>
</tr>
<tr>
<td>HYDROCORTISONE BUTYRATE</td>
<td>$7.30</td>
</tr>
<tr>
<td>IMIQUIMOD</td>
<td>$21.72</td>
</tr>
<tr>
<td>PODOPHYLLOTOXIN</td>
<td>$33.60</td>
</tr>
<tr>
<td>SILVER NITRATE</td>
<td></td>
</tr>
<tr>
<td>Other Skin Preparations</td>
<td></td>
</tr>
<tr>
<td>DIPHEMANIL METILSULFATE</td>
<td></td>
</tr>
<tr>
<td>SUNSCREEN, PROPRIETARY</td>
<td></td>
</tr>
<tr>
<td>Antineoplastics</td>
<td></td>
</tr>
<tr>
<td>Wound Management Products</td>
<td></td>
</tr>
</tbody>
</table>

**Dermatologicals**

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLOBETASOL PROPIONATE</td>
<td>$5.69</td>
</tr>
<tr>
<td>HYDROCORTISONE BUTYRATE</td>
<td>$7.30</td>
</tr>
<tr>
<td>IMIQUIMOD</td>
<td>$21.72</td>
</tr>
<tr>
<td>PODOPHYLLOTOXIN</td>
<td>$33.60</td>
</tr>
<tr>
<td>SILVER NITRATE</td>
<td></td>
</tr>
<tr>
<td>Other Skin Preparations</td>
<td></td>
</tr>
<tr>
<td>DIPHEMANIL METILSULFATE</td>
<td></td>
</tr>
<tr>
<td>SUNSCREEN, PROPRIETARY</td>
<td></td>
</tr>
<tr>
<td>Antineoplastics</td>
<td></td>
</tr>
<tr>
<td>Wound Management Products</td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## GENITO-URINARY SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic</td>
<td>Manufacturer</td>
</tr>
</tbody>
</table>

### Anti-Infective Agents

<table>
<thead>
<tr>
<th>Agent</th>
<th>Formulation</th>
<th>Composition</th>
<th>Price</th>
<th>Quantity</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACETIC ACID</td>
<td>Soln 3%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Soln 5%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACETIC ACID WITH HYDROXYQUINOLINE, GLYCEROL AND RICINOLEIC ACID</td>
<td>Jelly 0.94% with hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHLORHEXIDINE GLUCONATE</td>
<td>Crm 1%</td>
<td></td>
<td>1.21</td>
<td>50 g</td>
<td>healthE</td>
</tr>
<tr>
<td></td>
<td>Lotn 1%, 200 ml</td>
<td></td>
<td>2.98</td>
<td>1</td>
<td>healthE</td>
</tr>
<tr>
<td>CLOTRIMAZOLE</td>
<td>Vaginal crm 1% with applicator – 1% DV Jan-20 to 2022</td>
<td></td>
<td>2.50</td>
<td>35 g</td>
<td>Clomazol</td>
</tr>
<tr>
<td></td>
<td>Vaginal crm 2% with applicator – 1% DV Jan-20 to 2022</td>
<td></td>
<td>3.00</td>
<td>20 g</td>
<td>Clomazol</td>
</tr>
<tr>
<td>MICONAZOLE NITRATE</td>
<td>Vaginal crm 2% with applicator – 1% DV Sep-17 to 2020</td>
<td></td>
<td>3.88</td>
<td>40 g</td>
<td>Micreme</td>
</tr>
<tr>
<td>NYSTATIN</td>
<td>Vaginal crm 100,000 u per 5 g with applicator(s) – 1% DV Aug-17 to 2020</td>
<td></td>
<td>4.45</td>
<td>75 g</td>
<td>Nilstat</td>
</tr>
</tbody>
</table>

### Contraceptives

#### Antiandrogen Oral Contraceptives

<table>
<thead>
<tr>
<th>Agent</th>
<th>Formulation</th>
<th>Composition</th>
<th>Price</th>
<th>Quantity</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYPROTERONE ACETATE WITH ETHINYL Estradiol</td>
<td>Tab 2 mg with ethinylestradiol 35 mcg and 7 inert tablets – 1% DV Sep-17 to 2020</td>
<td></td>
<td>4.67</td>
<td>168</td>
<td>Ginet</td>
</tr>
</tbody>
</table>

#### Combined Oral Contraceptives

<table>
<thead>
<tr>
<th>Agent</th>
<th>Formulation</th>
<th>Composition</th>
<th>Price</th>
<th>Quantity</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETHINYL Estradiol WITH DESOGESTREL</td>
<td>Tab 20 mcg with desogestrel 150 mcg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 30 mcg with desogestrel 150 mcg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETHINYL Estradiol WITH Levonorgestrel</td>
<td>Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets – 1% DV Jan-18 to 2020</td>
<td></td>
<td>2.18</td>
<td>84</td>
<td>Microgynon 20 ED</td>
</tr>
<tr>
<td></td>
<td>Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets – 1% DV Jan-18 to 2020</td>
<td></td>
<td>1.77</td>
<td>84</td>
<td>Levlen ED</td>
</tr>
<tr>
<td></td>
<td>Tab 20 mcg with levonorgestrel 100 mcg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 30 mcg with levonorgestrel 150 mcg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 50 mcg with levonorgestrel 125 mcg</td>
<td></td>
<td>9.45</td>
<td>84</td>
<td>Microgynon 50 ED</td>
</tr>
<tr>
<td>ETHINYL Estradiol WITH NORETHISTERONE</td>
<td>Tab 35 mcg with norethisterone 1 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 35 mcg with norethisterone 1 mg and 7 inert tab – 1% DV Mar-20 to 2022</td>
<td></td>
<td>6.95</td>
<td>84</td>
<td>Brevinor 1/28</td>
</tr>
<tr>
<td></td>
<td>Tab 35 mcg with norethisterone 500 mcg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NORETHISTERONE WITH MESTRANOL</td>
<td>Tab 1 mg with mestranol 50 mcg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Contraceptive Devices

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**INTRA-UTERINE DEVICE**
- IUD 29.1 mm length x 23.2 mm width – 1% DV Nov-19 to 2022 ................. 18.45 1 Choice TT380 Short
- IUD 33.6 mm length x 29.9 mm width – 1% DV Nov-19 to 2022 ................. 18.45 1 Choice TT380 Standard
- IUD 35.5 mm length x 19.6 mm width – 1% DV Nov-19 to 2022 ................. 15.50 1 Choice Load 375

**Emergency Contraception**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LEVONORGESTREL</strong></td>
<td>Tab 1.5 mg</td>
<td>4.95 1</td>
</tr>
</tbody>
</table>

**Progestogen-Only Contraceptives**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LEVONORGESTREL</strong></td>
<td>Tab 30 mcg</td>
<td></td>
</tr>
<tr>
<td>Subdermal implant (2 x 75 mg rods) – 1% DV Mar-18 to 2020</td>
<td>106.92 1</td>
<td>Jadelle</td>
</tr>
<tr>
<td>Intra-uterine device 52 mg – 1% DV Nov-19 to 31 Oct 2022</td>
<td>269.50 1</td>
<td>Mirena</td>
</tr>
<tr>
<td>Intra-uterine device 13.5 mg – 1% DV Nov-19 to 31 Oct 2022</td>
<td>215.60 1</td>
<td>Jadess</td>
</tr>
</tbody>
</table>

**MEDROXYPROGESTERONE ACETATE**
- Inj 150 mg per ml, 1 ml syringe – 1% DV Dec-19 to 2022 | 7.98 1 | Depo-Provera |

**NORETHISTERONE**
- Tab 350 mcg – 1% DV Sep-18 to 2021 | 6.25 84 | Noriday 28 |

### Obstetric Preparations

#### Antiprogesterons

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MIFEPRISTONE</strong></td>
<td>Tab 200 mg</td>
<td></td>
</tr>
</tbody>
</table>

#### Oxytocics

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CARBOPROST TROMETAMOL</strong></td>
<td>Inj 250 mcg per ml, 1 ml ampoule</td>
<td></td>
</tr>
<tr>
<td><strong>DINOPROSTONE</strong></td>
<td>Pessaries 10 mg</td>
<td></td>
</tr>
<tr>
<td>Vaginal gel 1 mg in 3 g</td>
<td>52.65 1</td>
<td>Prostin E2</td>
</tr>
<tr>
<td>Vaginal gel 2 mg in 3 g</td>
<td>64.60 1</td>
<td>Prostin E2</td>
</tr>
<tr>
<td><strong>ERGOMETRINE MALEATE</strong></td>
<td>Inj 500 mcg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020</td>
<td>105.00 5</td>
</tr>
<tr>
<td><strong>OXYTOCIN</strong></td>
<td>Inj 5 iu per ml, 1 ml ampoule – 1% DV Nov-18 to 2021</td>
<td>3.98 5</td>
</tr>
<tr>
<td>Inj 10 iu per ml, 1 ml ampoule – 1% DV Nov-18 to 2021</td>
<td>4.98 5</td>
<td>Oxytocin BNM</td>
</tr>
<tr>
<td><strong>OXYTOCIN WITH ERGOMETRINE MALEATE</strong></td>
<td>Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – 1% DV Oct-18 to 2021</td>
<td>15.00 5</td>
</tr>
</tbody>
</table>

#### Tocolytics

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PROGESTERONE</strong> – Restricted</td>
<td>Cap 100 mg</td>
<td>16.50 30</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
**GENITO-URINARY SYSTEM**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Restricted (RS1533)**

**Initiation**

Gynaecologist or obstetrician

*Re-assessment required after 12 months*

Both:

1. For the prevention of pre-term labour*; and
2. Either:
   2.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks); or
   2.2 The patient has a history of pre-term birth at less than 28 weeks.

**Continuation**

Gynaecologist or obstetrician

*Re-assessment required after 12 months*

All of the following:

1. For the prevention of pre-term labour*; and
2. Treatment is required for second or subsequent pregnancy; and
3. Either:
   3.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks); or
   3.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are unapproved indications.

**TERBUTALINE**

*Restricted* see terms below

<table>
<thead>
<tr>
<th>Inj 500 mcg ampoule</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Oestriol**

<table>
<thead>
<tr>
<th>Crm 1 mg per g with applicator – 1% DV Oct-17 to 2020</th>
<th>6.62</th>
<th>15 g</th>
<th>Ovestin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pessaries 500 mcg – 1% DV Oct-17 to 2020</td>
<td>6.86</td>
<td>15</td>
<td>Ovestin</td>
</tr>
</tbody>
</table>

**Urologicals**

**5-Alph Reductase Inhibitors**

**FINASTERIDE**

*Restricted* see terms below

<table>
<thead>
<tr>
<th>Tab 5 mg – 1% DV Dec-17 to 2020</th>
<th>4.81</th>
<th>100</th>
<th>Ricit</th>
</tr>
</thead>
</table>

**TAMSULOSIN HYDROCHLORIDE**

*Restricted* see terms below

<table>
<thead>
<tr>
<th>Cap 400 mcg – 1% DV Jan-20 to 2022</th>
<th>17.73</th>
<th>100</th>
<th>Tamsulosin-Rex</th>
</tr>
</thead>
</table>

**Alpha-1A Adrenoceptor Blockers**

<table>
<thead>
<tr>
<th>Cap 400 mcg – 1% DV Jan-20 to 2022</th>
<th>17.73</th>
<th>100</th>
<th>Tamsulosin-Rex</th>
</tr>
</thead>
</table>

---

*Item restricted (see [above]); Item restricted (see [below])

e.g. *Brand* indicates brand example only. It is not a contracted product.*
continued...

1. Patient has symptomatic benign prostatic hyperplasia; and
2. The patient is intolerant of non-selective alpha blockers or these are contraindicated.

### Urinary Alkalisers

**POTASSIUM CITRATE** – Restricted see terms below

- Oral liq 3 mmol per ml – 1% DV Oct-18 to 2021

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$31.80</td>
<td>Biomed</td>
</tr>
</tbody>
</table>

Initiation

Both:

1. The patient has recurrent calcium oxalate urolithiasis; and
2. The patient has had more than two renal calculi in the two years prior to the application.

**SODIUM CITRO-TARTRATE**

- Gran eff 4 g sachets – 1% DV Sep-17 to 2020

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2.34</td>
<td>Ural</td>
</tr>
</tbody>
</table>

### Urinary Antispasmodics

**OXYBUTYNIN**

- Tab 5 mg

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$8.85</td>
<td>Apo-Oxybutynin</td>
</tr>
</tbody>
</table>

- Oral liq 5 mg per 5 ml

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$60.40</td>
<td>Apo-Oxybutynin</td>
</tr>
</tbody>
</table>

**SOLIFENACIN SUCCINATE** – Some items restricted see terms below

- Tab 5 mg – 1% DV Dec-18 to 2021

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$3.00</td>
<td>Solifenacin Mylan</td>
</tr>
</tbody>
</table>

- Tab 10 mg – 1% DV Dec-18 to 2021

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$5.50</td>
<td>Solifenacin Mylan</td>
</tr>
</tbody>
</table>

Initiation

Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.

**TOLTERODINE TARTRATE** – Restricted see terms below

- Tab 1 mg

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$14.56</td>
<td>Arrow-Tolterodine</td>
</tr>
</tbody>
</table>

- Tab 2 mg

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$14.56</td>
<td>Arrow-Tolterodine</td>
</tr>
</tbody>
</table>

*Arrow-Tolterodine Tab 1 mg to be delisted 1 March 2020*

Initiation

Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.
Anabolic Agents

OXANDROLONE

Tab 2.5 mg

Restricted (RS1302)

Initiation

For the treatment of burns patients.

Androgen Agonists and Antagonists

CYPROTERONE ACETATE

Tab 50 mg – 1% DV Dec-18 to 2021

Tab 100 mg – 1% DV Dec-18 to 2021

Siterone

Siterone

TESTOSTERONE

Patch 5 mg per day

90.00

30

Androderm

TESTOSTERONE CIPIONATE

Inj 100 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020

76.50

1

Depo-Testosterone

TESTOSTERONE ESTERS

Inj testosterone decanoate 100 mg, testosterone isocaprate 60 mg, testosterone phenylpropionate 60 mg and testosterone propionate 30 mg per ml, 1 ml ampoule

TESTOSTERONE UNDECANOATE

Cap 40 mg – 1% DV Nov-18 to 2021

Inj 250 mg per ml, 4 ml vial

21.00

60

Andriol Testocaps

Reandron 1000

Calcium Homeostasis

CALCITONIN

Inj 100 iu per ml, 1 ml ampoule

121.00

5

Miacalcic

CINACALCET

Tab 30 mg – 1% DV Sep-18 to 2021

210.30

28

Sensipar

Restricted (RS1540)

Initiation

Nephrologist or endocrinologist

Re-assessment required after 6 months

Either:

1. All of the following:
   1.1 The patient has been diagnosed with a parathyroid carcinoma (see Note); and
   1.2 The patient has persistent hypercalcaemia (serum calcium greater than or equal to 3 mmol/L) despite previous first-line treatments including sodium thiosulfate (where appropriate) and bisphosphonates; and
   1.3 The patient is symptomatic; or

2. All of the following:
   2.1 The patient has been diagnosed with calciphylaxis (calcific uraemic arteriolopathy); and
   2.2 The patient has symptomatic (e.g. painful skin ulcers) hypercalcaemia (serum calcium greater than or equal to 3 mmol/L); and
   2.3 The patient's condition has not responded to previous first-line treatments including bisphosphonates and sodium thiosulfate.

continued…
Nephrologist or endocrinologist
Both:
1. The patient's serum calcium level has fallen to < 3mmol/L; and
2. The patient has experienced clinically significant symptom improvement.

Note: This does not include parathyroid adenomas unless these have become malignant.

ZOLEDRONIC ACID

† Inj 4 mg per 5 ml, vial – 1% DV May-19 to 2021 ................................................... 38.03 1

Zoledronic acid Mylan

Initiation – bone metastases
Oncologist, haematologist or palliative care specialist
Any of the following:
1. Patient has hypercalcaemia of malignancy; or
2. Both:
   2.1 Patient has bone metastases or involvement; and
   2.2 Patient has severe bone pain resistant to standard first-line treatments; or
3. Both:
   3.1 Patient has bone metastases or involvement; and
   3.2 Patient is at risk of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone).

Initiation – early breast cancer
Oncologist
All of the following:
1. Treatment to be used as adjuvant therapy for early breast cancer; and
2. Patient has been amenorrhoeic for 12 months or greater, either naturally or induced, with endocrine levels consistent with a postmenopausal state; and
3. Treatment to be administered at a minimum interval of 6-monthly for a maximum of 2 years.

Corticosteroids

BETAMETHASONE
Tab 500 mcg
Inj 4 mg per ml, 1 ml ampoule

BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE
Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ampoule

DEXAMETHASONE
Tab 0.5 mg – 1% DV Oct-18 to 2021 ................................................................. 0.99 30
Tab 4 mg – 1% DV Oct-18 to 2021 ............................................................... 1.90 30
Oral liq 1 mg per ml ....................................................................................... 45.00 25 ml

DEXAMETHASONE PHOSPHATE
Inj 4 mg per ml, 1 ml ampoule ................................................................. 14.19 10 Max Health
Inj 4 mg per ml, 2 ml ampoule .............................................................. 25.18 10 Max Health

FLUDROCORTISONE ACETATE
Tab 100 mcg .......................................................................................... 14.32 100 Florinef

HYDROCORTISONE
Tab 5 mg – 1% DV Sep-18 to 2021 ......................................................... 8.10 100 Douglas
Tab 20 mg – 1% DV Sep-18 to 2021 ....................................................... 20.32 100 Douglas
Inj 100 mg vial ................................................................................. 5.30 1 Solu-Cortef

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### HORMONE PREPARATIONS

<table>
<thead>
<tr>
<th></th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

#### METHYPREDNISOLONE (AS SODIUM SUCCINATE)

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 4 mg – 1% DV Dec-18 to 2021</td>
<td>112.00</td>
<td>Medrol</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Dec-18 to 2021</td>
<td>194.00</td>
<td>Medrol</td>
</tr>
<tr>
<td>Inj 40 mg vial – 1% DV Dec-18 to 2021</td>
<td>18.90</td>
<td>Solu-Medrol Act-O-Vial</td>
</tr>
<tr>
<td>Inj 125 mg vial – 1% DV Dec-18 to 2021</td>
<td>28.90</td>
<td>Solu-Medrol Act-O-Vial</td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Dec-18 to 2021</td>
<td>22.78</td>
<td>Solu-Medrol Act-O-Vial</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Dec-18 to 2021</td>
<td>27.83</td>
<td>Solu-Medrol</td>
</tr>
</tbody>
</table>

#### METHYPREDNISOLONE ACETATE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 40 mg per ml, 1 ml vial – 1% DV Dec-18 to 2021</td>
<td>44.40</td>
<td>Depo-Medrol</td>
</tr>
</tbody>
</table>

#### PREDNISOLONE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 5 mg per ml – 1% DV Jun-18 to 2021</td>
<td>6.00</td>
<td>Redipred</td>
</tr>
<tr>
<td>Enema 200 mcg per ml, 100 ml</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### PREDNISONE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg – 1% DV Jun-17 to 2020</td>
<td>10.68</td>
<td>Apo-Prednisone</td>
</tr>
<tr>
<td>Tab 2.5 mg – 1% DV Jun-17 to 2020</td>
<td>12.09</td>
<td>Apo-Prednisone</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Jun-17 to 2020</td>
<td>11.09</td>
<td>Apo-Prednisone</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Jun-17 to 2020</td>
<td>29.03</td>
<td>Apo-Prednisone</td>
</tr>
</tbody>
</table>

#### TRIAMCINOLONE ACETONIDE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>20.80</td>
<td>Kenacort-A 10</td>
</tr>
<tr>
<td>Inj 40 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>51.10</td>
<td>Kenacort-A 40</td>
</tr>
</tbody>
</table>

#### TRIAMCINOLONE HEXACETONIDE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 20 mg per ml, 1 ml vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Hormone Replacement Therapy

#### Oestrogens

#### OESTRADIOL

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patch 25 mcg per day</td>
<td>6.12</td>
<td>Estradot</td>
</tr>
<tr>
<td>Patch 50 mcg per day</td>
<td>7.04</td>
<td>Estradot</td>
</tr>
<tr>
<td>Patch 75 mcg per day</td>
<td>7.91</td>
<td>Estradot</td>
</tr>
<tr>
<td>Patch 100 mcg per day</td>
<td>7.91</td>
<td>Estradot</td>
</tr>
</tbody>
</table>

#### OESTRADIOL VALERATE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg – 1% DV Sep-18 to 2021</td>
<td>12.36</td>
<td>Progynova</td>
</tr>
<tr>
<td>Tab 2 mg – 1% DV Sep-18 to 2021</td>
<td>12.36</td>
<td>Progynova</td>
</tr>
</tbody>
</table>

#### OESTROGENS (CONJUGATED EQUINE)

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 300 mcg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 625 mcg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Progestogen and Oestrogen Combined Preparations

#### OESTRADIOL WITH NORETHISTERONE ACETATE

<table>
<thead>
<tr>
<th>Item Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 1 mg with 0.5 mg norethisterone acetate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg with 1 mg norethisterone acetate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 2 mg with 1 mg norethisterone acetate (10), and tab 2 mg oestradiol (12) and tab 1 mg oestradiol (6)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
OESTROGENS WITH MEDROXYPROGESTERONE ACETATE
Tab 625 mcg conjugated equine with 2.5 mg medroxyprogesterone acetate
Tab 625 mcg conjugated equine with 5 mg medroxyprogesterone acetate

Progestogens

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Quantity</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEDROXYPROGESTERONE ACETATE</td>
<td>$3.75</td>
<td>30</td>
<td>Provera</td>
</tr>
<tr>
<td>Tab 2.5 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg</td>
<td>$14.00</td>
<td>100</td>
<td>Provera</td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td>$7.15</td>
<td>30</td>
<td>Provera</td>
</tr>
</tbody>
</table>

Other Endocrine Agents

CABERGOLINE – Restricted see terms below
- Tab 0.5 mg – 1% DV Sep-18 to 2021
  - $3.75 | 2 | Dostinex |
  - $15.20 | 8 | Dostinex |

Restricted (RS1319)
Initiation
Any of the following:
- 1 Inhibition of lactation; or
- 2 Patient has pathological hyperprolactinemia; or
- 3 Patient has acromegaly.

CLOMIFENE CITRATE
Tab 50 mg

DANAZOL
Cap 100 mg | $68.33 | 100 | Azol |
Cap 200 mg | $97.83 | 100 | Azol |

GESTRINONE
Cap 2.5 mg

METYRAPONE
Cap 250 mg

PENTAGASTRIN
Inj 250 mcg per ml, 2 ml ampoule

Other Oestrogen Preparations

ETHINYLESTRADIOL
Tab 10 mcg – 1% DV Sep-18 to 2021 | $17.60 | 100 | NZ Medical and Scientific |

OESTRADIOL
Implant 50 mg

OESTRIOL
Tab 2 mg

Other Progestogen Preparations

MEDROXYPROGESTERONE
Tab 100 mg

NORETHISTERONE
Tab 5 mg – 1% DV Dec-19 to 2021

Products with Hospital Supply Status (HSS) are in bold.
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
**Pituitary and Hypothalamic Hormones and Analogues**

**CORTICOTRORELIN (OVINE)**
- Inj 100 mcg vial

**THYROTROPIN ALFA**
- Inj 900 mcg vial

**Adrenocorticotropic Hormones**

**TETRACOSACTIDE [TETRACOSACTRIN]**
- Inj 250 mcg per ml, 1 ml ampoule $75.00 1 Synacthen
- Inj 1 mg per ml, 1 ml ampoule $690.00 1 Synacthen Depot

**GnRH Agonists and Antagonists**

**BUSERELIN**
- Inj 1 mg per ml, 5.5 ml vial

**GONADORELIN**
- Inj 100 mcg vial

**GOSERELIN**
- Implant 3.6 mg, syringe $66.48 1 Zoladex
- Implant 10.8 mg, syringe $177.50 1 Zoladex

**LEUPRORELIN ACETATE**
- Inj 3.75 mg prefilled dual chamber syringe $221.60 1 Lucrin Depot 1-month
- Inj 11.25 mg prefilled dual chamber syringe $591.68 1 Lucrin Depot 3-month

**Gonadotrophins**

**CHORIOGONADOTROPIN ALFA**
- Inj 250 mcg in 0.5 ml syringe

**Growth Hormone**

**SOMATROPIN – Restricted** see terms below

- Inj 5 mg cartridge – 1% DV Oct-18 to 2021 $34.88 1 Omnitrope
- Inj 10 mg cartridge – 1% DV Oct-18 to 2021 $69.75 1 Omnitrope
- Inj 15 mg cartridge – 1% DV Oct-18 to 2021 $104.63 1 Omnitrope

Initiation – growth hormone deficiency in children
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months
Either:

1. Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or

2. All of the following:
   2.1 Height velocity < 25th percentile for age; and adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and

continued…
continued...

2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and

2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and

2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and

2.5 Appropriate imaging of the pituitary gland has been obtained.

Continuation – growth hormone deficiency in children
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months

All of the following:

1 A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and

2 Height velocity is greater than or equal to 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and

3 Height velocity is greater than or equal to 2.0 cm per year, as calculated over 6 months; and

4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and

5 No malignancy has developed since starting growth hormone.

Initiation – Turner syndrome
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months

All of the following:

1 The patient has a post-natal genotype confirming Turner Syndrome; and

2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and

3 A current bone age is < 14 years.

Continuation – Turner syndrome
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months

All of the following:

1 Height velocity greater than or equal to 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke’s Turner Syndrome growth velocity charts); and

2 Height velocity is greater than or equal to 2 cm per year, calculated over six months; and

3 A current bone age is 14 years or under; and

4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and

5 No malignancy has developed since starting growth hormone.

Initiation – short stature without growth hormone deficiency
Endocrinologist or paediatric endocrinologist
Re-assessment required after 12 months

All of the following:

1 The patient’s height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and

2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and

3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and

4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

continued…

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
Continuation – short stature without growth hormone deficiency

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

1. Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2. Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
3. Current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4. No serious adverse effect that the patient’s specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initiation – short stature due to chronic renal insufficiency

Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of an endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

1. The patient's height is more than 2 standard deviations below the mean; and
2. Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
3. A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4. The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
5. The patient is under the supervision of a specialist with expertise in renal medicine; and
6. Either:
   6.1 The patient has a GFR less than or equal to 30 ml/min/1.73 m\(^2\) as measured by the Schwartz method:
       \[
       \text{GFR (ml/min/1.73 m}^2\) = \frac{\text{Height (cm)/plasma creatinine (umol/l} \times 40)}{\text{corrected GFR (ml/min/1.73 m}^2\)}
       \]
       in a child who may or may not be receiving dialysis; or
   6.2 The patient has received a renal transplant and has received < 5mg/ m\(^2\)/day of prednisone or equivalent for at least 6 months.

Continuation – short stature due to chronic renal insufficiency

Endocrinologist, paediatric endocrinologist or renal physician on the recommendation of an endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

1. Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2. Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
3. A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4. No serious adverse effect that the patient’s specialist considers is likely to be attributable to growth hormone has occurred; and
5. No malignancy has developed after growth hormone therapy was commenced; and
6. The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
7. The patient has not received renal transplantation since starting growth hormone treatment; and
8. If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Initiation – Prader-Willi syndrome

Endocrinologist or paediatric endocrinologist

Re-assessment required after 12 months

All of the following:

continued...
continued...

1. The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
2. The patient is aged six months or older; and
3. A current bone age is < 14 years (female patients) or < 16 years (male patients); and
4. Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
5. Either:
   5.1 Both:
      5.1.1 The patient is aged two years or older; and
      5.1.2 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months; or
   5.2 The patient is aged between six months and two years and a thorough upper airway assessment is planned to be undertaken prior to treatment commencement and at six to 12 weeks following treatment initiation.

**Continuation – Prader-Willi syndrome**

Endocrinologist or paediatric endocrinologist  
*Re-assessment required after 12 months*

All of the following:

1. Height velocity is greater than or equal to 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
2. Height velocity is greater than or equal to 2 cm per year as calculated over six months; and
3. A current bone age is 14 years or under (female patients) or 16 years or under (male patients); and
4. No serious adverse effect that the patient’s specialist considers is likely to be attributable to growth hormone treatment has occurred; and
5. No malignancy has developed after growth hormone therapy was commenced; and
6. The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by greater than or equal to 0.5 standard deviations in the preceding 12 months.

**Initiation – adults and adolescents**

Endocrinologist or paediatric endocrinologist  
*Re-assessment required after 12 months*

All of the following:

1. The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
2. The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
3. The patient has severe growth hormone deficiency (see notes); and
4. The patient’s serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
5. The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA®).

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of less than or equal to 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of less than or equal to 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until it is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

continued…
continued…

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

**Continuation – adults and adolescents**

Endocrinologist or paediatric endocrinologist

**Re-assessment required after 12 months**

Either:

1. All of the following:
   1.1 The patient has been treated with somatropin for < 12 months; and
   1.2 There has been an improvement in the Quality of Life Assessment defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA®) score from baseline; and
   1.3 Serum IGF-I levels have increased to within ±1SD of the mean of the normal range for age and sex; and
   1.4 The dose of somatropin does not exceed 0.7 mg per day for male patients, or 1 mg per day for female patients; or

2. All of the following:
   2.1 The patient has been treated with somatropin for more than 12 months; and
   2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA® score on treatment (other than due to obvious external factors such as external stressors); and
   2.3 Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex (other than for obvious external factors); and
   2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

### Thyroid and Antithyroid Preparations

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulation</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbimazole</td>
<td>Tab 5 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iodine</td>
<td>Soln BP 50 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levothyroxine</td>
<td>Tab 25 mcg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 50 mcg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tab 100 mcg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liothyronine Sodium</td>
<td>Tab 20 mcg</td>
<td><strong>Restricted (RS1301)</strong></td>
<td></td>
</tr>
<tr>
<td>Initiation</td>
<td>For a maximum of 14 days' treatment in patients with thyroid cancer who are due to receive radioiodine therapy.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 20 mcg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Potassium Iodate</td>
<td>Tab 170 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Potassium perchlorate</td>
<td>Cap 200 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Propylthiouracil</td>
<td>Tab 50 mg</td>
<td><strong>Restricted (RS1276)</strong></td>
<td></td>
</tr>
<tr>
<td>Initiation</td>
<td>Both: 1. The patient has hyperthyroidism; and 2. The patient is intolerant of carbimazole or carbimazole is contraindicated.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Note: Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
HORMONE PREPARATIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td>Per</td>
</tr>
</tbody>
</table>

**Protirelin**

Inj 100 mcg per ml, 2 ml ampoule

**Vasopressin Agents**

**Argipressin [Vasopressin]**

Inj 20 u per ml, 1 ml ampoule

**Desmopressin Acetate** – Some items restricted see terms below

- Tab 100 mcg..............................................................25.00 30 Minirin
- Tab 200 mcg..............................................................54.45 30 Minirin
- Nasal spray 10 mcg per dose – 1% DV Oct-17 to 2020...........................................23.95 6 ml Desmopressin-PH&T
- Inj 4 mcg per ml, 1 ml ampoule
- Inj 15 mcg per ml, 1 ml ampoule
- Nasal drops 100 mcg per ml

-> Restricted (RS1339)

Initiation – Nocturnal enuresis

Either:

1. The nasal forms of desmopressin are contraindicated; or
2. An enuresis alarm is contraindicated.

Note: Cranial diabetes insipidus and the nasal forms of desmopressin are contraindicated.

**Terlipressin**

Inj 0.1 mg per ml, 8.5 ml ampoule .........................................................450.00 5 Glypressin
Inj 1 mg per 8.5 ml ampoule .................................................................215.00 5 Glypressin
## INFECTIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic</td>
<td></td>
</tr>
</tbody>
</table>

### Antibacterials

#### Aminoglycosides

**AMIKACIN – Restricted** see terms below
- **Inj 5 mg per ml, 10 ml syringe**
- **Inj 5 mg per ml, 5 ml syringe**
- **Inj 15 mg per ml, 5 ml syringe**
- **Inj 250 mg per ml, 2 ml vial – 1% DV Aug-18 to 2021**
  - **18.50 1 Biomed**
  - **265.00 5 DBL Amikacin**

**GENTAMICIN SULPHATE**
- **Inj 10 mg per ml, 1 ml ampoule**
- **Inj 40 mg per ml, 2 ml ampoule**

**PAROMOMYCIN – Restricted** see terms below
- **Cap 250 mg**

**STREPTOMYCIN SULPHATE – Restricted** see terms below
- **Inj 400 mg per ml, 2.5 ml ampoule**

**TOBRAMYCIN**
- **Powder**

**Carbapenems**

**ERTAPENEM – Restricted** see terms below
- **Inj 1 g vial – 1% DV Aug-19 to 2022**

**IMIPENEM WITH CILASTATIN – Restricted** see terms below
- **Inj 500 mg with 500 mg cilastatin vial – 1% DV Jul-19 to 2022**

---

*Item restricted (see above); Item restricted (see below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Expiry Date</th>
<th>Price (excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
</table>
| **MEROPENEM** – Restricted see terms below
| Inj 500 mg vial – 1% DV Oct-18 to 2020 | | 4.00 | 1 Meropenem Ranbaxy |
| Inj 1 g vial – 1% DV Oct-18 to 2020 | | 8.00 | 1 Meropenem Ranbaxy |
| **Cephalosporins and Cephamycins - 1st Generation**
| **CEFALEXIN**
| Cap 250 mg – 1% DV Nov-19 to 2022 | | 3.33 | 20 Cephalexin ABM |
| Cap 500 mg | | 3.95 | 20 Cephalexin ABM |
| Grans for oral liq 25 mg per ml – 1% DV Oct-18 to 2021 | 8.75 | 100 ml Cefalexin Sandoz |
| Grans for oral liq 50 mg per ml – 1% DV Oct-18 to 2021 | 11.75 | 100 ml Cefalexin Sandoz |
| **CEFAZOLIN**
| Inj 500 mg vial – 1% DV Sep-17 to 2020 | 3.39 | 5 AFT |
| Inj 1 g vial – 1% DV Sep-17 to 2020 | 3.29 | 5 AFT |
| **Cephalosporins and Cephamycins - 2nd Generation**
| **CEFACLOR**
| Cap 250 mg – 1% DV Oct-19 to 2022 | 24.70 | 100 Ranbaxy-Cefaclor |
| Grans for oral liq 25 mg per ml – 1% DV Oct-19 to 2022 | 3.53 | 100 ml Ranbaxy-Cefaclor |
| **CEFOXITIN**
| Inj 1 g vial | 58.00 | 10 Cefoxitin Actavis |
| **CEFUROXIME**
| Tab 250 mg – 1% DV Feb-20 to 2022 | 45.93 | 50 Zinnat |
| Inj 750 mg vial – 1% DV Feb-18 to 2020 | 9.85 | 10 Cefuroxime Actavis |
| Inj 1.5 g vial – 1% DV Feb-18 to 2020 | 14.36 | 10 Cefuroxime Actavis |
| **Cephalosporins and Cephamycins - 3rd Generation**
| **CEFOTAXIME**
| Inj 500 mg vial | | 1.90 | 1 Cefotaxime Sandoz |
| Inj 1 g vial – 1% DV Sep-17 to 2020 | | 14.60 | 10 DBL Cefotaxime |
| **CEFTAZIDIME** – Restricted see terms below
| Inj 1 g vial | 34.00 | 5 Ceftazidime Mylan |
| **CEFTAZIDIME** (RS1048)
| Clinical microbiologist, infectious disease specialist or respiratory specialist |
| **CEFTRIAXONE**
| Inj 500 mg vial – 1% DV Jan-20 to 2022 | | 0.89 | 1 Ceftriaxone-AFT |
| Inj 1 g vial – 1% DV Jan-20 to 2022 | | 1.20 | DEVA |
| Inj 2 g vial – 1% DV Jan-20 to 2022 | | 0.84 | 1 Ceftriaxone-AFT |
| (DEVA Inj 500 mg vial to be delisted 1 January 2020) |
| (DEVA Inj 1 g vial to be delisted 1 January 2020) |
| **Cephalosporins and Cephamycins - 4th Generation**
| **CEFEPIME** – Restricted see terms on the next page
| Inj 1 g vial – 1% DV Sep-18 to 2021 | 3.75 | 1 Cefepime-AFT |
| Inj 2 g vial – 1% DV Sep-18 to 2021 | 5.69 | 1 Cefepime-AFT |

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
INFECTIONS

<table>
<thead>
<tr>
<th>-item restricted (RS1049)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical microbiologist or infectious disease specialist</td>
</tr>
</tbody>
</table>

#### Cephalosporins and Cephamycins - 5th Generation

**CEFTAROLINE FOSAMIL** — Restricted see terms below

- **Inj 600 mg vial** ........................................................... 1,450.00 10 Zinforo

**Restricted (RS1446)**

Initiation — multi-resistant organism salvage therapy

Clinical microbiologist or infectious disease specialist

Either:

1. for patients where alternative therapies have failed; or
2. for patients who have a contraindication or hypersensitivity to standard current therapies.

#### Macrolides

**AZITHROMYCIN** — Restricted see terms below

- **Tab 250 mg — 1% DV Sep-18 to 2021** ........................................................... 8.19 30 Apo-Azithromycin
- **Tab 500 mg — 1% DV Sep-18 to 2021** ........................................................... 0.93 2 Apo-Azithromycin
- **Grans for oral liq 200 mg per 5 ml (40 mg per ml) — 1% DV Dec-18** to 2021 ........................................................... 14.38 15 ml Zithromax

**Restricted (RS1598)**

Initiation — bronchiolitis obliterans syndrome, cystic fibrosis and atypical Mycobacterium infections

Any of the following:

1. Patient has received a lung transplant, stem cell transplant or bone marrow transplant and requires treatment for bronchiolitis obliterans syndrome*; or
2. Patient has received a lung transplant and requires prophylaxis for bronchiolitis obliterans syndrome*; or
3. Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas related gram negative organisms*; or
4. Patient has an atypical Mycobacterium infection.

Note: Indications marked with * are unapproved indications

**Initiation — non-cystic fibrosis bronchiectasis**

Respiratory specialist or paediatrician

Re-assessment required after 12 months

All of the following:

1. For prophylaxis of exacerbations of non-cystic fibrosis bronchiectasis*; and
2. Patient is aged 18 and under; and
3. Either:
   - 3.1 Patient has had 3 or more exacerbations of their bronchiectasis, within a 12 month period; or
   - 3.2 Patient has had 3 acute admissions to hospital for treatment of infective respiratory exacerbations within a 12 month period.

Note: Indications marked with * are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community.

**Continuation — non-cystic fibrosis bronchiectasis**

Respiratory specialist or paediatrician

Re-assessment required after 12 months

All of the following:

1. The patient has completed 12 months of azithromycin treatment for non-cystic fibrosis bronchiectasis; and
2. Following initial 12 months of treatment, the patient has not received any further azithromycin treatment for non-cystic fibrosis...
continued...

- fibrosis bronchiectasis for a further 12 months, unless considered clinically inappropriate to stop treatment; and

3 The patient will not receive more than a total of 24 months’ azithromycin cumulative treatment (see note).

Note: Indications marked with * are unapproved indications. A maximum of 24 months of azithromycin treatment for non-cystic fibrosis will be subsidised in the community.

**Initiation – other indications**

*Re-assessment required after 5 days*

For any other condition.

**Continuation – other indications**

*Re-assessment required after 5 days*

For any other condition.

**CLARITHROMYCIN – Restricted** see terms [below](#)

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $ Per Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg – 1% DV Sep-17 to 2020</td>
<td>3.98 14 Apo-Clarithromycin</td>
</tr>
<tr>
<td>Tab 500 mg – 1% DV Sep-17 to 2020</td>
<td>10.40 14 Apo-Clarithromycin</td>
</tr>
<tr>
<td>Grans for oral liq 50 mg per ml</td>
<td>192.00 50 ml Klacid</td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Dec-17 to 31 Aug 2020</td>
<td>12.04 1 Martindale</td>
</tr>
</tbody>
</table>

**Restriction (RS1709)**

**Initiation – Tab 250 mg and oral liquid**

Any of the following:

1 Atypical mycobacterial infection; or
2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or
3 Helicobacter pylori eradication; or
4 Prophylaxis of infective endocarditis associated with surgical or dental procedures if amoxicillin is contra-indicated.

**Initiation – Tab 500 mg**

Helicobacter pylori eradication.

**Initiation – Infusion**

Any of the following:

1 Atypical mycobacterial infection; or
2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or
3 Community-acquired pneumonia.

**ERYTHROMYCIN (AS ETHYLSUCCINATE)**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 400 mg</td>
<td>16.95 100 E-Mycin</td>
</tr>
<tr>
<td>Grans for oral liq 200 mg per 5 ml</td>
<td>5.00 100 ml E-Mycin</td>
</tr>
<tr>
<td>Grans for oral liq 400 mg per 5 ml</td>
<td>6.77 100 ml E-Mycin</td>
</tr>
</tbody>
</table>

**ERYTHROMYCIN (AS LACTOBIONATE)**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 g vial – 1% DV Dec-19 to 2022</td>
<td>10.00 1 Erythrocin IV</td>
</tr>
</tbody>
</table>

**ERYTHROMYCIN (AS STEARATE) – Restricted:** For continuation only

- Tab 250 mg
- Tab 500 mg

**ROXITHROMYCIN – Some items restricted** see terms [below](#)

<table>
<thead>
<tr>
<th>Product</th>
<th>Price (ex man. excl. GST) $</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab dispersible 50 mg</td>
<td>8.29 10 Rulide D</td>
</tr>
<tr>
<td>Tab 150 mg – 1% DV Sep-19 to 2022</td>
<td>8.28 50 Arrow-Roxithromycin</td>
</tr>
<tr>
<td>Tab 300 mg – 1% DV Sep-19 to 2022</td>
<td>16.33 50 Arrow-Roxithromycin</td>
</tr>
</tbody>
</table>

**Restriction (RS1569)**

**Initiation**

Only for use in patients under 12 years of age.
### Penicillins

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AMOXICILLIN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg – 1% DV Apr-20 to 2022</td>
<td>22.50</td>
<td>500</td>
</tr>
<tr>
<td>Cap 500 mg – 1% DV Apr-20 to 2022</td>
<td>14.97</td>
<td></td>
</tr>
<tr>
<td>Grans for oral liq 125 mg per 5 ml – 1% DV Feb-18 to 2020</td>
<td>1.00</td>
<td>100 ml</td>
</tr>
<tr>
<td>Grans for oral liq 250 mg per 5 ml – 1% DV Feb-18 to 2020</td>
<td>1.31</td>
<td>100 ml</td>
</tr>
<tr>
<td>Inj 250 mg vial – 1% DV Sep-17 to 2020</td>
<td>10.67</td>
<td>10</td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Sep-17 to 2020</td>
<td>12.41</td>
<td>10</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Sep-17 to 2020</td>
<td>17.29</td>
<td>10</td>
</tr>
<tr>
<td><strong>AMOXICILLIN WITH CLAVULANIC ACID</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 500 mg with clavulanic acid 125 mg – 1% DV Oct-17 to 2020</td>
<td>1.88</td>
<td>20</td>
</tr>
<tr>
<td>Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml</td>
<td>3.83</td>
<td>100 ml</td>
</tr>
<tr>
<td>Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml</td>
<td>2.20</td>
<td>100 ml</td>
</tr>
<tr>
<td>Inj 500 mg with clavulanic acid 100 mg vial</td>
<td>28.18</td>
<td>10</td>
</tr>
<tr>
<td>Inj 1,000 mg with clavulanic acid 200 mg vial</td>
<td>43.30</td>
<td>10</td>
</tr>
<tr>
<td><strong>BENZATHINE BENZYL PENICILLIN</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 900 mg (1.2 million units) in 2.3 ml syringe – 1% DV Dec-18 to 2021</td>
<td>344.93</td>
<td>10</td>
</tr>
<tr>
<td><strong>BENZYL PENICILLIN SODIUM [PENICILLIN G]</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 600 mg (1 million units) vial – 1% DV Sep-17 to 2020</td>
<td>25.88</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>10.35</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>103.50</td>
<td>100</td>
</tr>
<tr>
<td><strong>FLUCLOxacillin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg – 1% DV Sep-18 to 2021</td>
<td>16.83</td>
<td>250</td>
</tr>
<tr>
<td>Cap 500 mg – 1% DV Sep-18 to 2021</td>
<td>56.61</td>
<td>500</td>
</tr>
<tr>
<td>Grans for oral liq 25 mg per ml – 1% DV Oct-18 to 2021</td>
<td>2.29</td>
<td>100 ml</td>
</tr>
<tr>
<td>Grans for oral liq 50 mg per ml – 1% DV Oct-18 to 2021</td>
<td>3.68</td>
<td>100 ml</td>
</tr>
<tr>
<td>Inj 250 mg vial – 1% DV Sep-17 to 2020</td>
<td>9.00</td>
<td>10</td>
</tr>
<tr>
<td>Inj 500 mg vial – 1% DV Sep-17 to 2020</td>
<td>9.40</td>
<td>10</td>
</tr>
<tr>
<td>Inj 1 g vial – 1% DV Sep-17 to 2020</td>
<td>5.22</td>
<td>5</td>
</tr>
<tr>
<td><strong>PHENOXYMETHYPENICILLIN [PENICILLIN V]</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 250 mg – 1% DV Sep-18 to 2021</td>
<td>2.59</td>
<td>50</td>
</tr>
<tr>
<td>Cap 500 mg – 1% DV Sep-18 to 2021</td>
<td>4.26</td>
<td>50</td>
</tr>
<tr>
<td>Grans for oral liq 125 mg per 5 ml – 1% DV Jan-20 to 2022</td>
<td>2.99</td>
<td>100 ml</td>
</tr>
<tr>
<td>Grans for oral liq 250 mg per 5 ml – 1% DV Jan-20 to 2022</td>
<td>3.99</td>
<td>100 ml</td>
</tr>
<tr>
<td><strong>PIPERACILLIN WITH TAZOBACTAM</strong> – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 4 g with tazobactam 0.5 g vial</td>
<td>38.00</td>
<td>10</td>
</tr>
<tr>
<td>Restricted (RS1053)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist, infectious disease specialist or respiratory specialist</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PROCaine Penicillin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 1.5 g in 3.4 ml syringe – 1% DV Sep-17 to 2020</td>
<td>123.50</td>
<td>5</td>
</tr>
<tr>
<td><strong>Ticarcillin with Clavulanic Acid</strong> – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 3 g with clavulanic acid 0.1 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restricted (RS1054)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical microbiologist, infectious disease specialist or respiratory specialist</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Item restricted (see [RS1053] above); Item restricted (see [RS1054] below)

*e.g.* *Brand* indicates brand example only. It is not a contracted product.
INFECTIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**Quinolones**

**CIPROFLOXACIN**  – **Restricted** see terms below

- Tab 250 mg – 1% DV Sep-17 to 2020 ................................................................. 1.45 28 Cipflox
- Tab 500 mg – 1% DV Sep-17 to 2020 ................................................................. 1.99 28 Cipflox
- Tab 750 mg – 1% DV Sep-17 to 2020 ................................................................. 3.15 28 Cipflox
- Oral liq 50 mg per ml
- Oral liq 100 mg per ml
- Inj 2 mg per ml, 100 ml bag – 1% DV Oct-18 to 2021 .................................. 68.20 10 Cipflox

**Moxifloxacin**  – **Restricted** (RS1055)

Clinical microbiologist or infectious disease specialist

**MOXIFLOXACIN**  – **Restricted** see terms below

- Tab 400 mg ................................................................. 52.00 5 Avelox
- Inj 1.6 mg per ml, 250 ml bottle – 1% DV Apr-20 to 2022 .......................... 70.00 1 Avelox IV 400

(Moxifloxacin Kabi)

**Initiation – Mycobacterium infection**

Infectious disease specialist, clinical microbiologist or respiratory specialist

Any of the following:

1. Both:
   1.1 Active tuberculosis; and
   1.2 Any of the following:
      1.2.1 Documented resistance to one or more first-line medications; or
      1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or
      1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or
      1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
      1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or

2. Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated; or

3. Patient is under five years of age and has had close contact with a confirmed multi-drug resistant tuberculosis case.

**Initiation – Pneumonia**

Infectious disease specialist or clinical microbiologist

Either:

1. Immunocompromised patient with pneumonia that is unresponsive to first-line treatment; or
2. Pneumococcal pneumonia or other invasive pneumococcal disease highly resistant to other antibiotics.

**Initiation – Penetrating eye injury**

Ophthalmologist

Five days treatment for patients requiring prophylaxis following a penetrating eye injury.

**Initiation – Mycoplasma genitalium**

All of the following:

1. Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium and is symptomatic; and
2. Either:
   2.1 Has tried and failed to clear infection using azithromycin; or
   2.2 Has laboratory confirmed azithromycin resistance; and
3. Treatment is only for 7 days.

**NORFLOXACIN**

Tab 400 mg ................................................................. 135.00 100 Arrow-Norfloxacin

Products with Hospital Supply Status (HSS) are in **bold**

Expiration date of HSS period is 30 June of the year indicated unless otherwise stated.
## Tetracyclines

**DEMECLOCYCLINE HYDROCHLORIDE**
- Tab 150 mg
- Cap 150 mg
- Cap 300 mg

**DOXYCYCLINE**
- Tab 50 mg – **Restricted**: For continuation only
  - Tab 100 mg
  - Inj 5 mg per ml, 20 ml vial

**MINOCYCLINE**
- Tab 50 mg
- Cap 100 mg – **Restricted**: For continuation only

**TETRACYCLINE**
- Tab 250 mg
- Cap 500 mg
- Inj 50 mg vial

**TIGECYCLINE** – **Restricted** see terms below
- Inj 50 mg vial
- **Restricted** (RS1059)

Clinical microbiologist or infectious disease specialist

## Other Antibacterials

**AZTREONAM** – **Restricted** see terms below
- Inj 1 g vial
- **Restricted** (RS1277)

Clinical microbiologist or infectious disease specialist

**CHLORAMPHENICOL** – **Restricted** see terms below
- Inj 1 g vial
- **Restricted** (RS1277)

Clinical microbiologist or infectious disease specialist

**CLINDAMYCIN** – **Restricted** see terms below
- Oral liq 15 mg per ml
- Inj 150 mg per ml, 4 ml ampoule – 1% DV Oct-19 to 2022

(Clindamycin ABM Cap 150 mg to be delisted 1 April 2020)
- **Restricted** (RS1061)

Clinical microbiologist or infectious disease specialist

**COLISTIN SULPHOMETHATE [COLESTIMETHATE]** – **Restricted** see terms below
- Inj 150 mg per ml, 1 ml vial
- **Restricted** (RS1062)

Clinical microbiologist, infectious disease specialist or respiratory specialist

**DAPTOMYCIN** – **Restricted** see terms below
- Inj 500 mg vial
- **Restricted** (RS1063)

Clinical microbiologist or infectious disease specialist

**FOSFOMYCIN** – **Restricted** see terms on the next page
- Powder for oral solution, 3 g sachet
**INFECTIONS**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

**Restricted (RS1315)**
Clinical microbiologist or infectious disease specialist

**HEXAMINE HIPPURATE**
Tab 1 g

**Linecomycin – Restricted** see terms below
- Inj 300 mg per ml, 2 ml vial

**Restricted (RS1065)**
Clinical microbiologist or infectious disease specialist

**Linezolid – Restricted** see terms below
- Tab 600 mg – 1% DV Oct-18 to 2021 .......................................................... 553.77 10 Zyvox
- Oral liq 20 mg per ml – 1% DV Dec-18 to 2021 ........................................ 1,879.00 150 ml Zyvox
- Inj 2 mg per ml, 300 ml bottle – 1% DV Feb-19 to 2021 .......................... 18.50 1 Linezolid Kabi

**Restricted (RS1066)**
Clinical microbiologist or infectious disease specialist

**Nitrofurantoin**
- Tab 50 mg – 1% DV Apr-19 to 2021 ........................................................... 22.20 100 Nifuran
- Tab 100 mg – 1% DV Apr-19 to 2021 ......................................................... 37.50 100 Nifuran

**Pivmecillinam – Restricted** see terms below
- Tab 200 mg

**Restricted (RS1322)**
Clinical microbiologist or infectious disease specialist

**Sodium fusidate [Fusidic Acid] – Restricted** see terms below
- Tab 250 mg – 1% DV Jun-17 to 2020 ............................................................. 34.50 12 Fucidin

**Restricted (RS1064)**
Clinical microbiologist or infectious disease specialist

**Sulphadiazine – Restricted** see terms below
- Tab 500 mg

**Restricted (RS1067)**
Clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist

**Teicoplanin – Restricted** see terms below
- Inj 400 mg vial

**Restricted (RS1068)**
Clinical microbiologist or infectious disease specialist

**Trimethoprim**
- Tab 100 mg
- Tab 300 mg – 1% DV Oct-18 to 2021 ......................................................... 16.50 50 TMP

**Trimethoprim with sulphamethoxazole [Co-trimoxazole]**
- Tab 80 mg with sulphamethoxazole 400 mg
- Oral liq 8 mg with sulphamethoxazole 40 mg per ml – 1% DV Oct-17 to 2020 ................................................................. 2.97 100 ml Deprim
- Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule

**Vancomycin – Restricted** see terms below
- Inj 500 mg vial – 1% DV Sep-17 to 2020 ...................................................... 2.37 1 Mylan

**Restricted (RS1069)**
Clinical microbiologist or infectious disease specialist

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiration date of HSS period is 30 June of the year indicated unless otherwise stated.
### INFECTIONS

#### Antifungals

<table>
<thead>
<tr>
<th>Imidazoles</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>KETOCONAZOLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted (RS1410)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncologist</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Polyene Antimycotics

<table>
<thead>
<tr>
<th>AMPHOTERICIN B</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj (liposomal) 50 mg vial</td>
<td>3,450.00</td>
<td>10 AmBisome</td>
</tr>
<tr>
<td><strong>Restricted (RS1071)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Initiation</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist

Either:

1. Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
2. Both:
   1. Possible invasive fungal infection; and
   2. A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

<table>
<thead>
<tr>
<th>NYSTATIN</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 500,000 u</td>
<td>17.09</td>
<td>50 Nilstat</td>
</tr>
<tr>
<td>Cap 500,000 u</td>
<td>15.47</td>
<td>50 Nilstat</td>
</tr>
</tbody>
</table>

#### Triazoles

<table>
<thead>
<tr>
<th>FLUCONAZOLE – Restricted see terms below</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 50 mg – 1% DV Feb-18 to 2020</td>
<td>2.09</td>
<td>28 Mylan</td>
</tr>
<tr>
<td>Cap 150 mg – 1% DV Feb-18 to 2020</td>
<td>0.33</td>
<td>1 Mylan</td>
</tr>
<tr>
<td>Cap 200 mg – 1% DV Feb-18 to 2020</td>
<td>5.08</td>
<td>28 Mylan</td>
</tr>
<tr>
<td>Oral liquid 50 mg per 5 ml</td>
<td>98.50</td>
<td>35 ml Diflucan</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 50 ml vial – 1% DV Oct-19 to 2022</td>
<td>2.80</td>
<td>1 Fluconazole-Claris</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 100 ml vial – 1% DV Oct-19 to 2022</td>
<td>3.45</td>
<td>1 Fluconazole-Claris</td>
</tr>
<tr>
<td><strong>Restricted (RS1072)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consultant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITRACONAZOLE – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 100 mg – 1% DV Nov-19 to 2022</td>
<td>4.27</td>
<td>15 Itrazole</td>
</tr>
<tr>
<td>Oral liquid 10 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Restricted (RS1073)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical immunologist, clinical microbiologist, dermatologist or infectious disease specialist</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>POSACONAZOLE – Restricted see terms on the next page</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab modified-release 100 mg</td>
<td>869.86</td>
<td>24 Noxafil</td>
</tr>
<tr>
<td>Oral liq 40 mg per ml</td>
<td>761.13</td>
<td>105 ml Noxafil</td>
</tr>
</tbody>
</table>

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
**Restrict**ed (RS1074)

**Initiation**
Haematologist or infectious disease specialist

*Re-assessment required after 6 weeks*

Both:

1. Either:
   1.1 Patient has acute myeloid leukaemia; or
   1.2 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection; and

2. Patient is to be treated with high dose remission induction therapy or re-induction therapy.

**Continuation**
Haematologist or infectious disease specialist

*Re-assessment required after 6 weeks*

Both:

1. Patient has previously received posaconazole prophylaxis during remission induction therapy; and

2. Any of the following:
   2.1 Patient is to be treated with high dose remission re-induction therapy; or

   2.2 Patient is to be treated with high dose consolidation therapy; or

   2.3 Patient is receiving a high risk stem cell transplant.

**VORICONAZOLE** – Restricted see terms below

<table>
<thead>
<tr>
<th>Product</th>
<th>Price</th>
<th>Expiry</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg – 1% DV Sep-18 to 2021</td>
<td>91.00</td>
<td>Vttack</td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg – 1% DV Sep-18 to 2021</td>
<td>350.00</td>
<td>Vttack</td>
<td></td>
</tr>
<tr>
<td>Powder for oral suspension 40 mg per ml – 1% DV Dec-18 to 2021</td>
<td>1,437.00</td>
<td>Vfend</td>
<td></td>
</tr>
<tr>
<td>Inj 200 mg vial – 1% DV Oct-19 to 2022</td>
<td>44.00</td>
<td>Neo Health</td>
<td></td>
</tr>
</tbody>
</table>

**Initiation – Proven or probable aspergillus infection**

Clinical microbiologist, haematologist or infectious disease specialist

Both:

1. Patient is immunocompromised; and

2. Patient has proven or probable invasive aspergillus infection.

**Initiation – Possible aspergillus infection**

Clinical microbiologist, haematologist or infectious disease specialist

All of the following:

1. Patient is immunocompromised; and

2. Patient has possible invasive aspergillus infection; and

3. A multidisciplinary team (including an infectious disease physician) considers the treatment to be appropriate.

**Initiation – Resistant candidiasis infections and other moulds**

Clinical microbiologist, haematologist or infectious disease specialist

All of the following:

1. Patient is immunocompromised; and

2. Either:
   2.1 Patient has fluconazole resistant candidiasis; or

   2.2 Patient has mould strain such as Fusarium spp. and Scedosporium spp; and

3. A multidisciplinary team (including an infectious disease physician or clinical microbiologist) considers the treatment to be appropriate.
### Other Antifungals

<table>
<thead>
<tr>
<th>Drug</th>
<th>Status</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CASPOFUNGIN</td>
<td>Restricted</td>
<td>$667.50</td>
<td>1 Cancidas Max Health</td>
</tr>
<tr>
<td>Inj 50 mg vial – 1% DV Dec-19 to 2022</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$220.28</td>
<td></td>
</tr>
<tr>
<td>CASPOFUNGIN</td>
<td>Restricted</td>
<td>$862.50</td>
<td>1 Cancidas Max Health</td>
</tr>
<tr>
<td>Inj 70 mg vial – 1% DV Dec-19 to 2022</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$284.63</td>
<td></td>
</tr>
</tbody>
</table>

(Cancidas Inj 50 mg vial to be delisted 1 December 2019)
(Cancidas Inj 70 mg vial to be delisted 1 December 2019)

- Restricted (RS1076)

**Initiation**

Clinical microbiologist, haematologist, infectious disease specialist, oncologist, respiratory specialist or transplant specialist

Either:
1. Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
2. Both:
   2.1 Possible invasive fungal infection; and
   2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

### Antimycobacterials

#### Antileprotics

<table>
<thead>
<tr>
<th>Drug</th>
<th>Status</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLOFAZIMINE</td>
<td>Restricted</td>
<td>$268.50</td>
<td>100 Dapsone</td>
</tr>
<tr>
<td>Tab 25 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$329.50</td>
<td>100 Dapsone</td>
</tr>
</tbody>
</table>

- Restricted (RS1077)

Clinical microbiologist, dermatologist or infectious disease specialist

### Antituberculotics

<table>
<thead>
<tr>
<th>Drug</th>
<th>Status</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYCLOSERINE</td>
<td>Restricted</td>
<td>$49.34</td>
<td>56 Myambutol</td>
</tr>
<tr>
<td>Tab 100 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Restricted (RS1079)

Clinical microbiologist, infectious disease specialist or respiratory specialist

<table>
<thead>
<tr>
<th>Drug</th>
<th>Status</th>
<th>Price (ex man. excl. GST)</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETHAMBUTOL HYDROCHLORIDE</td>
<td>Restricted</td>
<td>$49.34</td>
<td>56 Myambutol</td>
</tr>
<tr>
<td>Tab 400 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Restricted (RS1080)

Clinical microbiologist, infectious disease specialist or respiratory specialist

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

*Example: Brand indicates brand example only. It is not a contracted product.*
<table>
<thead>
<tr>
<th>INFECTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ISONIAZID</strong> – <strong>Restricted</strong> see terms below</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Oct-18 to 2021………………………………..22.00 100 PSM</td>
</tr>
<tr>
<td><strong>Restricted (RS1281)</strong></td>
</tr>
<tr>
<td>Clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician</td>
</tr>
<tr>
<td><strong>ISONIAZID WITH RIFAMPICIN</strong> – <strong>Restricted</strong> see terms below</td>
</tr>
<tr>
<td>Tab 100 mg with rifampicin 150 mg – 1% DV Sep-18 to 2021……………….85.54 100 Rifinah</td>
</tr>
<tr>
<td>Tab 150 mg with rifampicin 300 mg – 1% DV Sep-18 to 2021………………170.60 100 Rifinah</td>
</tr>
<tr>
<td><strong>Restricted (RS1282)</strong></td>
</tr>
<tr>
<td>Clinical microbiologist, dermatologist, paediatrician, public health physician or internal medicine physician</td>
</tr>
<tr>
<td><strong>PARA-AMINOSALICYLIC ACID</strong> – <strong>Restricted</strong> see terms below</td>
</tr>
<tr>
<td>Grans for oral liq 4 g……………………………………………………280.00 30 Paser</td>
</tr>
<tr>
<td><strong>Restricted (RS1083)</strong></td>
</tr>
<tr>
<td>Clinical microbiologist, infectious disease specialist or respiratory specialist</td>
</tr>
<tr>
<td><strong>PROTIONAMIDE</strong> – <strong>Restricted</strong> see terms below</td>
</tr>
<tr>
<td>Tab 250 mg…………………………………………………………..305.00 100 Peteha</td>
</tr>
<tr>
<td><strong>Restricted (RS1084)</strong></td>
</tr>
<tr>
<td>Clinical microbiologist, infectious disease specialist or respiratory specialist</td>
</tr>
<tr>
<td><strong>PYRAZINAMIDE</strong> – <strong>Restricted</strong> see terms below</td>
</tr>
<tr>
<td>Tab 500 mg</td>
</tr>
<tr>
<td><strong>Restricted (RS1085)</strong></td>
</tr>
<tr>
<td>Clinical microbiologist, infectious disease specialist or respiratory specialist</td>
</tr>
<tr>
<td><strong>RIFABUTIN</strong> – <strong>Restricted</strong> see terms below</td>
</tr>
<tr>
<td>Cap 150 mg………………………………………………………...275.00 30 Mycobutin</td>
</tr>
<tr>
<td><strong>Restricted (RS1086)</strong></td>
</tr>
<tr>
<td>Clinical microbiologist, gastroenterologist, infectious disease specialist or respiratory specialist</td>
</tr>
<tr>
<td><strong>RIFAMPICIN</strong> – <strong>Restricted</strong> see terms below</td>
</tr>
<tr>
<td>Cap 150 mg – 1% DV Sep-17 to 2020………………………………….55.75 100 Rifadin</td>
</tr>
<tr>
<td>Cap 300 mg – 1% DV Sep-17 to 2020……………………………….116.25 100 Rifadin</td>
</tr>
<tr>
<td>Oral liq 100 mg per 5 ml – 1% DV Sep-17 to 2020…………………...12.00 60 ml Rifadin</td>
</tr>
<tr>
<td>Inj 600 mg vial – 1% DV Sep-17 to 2020…………………………….128.85 1 Rifadin</td>
</tr>
<tr>
<td><strong>Restricted (RS1087)</strong></td>
</tr>
<tr>
<td>Clinical microbiologist, dermatologist, internal medicine physician, paediatrician or public health physician</td>
</tr>
</tbody>
</table>

## Antiparasitics

### Anthelmintics

| ALBENDAZOLE – **Restricted** see terms below |
| Tab 200 mg |
| Tab 400 mg |
| **Restricted (RS1088)** |
| Clinical microbiologist or infectious disease specialist |
| **IVERMECTIN** – **Restricted** see terms below |
| Tab 3 mg……………………………………………………………..17.20 4 Stromectol |
| **Restricted (RS1283)** |
| Clinical microbiologist, dermatologist or infectious disease specialist |
| **MEBENDAZOLE** |
| Tab 100 mg………………………………………………………..24.19 24 De-Worm |
| Oral liq 100 mg per 5 ml |

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
INFECTIONS

Price
(ex man. excl. GST)
$ Per
Brand or
Generic
Manufacturer

PRAZIQUANTEL
Tab 600 mg

Antiprotozoals

ARTEMETHER WITH LUMEFANTRINE – Restricted see terms below
◆ Tab 20 mg with lumefantrine 120 mg
  ➥ Restricted (RS1090)
  Clinical microbiologist or infectious disease specialist
ARTESTUNATE – Restricted see terms below
◆ Inj 60 mg vial
  ➥ Restricted (RS1091)
  Clinical microbiologist or infectious disease specialist
ATOVAQUONE WITH PROGUANIL HYDROCHLORIDE – Restricted see terms below
◆ Tab 62.5 mg with proguanil hydrochloride 25 mg.................................25.00 12 Malarone Junior
◆ Tab 250 mg with proguanil hydrochloride 100 mg..............................64.00 12 Malarone
  ➥ Restricted (RS1092)
  Clinical microbiologist or infectious disease specialist
CHLOROQUINE PHOSPHATE – Restricted see terms below
◆ Tab 250 mg
  ➥ Restricted (RS1093)
  Clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist
MEFLOQUINE – Restricted see terms below
◆ Tab 250 mg
  ➥ Restricted (RS1094)
  Clinical microbiologist, dermatologist, infectious disease specialist or rheumatologist
METRONIDAZOLE
Tab 200 mg..............................................................10.45 100 Trichozole
Tab 400 mg...........................................................18.15 100 Trichozole
Oral liq benzoate 200 mg per 5 ml ................................................25.00 100 ml Flagyl-S
Inj 5 mg per ml, 100 ml bottle ...................................................1.39 100 ml AFT
Inj 5 mg per ml, 100 ml bag..................................................264.00 48 Baxter
Suppos 500 mg .............................................................24.48 10 Flagyl
NITAZOXANIDE – Restricted see terms below
◆ Tab 500 mg ..........................................................1,680.00 30 Alinia
◆ Oral liq 100 mg per 5 ml
  ➥ Restricted (RS1095)
  Clinical microbiologist or infectious disease specialist
ORNIDAZOLE
Tab 500 mg ..................................................23.00 10 Arrow-Ornidazole
PENTAMIDINE ISETHIONATE – Restricted see terms below
◆ Inj 300 mg vial – 1% DV Nov-19 to 2022.................................216.00 5 Pentacarinat
  ➥ Restricted (RS1096)
  Clinical microbiologist or infectious disease specialist
PRIMAQUINE PHOSPHATE – Restricted see terms below
◆ Tab 7.5 mg
  ➥ Restricted (RS1097)
  Clinical microbiologist or infectious disease specialist

Item restricted (see ➥ above); Item restricted (see ➥ below)
e.g. Brand indicates brand example only. It is not a contracted product.
INFECTIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

PYRIMETHAMINE – Restricted see terms below
- Tab 25 mg

- Restricted (RS1098)
Clinical microbiologist, infectious disease specialist or maternal-foetal medicine specialist

QUININE DIHYDROCHLORIDE – Restricted see terms below
- Inj 60 mg per ml, 10 ml ampoule
- Inj 300 mg per ml, 2 ml vial

- Restricted (RS1099)
Clinical microbiologist or infectious disease specialist

QUININE SULPHATE
- Tab 300 mg

SODIUM STIBOGLUCONATE – Restricted see terms below
- Inj 100 mg per ml, 1 ml vial

- Restricted (RS1100)
Clinical microbiologist or infectious disease specialist

SPIRAMYCIN – Restricted see terms below
- Tab 500 mg

- Restricted (RS1101)
Maternal-foetal medicine specialist

Antiretrovirals

Non-Nucleoside Reverse Transcriptase Inhibitors

- Restricted (RS1571)

Initiation – Confirmed HIV
Patient has confirmed HIV infection.

Initiation – Prevention of maternal transmission
Either:
  1. Prevention of maternal foetal transmission; or
  2. Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV
Both:
  1. Treatment course to be initiated within 72 hours post exposure; and
  2. Any of the following:
     2.1. Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
     2.2. Patient has shared intravenous injecting equipment with a known HIV positive person; or
     2.3. Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initiation – Percutaneous exposure
Patient has percutaneous exposure to blood known to be HIV positive.

EFAVIRENZ – Restricted see terms above
- Tab 50 mg
- Tab 200 mg
- Tab 600 mg
- Oral liq 30 mg per ml

(Stocrin Tab 50 mg to be delisted 1 December 2019)

ETRAVIRINE – Restricted see terms above
- Tab 200 mg

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Infections

<table>
<thead>
<tr>
<th>Brand or Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nevirapine</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 200 mg – 1% DV Sep-18 to 2021</td>
<td>60.00</td>
<td>60</td>
</tr>
<tr>
<td>Oral suspension 10 mg per ml</td>
<td>203.55</td>
<td>240 ml</td>
</tr>
</tbody>
</table>

**Nucleoside Reverse Transcriptase Inhibitors**

- **Initiation – Confirmed HIV**
  Patient has confirmed HIV infection.
- **Initiation – Prevention of maternal transmission**
  Either:
  1. Prevention of maternal foetal transmission; or
  2. Treatment of the newborn for up to eight weeks.
- **Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV**
  Both:
  1. Treatment course to be initiated within 72 hours post exposure; and
  2. Any of the following:
    1.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
    1.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
    1.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.
- **Initiation – Percutaneous exposure**
  Patient has percutaneous exposure to blood known to be HIV positive.

- **Abacavir Sulphate** – Restricted see terms above
  Tab 300 mg – 1% DV Jul-19 to 2022 | 180.00 | 60 |
  Oral liq 20 mg per ml | 256.31 | 240 ml |

- **Abacavir Sulphate with Lamivudine** – Restricted see terms above
  Tab 600 mg with lamivudine 300 mg – 1% DV Jul-19 to 2022 | 63.00 | 30 |

- **Efavirenz with Emtricitabine and Tenofovir Disoproxil** – Restricted see terms above
  Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) – 1% DV Jun-19 to 2022 | 106.88 | 30 |

- **Emtricitabine** – Restricted see terms above
  Cap 200 mg – 1% DV Jul-19 to 2022 | 307.20 | 30 |

- **Lamivudine** – Restricted see terms above
  Oral liq 10 mg per ml

- **Stavudine** – Restricted see terms above
  Cap 30 mg
  Cap 40 mg
  Powder for oral soln 1 mg per ml

- **Zidovudine [AZT]** – Restricted see terms above
  Cap 100 mg | 152.25 | 100 |
  Oral liq 10 mg per ml | 30.45 | 200 ml |
  Inj 10 mg per ml, 20 ml vial | 750.00 | 5 |

- **Zidovudine [AZT] with Lamivudine** – Restricted see terms above
  Tab 300 mg with lamivudine 150 mg – 1% DV Sep-17 to 2020 | 33.00 | 60 |

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
Protease Inhibitors

**Restricted (RS1573)**

**Initiation – Confirmed HIV**
Patient has confirmed HIV infection.

**Initiation – Prevention of maternal transmission**
Either:
1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

**Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV**
Both:
1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

**Initiation – Percutaneous exposure**
Patient has percutaneous exposure to blood known to be HIV positive.

**ATAZANAVIR SULPHATE** – Restricted see terms above
- Cap 150 mg – 1% DV Jun-19 to 2022.........................................................141.68 60 Teva
- Cap 200 mg – 1% DV Jun-19 to 2022.........................................................188.91 60 Teva

**DARUNAVIR** – Restricted see terms above
- Tab 400 mg – 1% DV Jun-17 to 2020.........................................................335.00 60 Prezista
- Tab 600 mg – 1% DV Jun-17 to 2020.........................................................476.00 60 Prezista

**INDINAVIR** – Restricted see terms above
- Cap 200 mg
- Cap 400 mg

**LOPINAVIR WITH RITONAVIR** – Restricted see terms above
- Tab 100 mg with ritonavir 25 mg ............................................................183.75 60 Kaletra
- Tab 200 mg with ritonavir 50 mg – 1% DV Sep-17 to 2020..............463.00 120 Kaletra
- Oral liq 80 mg with ritonavir 20 mg per ml.............................................735.00 300 ml Kaletra

**RITONAVIR** – Restricted see terms above
- Tab 100 mg – 1% DV Jul-19 to 2022.........................................................43.31 30 Norvir

Strand Transfer Inhibitors

**Restricted (RS1574)**

**Initiation – Confirmed HIV**
Patient has confirmed HIV infection.

**Initiation – Prevention of maternal transmission**
Either:
1. Prevention of maternal foetal transmission; or
2. Treatment of the newborn for up to eight weeks.

**Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV**
Both:

continued…
continued...

1. Treatment course to be initiated within 72 hours post exposure; and
2. Any of the following:
   2.1. Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2.2. Patient has shared intravenous injecting equipment with a known HIV positive person; or
   2.3. Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

**Initiation – Percutaneous exposure**

Patient has percutaneous exposure to blood known to be HIV positive.

**Dolutegravir** – *Restricted* see terms on the previous page

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg</td>
<td>Tivicay</td>
</tr>
<tr>
<td>1,090.00</td>
<td></td>
</tr>
</tbody>
</table>

**Raltegravir Potassium** – *Restricted* see terms on the previous page

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 400 mg</td>
<td>Isentress</td>
</tr>
<tr>
<td>1,090.00</td>
<td></td>
</tr>
<tr>
<td>Tab 600 mg</td>
<td>Isentress HD</td>
</tr>
<tr>
<td>1,090.00</td>
<td></td>
</tr>
</tbody>
</table>

**Antivirals**

### Hepatitis B

**Adefovir Dipivoxil** – *Restricted* see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg</td>
<td>Hepsera</td>
</tr>
<tr>
<td>670.00</td>
<td></td>
</tr>
</tbody>
</table>

*Restricted (RS1104)*

**Initiation**

Gastroenterologist or infectious disease specialist

All of the following:

1. Patient has confirmed Hepatitis B infection (HBsAg+); and
2. Patient has raised serum ALT (> 1 x ULN); and
3. Patient has HBV DNA greater than 100,000 copies per mL, or viral load greater than or equal to 10-fold over nadir; and
4. Detection of M204I or M204V mutation; and
5. Either:
   5.1. Both:
   5.1.1. Patient is cirrhotic; and
   5.1.2. Adefovir dipivoxil to be used in combination with lamivudine; or
   5.2. Both:
   5.2.1. Patient is not cirrhotic; and
   5.2.2. Adefovir dipivoxil to be used as monotherapy.

**Entecavir**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 0.5 mg – 1% DV Nov-18 to 2021</td>
<td>Entecavir Sandoz</td>
</tr>
<tr>
<td>52.00</td>
<td></td>
</tr>
</tbody>
</table>

**Lamivudine**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg – 1% DV Aug-18 to 2020</td>
<td>Zetlam</td>
</tr>
<tr>
<td>4.20</td>
<td></td>
</tr>
<tr>
<td>Oral liq 5 mg per ml</td>
<td>Zeffix</td>
</tr>
<tr>
<td>270.00</td>
<td></td>
</tr>
</tbody>
</table>

**Tenofovir Disoproxil**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 245 mg (300.6 mg as a succinate) – 1% DV Sep-18 to 2021</td>
<td>Tenofovir Disoproxil Teva</td>
</tr>
<tr>
<td>38.10</td>
<td></td>
</tr>
</tbody>
</table>
Hepatitis C

GLECAPREVIR WITH PIBRENTASVIR
Note: the supply of treatment is via PHARMAC’s approved direct distribution supply. Further details can be found on PHARMAC’s website https://www.pharmac.govt.nz/hepatitis-c-treatments/.
Tab 100 mg with pibrentasvir 40 mg ..........................................................24,750.00 84 Maviret

LEDIPASVIR WITH SOFOSBUVIR – Restricted see terms below
Tab 90 mg with sofosbuvir 400 mg ..........................................................24,363.46 28 Harvoni

Initiation
Note: Only for use in patients with approval by the Hepatitis C Treatment Panel (HepCTP). Applications will be considered by HepCTP at its regular meetings and approved subject to eligibility according to the Access Criteria (set out in Section B of the Pharmaceutical Schedule).

Herpesviridae

ACICLOVIR
Tab dispersible 200 mg – 1% DV Oct-19 to 2022 ..............................................1.60 25 Lovir
Tab dispersible 400 mg – 1% DV Oct-19 to 2022 ...........................................5.38 56 Lovir
Tab dispersible 800 mg – 1% DV Oct-19 to 2022 ...........................................5.98 35 Lovir
Inj 250 mg vial – 1% DV Sep-18 to 2021 .........................................................9.60 5 Aciclovir-Claris

CIDOFOVIR – Restricted see terms below
Inj 75 mg per ml, 5 ml vial
Restricted (RS1108)
Clinical microbiologist, infectious disease specialist, otolaryngologist or oral surgeon

FOSCARNET SODIUM – Restricted see terms below
Inj 24 mg per ml, 250 ml bottle
Restricted (RS1109)
Clinical microbiologist or infectious disease specialist

GANCICLOVIR – Restricted see terms below
Inj 500 mg vial ...............................................................................................380.00 5 Cymevene

Valganciclovir Mylan

Initiation – Transplant cytomegalovirus prophylaxis
Limited to 3 months treatment
Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

Initiation – Lung transplant cytomegalovirus prophylaxis
Limited to 6 months treatment
Both:

1 Patient has undergone a lung transplant; and
2 Either:

continued…
continued...

2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
2.2 The recipient is cytomegalovirus positive.

Initiation – Cytomegalovirus in immunocompromised patients
Both:
1 Patient is immunocompromised; and
2 Any of the following:
   2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
   2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
   2.3 Patient has cytomegalovirus retinitis.

HIV Prophylaxis and Treatment

EMTRICITABINE WITH TENOFOVIR DISOPROXIL – Restricted see terms below

Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate)
– 1% DV Jun-19 to 2022 ................................................................. 61.15 30 Teva

Initiation – Confirmed HIV
Patient has confirmed HIV infection.

Initiation – Prevention of maternal transmission
Either:
1 Prevention of maternal foetal transmission; or
2 Treatment of the newborn for up to eight weeks.

Initiation – Post-exposure prophylaxis following non-occupational exposure to HIV
Both:
1 Treatment course to be initiated within 72 hours post exposure; and
2 Any of the following:
   2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
   2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
   2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initiation – Percutaneous exposure
Patient has percutaneous exposure to blood known to be HIV positive.

Initiation – Pre-exposure prophylaxis
Re-assessment required after 3 months
All of the following:
1 Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis (refer to local health pathways or https://ashm.org.au/HIV/PrEP/ for training materials); and
2 Patient has undergone testing for HIV, syphilis, Hep B if not immune and a full STI screen in the previous two weeks; and
3 Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 3 months and is not contraindicated for treatment; and
4 Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
5 Patient has tested HIV negative and is not at risk of HIV seroconversion; and
6 Either:
   6.1 All of the following:
      6.1.1 Patient is male or transgender; and
      6.1.2 Patient has sex with men; and

continued…
continued...

6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
6.1.4 Any of the following:
   6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
   6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
   6.1.4.3 Patient has used methamphetamine in the last three months; or

6.2 All of the following:
   6.2.1 Patient has a regular partner who has HIV infection; and
   6.2.2 Partner is either not on treatment or has a detectable viral load; and
   6.2.3 Condoms have not been consistently used.

Continuation – Pre-exposure prophylaxis
Re-assessment required after 3 months
All of the following:
1 Applicant has an up to date knowledge of the safety issues and is competent to prescribe pre-exposure prophylaxis (refer to local health pathways or https://ashm.org.au/HIV/PrEP/ for training materials); and
2 Patient has undergone testing for HIV, syphilis, Hep B if not immune and a full STI screen in the previous two weeks; and
3 Patient has had renal function testing (creatinine, phosphate and urine protein/creatinine ratio) within the last 12 months and is not contraindicated for treatment; and
4 Patient has received advice regarding the reduction of risk of HIV and sexually transmitted infections and how to reduce those risks; and
5 Patient has tested HIV negative and is not at risk of HIV seroconversion; and
6 Either:
   6.1 All of the following:
      6.1.1 Patient is male or transgender; and
      6.1.2 Patient has sex with men; and
      6.1.3 Patient is likely to have multiple episodes of condomless anal intercourse in the next 3 months; and
      6.1.4 Any of the following:
         6.1.4.1 Patient has had at least one episode of condomless receptive anal intercourse with one or more casual male partners in the last 3 months; or
         6.1.4.2 A diagnosis of rectal chlamydia, rectal gonorrhoea, or infectious syphilis within the last 3 months; or
         6.1.4.3 Patient has used methamphetamine in the last three months; or
   6.2 All of the following:
      6.2.1 Patient has a regular partner who has HIV infection; and
      6.2.2 Partner is either not on treatment or has a detectable viral load; and
      6.2.3 Condoms have not been consistently used.

Influenza

OSELTMIVIR – Restricted see terms below
Note: The restriction on the use of oseltamivir to hospitalised patients means that supply into the community for a new course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

- Tab 75 mg
- Powder for oral suspension 6 mg per ml

Initiation
Either:
1 Only for hospitalised patient with known or suspected influenza; or
2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.
INFECTIONS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

ZANAMIVIR

Note: The restriction on the use of zanamivir to hospitalised patients means that supply into the community for a new course is not permitted. Supply of a part original pack on discharge where initiated as a hospital inpatient is permitted.

- Powder for inhalation 5 mg.................................................................37.38 20 dose Relenza Rotadisk

**Initiation**

Either:

1. Only for hospitalised patient with known or suspected influenza; or
2. For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

### Immune Modulators

**INTERFERON ALFA-2A**

- Inj 3 m iu prefilled syringe
- Inj 6 m iu prefilled syringe
- Inj 9 m iu prefilled syringe

**INTERFERON ALFA-2B**

- Inj 18 m iu, 1.2 ml multidose pen
- Inj 30 m iu, 1.2 ml multidose pen
- Inj 60 m iu, 1.2 ml multidose pen

**INTERFERON GAMMA** – **Restricted** see terms below

- Inj 100 mcg in 0.5 ml vial

**PEGYLATED INTERFERON ALFA-2A** – **Restricted** see terms below

- Inj 180 mcg prefilled syringe – 1% DV Oct-17 to 2020.................................500.00 4 Pegasys

**Initiation**

- Patient has chronic granulomatous disease and requires interferon gamma.

**Continuation** – Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant

*Limited to 48 weeks treatment*

Any of the following:

1. Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
2. Patient has chronic hepatitis C and is co-infected with HIV; or
3. Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant.

Notes: Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.

Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml.

**Continuation** – Chronic hepatitis C - genotype 1 infection

Gastroenterologist, infectious disease specialist or general physician

*Re-assessment required after 48 weeks*

All of the following:

1. Patient has chronic hepatitis C, genotype 1; and
2. Patient has had previous treatment with pegylated interferon and ribavirin; and
3. Either:
   3.1 Patient has responder relapsed; or
continued…

3.2 Patient was a partial responder; and
4 Patient is to be treated in combination with boceprevir.

**Initiation – Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior**

Gastroenterologist, infectious disease specialist or general physician

*Limited to 48 weeks treatment*

All of the following:

1 Patient has chronic hepatitis C, genotype 1; and
2 Patient has had previous treatment with pegylated interferon and ribavirin; and
3 Any of the following:
   3.1 Patient has responder relapsed; or
   3.2 Patient was a partial responder; or
   3.3 Patient received interferon treatment prior to 2004; and
4 Patient is to be treated in combination with boceprevir.

**Initiation – Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV**

*Limited to 6 months treatment*

Patient has chronic hepatitis C, genotype 2 or 3 infection.

**Initiation – Hepatitis B**

Gastroenterologist, infectious disease specialist or general physician

*Limited to 48 weeks treatment*

All of the following:

1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
2 Patient is Hepatitis B treatment-naive; and
3 ALT > 2 times Upper Limit of Normal; and
4 HBV DNA < 10 log10 IU/ml; and
5 Either:
   5.1 HBeAg positive; or
   5.2 Serum HBV DNA greater than or equal to 2,000 units/ml and significant fibrosis (greater than or equal to Metavir Stage F2 or moderate fibrosis); and
6 Compensated liver disease; and
7 No continuing alcohol abuse or intravenous drug use; and
8 Not co-infected with HCV, HIV or HDV; and
9 Neither ALT nor AST > 10 times upper limit of normal; and
10 No history of hypersensitivity or contraindications to pegylated interferon.

Notes: Approved dose is 180 mcg once weekly.
The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.
In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon alfa-2a dose should be reduced to 135 mcg once weekly.
In patients with neutropaenia and thrombocytopenia, dose should be reduced in accordance with the datasheet guidelines.
Pegylated Interferon alfa-2a is not approved for use in children.
# MUSCULOSKELETAL SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
<tr>
<td>Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

## Anticholinesterases

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Description</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>EDROPHONIUM CHLORIDE</td>
<td>Restricted see terms below</td>
<td>98.00</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td></td>
<td>10 mg per ml, 15 ml vial</td>
<td>50</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td></td>
<td>10 mg per ml, 1 ml ampoule</td>
<td>10</td>
<td>Max Health</td>
</tr>
<tr>
<td>NEOSTIGMINE METILSULFATE</td>
<td>2.5 mg per ml, 1 ml ampoule – 1% DV Nov-17 to 2020</td>
<td>45.79</td>
<td>Mestinon</td>
</tr>
<tr>
<td>NEOSTIGMINE METILSULFATE WITH GLYCOPYRRONIUM BROMIDE</td>
<td>2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule</td>
<td>40.90</td>
<td>Max Health</td>
</tr>
<tr>
<td>PYRIDOSTIGMINE BROMIDE</td>
<td>60 mg – 1% DV Nov-19 to 2022</td>
<td>45.79</td>
<td>Mestinon</td>
</tr>
</tbody>
</table>

## Antirheumatoid Agents

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Description</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROXYCHLOROQUINE</td>
<td>Tab 200 mg – 1% DV Sep-18 to 2021</td>
<td>7.98</td>
<td>Plaquenil</td>
</tr>
<tr>
<td>LEFLUNOMIDE</td>
<td>Tab 10 mg – 1% DV Jun-17 to 2020</td>
<td>2.90</td>
<td>Apo-Leflunomide</td>
</tr>
<tr>
<td></td>
<td>Tab 20 mg – 1% DV Jun-17 to 2020</td>
<td>2.90</td>
<td>Apo-Leflunomide</td>
</tr>
<tr>
<td>PENICILLAMINE</td>
<td>Tab 125 mg</td>
<td>67.23</td>
<td>D-Penamine</td>
</tr>
<tr>
<td></td>
<td>Tab 250 mg</td>
<td>110.12</td>
<td>D-Penamine</td>
</tr>
<tr>
<td>SODIUM AUROTHIOMALATE</td>
<td>10 mg in 0.5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>20 mg in 0.5 ml ampoule</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>50 mg in 0.5 ml ampoule</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Drugs Affecting Bone Metabolism

### Bisphosphonates

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Description</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALENDRONATE SODIUM</td>
<td>Tab 70 mg – 1% DV Apr-19 to 2022</td>
<td>2.44</td>
<td>Fosamax</td>
</tr>
<tr>
<td>ALENDRONATE SODIUM WITH COLECALCIFEROL</td>
<td>Tab 70 mg with colecaciferol 5,600 lu – 1% DV Apr-19 to 2022</td>
<td>1.51</td>
<td>Fosamax Plus</td>
</tr>
<tr>
<td>PAMIDRONATE DISODIUM</td>
<td>3 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020</td>
<td>5.98</td>
<td>Pamisol</td>
</tr>
<tr>
<td></td>
<td>6 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020</td>
<td>15.02</td>
<td>Pamisol</td>
</tr>
<tr>
<td></td>
<td>9 mg per ml, 10 ml vial – 1% DV Sep-17 to 2020</td>
<td>17.05</td>
<td>Pamisol</td>
</tr>
<tr>
<td>RISEDRONATE SODIUM</td>
<td>35 mg – 1% DV Oct-19 to 2022</td>
<td>3.10</td>
<td>Risedronate Sandoz</td>
</tr>
<tr>
<td>ZOLEDRONIC ACID</td>
<td>5 mg per 100 ml, vial – 1% DV Oct-19 to 2022</td>
<td>60.00</td>
<td>Aclasta</td>
</tr>
</tbody>
</table>

---

- Item restricted (see ➥ above); Item restricted (see ➥ below)
- e.g. Brand indicates brand example only. It is not a contracted product.
**Restricted (RS1663)**

**Initiation – Inherited bone fragility disorders**
Any specialist
Patient has been diagnosed with an inherited bone fragility disorder (e.g. osteogenesis imperfecta).

**Initiation – Osteoporosis**
Any specialist
*Therapy limited to 3 doses*

Both:

1. Any of the following:
   1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or
   1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
   1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
   1.4 Documented T-Score greater than or equal to -3.0 (see Note); or
   1.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
   1.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and

2. The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

**Initiation – glucocorticosteroid therapy**
Any specialist
*Re-assessment required after 12 months*

All of the following:

1. The patient is receiving systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and

2. Any of the following:
   2.1 The patient has documented BMD greater than or equal to 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -1.5) (see Note); or
   2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
   2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy) prior to 1 February 2019 or has had a Special Authority approval for raloxifene; and

3. The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

**Continuation – glucocorticosteroid therapy**
Any specialist
*Re-assessment required after 12 months*

Both:

1. The patient is continuing systemic glucocorticosteroid therapy (greater than or equal to 5 mg per day prednisone equivalents); and

2. The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

**Initiation – Paget’s disease**
Any specialist
*Re-assessment required after 12 months*

All of the following:

1. Paget’s disease; and

continued…
continued…

2 Any of the following:
   2.1 Bone or articular pain; or
   2.2 Bone deformity; or
   2.3 Bone, articular or neurological complications; or
   2.4 Asymptomatic disease, but risk of complications; or
   2.5 Preparation for orthopaedic surgery; and

3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Continuation – Paget’s disease
Any specialist
Re-assessment required after 12 months
Both:

1 Any of the following:
   1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
   1.2 The patient’s serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
   1.3 Symptomatic disease (prescriber determined); and

2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Notes:

1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.

3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Other Drugs Affecting Bone Metabolism

DENOSUMAB – Restricted see terms below

- Inj 60 mg prefilled syringe.................................................................326.00 1 Prolia

⇒ Restricted (RS1665)

Initiation
All of the following:

1 The patient has severe, established osteoporosis; and

2 Either:
   2.1 The patient is female and postmenopausal; or
   2.2 The patient is male or non-binary; and

3 Any of the following:
   3.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or equal to -2.5) (see Note); or

continued…
MUSCULOSKELETAL SYSTEM

Price
(ex man. excl. GST)
Per
Brand or
Generic
Manufacturer

continued...

3.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or
densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons; or
3.3 History of two significant osteoporotic fractures demonstrated radiologically; or
3.4 Documented T-Score less than or equal to -3.0 (see Note); or
3.5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm
(e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
3.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February
2019 or has had a Special Authority approval for raloxifene; and

4 Zoledronic acid is contraindicated because the patient’s creatinine clearance is less than 35 mL/min; and
5 The patient has experienced at least one symptomatic new fracture after at least 12 months’ continuous therapy with a
funded antiresorptive agent at adequate doses (see Notes); and
6 The patient must not receive concomitant treatment with any other funded antiresorptive agent for this condition or
teriparatide.

Notes:
1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA).
Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture
demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD
measurement for treatment with denosumab.
3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO
definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below
-2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical
forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a
fall from a standing height or less.
4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body
relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral
body above or below the affected vertebral body.
5 Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: risedronate
sodium tab 35 mg once weekly; alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly;
raloxifene hydrochloride tab 60 mg once daily. If an intolerance of a severity necessitating permanent treatment
withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that
the patient achieves the minimum requirement of 12 months’ continuous therapy.

RALOXIFENE – Restricted see terms below

● Tab 60 mg .......................................................................................................53.76 28 Evista

→ Restricted (RS1666)

Initiation

Any of the following:

1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD)
greater than or equal to 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score less than or
equal to -2.5) (see Notes); or
2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or
densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is
unlikely that this provision would apply to many patients under 75 years of age; or
3 History of two significant osteoporotic fractures demonstrated radiologically; or
4 Documented T-Score greater than or equal to -3.0 (see Notes); or
5 A 10-year risk of hip fracture greater than or equal to 3%, calculated using a published risk assessment algorithm (e.g.
FRAX or Garvan) which incorporates BMD measurements (see Notes); or

continued…
continued…

6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) prior to 1 February 2019.

Notes:

1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score less than or equal to -2.5 and, therefore, do not require BMD measurement for raloxifene funding.

3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.

4 A vertebral fracture is defined as a 20% or greater reduction in height in the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

TERIPARATIDE – Restricted see terms below

Inj 250 mcg per ml, 2.4 ml cartridge .............................................................. 490.00 1 Forteo

Initiation

Limited to 18 months treatment

All of the following:

1 The patient has severe, established osteoporosis; and
2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
3 The patient has had two or more fractures due to minimal trauma; and
4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

1 The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

2 Antiresorptive agents and their adequate doses for the purposes of this restriction are defined as: alendronate sodium tab 70 mg or tab 70 mg with colecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.

3 A vertebral fracture is defined as a 20% or greater reduction in height in the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Enzymes

HYALURONIDASE

Inj 1,500 iu ampoule

Hyperuricaemia and Antigout

ALLOPURINOL

Tab 100 mg – 1% DV Jan-18 to 2020 .............................................................. 4.54 500 DP-Allopurinol
Tab 300 mg – 1% DV Jan-18 to 2020 .............................................................. 10.35 500 DP-Allopurinol
BENZBROMARONE – **Restricted** see terms below

- **Tab 100 mg**.....................................................................................................45.00 100 Benzbromaron AL 100

**Initiation**

Any specialist

All of the following:

1 Patient has been diagnosed with gout; and
2 Any of the following:
   2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   2.3 Both:
      2.3.1 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
      2.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or

3 The patient is receiving monthly liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity. In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose. The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at www.rheumatology.org.nz/home/resources-2/

**COLCHICINE**

- **Tab 500 mcg – 1% DV Jan-19 to 2021**............................................................9.58 100 Colgout

**FEBUXOSTAT – **Restricted** see terms below

- **Tab 80 mg**.....................................................................................................39.50 28 Adenuric
- **Tab 120 mg**.....................................................................................................39.50 28 Adenuric

**Initiation**

Any specialist

Both:

1 Patient has been diagnosed with gout; and
2 Any of the following:
   2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
   2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note).

Note: In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be...
MUSCULOSKELETAL SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

continued…

effective. The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

PROBENECID

Tab 500 mg

RASBURICASE – Restricted see terms below

$ Inj 1.5 mg vial

→ Restricted (RS1016)

Haematologist

### Muscle Relaxants and Related Agents

<table>
<thead>
<tr>
<th>ATRACURIUM BESYLATE</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mg per ml, 2.5 ml ampoule – 1% DV Jun-18 to 2021</td>
<td>10.00</td>
<td>Tracrium</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 5 ml ampoule – 1% DV Jun-18 to 2021</td>
<td>12.50</td>
<td>Tracrium</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BACLOFEN</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Oct-18 to 2021</td>
<td>4.20</td>
<td>Pacifen</td>
</tr>
<tr>
<td>Oral liq 1 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 0.05 mg per ml, 1 ml ampoule</td>
<td>11.55</td>
<td>Lioresal Intrathecal</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 5 ml ampoule – 1% DV Apr-19 to 2021</td>
<td>372.98</td>
<td>Medsurge</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CLOSTRIDIUM BOTULINUM TYPE A TOXIN</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 100 u vial</td>
<td>467.50</td>
<td>Botox</td>
</tr>
<tr>
<td>Inj 300 u vial</td>
<td>388.50</td>
<td>Dysport</td>
</tr>
<tr>
<td>Inj 500 u vial</td>
<td>1,295.00</td>
<td>Dysport</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DANTROLENE</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 25 mg</td>
<td>65.00</td>
<td>Dantrium</td>
</tr>
<tr>
<td>Cap 50 mg</td>
<td>77.00</td>
<td>Dantrium</td>
</tr>
<tr>
<td>Inj 20 mg vial</td>
<td>800.00</td>
<td>Dantrium IV</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MIVACURIUM CHLORIDE</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2 mg per ml, 5 ml ampoule</td>
<td>33.92</td>
<td>Mivacron</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 10 ml ampoule</td>
<td>67.17</td>
<td>Mivacron</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ORPHENADRINE CITRATE</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg – 1% DV Jun-18 to 2021</td>
<td>18.54</td>
<td>Norflex</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PANCURONIUM BROMIDE</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2 mg per ml, 2 ml ampoule</td>
<td>260.00</td>
<td>AstraZeneca</td>
</tr>
</tbody>
</table>

(AstraZeneca Inj 2 mg per ml, 2 ml ampoule to be delisted 1 January 2020)

<table>
<thead>
<tr>
<th>ROCURONIUM BROMIDE</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mg per ml, 5 ml vial</td>
<td>25.95</td>
<td>DBL Rocuronium Bromide</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SUXAMETHONIUM CHLORIDE</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 50 mg per ml, 2 ml ampoule – 1% DV Nov-17 to 2020</td>
<td>78.00</td>
<td>AstraZeneca</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>VECURONIUM BROMIDE</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 10 mg vial</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Reversers of Neuromuscular Blockade

**SUGAMMADEX** – **Restricted** see terms below

- **Inj 100 mg per ml, 2 ml vial**: $1,200.00 10 Bridion
- **Inj 100 mg per ml, 5 ml vial**: $3,000.00 10 Bridion

**Non-Steroidal Anti-Inflammatory Drugs**

**CELECOXIB**

- Note - The DV limit of 1% applies to the celecoxib chemical rather than each individual line item.
  - **Cap 100 mg**: $3.63 60 Celecoxib Pfizer
  - **Cap 200 mg – 1% DV Aug-17 to 2020**: $2.30 30 Celecoxib Pfizer

**DICLOFENAC SODIUM**

- **Tab EC 25 mg – 1% DV Oct-18 to 2021**: $1.23 50 Diclofenac Sandoz
- **Tab 50 mg dispersible**: $1.50 20 Voltaren D
- **Tab EC 50 mg – 1% DV Oct-18 to 2021**: $1.23 50 Diclofenac Sandoz
- **Tab long-acting 75 mg – 1% DV Oct-18 to 2021**: $22.80 500 Apo-Diclo SR
- **Tab long-acting 100 mg – 1% DV Oct-18 to 2021**: $25.15 500 Apo-Diclo SR
- **Inj 25 mg per ml, 3 ml ampoule**: $13.20 5 Voltaren
- **Suppos 12.5 mg**: $2.04 10 Voltaren
- **Suppos 25 mg**: $2.44 10 Voltaren
- **Suppos 50 mg**: $4.22 10 Voltaren
- **Suppos 100 mg**: $7.00 10 Voltaren

**ETORICOXIB** – **Restricted** see terms below

- **Tab 30 mg**
- **Tab 60 mg**
- **Tab 90 mg**
- **Tab 120 mg**

**IBUPROFEN**

- **Tab 200 mg – 1% DV Feb-18 to 2020**: $11.71 1,000 Relieve
- **Tab 400 mg – Restricted**: For continuation only
- **Tab 600 mg – Restricted**: For continuation only
- **Tab long-acting 800 mg**: $7.99 30 Brufen SR
- **Oral liq 20 mg per ml – 1% DV May-19 to 2021**: $1.88 200 ml Ethics
- **Inj 5 mg per ml, 2 ml ampoule**
- **Inj 10 mg per ml, 2 ml vial**

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### MUSCULOSKELETAL SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**INDOMETHACIN**
- Cap 25 mg
- Cap 50 mg
- Cap long-acting 75 mg
- Inj 1 mg vial
- Suppos 100 mg

**KETOPROFEN**
- Cap long-acting 200 mg ................................................................. 12.07 28 Oruvail SR

**MEFENAMIC ACID – Restricted: For continuation only**
- Cap 250 mg

**NAPROXEN**
- Tab 250 mg – 1% DV Dec-18 to 2021 ..................................................... 32.69 500 Noflam 250
- Tab 500 mg – 1% DV Dec-18 to 2021 ..................................................... 22.19 250 Noflam 500
- Tab long-acting 750 mg – 1% DV Oct-18 to 2021 .............................. 6.16 28 Naprosyn SR 750
- Tab long-acting 1 g – 1% DV Oct-18 to 2021 ..................................... 8.21 28 Naprosyn SR 1000

**PARECOXIB**
- Inj 40 mg vial .................................................................................... 100.00 10 Dynastat

**SULINDAC**
- Tab 100 mg
- Tab 200 mg

**TENOXICAM**
- Tab 20 mg – 1% DV Oct-19 to 2022 ................................................... 9.15 100 Tilcotil
- Inj 20 mg vial ...................................................................................... 9.95 1 AFT

### Topical Products for Joint and Muscular Pain

**CAPSAICIN – Restricted see terms below**
- Crm 0.025%......................................................................................... 9.95 45 g Zostrix

**Restricted (RS1309)**

Initiation
- Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.
Agents for Parkinsonism and Related Disorders

Agents for Essential Tremor, Chorea and Related Disorders

RILUZOLE – Restricted see terms below

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rilutek</td>
<td>130.00 56</td>
</tr>
</tbody>
</table>

Initiation

Neurologist or respiratory specialist

Re-assessment required after 6 months

All of the following:

1. The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
2. The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
3. The patient has not undergone a tracheostomy; and
4. The patient has not experienced respiratory failure; and
5. Any of the following:
   5.1 The patient is ambulatory; or
   5.2 The patient is able to use upper limbs; or
   5.3 The patient is able to swallow.

Continuation

Re-assessment required after 18 months

All of the following:

1. The patient has not undergone a tracheostomy; and
2. The patient has not experienced respiratory failure; and
3. Any of the following:
   3.1 The patient is ambulatory; or
   3.2 The patient is able to use upper limbs; or
   3.3 The patient is able to swallow.

TETRABENAZINE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Motetis</td>
<td>91.10 112</td>
</tr>
</tbody>
</table>

Anticholinergics

BENZATROPINE MESYLATE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benztrop</td>
<td>7.99 60</td>
</tr>
</tbody>
</table>

PROCYCLIDINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cogentin</td>
<td>95.00 5</td>
</tr>
</tbody>
</table>

Dopamine Agonists and Related Agents

AMANTADINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symmetrel</td>
<td>38.24 60</td>
</tr>
</tbody>
</table>

APOMORPHINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Movapo</td>
<td>119.00 5</td>
</tr>
</tbody>
</table>

BROMOCRIPTINE

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Entapone</td>
<td>22.00 100</td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Precautions</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>(ex man. excl. GST)</td>
<td>$ Per</td>
</tr>
</tbody>
</table>

Brand or Generic Manufacturer

LEVODOPA WITH BENSERAIZE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab dispersible 50 mg with benzerazide 12.5 mg</td>
<td>13.25</td>
<td>100 Madopar Rapid</td>
</tr>
<tr>
<td>Cap 50 mg with benzerazide 12.5 mg</td>
<td>13.75</td>
<td>100 Madopar 62.5</td>
</tr>
<tr>
<td>Cap 100 mg with benzerazide 25 mg</td>
<td>15.80</td>
<td>100 Madopar 125</td>
</tr>
<tr>
<td>Cap long-acting 100 mg with benzerazide 25 mg</td>
<td>22.85</td>
<td>100 Madopar HBS</td>
</tr>
<tr>
<td>Cap 200 mg with benzerazide 50 mg</td>
<td>26.25</td>
<td>100 Madopar 250</td>
</tr>
</tbody>
</table>

LEVODOPA WITH CARBIDOPA

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg with carbipoda 25 mg – 1% DV Feb-18 to 2020</td>
<td>17.97</td>
<td>100 Sinemet</td>
</tr>
<tr>
<td>Tab long-acting 100 mg with carbipoda 25 mg</td>
<td>37.15</td>
<td>100 Sinemet CR</td>
</tr>
<tr>
<td>Tab 250 mg with carbipoda 25 mg – 1% DV Feb-18 to 2020</td>
<td>32.67</td>
<td>100 Sinemet</td>
</tr>
</tbody>
</table>

PRAMIPEXOLE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 0.25 mg – 1% DV Oct-19 to 2022</td>
<td>6.12</td>
<td>100 Ramipex</td>
</tr>
<tr>
<td>Tab 1 mg – 1% DV Oct-19 to 2022</td>
<td>20.73</td>
<td>100 Ramipex</td>
</tr>
</tbody>
</table>

ROPINIROLE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 0.25 mg – 1% DV Mar-20 to 2022</td>
<td>2.78</td>
<td>100 Apo-Ropinirole</td>
</tr>
<tr>
<td>Tab 1 mg – 1% DV Mar-20 to 2022</td>
<td>5.00</td>
<td>100 Apo-Ropinirole</td>
</tr>
<tr>
<td>Tab 2 mg – 1% DV Mar-20 to 2022</td>
<td>7.72</td>
<td>100 Apo-Ropinirole</td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Mar-20 to 2022</td>
<td>16.51</td>
<td>100 Apo-Ropinirole</td>
</tr>
</tbody>
</table>

SELEGILINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg</td>
<td>132.50</td>
</tr>
</tbody>
</table>

TOLCAPONE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg</td>
<td>132.50</td>
<td>100 Tasmar</td>
</tr>
</tbody>
</table>

General Anaesthetics

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>DESFLURANE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln for inhalation 100%, 240 ml bottle – 1% DV Sep-16 to 2020</td>
<td>1,350.00</td>
<td>6 Suprane</td>
</tr>
</tbody>
</table>

DEXMEDETOMIDINE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 100 mcg per ml, 2 ml vial – 1% DV Sep-17 to 2020</td>
<td>357.00</td>
<td>5 Precedex</td>
</tr>
</tbody>
</table>

ETOMIDATE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2 mg per ml, 10 ml ampoule</td>
<td></td>
</tr>
</tbody>
</table>

ISOFLURANE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soln for inhalation 100%, 250 ml bottle – 1% DV Sep-16 to 2020</td>
<td>1,020.00</td>
<td>6 Aerrane</td>
</tr>
</tbody>
</table>

KETAMINE

<table>
<thead>
<tr>
<th>Description</th>
<th>Price</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mg per ml, 100 ml bag – 1% DV Feb-20 to 2022</td>
<td>270.00</td>
<td>10 Biomed</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 10 ml syringe – 1% DV Feb-20 to 2022</td>
<td>70.00</td>
<td>5 Biomed</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 2 ml vial – 1% DV Jan-19 to 2021</td>
<td>31.50</td>
<td>5 Ketalar</td>
</tr>
<tr>
<td></td>
<td>155.60</td>
<td>Ketamine-Claris</td>
</tr>
</tbody>
</table>

Item restricted (see above); Item restricted (see below)
e.g. Brand indicates brand example only. It is not a contracted product.
## NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

### METHOHEXITAL SODIUM

- Inj 10 mg per ml, 50 ml vial

### PROPOFOL

- Inj 10 mg per ml, 20 ml ampoule – 10% DV Dec-19 to 2022.................................4.35 5 Fresofol 1% MCT/LCT
- Inj 10 mg per ml, 20 ml vial........................................................................5.27 5 Fresofol 1% MCT/LCT
- Inj 10 mg per ml, 50 ml vial – 10% DV Oct-19 to 2022.................................19.50 10 Fresofol 1% MCT/LCT
- Inj 10 mg per ml, 100 ml vial – 10% DV Oct-19 to 2022.................................39.00 10 Fresofol 1% MCT/LCT

*(Provive MCT-LCT 1% Inj 10 mg per ml, 20 ml vial to be delisted 1 December 2019)*

### SEVOFLURANE

- Soln for inhalation 100%, 250 ml bottle – 1% DV Sep-16 to 2020.................840.00 6 Baxter

### THIOPENTAL [THIOPENTONE] SODIUM

- Inj 500 mg ampoule

#### Local Anaesthetics

### ARTICAINE HYDROCHLORIDE

- Inj 1%

### ARTICAINE HYDROCHLORIDE WITH ADRENALINE

- Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge
- Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge
- Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge
- Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge

### BENZOCAINE

- Gel 20%

### BENZOCAINE WITH TETRACAIN HYDROCHLORIDE

- Gel 18% with tetracaine hydrochloride 2%
  - e.g. ZAP Topical Anaesthetic Gel

### BUPIVACAINE HYDROCHLORIDE

- Inj 5 mg per ml, 4 ml ampoule – 1% DV Sep-17 to 2020.................................50.00 5 Marcain Isobaric
- Inj 2.5 mg per ml, 20 ml ampoule
- Inj 2.5 mg per ml, 20 ml ampoule sterile pack.................................................29.20 5 Marcain
- Inj 5 mg per ml, 10 ml ampoule sterile pack....................................................20.25 5 Marcain
- Inj 5 mg per ml, 20 ml ampoule
- Inj 5 mg per ml, 20 ml ampoule sterile pack....................................................20.70 5 Marcain
- Inj 1.25 mg per ml, 100 ml bag
- Inj 1.25 mg per ml, 200 ml bag
- Inj 2.5 mg per ml, 100 ml bag – 1% DV Sep-17 to 2020.................................150.00 5 Marcain
- Inj 2.5 mg per ml, 200 ml bag
- Inj 1.25 mg per ml, 500 ml bag

### BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE

- Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial – 1% DV Aug-19 to 2022................................................94.50 5 Marcain with Adrenaline
- Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial – 1% DV Aug-19 to 2022................................................80.50 5 Marcain with Adrenaline

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>NERVOUS SYSTEM</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>BUPIVACAINE HYDROCHLORIDE WITH FENTANYL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag</td>
</tr>
<tr>
<td>Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag – 1% DV Apr-20</td>
</tr>
<tr>
<td>106 to 2022 .......................................................... 305.00</td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe</td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag – 1% DV Nov-19</td>
</tr>
<tr>
<td>106 to 2022 .......................................................... 225.00</td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag – 1% DV Nov-19</td>
</tr>
<tr>
<td>106 to 2022 .......................................................... 235.00</td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe</td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe ..................................... 72.00</td>
</tr>
<tr>
<td>Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe ..................................... 92.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BUPIVACAINE HYDROCHLORIDE WITH GLUCOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 0.5% with glucose 8%, 4 ml ampoule .................................................. 38.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COCAINE HYDROCHLORIDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paste 5%</td>
</tr>
<tr>
<td>Soln 15%, 2 ml syringe</td>
</tr>
<tr>
<td>Soln 4%, 2 ml syringe .......................................................... 25.46</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COCAINE HYDROCHLORIDE WITH ADRENALINE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paste 15% with adrenaline 0.06%</td>
</tr>
<tr>
<td>Paste 25% with adrenaline 0.06%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ETHYL CHLORIDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spray 100%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIDOCAINE [LIGNOCAINE]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crm 4% .......................................................... 5.40</td>
</tr>
<tr>
<td>.......................................................... 27.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gel 2% – 1% DV Nov-18 to 2021 ............ 4.87</td>
</tr>
<tr>
<td>Soln 4%</td>
</tr>
<tr>
<td>Spray 10% – 1% DV Jul-19 to 2022 ........... 75.00</td>
</tr>
<tr>
<td>Oral (gel) soln 2% – 1% DV Oct-17 to 2020 ... 38.00</td>
</tr>
<tr>
<td>Inj 1%, 20 ml ampoule, sterile pack</td>
</tr>
<tr>
<td>Inj 2%, 20 ml ampoule, sterile pack</td>
</tr>
<tr>
<td>Inj 1%, 5 ml ampoule .................................. 8.75</td>
</tr>
<tr>
<td>Inj 1%, 20 ml vial – 1% DV Jul-19 to 2022 . 6.20</td>
</tr>
<tr>
<td>Inj 2%, 5 ml ampoule – 1% DV Nov-19 to 2022 ... 8.25</td>
</tr>
<tr>
<td>Inj 2%, 20 ml vial – 1% DV Jul-19 to 2022 ...... 6.45</td>
</tr>
<tr>
<td>Gel 2%, 10 ml urethral syringe – 1% DV Nov-19 to 2022 .......... 105.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1% with adrenaline 1:100,000, 5 ml ampoule – 1% DV Nov-19</td>
</tr>
<tr>
<td>106 to 2022 .......................................................... 29.00</td>
</tr>
<tr>
<td>Inj 1% with adrenaline 1:200,000, 20 ml vial ..................... 50.00</td>
</tr>
<tr>
<td>Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge</td>
</tr>
<tr>
<td>Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge</td>
</tr>
<tr>
<td>Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge</td>
</tr>
<tr>
<td>Inj 2% with adrenaline 1:200,000, 20 ml vial ..................... 60.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe – 1% DV Sep-17 to 2020 .... 17.50</td>
</tr>
</tbody>
</table>
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH CHLORHEXIDINE
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe ................. 81.50 10 Pfizer

LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH PHENYLEPHRINE HYDROCHLORIDE
Nasal spray 5% with phenylephrine hydrochloride 0.5%

LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE
Crm 2.5% with prilocaine 2.5% ......................................................... 45.00 30 g EMLA
Patch 25 mcg with prilocaine 25 mcg ........................................... 115.00 20 EMLA
Crm 2.5% with prilocaine 2.5%, 5 g .................................................. 45.00 5 EMLA

MEPIVACAINE HYDROCHLORIDE
Inj 3%, 1.8 ml dental cartridge .......................................................... 43.60 50 Scandonest 3%
Inj 3%, 2.2 ml dental cartridge .......................................................... 43.60 50 Scandonest 3%

PRILOCAINE HYDROCHLORIDE
Inj 0.5%, 50 ml vial ......................................................................... 100.00 5 Citanest
Inj 2%, 5 ml ampoule

PRILOCAINE HYDROCHLORIDE WITH FELYPRESSIN
Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge
Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge

ROPIVACAINE HYDROCHLORIDE
Inj 2 mg per ml, 10 ml ampoule – 1% DV Sep-17 to 2020 ................. 8.80 5 Ropivacaine Kabi
Inj 2 mg per ml, 20 ml ampoule – 1% DV Sep-17 to 2020 ................. 9.20 5 Ropivacaine Kabi
Inj 2 mg per ml, 100 ml bag – 1% DV Sep-17 to 2020 ..................... 29.50 5 Ropivacaine Kabi
Inj 2 mg per ml, 200 ml bag – 1% DV Sep-17 to 2020 ..................... 39.00 5 Ropivacaine Kabi
Inj 7.5 mg per ml, 10 ml ampoule – 1% DV Sep-17 to 2020 ............. 9.90 5 Ropivacaine Kabi
Inj 7.5 mg per ml, 20 ml ampoule – 1% DV Sep-17 to 2020 ............. 12.15 5 Ropivacaine Kabi
Inj 10 mg per ml, 10 ml ampoule – 1% DV Sep-17 to 2020 ............. 15.80 5 Ropivacaine Kabi
Inj 10 mg per ml, 20 ml ampoule – 1% DV Sep-17 to 2020 ............. 15.80 5 Ropivacaine Kabi

ROPIVACAINE HYDROCHLORIDE WITH FENTANYL
Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag ......................... 198.50 5 Naropin
Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag ......................... 270.00 5 Naropin

TETRACAINE [AMETHOCAINE] HYDROCHLORIDE
Gel 4%

Analgesics
Non-Opioid Analgesics

ASPIRIN
Tab dispersible 300 mg – 1% DV Oct-19 to 2022 ...................... 4.50 100 Ethics Aspirin

CAPSAICIN – Restricted see terms below
Crn 0.075% ................................................................................. 12.50 45 g Zostrix HP
Restricted (RS1145)
Initiation
For post-herpetic neuralgia or diabetic peripheral neuropathy.

METHOXYFLURANE – Restricted see terms below
Soln for inhalation 99.9%, 3 ml bottle
Restricted (RS1292)
Initiation
Both:

continued...
continued...

1 Patient is undergoing a painful procedure with an expected duration of less than one hour; and
2 Only to be used under supervision by a medical practitioner or nurse who is trained in the use of methoxyflurane.

**NEFOPAM HYDROCHLORIDE**

Tab 30 mg

**PARACETAMOL** – Some items restricted see terms below

Tab soluble 500 mg
Tab 500 mg

<table>
<thead>
<tr>
<th>Item</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 120 mg per 5 ml – 1% DV Dec-17 to 2020</td>
<td>5.35</td>
</tr>
<tr>
<td>Oral liq 250 mg per 5 ml – 20% DV Aug-18 to 2020</td>
<td>5.81</td>
</tr>
</tbody>
</table>

Inj 10 mg per ml, 100 ml vial – 1% DV Sep-17 to 2020

Suppos 25 mg – 1% DV Nov-19 to 2022
Suppos 50 mg – 1% DV Nov-19 to 2022
Suppos 125 mg – 1% DV Nov-18 to 2021
Suppos 250 mg – 1% DV Nov-18 to 2021
Suppos 500 mg – 1% DV Feb-19 to 2021

**SUCROSE**

Oral liq 25% – 1% DV Feb-20 to 2022

---

**Opioid Analgesics**

**ALFENTANIL**

Inj 0.5 mg per ml, 2 ml ampoule – 1% DV Sep-17 to 2020

**CODEINE PHOSPHATE**

Tab 15 mg
Tab 30 mg
Tab 60 mg

**DIHYDROCODEINE TARTRATE**

Tab long-acting 60 mg – 1% DV Oct-19 to 2022

**FENTANYL**

Inj 10 mcg per ml, 10 ml syringe
Inj 50 mcg per ml, 2 ml ampoule – 1% DV Nov-18 to 2021
Inj 10 mcg per ml, 50 ml syringe
Inj 10 mcg per ml, 50 ml syringe + 1% DV Nov-18 to 2021
Inj 10 mcg per ml, 100 ml bag – 1% DV Nov-19 to 2022
Inj 10 mcg per ml, 100 ml bag – 1% DV Oct-18 to 2019

Patch 12.5 mcg per hour – 1% DV Oct-17 to 2020
Patch 25 mcg per hour – 1% DV Oct-17 to 2020
Patch 50 mcg per hour – 1% DV Oct-17 to 2020
Patch 75 mcg per hour – 1% DV Oct-17 to 2020
Patch 100 mcg per hour – 1% DV Oct-17 to 2020

---

Item restricted (see ➥ above); Item restricted (see ➥ below)

* e.g. Brand indicates brand example only. It is not a contracted product.
### METHADONE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg – 1% DV Sep-19 to 2022</td>
<td>$1.40</td>
<td>Methatabs</td>
</tr>
<tr>
<td>Tab 5 mg - bottle pack</td>
<td>$1.40</td>
<td>Methatabs</td>
</tr>
<tr>
<td>Oral liq 2 mg per ml – 1% DV Oct-18 to 2021</td>
<td>$5.79</td>
<td>Biodone</td>
</tr>
<tr>
<td>Oral liq 5 mg per ml – 1% DV Oct-18 to 2021</td>
<td>$5.79</td>
<td>Biodone Extra Forte</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml – 1% DV Oct-18 to 2021</td>
<td>$6.79</td>
<td>Biodone Extra Forte</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml vial</td>
<td>$61.00</td>
<td>AFT</td>
</tr>
</tbody>
</table>

*Methatabs Tab 5 mg - bottle pack to be delisted 1 December 2019*

### MORPHINE HYDROCHLORIDE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral liq 1 mg per ml – 1% DV Dec-18 to 2021</td>
<td>$9.28</td>
<td>RA-Morph</td>
</tr>
<tr>
<td>Oral liq 2 mg per ml – 1% DV Dec-18 to 2021</td>
<td>$16.24</td>
<td>RA-Morph</td>
</tr>
<tr>
<td>Oral liq 5 mg per ml – 1% DV Dec-18 to 2021</td>
<td>$19.44</td>
<td>RA-Morph</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml – 1% DV Dec-18 to 2021</td>
<td>$27.74</td>
<td>RA-Morph</td>
</tr>
</tbody>
</table>

### MORPHINE SULPHATE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab long-acting 10 mg</td>
<td>$1.93</td>
<td>Arrow-Morphine LA</td>
</tr>
<tr>
<td>Tab immediate-release 10 mg – 1% DV Sep-17 to 2020</td>
<td>$2.80</td>
<td>Sevredol</td>
</tr>
<tr>
<td>Tab immediate-release 20 mg – 1% DV Sep-17 to 2020</td>
<td>$5.52</td>
<td>Sevredol</td>
</tr>
<tr>
<td>Tab long-acting 30 mg</td>
<td>$2.85</td>
<td>Arrow-Morphine LA</td>
</tr>
<tr>
<td>Tab long-acting 60 mg</td>
<td>$5.60</td>
<td>Arrow-Morphine LA</td>
</tr>
<tr>
<td>Tab long-acting 100 mg</td>
<td>$6.10</td>
<td>Arrow-Morphine LA</td>
</tr>
<tr>
<td>Cap long-acting 10 mg – 1% DV Jan-20 to 2022</td>
<td>$2.05</td>
<td>m-Eslon</td>
</tr>
<tr>
<td>Cap long-acting 30 mg – 1% DV Jan-20 to 2022</td>
<td>$3.00</td>
<td>m-Eslon</td>
</tr>
<tr>
<td>Cap long-acting 60 mg – 1% DV Jan-20 to 2022</td>
<td>$6.12</td>
<td>m-Eslon</td>
</tr>
<tr>
<td>Cap long-acting 100 mg</td>
<td>$7.13</td>
<td>m-Eslon</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 100 ml bag – 1% DV Oct-17 to 2020</td>
<td>$97.25</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 10 ml syringe – 1% DV Oct-17 to 2020</td>
<td>$24.00</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 50 ml syringe – 1% DV Oct-17 to 2020</td>
<td>$50.75</td>
<td>Biomed</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 2 ml syringe</td>
<td>$135.00</td>
<td>DBL Morphine Sulphate</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$6.27</td>
<td>DBL Morphine Sulphate</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$4.47</td>
<td>DBL Morphine Sulphate</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 mg cassette</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 15 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$4.76</td>
<td>DBL Morphine Sulphate</td>
</tr>
<tr>
<td>Inj 30 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$6.19</td>
<td>DBL Morphine Sulphate</td>
</tr>
<tr>
<td>Inj 200 mcg in 0.4 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 300 mcg in 0.3 ml syringe</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### MORPHINE TARTRATE

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 80 mg per ml, 1.5 ml ampoule</td>
<td>$42.72</td>
<td>DBL Morphine Tartrate</td>
</tr>
</tbody>
</table>

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## NERVOUS SYSTEM

### Oxycodone Hydrochloride

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab controlled-release 5 mg – 1% DV May-19 to 2021</td>
<td>$2.15</td>
<td>Oxycodone Sandoz</td>
</tr>
<tr>
<td>Tab controlled-release 10 mg – 1% DV May-19 to 2021</td>
<td>$2.15</td>
<td>Oxycodone Sandoz</td>
</tr>
<tr>
<td>Tab controlled-release 20 mg – 1% DV May-19 to 2021</td>
<td>$2.15</td>
<td>Oxycodone Sandoz</td>
</tr>
<tr>
<td>Tab controlled-release 40 mg – 1% DV May-19 to 2021</td>
<td>$3.20</td>
<td>Oxycodone Sandoz</td>
</tr>
<tr>
<td>Tab controlled-release 80 mg – 1% DV May-19 to 2021</td>
<td>$10.98</td>
<td>Oxycodone Sandoz</td>
</tr>
<tr>
<td>Cap immediate-release 5 mg – 1% DV Sep-18 to 2021</td>
<td>$1.88</td>
<td>OxyNorm</td>
</tr>
<tr>
<td>Cap immediate-release 10 mg – 1% DV Sep-18 to 2021</td>
<td>$3.32</td>
<td>OxyNorm</td>
</tr>
<tr>
<td>Cap immediate-release 20 mg – 1% DV Sep-18 to 2021</td>
<td>$5.81</td>
<td>OxyNorm</td>
</tr>
<tr>
<td>Oral liq 5 mg per 5 ml – 1% DV May-19 to 2021</td>
<td>$11.20</td>
<td>OxyNorm</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 100 ml bag – 1% DV Sep-18 to 2021</td>
<td>$7.28</td>
<td>OxyNorm</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 2 ml ampoule – 1% DV Sep-18 to 2021</td>
<td>$14.36</td>
<td>OxyNorm</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule – 1% DV Sep-18 to 2021</td>
<td>$30.60</td>
<td>OxyNorm</td>
</tr>
</tbody>
</table>

### Paracetamol with Codeine

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab paracetamol 500 mg with codeine phosphate 8 mg – 1% DV Sep-17 to 2020</td>
<td>$18.21</td>
<td>Paracetamol + Codeine (Relieve)</td>
</tr>
</tbody>
</table>

### Pethidine Hydrochloride

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg – 1% DV Sep-18 to 2021</td>
<td>$4.46</td>
<td>PSM</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 10 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 5 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 50 ml syringe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$4.98</td>
<td>DBL Pethidine Hydrochloride</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 2 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$5.12</td>
<td>DBL Pethidine Hydrochloride</td>
</tr>
</tbody>
</table>

### Remifentanil

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mg vial – 1% DV Oct-17 to 2020</td>
<td>$13.95</td>
<td>Remifentanil-AFT</td>
</tr>
<tr>
<td>Inj 2 mg vial – 1% DV Oct-17 to 2020</td>
<td>$19.95</td>
<td>Remifentanil-AFT</td>
</tr>
</tbody>
</table>

### Tramadol Hydrochloride

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab sustained-release 100 mg – 1% DV Sep-17 to 2020</td>
<td>$1.55</td>
<td>Tramal SR 100</td>
</tr>
<tr>
<td>Tab sustained-release 150 mg – 1% DV Sep-17 to 2020</td>
<td>$2.10</td>
<td>Tramal SR 150</td>
</tr>
<tr>
<td>Tab sustained-release 200 mg – 1% DV Sep-17 to 2020</td>
<td>$2.75</td>
<td>Tramal SR 200</td>
</tr>
<tr>
<td>Cap 50 mg – 1% DV Sep-17 to 2020</td>
<td>$2.25</td>
<td>Arrow-Tramadol</td>
</tr>
<tr>
<td>Oral soln 10 mg per ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 10 mg per ml, 100 ml bag</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$4.50</td>
<td>Tramal 50</td>
</tr>
<tr>
<td>Inj 50 mg per ml, 2 ml ampoule – 1% DV Sep-17 to 2020</td>
<td>$4.50</td>
<td>Tramal 100</td>
</tr>
</tbody>
</table>

### Antidepressants

#### Cyclic and Related Agents

### Amitriptyline

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Apr-18 to 2020</td>
<td>$1.96</td>
<td>Arrow-Amitriptyline</td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Apr-18 to 2020</td>
<td>$1.52</td>
<td>Arrow-Amitriptyline</td>
</tr>
<tr>
<td>Tab 50 mg – 1% DV Apr-18 to 2020</td>
<td>$2.51</td>
<td>Arrow-Amitriptyline</td>
</tr>
</tbody>
</table>

### Clomipramine Hydrochloride

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Oct-18 to 2021</td>
<td>$13.99</td>
<td>Apo-Clomipramine</td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Oct-18 to 2021</td>
<td>$9.46</td>
<td>Apo-Clomipramine</td>
</tr>
</tbody>
</table>
## NERVOUS SYSTEM

**Price** (ex man. excl. GST) $ Per Brand or Generic Manufacturer

### DOSULEPIN [DOTHIEPIN] HYDROCHLORIDE  – **Restricted:** For continuation only
- Tab 75 mg ....................................................................................................... 11.19 100 Dopress
- Cap 25 mg ...................................................................................................... 6.45 100 Dopress

*(Dopress Tab 75 mg to be delisted 1 August 2020)*
*(Dopress Cap 25 mg to be delisted 1 January 2020)*

### DOXEPIN HYDROCHLORIDE  – **Restricted:** For continuation only
- Cap 10 mg
- Cap 25 mg
- Cap 50 mg

### IMIPRAMINE HYDROCHLORIDE
- Tab 10 mg ......................................................................................................... 5.48 50 Tofranil
- Tab 25 mg ......................................................................................................... 6.58 60 Tofranil
- Tab 50 mg ......................................................................................................... 8.80 50 Tofranil

### MAPROTILINE HYDROCHLORIDE
- Tab 25 mg
- Tab 75 mg

### MIANSERIN HYDROCHLORIDE  – **Restricted:** For continuation only
- Tab 30 mg

### NORTRIPTYLINE HYDROCHLORIDE
- Tab 10 mg  – 1% DV Oct-19 to 2022........................................................................ 2.44 100 Norpress
- Tab 25 mg  – 1% DV Oct-19 to 2022........................................................................ 5.98 180 Norpress

### Monoamine-Oxidase Inhibitors - Non-Selective

#### PHENELZINE SULPHATE
- Tab 15 mg

#### TRANYLCYPROMINE SULPHATE
- Tab 10 mg

### Monoamine-Oxidase Type A Inhibitors

#### MOCLOBEMIDE
- Tab 150 mg  – 1% DV Apr-19 to 2021................................................................. 6.40 60 Aurorix
- Tab 300 mg  – 1% DV Apr-19 to 2021................................................................. 9.80 60 Aurorix

### Other Antidepressants

#### MIRTAZAPINE
- Tab 30 mg  – 1% DV Oct-18 to 2021................................................................. 2.63 30 Apo-Mirtazapine
- Tab 45 mg  – 1% DV Oct-18 to 2021................................................................. 3.48 30 Apo-Mirtazapine

#### VENLAFAXINE
- Cap 37.5 mg  – 1% DV Jun-17 to 2020................................................................. 6.38 84 Enlafax XR
- Cap 75 mg  – 1% DV Jun-17 to 2020................................................................. 8.11 84 Enlafax XR
- Cap 150 mg  – 1% DV Jun-17 to 2020................................................................. 11.16 84 Enlafax XR

### Selective Serotonin Reuptake Inhibitors

#### CITALOPRAM HYDROBROMIDE
- Tab 20 mg  – 1% DV Sep-18 to 2021................................................................. 1.52 84 PSM Citalopram

---

Products with Hospital Supply Status (HSS) are in **bold**
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

ESCITALOPRAM

Tab 10 mg – 1% DV Dec-17 to 2020 ............................................................ 1.11 28 Escitalopram-Apotex
Tab 20 mg – 1% DV Dec-17 to 2020 ............................................................ 1.90 28 Escitalopram-Apotex

FLUOXETINE HYDROCHLORIDE

Tab dispersible 20 mg, scored – 1% DV Apr-20 to 2022 .................................. 2.47 30 Arrow-Fluoxetine
Cap 20 mg – 1% DV Apr-20 to 2022 ............................................................... 1.98 90 Arrow-Fluoxetine

(Arrow-Fluoxetine Tab dispersible 20 mg, scored to be delisted 1 April 2020)
(Arrow-Fluoxetine Cap 20 mg to be delisted 1 April 2020)

PAROXETINE

Tab 20 mg – 1% DV Mar-20 to 2022 ............................................................... 4.02 90 Apo-Paroxetine

(Apo-Paroxetine Tab 20 mg to be delisted 1 March 2020)

SERTRALINE

Tab 50 mg – 1% DV Mar-20 to 2022 ............................................................... 3.05 90 Arrow-Sertraline
Tab 100 mg – 1% DV Mar-20 to 2022 ............................................................ 5.25 90 Arrow-Sertraline

(Arrow-Sertraline Tab 50 mg to be delisted 1 March 2020)
(Arrow-Sertraline Tab 100 mg to be delisted 1 March 2020)

Antiepilepsy Drugs

Agents for the Control of Status Epilepticus

CLONAZEPAM

Inj 1 mg per ml, 1 ml ampoule ........................................................................ 21.00 5 Rivotril

DIAZEPAM

Inj 5 mg per ml, 2 ml ampoule .......................................................................... 11.83 5 Hospira
Rectal tubes 5 mg ............................................................................................... 40.87 5 Stesolid
Rectal tubes 10 mg ............................................................................................. 40.87 5 Stesolid

LORAZEPAM

Inj 2 mg vial
Inj 4 mg per ml, 1 ml vial

PARALDEHYDE

Inj 5 ml ampoule

PHENYTOIN SODIUM

Inj 50 mg per ml, 2 ml ampoule ....................................................................... 88.63 5 Hospira
Inj 50 mg per ml, 5 ml ampoule ....................................................................... 133.92 5 Hospira

Control of Epilepsy

CARBAMAZEPINE

Tab 200 mg ................................................................................................. 14.53 100 Tegretol
Tab long-acting 200 mg .................................................................................. 16.98 100 Tegretol CR
Tab 400 mg ................................................................................................. 34.58 100 Tegretol
Tab long-acting 400 mg .................................................................................. 39.17 100 Tegretol CR
Oral liq 20 mg per ml ....................................................................................... 26.37 250 ml Tegretol

CLOBAZAM

Tab 10 mg

Item restricted (see above); Item restricted (see below)
e.g. Brand indicates brand example only. It is not a contracted product.
<table>
<thead>
<tr>
<th>NERVOUS SYSTEM</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>CLONAZEPAM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral drops 2.5 mg per ml</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ETHOSUXIMIDE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 250 mg</td>
</tr>
<tr>
<td>Oral liq 50 mg per ml</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GABAPENTIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Note: Gabapentin not to be given in combination with pregabalin</td>
</tr>
<tr>
<td>Cap 100 mg – 1% DV Aug-18 to 2021</td>
</tr>
<tr>
<td>Cap 300 mg – 1% DV Aug-18 to 2021</td>
</tr>
<tr>
<td>Cap 400 mg – 1% DV Aug-18 to 2021</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LACOSAMIDE – Restricted see terms below</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 50 mg</td>
</tr>
<tr>
<td>Tab 100 mg</td>
</tr>
<tr>
<td>Tab 150 mg</td>
</tr>
<tr>
<td>Tab 200 mg</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 20 ml vial</td>
</tr>
<tr>
<td>Restricted (RS1151)</td>
</tr>
</tbody>
</table>

Initialization

Re-assessment required after 15 months
Both:
1. Patient has partial-onset epilepsy; and
2. Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: “Optimal treatment” is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

Continuation

Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective

<table>
<thead>
<tr>
<th>LAMOTRIGINE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab dispersible 2 mg</td>
</tr>
<tr>
<td>Tab dispersible 5 mg</td>
</tr>
<tr>
<td>Tab dispersible 25 mg – 5% DV Oct-19 to 2022</td>
</tr>
<tr>
<td>Tab dispersible 50 mg – 5% DV Oct-19 to 2022</td>
</tr>
<tr>
<td>Tab dispersible 100 mg – 5% DV Oct-19 to 2022</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LEVETIRACETAM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg – 1% DV Aug-19 to 2022</td>
</tr>
<tr>
<td>Tab 500 mg – 1% DV Aug-19 to 2022</td>
</tr>
<tr>
<td>Tab 750 mg – 1% DV Aug-19 to 2022</td>
</tr>
<tr>
<td>Tab 1,000 mg – 1% DV Aug-19 to 2022</td>
</tr>
<tr>
<td>Oral liq 100 mg per ml – 1% DV Apr-18 to 2020</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 5 ml vial – 1% DV Oct-19 to 2022</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PHENOBARBITONE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 15 mg – 1% DV Oct-18 to 2021</td>
</tr>
<tr>
<td>Tab 30 mg – 1% DV Oct-18 to 2021</td>
</tr>
</tbody>
</table>
NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price (ex man. excl. GST) $ Per</td>
</tr>
</tbody>
</table>

**PHENYTOIN**
- Tab 50 mg

**PHENYTOIN SODIUM**
- Cap 30 mg
- Cap 100 mg
- Oral liq 6 mg per ml

**PREGABALIN**
- Note: Pregabalin not to be given in combination with gabapentin

<table>
<thead>
<tr>
<th>Size/Strength</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 25 mg → 1% DV Jul-18 to 2021</td>
<td>2.25</td>
<td>Pregabalin Pfizer</td>
</tr>
<tr>
<td>Cap 75 mg → 1% DV Jul-18 to 2021</td>
<td>2.65</td>
<td>Pregabalin Pfizer</td>
</tr>
<tr>
<td>Cap 150 mg → 1% DV Jul-18 to 2021</td>
<td>4.01</td>
<td>Pregabalin Pfizer</td>
</tr>
<tr>
<td>Cap 300 mg → 1% DV Jul-18 to 2021</td>
<td>7.38</td>
<td>Pregabalin Pfizer</td>
</tr>
</tbody>
</table>

**PRIMIDONE**
- Tab 250 mg

**SODIUM VALPROATE**
- Tab 100 mg
- Tab EC 200 mg
- Tab EC 500 mg
- Oral liq 40 mg per ml
- Inj 100 mg per ml, 4 ml vial → 1% DV Sep-18 to 2021 9.98 |

**STIRIPENTOL – Restricted see terms below**
- Cap 250 mg 509.29 60 Diacomit
- Powder for oral liq 250 mg sachet 509.29 60 Diacomit

**Initiation**
- Paediatric neurologist
- Re-assessment required after 6 months

Both:
1. Patient has confirmed diagnosis of Dravet syndrome; and
2. Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

**Continuation**
- Paediatric neurologist
- Patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

**TOPIRAMATE**
- Tab 25 mg 11.07 60 Arrow-Topiramate
- Tab 50 mg 26.04 60 Topamax
- Tab 100 mg 44.26 60 Topiramate Actavis
- Tab 200 mg 75.25 60 Topiramate Actavis
- Cap sprinkle 15 mg 20.84 60 Topamax
- Cap sprinkle 25 mg 26.04 60 Topamax

---

*Item restricted (see ➥ above); ➤ Item restricted (see ➤ below)*
e.g. Brand indicates brand example only. It is not a contracted product.
NERVOUS SYSTEM

VIGABATRIN – Restricted see terms below

† Tab 500 mg

► Restricted (RS1153)

Initiation
Re-assessment required after 15 months

Both:
1 Either:
   1.1 Patient has infantile spasms; or
   1.2 Both:
      1.2.1 Patient has epilepsy; and
      1.2.2 Either:
         1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
         1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from
         optimal treatment with other antiepilepsy agents; and

2 Either:
   2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a
       6-monthly basis thereafter); or
   2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are
indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features
affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Continuation

Both:
1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
2 Either:
   2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration
       of treatment with vigabatrin; or
   2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with
anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Antimigraine Preparations

Acute Migraine Treatment

DIHYDROERGOTAMINE MESYLATE
   Inj 1 mg per ml, 1 ml ampoule

ERGOTAMINE TARTRATE WITH CAFFEINE
   Tab 1 mg with caffeine 100 mg

METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL
   Tab 5 mg with paracetamol 500 mg

RIZATRIPTAN
   Tab orodispersible 10 mg – 1% DV Sep-17 to 2020 ........................................ 5.26 30 Rizamelt

SUMATRIPTAN
   Tab 50 mg – 1% DV Oct-19 to 2022 .......................................................... 24.44 100 Apo-Sumatriptan
   Tab 100 mg – 1% DV Oct-19 to 2022 ......................................................... 46.23 100 Apo-Sumatriptan
   Inj 12 mg per ml, 0.5 ml prefilled pen .................................................... 81.15 2 Clustran

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
# NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

## Prophylaxis of Migraine

| PIZOTIFEN | Tab 500 mcg | 23.21 | 100 | Sandomigran |

## Antinausea and Vertigo Agents

### Antireflux (see terms below)

| APREPITANT – Restricted | see terms below |

| A | Cap 2 x 80 mg and 1 x 125 mg – 1% DV Jul-18 to 2021 | 84.00 | 3 | Emend Tri-Pack |

### Initiation

- Patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

| BETAHISTINE DIHYDROCHLORIDE | Tab 16 mg – 1% DV Sep-17 to 2020 | 2.89 | 84 | Vergo 16 |

### Vertigo Agents

| CYCLIZINE HYDROCHLORIDE | Tab 50 mg – 1% DV Jan-19 to 2021 | 0.55 | 10 | Nausicalm |

### Vertigo Agents

| CYCLIZINE LACTATE | Inj 50 mg per ml, 1 ml ampoule | 14.95 | 5 | Nausicalm |

### Vertigo Agents

| DOMPERIDONE | Tab 10 mg – 1% DV Mar-19 to 2021 | 2.25 | 100 | Pharmacy Health |

### Vertigo Agents

| DROPERIDOL | Inj 2.5 mg per ml, 1 ml ampoule | 35.00 | 10 | Droperidol Panpharma |

### Vertigo Agents

| GRANISETRON | Inj 1 mg per ml, 3 ml ampoule – 1% DV Dec-18 to 2020 | 0.40 | 1 | Deva |

### Vertigo Agents

| HYOSCINE HYDROBROMIDE | Inj 400 mcg per ml, 1 ml ampoule | 46.50 | 5 | Hospira |

### Vertigo Agents

| Restricted (RS1155) | Patch 1.5 mg | 14.11 | 2 | Scopoderm TTS |

### Initiation

- **Any of the following:**
  1. Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or
  2. Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective; or
  3. For treatment of post-operative nausea and vomiting where cyclizine, droperidol and a 5HT3 antagonist have proven ineffective, are not tolerated or are contraindicated.

| METOCLOPRAMIDE HYDROCHLORIDE | Tab 10 mg – 1% DV Jan-18 to 2020 | 1.30 | 100 | Metoclopramide Actavis 10 |

### Vomiting and Vertigo Agents

| Oral liq 5 mg per 5 ml | 1.30 | 100 | Metoclopramide Actavis 10 |

### Dosing

| Inj 5 mg per ml, 2 ml ampoule – 1% DV Jan-20 to 2022 | 9.50 | 10 | Pfizer |

---

- Item restricted (see ➥ above);
- Item restricted (see ➥ below)

*e.g. Brand* indicates brand example only. It is not a contracted product.
<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>(ex man. excl. GST) $</td>
<td>Brand or Generic Manufacturer</td>
</tr>
<tr>
<td>ONDANSETRON</td>
<td></td>
</tr>
<tr>
<td>Tab 4 mg – 1% DV Apr-20 to 2022</td>
<td>3.36 50 Apo-ondansetron</td>
</tr>
<tr>
<td>Onrex</td>
<td>2.68</td>
</tr>
<tr>
<td>Tab dispersible 4 mg – 1% DV Apr-18 to 2020</td>
<td>0.95 10 Ondansetron ODT-DRLA</td>
</tr>
<tr>
<td>Tab 8 mg – 1% DV Apr-20 to 2022</td>
<td>4.77 50 Apo-ondansetron</td>
</tr>
<tr>
<td>Onrex</td>
<td>4.57</td>
</tr>
<tr>
<td>Tab dispersible 8 mg – 1% DV Apr-18 to 2020</td>
<td>1.43 10 Ondansetron ODT-DRLA</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 2 ml ampoule</td>
<td>1.50 5 Ondansetron-claris</td>
</tr>
<tr>
<td>Inj 2 mg per ml, 4 ml ampoule</td>
<td>2.20 5 Ondansetron Kabi</td>
</tr>
</tbody>
</table>

(Apo-ondansetron Tab 4 mg to be delisted 1 April 2020)
(Apo-ondansetron Tab 8 mg to be delisted 1 April 2020)

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROCHLORPERAZINE</td>
<td></td>
</tr>
<tr>
<td>Tab buccal 3 mg</td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Mar-18 to 2020</td>
<td>6.35 250 Nausafix</td>
</tr>
<tr>
<td>Inj 12.5 mg per ml, 1 ml ampoule</td>
<td></td>
</tr>
<tr>
<td>Suppos 25 mg</td>
<td></td>
</tr>
</tbody>
</table>

TROPISETRON

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 mg per ml, 2 ml ampoule – 1% DV Sep-18 to 2021</td>
<td>8.95 1 Tropisetron-AFT</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 5 ml ampoule</td>
<td>13.95 1 Tropisetron-AFT</td>
</tr>
</tbody>
</table>

**Antipsychotic Agents**

**General**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMISULPRIDE</td>
<td></td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Nov-19 to 2022</td>
<td>5.15 30 Sulprix</td>
</tr>
<tr>
<td>Tab 200 mg – 1% DV Nov-19 to 2022</td>
<td>14.96 60 Sulprix</td>
</tr>
<tr>
<td>Tab 400 mg – 1% DV Feb-20 to 2022</td>
<td>29.78 60 Sulprix</td>
</tr>
<tr>
<td>Oral liq 100 mg per ml</td>
<td>65.53 60 ml Solian</td>
</tr>
</tbody>
</table>

(Solian Oral liq 100 mg per ml to be delisted 1 July 2020)

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARIPIPRAZOLE</td>
<td></td>
</tr>
<tr>
<td>Tab 5 mg – 1% DV Aug-18 to 2021</td>
<td>17.50 30 Aripiprazole Sandoz</td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Aug-18 to 2021</td>
<td>17.50 30 Aripiprazole Sandoz</td>
</tr>
<tr>
<td>Tab 15 mg – 1% DV Aug-18 to 2021</td>
<td>17.50 30 Aripiprazole Sandoz</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Aug-18 to 2021</td>
<td>17.50 30 Aripiprazole Sandoz</td>
</tr>
<tr>
<td>Tab 30 mg – 1% DV Aug-18 to 2021</td>
<td>17.50 30 Aripiprazole Sandoz</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHLORPROMAZINE HYDROCHLORIDE</td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Jan-20 to 2022</td>
<td>14.83 100 Largactil</td>
</tr>
<tr>
<td>Tab 25 mg – 1% DV Jan-20 to 2022</td>
<td>15.62 100 Largactil</td>
</tr>
<tr>
<td>Tab 100 mg – 1% DV Jan-20 to 2022</td>
<td>36.73 100 Largactil</td>
</tr>
<tr>
<td>Oral liq 10 mg per ml</td>
<td></td>
</tr>
<tr>
<td>Oral liq 20 mg per ml</td>
<td></td>
</tr>
<tr>
<td>Inj 25 mg per ml, 2 ml ampoule – 1% DV Jan-20 to 2022</td>
<td>30.79 10 Largactil</td>
</tr>
<tr>
<td>Brand or Generic Manufacturer</td>
<td>Price Excl. GST</td>
</tr>
<tr>
<td>------------------------------</td>
<td>----------------</td>
</tr>
</tbody>
</table>

### CLOZAPINE
- **Tab 25 mg**
  - 6.69 $ 50 Clopine
  - 13.37 $ 100 Clopine
  - 5.69 $ 50 Clozaril
  - 11.36 $ 100 Clozaril
- **Tab 50 mg**
  - 8.67 $ 50 Clopine
  - 17.33 $ 100 Clopine
- **Tab 100 mg**
  - 17.33 $ 50 Clopine
  - 34.65 $ 100 Clopine
  - 14.73 $ 50 Clozaril
  - 29.45 $ 100 Clozaril
- **Tab 200 mg**
  - 34.65 $ 50 Clopine
  - 69.30 $ 100 Clopine
- **Oral liq 50 mg per ml**
  - 17.33 $ 100 ml Clopine

### HALOPERIDOL
- **Tab 500 mcg – 1% DV Oct-19 to 2022**
  - 6.23 $ 100 Serenace
- **Tab 1.5 mg – 1% DV Oct-19 to 2022**
  - 9.43 $ 100 Serenace
- **Tab 5 mg – 1% DV Oct-19 to 2022**
  - 29.72 $ 100 Serenace
- **Oral liq 2 mg per ml – 1% DV Oct-19 to 2022**
  - 23.84 $ 100 ml Serenace
- **Inj 5 mg per ml, 1ml ampoule – 1% DV Oct-19 to 2022**
  - 21.55 $ 10 Serenace

### LEVOMEPROMAZINE
- **Tab 25 mg – 1% DV Sep-19 to 2022**
  - 16.10 $ 100 Nozinan
- **Tab 100 mg – 1% DV Sep-19 to 2022**
  - 41.75 $ 100 Nozinan

### LEVOMEPROMAZINE HYDROCHLORIDE
- **Inj 25 mg per ml, 1 ml ampoule – 1% DV Apr-20 to 2022**
  - 33.50 $ 10 Nozinan
  - 47.89 $ Wockhardt

*(Wockhardt Inj 25 mg per ml, 1 ml ampoule to be delisted 1 April 2020)*

### LITHIUM CARBONATE
- **Tab long-acting 400 mg**
  - 34.30 $ 500 Lithicarb FC
- **Cap 250 mg**
  - 9.42 $ 100 Douglas

### OLANZAPINE
- **Tab 2.5 mg – 1% DV Sep-17 to 2020**
  - 0.64 $ 28 Zypine
- **Tab 5 mg – 1% DV Sep-17 to 2020**
  - 1.15 $ 28 Zypine
- **Tab orodispersible 5 mg – 1% DV Sep-17 to 2020**
  - 1.25 $ 28 Zypine ODT
- **Tab 10 mg – 1% DV Sep-17 to 2020**
  - 1.65 $ 28 Zypine
- **Tab orodispersible 10 mg – 1% DV Sep-17 to 2020**
  - 2.05 $ 28 Zypine ODT
- **Inj 10 mg vial**

### PERICYAZINE
- **Tab 2.5 mg**
- **Tab 10 mg**

### QUETIAPINE
- **Tab 25 mg – 1% DV Sep-17 to 2020**
  - 1.79 $ 90 Quetapal
- **Tab 100 mg – 1% DV Sep-17 to 2020**
  - 3.45 $ 90 Quetapal
- **Tab 200 mg – 1% DV Sep-17 to 2020**
  - 5.75 $ 90 Quetapal
- **Tab 300 mg – 1% DV Sep-17 to 2020**
  - 9.60 $ 90 Quetapal

---

*e.g. Brand indicates brand example only. It is not a contracted product.*
## NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Dose Form</th>
<th>Expiry Date</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RISPERIDONE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 0.5 mg – 1% DV Dec-17 to 2020</td>
<td></td>
<td></td>
<td>1.86</td>
<td>60</td>
<td>Actavis</td>
</tr>
<tr>
<td>Tab 1 mg – 1% DV Dec-17 to 2020</td>
<td></td>
<td></td>
<td>2.06</td>
<td>60</td>
<td>Actavis</td>
</tr>
<tr>
<td>Tab 2 mg – 1% DV Dec-17 to 2020</td>
<td></td>
<td></td>
<td>2.29</td>
<td>60</td>
<td>Actavis</td>
</tr>
<tr>
<td>Tab 3 mg – 1% DV Dec-17 to 2020</td>
<td></td>
<td></td>
<td>2.50</td>
<td>60</td>
<td>Actavis</td>
</tr>
<tr>
<td>Tab 4 mg – 1% DV Dec-17 to 2020</td>
<td></td>
<td></td>
<td>3.43</td>
<td>60</td>
<td>Actavis</td>
</tr>
<tr>
<td>Oral liq 1 mg per ml – 1% DV Sep-17 to 2020</td>
<td></td>
<td></td>
<td>7.66</td>
<td>30 ml</td>
<td>Risperon</td>
</tr>
<tr>
<td><strong>ZIPRASIDONE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 20 mg – 1% DV Dec-18 to 2021</td>
<td></td>
<td></td>
<td>14.50</td>
<td>60</td>
<td>Zusdone</td>
</tr>
<tr>
<td>Cap 40 mg – 1% DV Sep-18 to 2021</td>
<td></td>
<td></td>
<td>24.70</td>
<td>60</td>
<td>Zusdone</td>
</tr>
<tr>
<td>Cap 60 mg – 1% DV Sep-18 to 2021</td>
<td></td>
<td></td>
<td>33.80</td>
<td>60</td>
<td>Zusdone</td>
</tr>
<tr>
<td>Cap 80 mg – 1% DV Sep-18 to 2021</td>
<td></td>
<td></td>
<td>39.70</td>
<td>60</td>
<td>Zusdone</td>
</tr>
<tr>
<td><strong>ZUCLOPENTHIXOL ACETATE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 50 mg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ZUCLOPENTHIXOL HYDROCHLORIDE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg</td>
<td></td>
<td></td>
<td>31.45</td>
<td>100</td>
<td>Clopixol</td>
</tr>
</tbody>
</table>

### Depot Injections

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Dose Form</th>
<th>Expiry Date</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FLUPENTHIXOL DECANOATE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 20 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td>13.14</td>
<td>5</td>
</tr>
<tr>
<td>Inj 20 mg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
<td>20.90</td>
<td>5</td>
</tr>
<tr>
<td>Inj 100 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td>40.87</td>
<td>5</td>
</tr>
</tbody>
</table>

| **HALOPERIDOL DECANOATE** | | | | |
| Inj 50 mg per ml, 1 ml ampoule | | | 28.39 | 5 | Haldol |
| Inj 100 mg per ml, 1 ml ampoule | | | 55.90 | 5 | Haldol Concentrate |

| **OLANZAPINE – Restricted** | see terms below | | | |
| Inj 210 mg vial – 1% DV Oct-18 to 2021 | | | 252.00 | 1 | Zyprexa Relprevv |
| Inj 300 mg vial – 1% DV Oct-18 to 2021 | | | 414.00 | 1 | Zyprexa Relprevv |
| Inj 405 mg vial – 1% DV Oct-18 to 2021 | | | 504.00 | 1 | Zyprexa Relprevv |

- **Restricted (RS1379)**

#### Initiation

- Re-assessment required after 12 months

Either:

1. The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection; or
2. All of the following:
   1. The patient has schizophrenia; and
   2. The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
   3. The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

#### Continuation

- Re-assessment required after 12 months

The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

| **PALIPERIDONE – Restricted** | see terms on the next page |
| Inj 25 mg syringe | 194.25 | 1 | Invega Sustenna |
| Inj 50 mg syringe | 271.95 | 1 | Invega Sustenna |
| Inj 75 mg syringe | 357.42 | 1 | Invega Sustenna |
| Inj 100 mg syringe | 435.12 | 1 | Invega Sustenna |
| Inj 150 mg syringe | 435.12 | 1 | Invega Sustenna |
NERVOUS SYSTEM

Price (ex man. excl. GST) $ Per Generic Manufacturer

**Restricted (RS1381)**

**Initiation**

*Re-assessment required after 12 months*

Either:

1. The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
2. All of the following:
   2.1. The patient has schizophrenia or other psychotic disorder; and
   2.2. The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
   2.3. The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

**Continuation**

*Re-assessment required after 12 months*

The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

**PIPOTHIAZINE PALMITATE** – Restricted: For continuation only

- **Inj 50 mg per ml, 1 ml ampoule**
- **Inj 50 mg per ml, 2 ml ampoule**

**RISPERIDONE** – Restricted see terms below

- **Inj 25 mg vial** ................................................................. 135.98 1 Risperdal Consta
- **Inj 37.5 mg vial** .............................................................. 178.71 1 Risperdal Consta
- **Inj 50 mg vial** ................................................................. 217.56 1 Risperdal Consta

**Restricted (RS1380)**

**Initiation**

*Re-assessment required after 12 months*

Either:

1. The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
2. All of the following:
   2.1. The patient has schizophrenia or other psychotic disorder; and
   2.2. The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
   2.3. The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

**Continuation**

*Re-assessment required after 12 months*

The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

**ZUCLOPENTHIXOL DECANOATE**

- **Inj 200 mg per ml, 1 ml ampoule** ................................................. 19.80 5 Clopixol
- **Inj 500 mg per ml, 1 ml ampoule**

**Anxiolytics**

**BUSPIRONE HYDROCHLORIDE**

- **Tab 5 mg – 1% DV Sep-18 to 2021** .................................................. 20.23 100 Orion
- **Tab 10 mg – 1% DV Sep-18 to 2021** ............................................. 13.16 100 Orion

**CLONAZEPAM**

- **Tab 500 mcg – 1% DV Jun-18 to 2021** ................................................. 5.64 100 Paxam
- **Tab 2 mg – 1% DV Jun-18 to 2021** .................................................. 10.78 100 Paxam

**DIAZEPAM**

- **Tab 2 mg – 1% DV Mar-18 to 2020** .................................................. 15.05 500 Arrow-Diazepam
- **Tab 5 mg – 1% DV Mar-18 to 2020** .................................................. 16.18 500 Arrow-Diazepam

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
**NERVOUS SYSTEM**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LORAZEPAM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 1 mg – 1% DV Sep-18 to 2021</td>
<td>$9.72</td>
<td>Ativan</td>
</tr>
<tr>
<td>Tab 2.5 mg – 1% DV Sep-18 to 2021</td>
<td>$12.50</td>
<td>Ativan</td>
</tr>
<tr>
<td><strong>OXAZEPAM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 10 mg – 1% DV Sep-17 to 2020</td>
<td>$6.17</td>
<td>Ox-Pam</td>
</tr>
<tr>
<td>Tab 15 mg – 1% DV Sep-17 to 2020</td>
<td>$8.53</td>
<td>Ox-Pam</td>
</tr>
</tbody>
</table>

**Multiple Sclerosis Treatments**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DIMETHYL FUMARATE</strong> – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 120 mg</td>
<td>$520.00</td>
<td>Tecfidera</td>
</tr>
<tr>
<td>Cap 240 mg</td>
<td>$2,000.00</td>
<td>Tecfidera</td>
</tr>
<tr>
<td><strong>FINGOLIMOD</strong> – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 0.5 mg</td>
<td>$2,200.00</td>
<td>Gilenya</td>
</tr>
<tr>
<td><strong>NATALIZUMAB</strong> – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 20 mg per ml, 15 ml vial</td>
<td>$1,750.00</td>
<td>Tysabri</td>
</tr>
<tr>
<td><strong>TERIFLUNOMIDE</strong> – Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tab 14 mg</td>
<td>$1,582.62</td>
<td>Aubagio</td>
</tr>
<tr>
<td><strong>GLATIRAMER ACETATE</strong> – Restricted see terms above</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 40 mg prefilled syringe</td>
<td>$2,275.00</td>
<td>Copaxone</td>
</tr>
</tbody>
</table>

**Other Multiple Sclerosis Treatments**

<table>
<thead>
<tr>
<th>Product</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GLATIRAMER ACETATE</strong> – Restricted see terms above</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 40 mg prefilled syringe</td>
<td>$2,275.00</td>
<td>Copaxone</td>
</tr>
</tbody>
</table>
INTERFERON BETA-1-ALPHA – Restricted see terms on the previous page

1. Inj 6 million iu in 0.5 ml pen injector ............................................................ 1,170.00 4 Avonex Pen
2. Inj 6 million iu in 0.5 ml syringe ................................................................. 1,170.00 4 Avonex

INTERFERON BETA-1-BETA – Restricted see terms on the previous page

1. Inj 8 million iu per ml, 1 ml vial

Sedatives and Hypnotics

CHLORAL HYDRATE
- Oral liq 100 mg per ml
- Oral liq 200 mg per ml

LORMETAZEPAM – Restricted: For continuation only

- Tab 1 mg

MELATONIN – Restricted see terms below

1. Tab modified-release 2 mg ............................................................................. 28.22 30 Circadin
2. Tab 3 mg

Note: Only for use in compounding an oral liquid formulation, for in-hospital use only.

Restricted (RS1576)

Initiation – insomnia secondary to neurodevelopmental disorder
Psychiatrist, paediatrician, neurologist or respiratory specialist
Re-assessment required after 12 months

All of the following:
1. Patient has been diagnosed with persistent and distressing insomnia secondary to a neurodevelopmental disorder (including, but not limited to, autism spectrum disorder or attention deficit hyperactivity disorder); and
2. Behavioural and environmental approaches have been tried or are inappropriate; and
3. Funded modified-release melatonin is to be given at doses no greater than 10 mg per day; and
4. Patient is aged 18 years or under.

Continuation – insomnia secondary to neurodevelopmental disorder
Psychiatrist, paediatrician, neurologist or respiratory specialist
Re-assessment required after 12 months

All of the following:
1. Patient is aged 18 years or under; and
2. Patient has demonstrated clinically meaningful benefit from funded modified-release melatonin (clinician determined); and
3. Patient has had a trial of funded modified-release melatonin discontinuation within the past 12 months and has had a recurrence of persistent and distressing insomnia; and
4. Funded modified-release melatonin is to be given at doses no greater than 10 mg per day.

Initiation – insomnia where benzodiazepines and zopiclone are contraindicated
Both:
1. Patient has insomnia and benzodiazepines and zopiclone are contraindicated; and
2. For in-hospital use only.

MIDAZOLAM

- Tab 7.5 mg
- Oral liq 2 mg per ml

Inj 1 mg per ml, 5 ml ampoule – 1% DV Jan-19 to 2021 ................................. 2.98 10 Mylan Midazolam
Inj 5 mg per ml, 3 ml ampoule – 1% DV Jan-19 to 2021 ................................. 2.36 5 Mylan Midazolam

NITRAZEPAM – Restricted: For continuation only

- Tab 5 mg ........................................................................................................... 5.22 100 Nitrados

(Nitrados Tab 5 mg to be delisted 1 September 2020)

PHENOBARBITONE

- Inj 200 mg per ml, 1 ml ampoule
NERVOUS SYSTEM

**Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer**

**TEMAZEPAM**
Tab 10 mg – 1% DV Sep-17 to 2020...............................................................1.27 25 Normison

**TRIAZOLAM** – Restricted: For continuation only
  ➞ Tab 125 mcg
  ➞ Tab 250 mcg

**ZOPICLONE**
Tab 7.5 mg ........................................................................................................0.98 30 Zopiclone Actavis

---

**Stimulants / ADHD Treatments**

**ATOMOXETINE** – Restricted see terms below

<table>
<thead>
<tr>
<th>Size</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 10 mg.................................................................107.03 28 Strattera</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 18 mg.................................................................107.03 28 Strattera</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 25 mg.................................................................107.03 28 Strattera</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 40 mg.................................................................107.03 28 Strattera</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 60 mg.................................................................107.03 28 Strattera</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 80 mg.................................................................107.03 28 Strattera</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 100 mg.................................................................107.03 28 Strattera</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Restricted (RS1371)**

Initiation
All of the following:

1. Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
2. Once-daily dosing; and
3. Any of the following:
   3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
   3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
   3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; or
   3.4 Treatment with a subsidised formulation of a stimulant is considered inappropriate because the patient has a history of psychoses or has a first-degree relative with schizophrenia; and
4. The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Note: A "subsidised formulation of a stimulant" refers to currently listed methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets.

**CAFFEINE**
Tab 100 mg

**DEXAMFETAMINE SULFATE** – Restricted see terms below

<table>
<thead>
<tr>
<th>Size</th>
<th>Price</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 5 mg – 1% DV Oct-18 to 2021...........................................................20.00 100 PSM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Restricted (RS1169)**

Initiation – ADHD
Paediatrician or psychiatrist
Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria.

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### NERVOUS SYSTEM

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

---

**Initiation – Narcolepsy**  
Neurologist or respiratory specialist  
*Re-assessment required after 24 months*  
Patient suffers from narcolepsy.

**Continuation – Narcolepsy**  
Neurologist or respiratory specialist  
*Re-assessment required after 24 months*  
The treatment remains appropriate and the patient is benefiting from treatment.

**METHYLPHENIDATE HYDROCHLORIDE – Restricted** see terms below

- Tab extended-release 18 mg...............................................................58.96 30 Concerta
  - 18.20 Methylphenidate ER - Teva
- Tab extended-release 27 mg...............................................................65.44 30 Concerta
  - 22.00 Methylphenidate ER - Teva
- Tab extended-release 36 mg...............................................................71.93 30 Concerta
  - 22.40 Methylphenidate ER - Teva
- Tab extended-release 54 mg...............................................................86.24 30 Concerta
  - 26.40 Methylphenidate ER - Teva
- Tab immediate-release 5 mg...............................................................3.20 30 Rubifen
- Tab immediate-release 10 mg.............................................................3.00 30 Ritalin
- Tab immediate-release 20 mg.............................................................7.85 30 Rubifen
- Tab sustained-release 20 mg.............................................................50.00 100 Ritalin SR
  - 10.95 30 Rubifen SR
- Cap modified-release 10 mg ..............................................................15.60 30 Ritalin LA
- Cap modified-release 20 mg ..............................................................20.40 30 Ritalin LA
- Cap modified-release 30 mg ..............................................................25.52 30 Ritalin LA
- Cap modified-release 40 mg ..............................................................30.60 30 Ritalin LA

**Initiation – ADHD (immediate-release and sustained-release formulations)**  
Paediatrician or psychiatrist  
Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria.

**Initiation – Narcolepsy (immediate-release and sustained-release formulations)**  
Neurologist or respiratory specialist  
*Re-assessment required after 24 months*  
Patient suffers from narcolepsy.

**Continuation – Narcolepsy (immediate-release and sustained-release formulations)**  
Neurologist or respiratory specialist  
*Re-assessment required after 24 months*  
The treatment remains appropriate and the patient is benefiting from treatment.

**Initiation – Extended-release and modified-release formulations**  
Paediatrician or psychiatrist  
Both:

1. Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria; and
2. Either:
continued...

2.1 Patient is taking a currently listed formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or

2.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

MODAFINIL – Restricted see terms below

Tab 100 mg .............................................................................................................64.00 60 Modavigil

Initiation – Narcolepsy
Neurologist or respiratory specialist
Re-assessment required after 24 months

All of the following:

1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and

2 Either:

2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or

2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and

3 Either:

3.1 An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or

3.2 Methylphenidate and dexamphetamine are contraindicated.

Continuation – Narcolepsy
Neurologist or respiratory specialist
Re-assessment required after 24 months

The treatment remains appropriate and the patient is benefiting from treatment.

Treatments for Dementia

DONEPEZIL HYDROCHLORIDE

Tab 5 mg – 1% DV Sep-17 to 2020 .................................................................4.34 90 Donepezil-Rex
Tab 10 mg – 1% DV Sep-17 to 2020 .............................................................6.64 90 Donepezil-Rex

RIVASTIGMINE – Restricted see terms below

Patch 4.6 mg per 24 hour ................................................................................90.00 30 Exelon
Patch 9.5 mg per 24 hour ................................................................................90.00 30 Exelon

Initiation
Re-assessment required after 6 months
Both:

1 The patient has been diagnosed with dementia; and

2 The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.

Continuation
Re-assessment required after 12 months
Both:

1 The treatment remains appropriate; and

2 The patient has demonstrated a significant and sustained benefit from treatment.
Treatments for Substance Dependence

**BUPRENORPHINE WITH NALOXONE** – **Restricted** see terms below

† Tab 2 mg with naloxone 0.5 mg – 1% DV **Apr-20 to 2022** ............................... 18.37 28 Buprenorphine Naloxone BNM Suboxone

† Tab 8 mg with naloxone 2 mg – 1% DV **Apr-20 to 2022** ............................... 53.12 28 Buprenorphine Naloxone BNM Suboxone

*(Suboxone Tab 2 mg with naloxone 0.5 mg to be delisted 1 April 2020)* *(Suboxone Tab 8 mg with naloxone 2 mg to be delisted 1 April 2020)*

⇒ **Restricted** (RS1172)

**Initiation – Detoxification**

All of the following:

1. Patient is opioid dependent; and
2. Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
3. Prescriber works in an opioid treatment service approved by the Ministry of Health.

**Initiation – Maintenance treatment**

All of the following:

1. Patient is opioid dependent; and
2. Patient will not be receiving methadone; and
3. Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
4. Prescriber works in an opioid treatment service approved by the Ministry of Health.

**BUPROPION HYDROCHLORIDE**

Tab modified-release 150 mg – 1% DV **Jun-17 to 2020**........................................11.00 30 Zyban

**DISULFIRAM**

Tab 200 mg ..............................................................................................................153.00 100 Antabuse

**NALTREXONE HYDROCHLORIDE** – **Restricted** see terms below

† Tab 50 mg – 1% DV **Sep-17 to 2020**................................................................. 112.55 30 Naltraccord

⇒ **Restricted** (RS1173)

**Initiation – Alcohol dependence**

Both:

1. Patient is currently enrolled, or is planned to be enrolled, in a recognised comprehensive treatment programme for alcohol dependence; and
2. Naltrexone is to be prescribed by, or on the recommendation of, a physician working in an Alcohol and Drug Service.

**Initiation – Constipation**

For the treatment of opioid-induced constipation.

**NICOTINE** – **Some items restricted** see terms on the next page

Patch 7 mg per 24 hours – 1% DV **Apr-18 to 2020**............................................. 17.28 28 Habitrol

Patch 14 mg per 24 hours – 1% DV **Apr-18 to 2020**........................................... 19.00 28 Habitrol

Patch 21 mg per 24 hours – 1% DV **Apr-18 to 2020**........................................... 21.77 28 Habitrol

† Oral spray 1 mg per dose

Lozenge 1 mg – 1% DV **Apr-18 to 2020**............................................................. 18.27 216 Habitrol (Mint)

Lozenge 2 mg – 1% DV **Apr-18 to 2020**............................................................. 20.02 216 Habitrol (Mint)

† Soln for inhalation 15 mg cartridge

Gum 2 mg – 1% DV **Apr-18 to 2020**................................................................. 36.39 384 Habitrol (Fruit)

Gum 4 mg – 1% DV **Apr-18 to 2020**................................................................. 42.07 384 Habitrol (Mint)

*Item restricted (see ➥ above); † Item restricted (see ➥ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
**NEUROLOGICAL SYSTEM**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**Restricted (RS1310)**

**Initiation**

Any of the following:

1. For perioperative use in patients who have a ‘nil by mouth’ instruction; or
2. For use within mental health inpatient units; or
3. For acute use in agitated patients who are unable to leave the hospital facilities.

**VARENICLINE** — **Restricted** see terms below

1. Tab 0.5 mg x 11 and 1 mg x 42 – 1% DV Mar-19 to 2021 .........................25.64 53  Varenicline Pfizer
2. Tab 1 mg – 1% DV Mar-19 to 2021 ...............................................................27.10 56  Varenicline Pfizer

**Restricted (RS1702)**

**Initiation**

All of the following:

1. Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
2. The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
3. Either:
   3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
   3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
4. The patient has not had a Special Authority for varenicline approved in the last 6 months; and
5. Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
6. The patient is not pregnant; and
7. The patient will not be prescribed more than 12 weeks' funded varenicline in a 12 month period.

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
**Chemotherapeutic Agents**

**Alkylating Agents**

**BENDAMUSTINE HYDROCHLORIDE** – **Restricted** see terms below

- **Inj 25 mg vial** ........................................................................................................ 271.35 1 Ribomustin
- **Inj 100 mg vial** .................................................................................................... 1,085.38 1 Ribomustin

**Initiation – treatment naive CLL**

All of the following:

1. The patient has Binet stage B or C, or progressive stage A chronic lymphocytic leukaemia requiring treatment; and
2. The patient is chemotherapy treatment naive; and
3. The patient is unable to tolerate toxicity of full-dose FCR; and
4. Patient has ECOG performance status 0-2; and
5. Patient has a Cumulative Illness Rating Scale (CIRS) score of < 6; and
6. Bendamustine is to be administered at a maximum dose of 100 mg/m² on days 1 and 2 every 4 weeks for a maximum of 6 cycles.

Note: ‘Chronic lymphocytic leukaemia (CLL)’ includes small lymphocytic lymphoma (SLL). Chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

**Initiation – Indolent, Low-grade lymphomas**

*Re-assessment required after 9 months*

All of the following:

1. The patient has indolent low grade NHL requiring treatment; and
2. Patient has a WHO performance status of 0-2; and
3. Either:
   - 3.1 Both:
     - 3.1.1 Patient is treatment naive; and
     - 3.1.2 Bendamustine is to be administered for a maximum of 6 cycles (in combination with rituximab when CD20+); or
   - 3.2 All of the following:
     - 3.2.1 Patient has relapsed refractory disease following prior chemotherapy; and
     - 3.2.2 The patient has not received prior bendamustine therapy; and
     - 3.2.3 Either:
       - 3.2.3.1 Both:
         - 3.2.3.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
         - 3.2.3.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or
       - 3.2.3.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.

**Continuation – Indolent, Low-grade lymphomas**

*Re-assessment required after 9 months*

Both:

1. Patients have not received a bendamustine regimen within the last 12 months; and
2. Either:
   - 2.1 Both:
     - 2.1.1 Bendamustine is to be administered for a maximum of 6 cycles in relapsed patients (in combination with rituximab when CD20+); and
     - 2.1.2 Patient has had a rituximab treatment-free interval of 12 months or more; or

continued…

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

e.g. *Brand* indicates brand example only. It is not a contracted product.
continued...

2.2 Bendamustine is to be administered as a monotherapy for a maximum of 6 cycles in rituximab refractory patients.

Note: 'indolent, low-grade lymphomas' includes follicular, mantle cell, marginal zone and lymphoplasmacytic/ Waldenström’s macroglobulinaemia.

<table>
<thead>
<tr>
<th>ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price (ex man. excl. GST) $ Per</td>
</tr>
</tbody>
</table>

| Brand or Generic Manufacturer |

<table>
<thead>
<tr>
<th>PRODUCTS WITH HOSPITAL SUPPLY STATUS (HSS)</th>
<th>are in <strong>bold</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BUSULFAN</th>
<th>Tab 2 mg</th>
<th>89.25</th>
<th>100 Myleran</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 6 mg per ml, 10 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CARMUSTINE</th>
<th>Inj 100 mg vial</th>
<th>1,387.00</th>
<th>1 BiCNU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bicnu Heritage</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| CHLORAMBUCIL | Tab 2 mg | |
|--------------|---------||

<table>
<thead>
<tr>
<th>CYCLOPHOSPHAMIDE</th>
<th>Tab 50 mg</th>
<th>79.00</th>
<th>50 Endoxan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 1 g vial – 1% DV Oct-18 to 2021</td>
<td>35.65</td>
<td>1 Endoxan</td>
<td></td>
</tr>
<tr>
<td>Inj 2 g vial – 1% DV Oct-18 to 2021</td>
<td>71.25</td>
<td>1 Endoxan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IFOSFAMIDE</th>
<th>Inj 1 g vial</th>
<th>96.00</th>
<th>1 Holoxan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2 g vial</td>
<td>180.00</td>
<td>1 Holoxan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LOMUSTINE</th>
<th>Cap 10 mg</th>
<th>132.59</th>
<th>20 Ceenu</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 40 mg</td>
<td>399.15</td>
<td>20 Ceenu</td>
<td></td>
</tr>
</tbody>
</table>

| MELPHALAN | Tab 2 mg | |
|-----------|---------||
| Inj 50 mg vial |

| THIOTEPA | Inj 15 mg vial | |
|-----------|----------------||
| Inj 100 mg vial |

<table>
<thead>
<tr>
<th>ANTHRACYCLINES AND OTHER CYTOTOXIC ANTIBIOTICS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price (ex man. excl. GST) $ Per</td>
</tr>
</tbody>
</table>

| Brand or Generic Manufacturer |

<table>
<thead>
<tr>
<th>BLEOMYCIN SULPHATE</th>
<th>Inj 15,000 iu vial – 1% DV Dec-18 to 2021</th>
<th>161.01</th>
<th>1 DBL Bleomycin Sulfate</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>ACTINOMYCIN [ACTINOMYCIN D]</th>
<th>Inj 0.5 mg vial</th>
<th>166.75</th>
<th>1 Cosmegen</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>DAUNORUBICIN</th>
<th>Inj 2 mg per ml, 10 ml vial</th>
<th>130.00</th>
<th>1 Pfizer</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>DOXORUBICIN HYDROCHLORIDE</th>
<th>Inj 2 mg per ml, 5 ml vial</th>
<th>11.50</th>
<th>1 Doxorubicin Ebewe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2 mg per ml, 25 ml vial</td>
<td>11.50</td>
<td>1 Doxorubicin Ebewe</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EPIRUBICIN HYDROCHLORIDE</th>
<th>Inj 2 mg per ml, 5 ml vial</th>
<th>25.00</th>
<th>1 Epirubicin Ebewe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2 mg per ml, 25 ml vial</td>
<td>30.00</td>
<td>1 Epirubicin Ebewe</td>
<td></td>
</tr>
<tr>
<td>Inj 2 mg per ml, 100 ml vial – 1% DV Jan-19 to 2021</td>
<td>56.15</td>
<td>1 Epirubicin Ebewe</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Products with Hospital Supply Status (HSS) are in <strong>bold</strong></th>
</tr>
</thead>
</table>

| 129 |

<table>
<thead>
<tr>
<th>Note: DV limit applies to all 50 mg presentations of doxorubicin hydrochloride.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Inj 50 mg vial</th>
<th>23.00</th>
<th>1 Doxorubicin Ebewe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 2 mg per ml, 100 ml vial – 1% DV Jan-19 to 2021</td>
<td>56.15</td>
<td>1 Doxorubicin Ebewe</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Inj 2 mg per ml, 100 ml vial – 1% DV Apr-19 to 2021</th>
<th>85.00</th>
<th>1 Epirubicin Ebewe</th>
</tr>
</thead>
</table>

### Antimetabolites

#### IDARUBICIN HYDROCHLORIDE
- **Inj 5 mg vial** – 1% DV Sep-18 to 2021 ........................................................... 93.00 1 Zavedos
- **Inj 10 mg vial** – 1% DV Sep-18 to 2021 ..................................................... 198.00 1 Zavedos

#### MITOMYCIN C
- **Inj 5 mg vial** .......................................................................................... 204.08 1 Arrow

#### MITOZANTRONE
- **Inj 2 mg per ml, 10 ml vial** ...................................................................... 97.50 1 Mitozantrone Ebewe

#### AZACITIDINE – Restricted see terms below
- **Inj 100 mg vial** – 1% DV Dec-18 to 2021 .................................................. 139.00 1 Azacitidine Dr Reddy’s

**Initiation**
Haematologist
*Re-assessment required after 12 months*

All of the following:
1. Any of the following:
   1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
   1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
   1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and
2. The patient has performance status (WHO/ECOG) grade 0-2; and
3. The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and
4. The patient has an estimated life expectancy of at least 3 months.

**Continuation**
Haematologist
*Re-assessment required after 12 months*

Both:
1. No evidence of disease progression, and; and
2. The treatment remains appropriate and patient is benefitting from treatment.

#### CAPECITABINE
- **Tab 150 mg** ........................................................................................... 11.15 60 Brinov
- **Tab 500 mg** ........................................................................................... 62.28 120 Brinov

#### CLADRIBINE
- **Inj 2 mg per ml, 5 ml vial**
- **Inj 1 mg per ml, 10 ml vial** ..................................................................... 5,249.72 7 Leustatin

#### CYTARABINE
- **Inj 20 mg per ml, 5 ml vial** ................................................................... 400.00 5 Pfizer
- **Inj 100 mg per ml, 20 ml vial** – 1% DV Dec-18 to 2021 ...................... 41.36 1 Pfizer

#### FLUDARABINE PHOSPHATE
- **Tab 10 mg** – 1% DV Sep-18 to 2021 .................................................... 412.00 20 Fludara Oral
- **Inj 50 mg vial** – 1% DV Nov-19 to 2022 .............................................. 576.45 5 Fludarabine Ebewe

#### FLUOROURACIL
- **Inj 50 mg per ml, 20 ml vial** – 1% DV Oct-18 to 2021 ....................... 12.00 1 Fluorouracil Ebewe
- **Inj 50 mg per ml, 100 ml vial** – 1% DV Oct-18 to 2021 ..................... 30.00 1 Fluorouracil Ebewe

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>GEMCITABINE</td>
<td>Inj 10 mg per ml, 100 ml vial</td>
<td>$15.89</td>
<td>Gemcitabine Ebewe</td>
</tr>
<tr>
<td>MERCAPTOPURINE</td>
<td>Tab 50 mg – 1% DV Jul-19 to 2022</td>
<td>$37.00</td>
<td>Puri-nethol</td>
</tr>
<tr>
<td></td>
<td>Oral suspension 20 mg per ml</td>
<td>$428.00</td>
<td>Allmercap</td>
</tr>
<tr>
<td></td>
<td>▶ Restricted (RS1635)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Initiation</td>
<td>Paediatric haematologist or paediatric oncologist</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Re-assessment required after 12 months</td>
<td>The patient requires a total dose of less than one full 50 mg tablet per day.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Continuation</td>
<td>Paediatric haematologist or paediatric oncologist</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Re-assessment required after 12 months</td>
<td>The patient requires a total dose of less than one full 50 mg tablet per day.</td>
<td></td>
</tr>
<tr>
<td>METHOTREXATE</td>
<td>Tab 2.5 mg – 1% DV Jan-19 to 2021</td>
<td>$8.05</td>
<td>Trexate</td>
</tr>
<tr>
<td></td>
<td>Tab 10 mg – 1% DV Jan-19 to 2021</td>
<td>$31.75</td>
<td>Trexate</td>
</tr>
<tr>
<td></td>
<td>Inj 2.5 mg per ml, 2 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 7.5 mg prefilled syringe</td>
<td>$14.61</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg prefilled syringe</td>
<td>$14.66</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 15 mg prefilled syringe</td>
<td>$14.77</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 20 mg prefilled syringe</td>
<td>$14.88</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 25 mg prefilled syringe</td>
<td>$14.99</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 30 mg prefilled syringe</td>
<td>$15.09</td>
<td>Methotrexate Sandoz</td>
</tr>
<tr>
<td></td>
<td>Inj 25 mg per ml, 2 ml vial</td>
<td>$30.00</td>
<td>DBL Methotrexate Onco-Vial</td>
</tr>
<tr>
<td></td>
<td>Inj 25 mg per ml, 20 ml vial</td>
<td>$45.00</td>
<td>DBL Methotrexate Onco-Vial</td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg per ml, 10 ml vial</td>
<td>$25.00</td>
<td>Methotrexate Ebewe</td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg per ml, 50 ml vial – 1% DV Sep-17 to 2020</td>
<td>$79.99</td>
<td>Methotrexate Ebewe</td>
</tr>
<tr>
<td>PEMETREXED</td>
<td>▶ Restricted see terms below</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 100 mg vial</td>
<td>$60.89</td>
<td>Juno Pemtrexed</td>
</tr>
<tr>
<td></td>
<td>Inj 500 mg vial</td>
<td>$217.77</td>
<td>Juno Pemtrexed</td>
</tr>
<tr>
<td></td>
<td>▶ Restricted (RS1596)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Initiation – Mesothelioma</td>
<td>Re-assessment required after 8 months</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Both:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 Patient has been diagnosed with mesothelioma; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 Pemetrexed to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Continuation – Mesothelioma</td>
<td>Re-assessment required after 8 months</td>
<td></td>
</tr>
<tr>
<td></td>
<td>All of the following:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 No evidence of disease progression; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 The treatment remains appropriate and the patient is benefitting from treatment; and</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 Pemetrexed to be administered at a dose of 500mg/m² every 21 days for a maximum of 6 cycles.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Products with Hospital Supply Status (HSS) are in **bold**. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
continued…

Initiation – Non small cell lung cancer
Re-assessment required after 8 months
Both:

1. Patient has locally advanced or metastatic non-squamous non-small cell lung carcinoma; and
2. Either:
   2.1 Both:
      2.1.1 Patient has chemotherapy-naïve disease; and
      2.1.2 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days in combination with cisplatin or carboplatin for a maximum of 6 cycles; or
   2.2 All of the following:
      2.2.1 Patient has had first-line treatment with platinum based chemotherapy; and
      2.2.2 Patient has not received prior funded treatment with pemetrexed; and
      2.2.3 Pemetrexed is to be administered at a dose of 500 mg/m² every 21 days for a maximum of 6 cycles.

Continuation – Non small cell lung cancer
Re-assessment required after 8 months
All of the following:

1. No evidence of disease progression; and
2. The treatment remains appropriate and the patient is benefitting from treatment; and
3. Pemetrexed is to be administered at a dose of 500mg/m² every 21 days.

THIOGUANINE
   Tab 40 mg

Other Cytotoxic Agents

AMSACRINE
   Inj 50 mg per ml, 1.5 ml ampoule
   Inj 75 mg

ANAGRELINE HYDROCHLORIDE
   Cap 0.5 mg

ARSENIC TRIOXIDE
   Inj 1 mg per ml, 10 ml vial..............................................................4,817.00 10 Phenasen

BORTEZOMIB – Restricted see terms below
   $ Inj 3.5 mg vial ..............................................................................1,892.50 1 Velcade

Initiation – treatment naive multiple myeloma/amyloidosis
Limited to 15 months treatment
Both:

1. Either:
   1.1 The patient has treatment-naïve symptomatic multiple myeloma; or
   1.2 The patient has treatment-naïve symptomatic systemic AL amyloidosis; and

Initiation – relapsed/refractory multiple myeloma/amyloidosis
Re-assessment required after 8 months
All of the following:

1. Either:
   1.1 The patient has relapsed or refractory multiple myeloma; or

continued…
continued…

1.2 The patient has relapsed or refractory systemic AL amyloidosis; and
2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and
3 The patient has not had prior publicly funded treatment with bortezomib; and
4 Maximum of 4 treatment cycles.

Continuation – relapsed/refractory multiple myeloma/amyloidosis

Re-assessment required after 8 months

Both:
1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and
2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).

Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:

1 A known therapeutic chemotherapy regimen and supportive treatments; or
2 A transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.

Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.

<table>
<thead>
<tr>
<th>Products</th>
<th>Brand or Generic Manufacturer</th>
<th>Price (per)</th>
</tr>
</thead>
<tbody>
<tr>
<td>COLASPASE [L-ASPARAGINASE]</td>
<td>Leunase</td>
<td>$102.32</td>
</tr>
<tr>
<td>Inj 10,000 IU vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DACARBAZINE</td>
<td>DBL Dacarbazine</td>
<td>$58.06</td>
</tr>
<tr>
<td>Inj 200 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETOPOSIDE</td>
<td>Vepesid</td>
<td>$340.73</td>
</tr>
<tr>
<td>Cap 50 mg – 1% DV Jul-19 to 2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 100 mg – 1% DV Jul-19 to 2022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 20 mg per ml, 5 ml vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETOPOSIDE (AS PHOSPHATE)</td>
<td>Etopophos</td>
<td>$40.00</td>
</tr>
<tr>
<td>Inj 100 mg vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYDROXYUREA</td>
<td>Hydrea</td>
<td>$31.76</td>
</tr>
<tr>
<td>Cap 500 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRINOTECAN HYDROCHLORIDE</td>
<td>Irinotecan Actavis 100</td>
<td>$71.44</td>
</tr>
<tr>
<td>Inj 20 mg per ml, 5 ml vial – 1% DV Apr-19 to 2021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LENALIDOMIDE – Restricted see terms below</td>
<td>Revlimid</td>
<td>$6,207.00</td>
</tr>
<tr>
<td>Cap 10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 15 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cap 25 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Initiation

Haematologist

Re-assessment required after 6 months

All of the following:

1 Patient has relapsed or refractory multiple myeloma with progressive disease; and
2 Either:
   2.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or
   2.2 Both:
      2.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and
      2.2.2 The patient has experienced severe (grade 3 or higher), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and
3 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic</td>
<td></td>
</tr>
</tbody>
</table>

continued...

Continuation

Haematologist

Re-assessment required after 6 months

Both:

1. No evidence of disease progression; and
2. The treatment remains appropriate and patient is benefitting from treatment.

Note: Indication marked with * is an unapproved indication. A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

PEGASPARAGASE – Restricted see terms below

1. Inj 750 iu per ml, 5 ml vial

   Restricted (RS1190)

   Initiation – Newly diagnosed ALL

   Limited to 12 months treatment

   All of the following:

   1. The patient has newly diagnosed acute lymphoblastic leukaemia; and
   2. Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
   3. Treatment is with curative intent.

   Initiation – Relapsed ALL

   Limited to 12 months treatment

   All of the following:

   1. The patient has relapsed acute lymphoblastic leukaemia; and
   2. Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
   3. Treatment is with curative intent.

PENTOSTATIN [DEOXYCOFORMYCIN]

Inj 10 mg vial

PROCARBAZINE HYDROCHLORIDE

Cap 50 mg

TEMOZOLOMIDE – Restricted see terms below

1. Cap 5 mg

2. Cap 20 mg

3. Cap 100 mg

4. Cap 140 mg

5. Cap 250 mg

(Orion Temozolomide Cap 20 mg to be delisted 1 May 2020)
(Orion Temozolomide Cap 100 mg to be delisted 1 May 2020)
(Orion Temozolomide Cap 250 mg to be delisted 1 May 2020)

Restricted (RS1645)

Initiation – High grade gliomas

Re-assessment required after 12 months

All of the following:

1. Either:

continued…
continued...

1.1 Patient has newly diagnosed glioblastoma multiforme; or
1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
3 Following concomitant treatment temozolomide is to be used for a maximum of 5 days treatment per cycle at a maximum
dose of 200 mg/m² per day.

Continuation – High grade gliomas
Re-assessment required after 12 months
Either:
1 Both:
   1.1 Patient has glioblastoma multiforme; and
   1.2 The treatment remains appropriate and the patient is benefitting from treatment; or
2 All of the following:
   2.1 Patient has anaplastic astrocytoma*; and
   2.2 The treatment remains appropriate and the patient is benefitting from treatment; and
   2.3 Adjuvant temozolomide is to be used for a maximum of 24 months.

Initiation – Neuroendocrine tumours
Re-assessment required after 9 months
All of the following:
1 Patient has been diagnosed with metastatic or unresectable well-differentiated neuroendocrine tumour*; and
2 Temozolomide is to be given in combination with capecitabine; and
3 Temozolomide is to be used in 28 day treatment cycles for a maximum of 5 days treatment per cycle at a maximum dose
   of 200 mg/m² per day; and
4 Temozolomide to be discontinued at disease progression.

Continuation – Neuroendocrine tumours
Re-assessment required after 6 months
Both:
1 No evidence of disease progression; and
2 The treatment remains appropriate and the patient is benefitting from treatment.

Initiation – ewing's sarcoma
Re-assessment required after 9 months
Patient has relapse or refractory Ewing's sarcoma.

Continuation – ewing's sarcoma
Re-assessment required after 6 months
Both:
1 No evidence of disease progression; and
2 The treatment remains appropriate and the patient is benefitting from treatment.

Note: Indication marked with a * is an unapproved indication. Temozolomide is not funded for the treatment of relapsed high
grade glioma.

THALIDOMIDE – Restricted see terms below
Cap 50 mg.....................................................................................................378.00 28 Thalomid
Cap 100 mg...................................................................................................756.00 28 Thalomid

Continuation – ewing's sarcoma
Re-assessment required after 12 months
Any of the following:
1 The patient has multiple myeloma; or

continued…
## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$</td>
<td></td>
</tr>
</tbody>
</table>

continued…

2 The patient has systemic AL amyloidosis*; or
3 The patient has erythema nodosum leprosum.

### Continuation

Patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen

Indication marked with * is an unapproved indication

**TRETINOIN**

- Cap 10 mg.....................................................................................................479.50 100 Vesanoïd

<table>
<thead>
<tr>
<th>Platinum Compounds</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARBOPLATIN</td>
</tr>
<tr>
<td>Inj 10 mg per ml, 45 ml vial – 1% DV Jun-19 to 2021 .................................................45.20 1 Carboplatin Ebewe</td>
</tr>
<tr>
<td>CISPLATIN</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 50 ml vial................................................................................12.29 1 DBL Cisplatin</td>
</tr>
<tr>
<td>Inj 1 mg per ml, 100 ml vial – 1% DV Sep-18 to 2021 .................................................19.70 1 DBL Cisplatin</td>
</tr>
<tr>
<td>OXALIPLATIN</td>
</tr>
<tr>
<td>Inj 5 mg per ml, 20 ml vial – 1% DV Feb-20 to 2021 ..................................................46.32 1 Oxalicoord Oxaliplatin Accord</td>
</tr>
</tbody>
</table>

(Oxalicoord Inj 5 mg per ml, 20 ml vial to be delisted 1 February 2020)

**Protein-Tyrosine Kinase Inhibitors**

**DASATINIB** – Restricted see terms below

- Tab 20 mg ........................................................................................................3,774.06 60 Sprycel
- Tab 50 mg ........................................................................................................6,214.20 60 Sprycel
- Tab 70 mg ........................................................................................................7,692.58 60 Sprycel

- Restricted (RS1685)

Initiation

Haematologist or any relevant practitioner on the recommendation of a haematologist

*Re-assessment required after 6 months*

Any of the following:

1 Both:
   1.1 The patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis or accelerated phase; and
   1.2 Maximum dose of 140 mg/day; or
2 Both:
   2.1 The patient has a diagnosis of Philadelphia chromosome-positive acute lymphoid leukaemia (Ph+ ALL); and
   2.2 Maximum dose of 140 mg/day; or
3 All of the following:
   3.1 The patient has a diagnosis of CML in chronic phase; and
   3.2 Maximum dose of 100 mg/day; and
   3.3 Any of the following:
      3.3.1 Patient has documented treatment failure* with imatinib; or
      3.3.2 Patient has experienced treatment-limiting toxicity with imatinib precluding further treatment with imatinib; or
      3.3.3 Patient has high-risk chronic-phase CML defined by the Sokal or EURO scoring system; or

continued…

*Item restricted (see ➥ above); † Item restricted (see ➥ below)

*e.g. Brand* indicates brand example only. It is not a contracted product.
3.3.4 Patients is enrolled in the KISS study** and requires dasatinib treatment according to the study protocol.

**Kinase-Inhibition Study with Sprycel Start-up
https://www.cancertrialsnz.ac.nz/kiss/

ERLOTINIB – Restricted see terms below

<table>
<thead>
<tr>
<th></th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 100 mg</td>
<td>764.00</td>
<td>Per</td>
</tr>
<tr>
<td>Tab 150 mg</td>
<td>1,146.00</td>
<td>Per</td>
</tr>
</tbody>
</table>

Initiation
Re-assessment required after 4 months

All of the following:

1. Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
2. There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
3. Either:
   3.1 Patient is treatment naive; or
   3.2 Both:
      3.2.1 The patient has discontinued gefitinib due to intolerance; and
      3.2.2 The cancer did not progress whilst on gefitinib; and
4. Erlotinib is to be given for a maximum of 3 months.

Continuation
Re-assessment required after 6 months

Both:

1. Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and
2. Erlotinib is to be given for a maximum of 3 months.

GEFITINIB – Restricted see terms below

<table>
<thead>
<tr>
<th></th>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 250 mg</td>
<td>1,700.00</td>
<td>Per</td>
</tr>
</tbody>
</table>

Initiation
Re-assessment required after 4 months

All of the following:

1. Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
2. Either:
   2.1 Patient is treatment naive; or
   2.2 Both:
      2.2.1 The patient has discontinued erlotinib due to intolerance; and
      2.2.2 The cancer did not progress whilst on erlotinib; and
3. There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
4. Gefitinib is to be given for a maximum of 3 months.

continued…
Continuation

Re-assessment required after 6 months

Both:

1. Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; and
2. Gefitinib is to be given for a maximum of 3 months.

IMATINIB MESILATE

Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule

📋 Tab 100 mg ................................................................................................2,400.00 60 Glivec

➡️ Restricted (RS1402)

Initiation

Re-assessment required after 12 months

Both:

1. Patient has diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and
2. Maximum dose of 400 mg/day.

Continuation

Re-assessment required after 12 months

Adequate clinical response to treatment with imatinib (prescriber determined).

Note: The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

Cap 100 mg – 1% DV Oct-17 to 2020 ..................................................98.00 60 Imatinib-AFT

Cap 400 mg – 1% DV Oct-17 to 2020 ..............................................197.50 30 Imatinib-AFT

LAPATINIB – Restricted see terms below

📋 Tab 250 mg ......................................................................................1,899.00 70 Tykerb

➡️ Restricted (RS1197)

Initiation

Re-assessment required after 12 months

Either:

1. All of the following:
   1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
   1.3 Lapatinib not to be given in combination with trastuzumab; and
   1.4 Lapatinib to be discontinued at disease progression; or

2. All of the following:
   2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
   2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
   2.3 The cancer did not progress whilst on trastuzumab; and
   2.4 Lapatinib not to be given in combination with trastuzumab; and
   2.5 Lapatinib to be discontinued at disease progression.

continued…
### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**Continuation**

Re-assessment required after 12 months

All of the following:
1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
3. Lapatinib not to be given in combination with trastuzumab; and
4. Lapatinib to be discontinued at disease progression.

**NILOTINIB – Restricted** see terms below

<table>
<thead>
<tr>
<th>Product</th>
<th>Price</th>
<th>Re-assessment</th>
<th>Haematologist</th>
<th>Re-assessment required after 6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cap 150 mg</td>
<td>4,680.00</td>
<td>120 Tasigna</td>
<td>Initiation</td>
<td>All of the following:</td>
</tr>
<tr>
<td>Cap 200 mg</td>
<td>6,532.00</td>
<td>120 Tasigna</td>
<td>Continuation</td>
<td>Haematologist</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>All of the following:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 Either:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.1 Patient has documented CML treatment failure* with imatinib; or</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3 Maximum nilotinib dose of 800 mg/day; and</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4 Subsidised for use as monotherapy only.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Note: *treatment failure as defined by Leukaemia Net Guidelines.</td>
</tr>
</tbody>
</table>

**PAZOPANIB – Restricted** see terms below

<table>
<thead>
<tr>
<th>Product</th>
<th>Price</th>
<th>Re-assessment</th>
<th>Haematologist</th>
<th>Re-assessment required after 3 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 200 mg</td>
<td>1,334.70</td>
<td>30 Votrient</td>
<td>Initiation</td>
<td>All of the following:</td>
</tr>
<tr>
<td>Tab 400 mg</td>
<td>2,669.40</td>
<td>30 Votrient</td>
<td>Continuation</td>
<td>Haematologist</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>All of the following:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 The patient has metastatic renal cell carcinoma; and</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 Any of the following:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.1 The patient is treatment naive; or</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.2 The patient has only received prior cytokine treatment; or</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.3 Both:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.3.2 The cancer did not progress whilst on sunitinib; and</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3 The patient has good performance status (WHO/ECOG grade 0-2); and</td>
</tr>
</tbody>
</table>

continued…
continued…

4 The disease is of predominant clear cell histology; and
5 All of the following:
   5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; and
   5.2 Haemoglobin level < lower limit of normal; and
   5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
   5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; and
   5.5 Karnofsky performance score of less than or equal to 70; and
   5.6 2 or more sites of organ metastasis.

Continuation
Re-assessment required after 3 months
Both:
   1 No evidence of disease progression; and
   2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.
Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

RUXOLITINIB – Restricted see terms below

<table>
<thead>
<tr>
<th>Tablet Size</th>
<th>Price (excl. GST)</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mg</td>
<td>2,500.00</td>
<td>Jakavi</td>
</tr>
<tr>
<td>15 mg</td>
<td>5,000.00</td>
<td>Jakavi</td>
</tr>
<tr>
<td>20 mg</td>
<td>5,000.00</td>
<td>Jakavi</td>
</tr>
</tbody>
</table>

→ Restricted (RS1650)

Initiation
Haematologist
Re-assessment required after 12 months
All of the following:
   1 The patient has primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis; and
   2 A classification of risk of intermediate-2 or high-risk myelofibrosis according to either the International Prognostic Scoring System (IPSS), Dynamic International Prognostic Scoring System (DIPSS), or the Age-Adjusted DIPSS; and
   3 A maximum dose of 20 mg twice daily is to be given.

Continuation
Haematologist
Re-assessment required after 12 months
Both:
   1 The treatment remains appropriate and the patient is benefiting from treatment; and
   2 A maximum dose of 20 mg twice daily is to be given.

SUNITINIB – Restricted see terms below

<table>
<thead>
<tr>
<th>Tablet Size</th>
<th>Price (excl. GST)</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.5 mg</td>
<td>2,315.38</td>
<td>Sutent</td>
</tr>
<tr>
<td>25 mg</td>
<td>4,630.77</td>
<td>Sutent</td>
</tr>
<tr>
<td>50 mg</td>
<td>9,261.54</td>
<td>Sutent</td>
</tr>
</tbody>
</table>

→ Restricted (RS1199)

Initiation – RCC
Re-assessment required after 3 months
All of the following:
   1 The patient has metastatic renal cell carcinoma; and
   2 Any of the following:

continued…
2.1 The patient is treatment naive; or
2.2 The patient has only received prior cytokine treatment; or
2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
2.4 Both:
   2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
   2.4.2 The cancer did not progress whilst on pazopanib; and
3 The patient has good performance status (WHO/ECOG grade 0-2); and
4 The disease is of predominant clear cell histology; and
5 All of the following:
   5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; and
   5.2 Haemoglobin level < lower limit of normal; and
   5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); and
   5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; and
   5.5 Karnofsky performance score of less than or equal to 70; and
   5.6 2 or more sites of organ metastasis; and
6 Sunitinib to be used for a maximum of 2 cycles.

Notes: RCC - Sunitinib treatment should be stopped if disease progresses. Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

Continuation – RCC
Re-assessment required after 3 months
Both:
1 No evidence of disease progression; and
2 The treatment remains appropriate and the patient is benefiting from treatment.

Initiation – GIST
Re-assessment required after 3 months
Both:
1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
2 Either:
   2.1 The patient’s disease has progressed following treatment with imatinib; or
   2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Continuation – GIST
Re-assessment required after 6 months
Both:
   The patient has responded to treatment or has stable disease as determined by Choi’s modified CT response evaluation criteria as follows:
1 Any of the following:
   1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
   1.2 The patient has had a partial response (a decrease in size of 10% or more or decrease in tumour density in Hounsfield Units (HU) of 15% or more on CT and no new lesions and no obvious progression of non-measurable disease); or
   1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of 10% or more and not
meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

### Taxanes

**DOCETAXEL**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>DBL Docetaxel</td>
<td>$12.40 1</td>
</tr>
<tr>
<td>DBL Docetaxel</td>
<td>$26.95 1</td>
</tr>
</tbody>
</table>

**PACLITAXEL**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paclitaxel Ebewe</td>
<td>$47.30 5</td>
</tr>
<tr>
<td>Paclitaxel Ebewe</td>
<td>$20.00 1</td>
</tr>
<tr>
<td>Paclitaxel Ebewe</td>
<td>$35.35 1</td>
</tr>
</tbody>
</table>

### Treatment of Cytotoxic-Induced Side Effects

**CALCIUM FOLINATE**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>DBL Leucovorin Calcium</td>
<td>$104.26 10</td>
</tr>
</tbody>
</table>

**MESNA**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uromitexan</td>
<td>$314.00 50</td>
</tr>
</tbody>
</table>

### Treatment of Cytotoxic-Induced Side Effects

**CALCIUM FOLINATE**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium Folate Ebewe</td>
<td>$7.28 1</td>
</tr>
<tr>
<td>Calcium Folate Ebewe</td>
<td>$7.33 1</td>
</tr>
<tr>
<td>Calcium Folate Ebewe</td>
<td>$22.51 1</td>
</tr>
<tr>
<td>Calcium Folate Ebewe</td>
<td>$67.51 1</td>
</tr>
</tbody>
</table>

(Calcium Folate Ebewe Inj 10 mg per ml, 10 ml vial to be delisted 1 January 2020)
(Calcium Folate Ebewe Inj 10 mg per ml, 100 ml vial to be delisted 1 March 2020)

**DEXRAZOXANE** – Restricted see terms below

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>e.g. Cardioxane</td>
<td>$314.00 50</td>
</tr>
</tbody>
</table>

**MESNA**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uromitexan</td>
<td>$314.00 50</td>
</tr>
</tbody>
</table>

(Calcium Folate Ebewe Inj 10 mg per ml, 10 ml vial to be delisted 1 January 2020)
(Calcium Folate Ebewe Inj 10 mg per ml, 100 ml vial to be delisted 1 March 2020)

(Dexrazoxane – Restricted see terms below)

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uromitexan</td>
<td>$314.00 50</td>
</tr>
</tbody>
</table>

**MESNA**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uromitexan</td>
<td>$314.00 50</td>
</tr>
</tbody>
</table>

### Treatment of Cytotoxic-Induced Side Effects

**CALCIUM FOLINATE**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium Folate Ebewe</td>
<td>$7.28 1</td>
</tr>
<tr>
<td>Calcium Folate Ebewe</td>
<td>$7.33 1</td>
</tr>
<tr>
<td>Calcium Folate Ebewe</td>
<td>$22.51 1</td>
</tr>
<tr>
<td>Calcium Folate Ebewe</td>
<td>$67.51 1</td>
</tr>
</tbody>
</table>

(Calcium Folate Ebewe Inj 10 mg per ml, 10 ml vial to be delisted 1 January 2020)
(Calcium Folate Ebewe Inj 10 mg per ml, 100 ml vial to be delisted 1 March 2020)

**DEXRAZOXANE** – Restricted see terms below

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>e.g. Cardioxane</td>
<td>$314.00 50</td>
</tr>
</tbody>
</table>

**MESNA**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uromitexan</td>
<td>$314.00 50</td>
</tr>
</tbody>
</table>

(Calcium Folate Ebewe Inj 10 mg per ml, 10 ml vial to be delisted 1 January 2020)
(Calcium Folate Ebewe Inj 10 mg per ml, 100 ml vial to be delisted 1 March 2020)

(Dexrazoxane – Restricted see terms below)

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uromitexan</td>
<td>$314.00 50</td>
</tr>
</tbody>
</table>

**MESNA**

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) $ Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uromitexan</td>
<td>$314.00 50</td>
</tr>
</tbody>
</table>
### Vinca Alkaloids

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Formulation</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>VINBLASTINE SULPHATE</td>
<td>Inj 1 mg per ml, 10 ml vial</td>
<td>$186.46</td>
<td>5 Hospira</td>
</tr>
<tr>
<td>VINCRIStine SULPHATE</td>
<td>Inj 1 mg per ml, 1 ml vial</td>
<td>$74.52</td>
<td>5 DBL Vincristine Sulfate</td>
</tr>
<tr>
<td></td>
<td>Inj 1 mg per ml, 2 ml vial</td>
<td>$85.61</td>
<td>5 DBL Vincristine Sulfate</td>
</tr>
<tr>
<td>VINORELBINE</td>
<td>Inj 10 mg per ml, 1 ml vial</td>
<td>$12.00</td>
<td>1 Navelbine</td>
</tr>
<tr>
<td></td>
<td>Inj 10 mg per ml, 5 ml vial</td>
<td>$56.00</td>
<td>1 Navelbine</td>
</tr>
</tbody>
</table>

### Endocrine Therapy

**ABIRATERONE ACETATE** – Restricted see terms below

- **Tab 250 mg** ........................................................... $4,276.19 | 120 Zytiga

- **Restricted (RS1658)**

  **Initiation**
  
  Medical oncologist, radiation oncologist or urologist
  
  *Re-assessment required after 6 months*

  All of the following:
  
  1. Patient has prostate cancer; and
  2. Patient has metastases; and
  3. Patient’s disease is castration resistant; and
  4. Either:
     4.1 All of the following:
        4.1.1 Patient is symptomatic; and
        4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and
        4.1.3 Patient has ECOG performance score of 0-1; and
        4.1.4 Patient has not had prior treatment with taxane chemotherapy; or
     4.2 All of the following:
        4.2.1 Patient’s disease has progressed following prior chemotherapy containing a taxane; and
        4.2.2 Patient has ECOG performance score of 0-2; and
        4.2.3 Patient has not had prior treatment with abiraterone.

  **Continuation**
  
  Medical oncologist, radiation oncologist or urologist
  
  *Re-assessment required after 6 months*

  All of the following:
  
  1. Significant decrease in serum PSA from baseline; and
  2. No evidence of clinical disease progression; and
  3. No initiation of taxane chemotherapy with abiraterone; and
  4. The treatment remains appropriate and the patient is benefiting from treatment.

**BICALUTAMIDE**

- **Tab 50 mg** – 1% DV Feb-18 to 2020 .................................................. $3.80 | 28 Binarex

**FLUTAMIDE**

- **Tab 250 mg** ........................................................... $119.50 | 100 Flutamin

**MEGESTROL ACETATE**

- **Tab 160 mg** – 1% DV Oct-18 to 2021 .................................................. $63.53 | 30 Apo-Megestrol
## OCTREOTIDE – Some items restricted see terms below

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
<tr>
<td>30.64</td>
<td>DBL Octreotide</td>
</tr>
<tr>
<td>18.69</td>
<td>DBL Octreotide</td>
</tr>
<tr>
<td>72.50</td>
<td>DBL Octreotide</td>
</tr>
<tr>
<td>1,772.50</td>
<td>Sandostatin LAR</td>
</tr>
<tr>
<td>2,358.75</td>
<td>Sandostatin LAR</td>
</tr>
<tr>
<td>2,951.25</td>
<td>Sandostatin LAR</td>
</tr>
</tbody>
</table>

### Restricted (RS1201)

**Initiation – Malignant bowel obstruction**

All of the following:

1. The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
2. Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
3. Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with * are unapproved indications

**Initiation – acromegaly**

*Re-assessment required after 3 months*

Both:

1. The patient has acromegaly; and
2. Any of the following:
   2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
   2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
   2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

**Continuation – acromegaly**

Both:

1. IGF1 levels have decreased since starting octreotide; and
2. The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks.

**Initiation – Other indications**

Any of the following:

1. VIPomas and glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
2. Both:
   2.1 Gastrinoma; and
   2.2 Either:
      2.2.1 Patient has failed surgery; or
      2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
3. Both:
   3.1 Insulinomas; and
   3.2 Surgery is contraindicated or has failed; or
4. For pre-operative control of hypoglycaemia and for maintenance therapy; or
5. Both:
   5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
   5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: restriction applies only to the long-acting formulations of octreotide
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>TAMOXIFEN CITRATE</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 10 mg – 1% DV Jan-19 to 2020</td>
<td>11.75</td>
<td>60</td>
<td>Tamoxifen Sandoz</td>
</tr>
<tr>
<td>Tab 20 mg – 1% DV Jan-19 to 2020</td>
<td>5.60</td>
<td>60</td>
<td>Tamoxifen Sandoz</td>
</tr>
</tbody>
</table>

Aromatase Inhibitors

ANASTROZOLE
- Tab 1 mg – 1% DV Jan-18 to 2020 | 5.04 | 30 | Rolin |

EXEMESTANE
- Tab 25 mg – 1% DV Sep-17 to 2020 | 14.50 | 30 | Pfizer Exemestane |

LETROZOLE
- Tab 2.5 mg – 1% DV Nov-18 to 2021 | 4.68 | 30 | Letrole |

Imaging Agents

AMINOLEVULIC ACID HYDROCHLORIDE – Restricted see terms below
- Powder for oral soln, 30 mg per ml, 1.5 g vial | 4,400.00 | 1 | Gliolan |
- Powder for oral soln, 30 mg per ml, 1.5 g vial | 44,000.00 | 10 | Gliolan |

- Restricted (RS1565)
Initiation – high grade malignant glioma
All of the following:
1. Patient has newly diagnosed, untreated, glioblastoma multiforme; and
2. Treatment to be used as adjuvant to fluorescence-guided resection; and
3. Patient’s tumour is amenable to complete resection.

Immunosuppressants

Calcineurin Inhibitors

CICLOSPORIN
- Cap 25 mg | 44.63 | 50 | Neoral |
- Cap 50 mg | 88.91 | 50 | Neoral |
- Cap 100 mg | 177.81 | 50 | Neoral |
- Oral liq 100 mg per ml | 198.13 | 50 ml | Neoral |
- Inj 50 mg per ml, 5 ml ampoule | 276.30 | 10 | Sandimmun |

TACROLIMUS – Restricted see terms below
- Cap 0.5 mg | 49.60 | 100 | Tacrolimus Sandoz |
- Cap 0.75 mg | 99.30 | 100 | Tacrolimus Sandoz |
- Cap 1 mg | 84.30 | 100 | Tacrolimus Sandoz |
- Cap 5 mg | 248.20 | 50 | Tacrolimus Sandoz |
- Inj 5 mg per ml, 1 ml ampoule

- Restricted (RS1651)
Initiation – organ transplant recipients
Any specialist
For use in organ transplant recipients.
Initiation – non-transplant indications*
Any specialist
Both:
1. Patient requires long-term systemic immunosuppression; and
2. Ciclosporin has been trialled and discontinued treatment because of unacceptable side effects or inadequate clinical response.

Note: Indications marked with * are unapproved indications

Products with Hospital Supply Status (HSS) are in bold
Expiration date of HSS period is 30 June of the year indicated unless otherwise stated.
Fusion Proteins

ETANERCEPT – Restricted see terms below

- Inj 25 mg vial – 5% DV Sep-19 to 2024 .......................................................799.96 4 Enbrel
- Inj 50 mg autoinjector – 5% DV Sep-19 to 2024 .......................................1,599.96 4 Enbrel
- Inj 50 mg syringe – 5% DV Sep-19 to 2024 ..............................................1,599.96 4 Enbrel

Initiation – juvenile idiopathic arthritis
Rheumatologist or named specialist
Re-assessment required after 6 months

Either:
1 Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or
2 All of the following:
   2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
   2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
   2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
   2.5 Both:
      2.5.1 Either:
         2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
         2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
      2.5.2 Physician's global assessment indicating severe disease.

Continuation – juvenile idiopathic arthritis
Rheumatologist or named specialist
Re-assessment required after 6 months

Both:
1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2 Either:
   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation – rheumatoid arthritis
Rheumatologist
Re-assessment required after 6 months

Either:
1 Both:

continued…
continued...

1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
1.2 Either:
   1.2.1 The patient has experienced intolerable side effects from adalimumab; or
   1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or

2 All of the following:
2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
2.5 Any of the following:
   2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
   2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
   2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
2.6 Either:
   2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
   2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
2.7 Either:
   2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation – rheumatoid arthritis
Rheumatologist
Re-assessment required after 6 months
All of the following:
1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2 Either:
   2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – ankylosing spondylitis
Rheumatologist
Re-assessment required after 6 months
Either:

continued…
continued...

1 Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab
      for ankylosing spondylitis; or

2 All of the following:
   2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
   2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
   2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
   2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal
      anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing
      at least 3 months of a regular exercise regimen for ankylosing spondylitis; and
   2.5 Either:
      2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by
      the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of
      less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left
      and right); or
      2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for
      age and gender (see Notes); and
   2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID
   treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-24</td>
<td>7.0 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>25-34</td>
<td>7.5 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>35-44</td>
<td>6.5 cm</td>
<td>4.5 cm</td>
</tr>
<tr>
<td>45-54</td>
<td>6.0 cm</td>
<td>5.0 cm</td>
</tr>
<tr>
<td>55-64</td>
<td>5.5 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>65-74</td>
<td>4.0 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>75+</td>
<td>3.0 cm</td>
<td>2.5 cm</td>
</tr>
</tbody>
</table>

Continuation – ankylosing spondylitis
Rheumatologist
Re-assessment required after 6 months
All of the following:
   1 Following 12 weeks' initial treatment and for subsequent renewals, treatment has resulted in an improvement in BASDAI of
      4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less;
      and
   2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
   3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – psoriatic arthritis
Rheumatologist
Re-assessment required after 6 months
Either:

continued…
1 Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or
2 All of the following:
   2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
   2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
   2.4 Either:
      2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
      2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
   2.5 Any of the following:
      2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
      2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
      2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation – psoriatic arthritis
Rheumatologist
Re-assessment required after 6 months
Both:
   1 Either:
      1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
      1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
   2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – severe chronic plaque psoriasis, prior TNF use
Dermatologist
Limited to 4 months treatment
All of the following:
   1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
   2 Either:
      2.1 The patient has experienced intolerable side effects from adalimumab; or
      2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; and
   3 Patient must be reassessed for continuation after 3 doses.

Initiation – severe chronic plaque psoriasis, treatment-naive
Dermatologist
Limited to 4 months treatment
All of the following:
   continued…
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer

continued...

1 Either:
   1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
   1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and

2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and

3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4 The most recent PASI or DLQI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation – severe chronic plaque psoriasis

Dermatologist
Re-assessment required after 6 months

Both:

1 Either:
   1.1 Both:
      1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
      1.1.2 Either:
         1.1.2.1 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-etanercept treatment baseline value; or
         1.1.2.2 Following each prior etanercept treatment course the patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or
   1.2 Both:
      1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
      1.2.2 Either:
         1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
         1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and

2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – pyoderma gangrenosum

Dermatologist

All of the following:

1 Patient has pyoderma gangrenosum; and

2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and

continued…
continued…

3 A maximum of 4 doses.

Note: Indications marked with * are unapproved indications.

Continuation – pyoderma gangrenosum

Dermatologist

All of the following:

1 Patient has shown clinical improvement; and
2 Patient continues to require treatment; and
3 A maximum of 4 doses.

Initiation – adult-onset Still’s disease

Rheumatologist

Re-assessment required after 6 months

Either:

1 Both:
   1.1 Either:
       1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still’s disease (AOSD); or
       1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H rules; and
   1.2 Either:
       1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
       1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
2 All of the following:
   2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
   2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
   2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation – adult-onset Still’s disease

Rheumatologist

Re-assessment required after 6 months

The patient has a sustained improvement in inflammatory markers and functional status.

Monoclonal Antibodies

ABCIXIMAB – Restricted see terms below

1 Inj 2 mg per ml, 5 ml vial.................................................................579.53 1 ReoPro

Initiation

Either:

1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or
2 For use in patients undergoing intra-cranial intervention.

ADALIMUMAB – Restricted see terms below

1 Inj 20 mg per 0.4 ml syringe..........................................................1,599.96 2 Humira
1 Inj 40 mg per 0.8 ml pen.................................................................1,599.96 2 HumiraPen
1 Inj 40 mg per 0.8 ml syringe..........................................................1,599.96 2 Humira

Initiation – juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

Either:

continued…

Products with Hospital Supply Status (HSS) are in bold

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
Continuation – juvenile idiopathic arthritis
Rheumatologist or named specialist
Re-assessment required after 6 months
Both:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Either:

   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or

   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation – fistulising Crohn's disease
Gastroenterologist
Re-assessment required after 4 months
All of the following:

1 Patient has confirmed Crohn's disease; and

2 Either:

   2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or

   2.2 Patient has one or more rectovaginal fistula(e); and

3 A Baseline Fistula Assessment (a copy of which is available at www.pharmac.govt.nz/latest/BaselineFistulaAssessment.pdf) has been completed and is no more than 1 month old at the time of application.

continued…
continued...

**Continuation – fistulising Crohn's disease**

Gastroenterologist

*Re-assessment required after 6 months*

Either:

1. The number of open draining fistulae have decreased from baseline by at least 50%; or
2. There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

**Initiation – Crohn's disease - adults**

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

1. Patient has severe active Crohn's disease; and
2. Any of the following:
   2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
   2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
   2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
   2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
3. Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4. Surgery (or further surgery) is considered to be clinically inappropriate.

**Continuation – Crohn's disease - adults**

Gastroenterologist

*Re-assessment required after 3 months*

Both:

1. Either:
   1.1 Either:
      1.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
      1.1.2 CDAI score is 150 or less; or
   1.2 Both:
      1.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
      1.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
2. Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – Crohn's disease - children**

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

1. Paediatric patient has severe active Crohn's disease; and
2. Either:
   2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
   2.2 Patient has extensive small intestine disease; and
3. Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4. Surgery (or further surgery) is considered to be clinically inappropriate.

continued…
Continuation – Crohn’s disease - children
Gastroenterologist
Re-assessment required after 3 months
Both:

1 Any of the following:
   1.1 PCDAI score has reduced by 100 points from the PCDAI score when the patient was initiated on adalimumab; or
   1.2 PCDAI score is 150 or less; or
   1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – rheumatoid arthritis
Rheumatologist
Re-assessment required after 6 months
Either:

1 Both:
   1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from etanercept; or
      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or

2 All of the following:
   2.1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and
   2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
   2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
   2.5 Any of the following:
      2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
      2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
      2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
   2.6 Either:
      2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
      2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
   2.7 Either:
      2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
      2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

continued...
Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

---

**Continuation – rheumatoid arthritis**

Rheumatologist

**Re-assessment required after 6 months**

All of the following:

1. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2. Either:

   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

3. Adalimumab to be administered at doses no greater than 40 mg every 14 days.

---

**Initiation – ankylosing spondylitis**

Rheumatologist

**Re-assessment required after 6 months**

Either:

1. Both:

   1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and

   1.2 Either:

      1.2.1 The patient has experienced intolerable side effects from etanercept; or

      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or

2. All of the following:

   2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and

   2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and

   2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and

   2.4 Patient’s ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of a regular exercise regimen for ankylosing spondylitis; and

   2.5 Either:

      2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or

      2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and

2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment. Average normal chest expansion measure corrected for age and gender:

---

Continued…
continued…

<table>
<thead>
<tr>
<th>Age</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-24</td>
<td>7.0 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>25-34</td>
<td>7.5 cm</td>
<td>5.5 cm</td>
</tr>
<tr>
<td>35-44</td>
<td>6.5 cm</td>
<td>4.5 cm</td>
</tr>
<tr>
<td>45-54</td>
<td>6.0 cm</td>
<td>5.0 cm</td>
</tr>
<tr>
<td>55-64</td>
<td>5.5 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>65-74</td>
<td>4.0 cm</td>
<td>4.0 cm</td>
</tr>
<tr>
<td>75+</td>
<td>3.0 cm</td>
<td>2.5 cm</td>
</tr>
</tbody>
</table>

**Continuation – ankylosing spondylitis**

*Rheumatologist*

*Re-assessment required after 6 months*

All of the following:

1. Following 12 weeks’ initial treatment and subsequent renewals, treatment has resulted in an improvement in BASDAI of 4 or more points from pre-treatment baseline on a 10 point scale, or an improvement in BASDAI of 50%, whichever is less; and

2. Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

3. Adalimumab to be administered at doses no greater than 40 mg every 14 days.

**Initiation – psoriatic arthritis**

*Rheumatologist*

*Re-assessment required after 6 months*

Either:

1. Both:
   
   1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
   
   1.2 Either:
      
      1.2.1 The patient has experienced intolerable side effects from etanercept; or
      
      1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or

2. All of the following:

   2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
   
   2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
   
   2.3 Patient has tried and not responded to at least three months of sulfasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
   
   2.4 Either:
      
      2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
      
      2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.5 Any of the following:

   2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   
   2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
   
   2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

continued…
Continuation – psoriatic arthritis
Rheumatologist
Re-assessment required after 6 months
Both:
1. Either:
   1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
2. Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – plaque psoriasis, prior TNF use
Dermatologist
Limited to 4 months treatment
Both:
1. The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
2. Either:
   2.1 The patient has experienced intolerable side effects from etanercept; or
   2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis.

Initiation – plaque psoriasis, treatment-naive
Dermatologist
Limited to 4 months treatment
All of the following:
1. Either:
   1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
   1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
2. Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
3. A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
4. The most recent PASI or DLQI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation – plaque psoriasis
Dermatologist
Re-assessment required after 6 months
Both:
1. Either:
   1.1 Both:
      1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and

continued…
1.1.2 Either:
   1.1.2.1 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by
   75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment
   baseline value; or
   1.1.2.2 Following each prior adalimumab treatment course the patient has a Dermatology Quality of Life
   Index (DLQI) improvement of 5 or more, when compared with the pre-treatment baseline value; or

1.2 Both:
   1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of
   treatment; and
   1.2.2 Either:
      1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom
      subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as
      compared to the treatment course baseline values; or
      1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the
      skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline
      value; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – pyoderma gangrenosum
Dermatologist
All of the following:
   1 Patient has pyoderma gangrenosum*; and
   2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g.
      prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
   3 A maximum of 4 doses.

Note: Indications marked with * are unapproved indications.

Continuation – pyoderma gangrenosum
Dermatologist
All of the following:
   1 Patient has shown clinical improvement; and
   2 Patient continues to require treatment; and
   3 A maximum of 4 doses.

Initiation – adult-onset Still’s disease
Rheumatologist
Re-assessment required after 6 months
Either:
   1 Both:
      1.1 Either:
         1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still’s disease
         (AOSD); or
         1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the Section H
         rules; and
      1.2 Either:
         1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
         1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or
         tocilizumab such that they do not meet the renewal criteria for AOSD; or
   2 All of the following:
      2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and

continued…
continued...

2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antinflammatory drugs (NSAIDs) and methotrexate; and

2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation – adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months

The patient has a sustained improvement in inflammatory markers and functional status.

Initiation – severe Behcet's disease

Any relevant practitioner

Re-assessment required after 3 months

All of the following:

1. The patient has severe Behcet's disease that is significantly impacting the patient's quality of life (see Notes); and

2. Either:

   2.1 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has not responded adequately to treatment with infliximab (see Notes); or

   2.2 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has experienced intolerable side effects from treatment with infliximab; and

3. The patient is experiencing significant loss of quality of life; and

4. Adalimumab to be administered at doses no greater than 40 mg every 14 days.


Continuation – severe Behcet's disease

Any relevant practitioner

Re-assessment required after 6 months

Both:

1. Patient has had a good clinical response to initial treatment with measurably improved quality of life; and

2. Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – severe ocular inflammation

Re-assessment required after 4 months

Either:

1. Both:

   1.1 The patient has had an initial Special Authority approval for infliximab for severe ocular inflammation; and

   1.2 Either:

      1.2.1 The patient has experienced intolerable side effects from infliximab; or

      1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for severe ocular inflammation; or

2. Both:

   2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and

   2.2 Any of the following:

      2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or

      2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or

      2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

continued...
Continuation – severe ocular inflammation
Re-assessment required after 12 months
Both:

1 Any of the following:
   1.1 The patient has had a good clinical response following 3 initial doses; or
   1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation
      (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active
      vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
   1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in
      prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely
high risk of irreversible vision loss if adalimumab is withdrawn.

Initiation – chronic ocular inflammation
Re-assessment required after 4 months
Either:

1 Both:
   1.1 The patient has had an initial Special Authority approval for infliximab for chronic ocular inflammation; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from infliximab; or
      1.2.2 The patient has received insufficient benefit from infliximab to meet the renewal criteria for infliximab for
chronic ocular inflammation; or

2 Both:
   2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk
of vision loss; and
   2.2 Any of the following:
      2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective;
or
      2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at a therapeutic
dose; or
      2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic
dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Continuation – chronic ocular inflammation
Re-assessment required after 12 months
Both:

1 Any of the following:
   1.1 The patient has had a good clinical response following 12 weeks’ initial treatment; or
   1.2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation
      (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active
      vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or
   1.3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in
      prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely
high risk of irreversible vision loss if adalimumab is withdrawn.

continued...
continued...

**Initiation – hidradenitis suppurativa**
Dermatologist

*Re-assessment required after 4 months*

All of the following:

1. Patient has hidradenitis suppurativa Hurley Stage II or Hurley Stage III lesions in distinct anatomic areas; and
2. Patient has tried, but had an inadequate response to at least a 90 day trial of systemic antibiotics or patient has demonstrated intolerance to or has contraindications for systemic antibiotics; and
3. The patient has 3 or more active lesions (e.g. inflammatory nodules, abscesses, draining fistulae); and
4. The patient has a Dermatology Quality of Life Index of 10 or more and the assessment is no more than 1 month old at time of application; and
5. Following the initial loading doses, adalimumab is to be administered at doses no greater than 40mg every 7 days.

**Continuation – hidradenitis suppurativa**
Dermatologist

*Re-assessment required after 6 months*

All of the following:

1. The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; and
2. The patient has a Dermatology Quality of Life Index improvement of 4 or more from baseline; and
3. Adalimumab is to be administered at doses no greater than 40mg every 7 days. Fortnightly dosing has been considered.

**AFLIBERCEPT – Restricted see terms below**

Initiation – Wet Age Related Macular Degeneration
Ophthalmologist

*Re-assessment required after 3 months*

Either:

1. All of the following:
   1.1 Any of the following:
      1.1.1 Wet age-related macular degeneration (wet AMD); or
      1.1.2 Polypoidal choroidal vasculopathy; or
      1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and
   1.2 Either:
      1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or
      1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and
   1.3 There is no structural damage to the central fovea of the treated eye; and
   1.4 Patient has not previously been treated with ranibizumab for longer than 3 months; or
2. Either:
   2.1 Patient has current approval to use ranibizumab for treatment of wAMD and was found to be intolerant to ranibizumab within 3 months; or
   2.2 Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment.

Continuation – Wet Age Related Macular Degeneration
Ophthalmologist

*Re-assessment required after 12 months*

All of the following:

continued...
continued…

1. Documented benefit must be demonstrated to continue; and
2. Patient’s vision is 6/36 or better on the Snellen visual acuity score; and
3. There is no structural damage to the central fovea of the treated eye.

Initiation – Diabetic Macular Oedema
Ophthalmologist
Re-assessment required after 4 months

All of the following:
1. Patient has centre involving diabetic macular oedema (DMO); and
2. Patient’s disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly; and
3. Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision; and
4. Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers; and
5. There is no centre-involving sub-retinal fibrosis or foveal atrophy.

Continuation – Diabetic Macular Oedema
Ophthalmologist
Re-assessment required after 12 months

All of the following:
1. There is stability or two lines of Snellen visual acuity gain; and
2. There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid); and
3. Patient’s vision is 6/36 or better on the Snellen visual acuity score; and
4. There is no centre-involving sub-retinal fibrosis or foveal atrophy; and
5. After each consecutive 12 months treatment with aflibercept, patient has retrialled with at least one injection of bevacizumab and had no response.

BASILIXIMAB – Restricted see terms below

♀ Inj 20 mg vial ................................................................. 2,560.00 1 Simulect

♀ Restricted (RS1203)

Initiation

For use in solid organ transplants.

BEVACIZUMAB – Restricted see terms below

♀ Inj 25 mg per ml, 4 ml vial
♀ Inj 25 mg per ml, 16 ml vial

♀ Restricted (RS1691)

Initiation – Recurrent Respiratory Papillomatosis
Otolaryngologist
Re-assessment required after 12 months

All of the following:
1. Maximum of 6 doses; and
2. The patient has recurrent respiratory papillomatosis; and
3. The treatment is for intra-lesional administration.

Continuation – Recurrent Respiratory Papillomatosis
Otolaryngologist
Re-assessment required after 12 months

All of the following:
1. Maximum of 6 doses; and
2. The treatment is for intra-lesional administration; and
3. There has been a reduction in surgical treatments or disease regrowth as a result of treatment.

continued…
continued...

**Initiation – ocular conditions**

Either:

1. Ocular neovascularisation; or
2. Exudative ocular angiopathy.

**CETUXIMAB – Restricted** see terms below

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$364.00</td>
<td>1 Erbitux</td>
</tr>
<tr>
<td>$1,820.00</td>
<td>1 Erbitux</td>
</tr>
</tbody>
</table>

**Restrict** (*RS1613*)

**Initiation**

Medical oncologist

All of the following:

1. Patient has locally advanced, non-metastatic, squamous cell cancer of the head and neck; and
2. Patient is contraindicated to, or is intolerant of, cisplatin; and
3. Patient has good performance status; and
4. To be administered in combination with radiation therapy.

**INFLIXIMAB – Restricted** see terms below

<table>
<thead>
<tr>
<th>Price</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$806.00</td>
<td>1 Remicade</td>
</tr>
</tbody>
</table>

**Restrict** (*RS1697*)

**Initiation – Graft vs host disease**

Patient has steroid-refractory acute graft vs. host disease of the gut.

**Initiation – rheumatoid arthritis**

Rheumatologist

*Re-assessment required after 4 months*

All of the following:

1. The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
2. Either:
   2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
   2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and
3. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance.

**Continuation – rheumatoid arthritis**

Rheumatologist

*Re-assessment required after 6 months*

All of the following:

1. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2. Either:
   2.1 Following 3 to 4 months’ initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
3. Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

continued…
ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

continued...

**Initiation – ankylosing spondylitis**
Rheumatologist
Re-assessment required after 3 months
Both:

1. The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and
2. Either:
   1. The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
   2. Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

**Continuation – ankylosing spondylitis**
Rheumatologist
Re-assessment required after 6 months
All of the following:

1. Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
2. Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
3. Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

**Initiation – psoriatic arthritis**
Rheumatologist
Re-assessment required after 4 months
Both:

1. The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic arthritis; and
2. Either:
   1. The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
   2. Following 3-4 months' initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis.

**Continuation – psoriatic arthritis**
Rheumatologist
Re-assessment required after 6 months
Both:

1. Either:
   1. Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   2. The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
2. Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

**Initiation – severe ocular inflammation**
Re-assessment required after 3 doses
Either:

1. Both:
   1. The patient has had an initial Special Authority approval for adalimumab for severe ocular inflammation; and
   2. Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab; or
      1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe ocular inflammation; or
2. Both:
   2.1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and

continued…
continued...

2.2 Any of the following:

2.2.1 Treatment with high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids has proven ineffective at controlling symptoms; or

2.2.2 Patient developed new inflammatory symptoms while receiving high dose steroids; or

2.2.3 Patient is aged under 8 years and treatment with high dose oral steroids and other immunosuppressants has proven ineffective at controlling symptoms.

Continuation – severe ocular inflammation
Re-assessment required after 12 months

Any of the following:

1 The patient has had a good clinical response following 3 initial doses; or

2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or

3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.

Initiation – chronic ocular inflammation
Re-assessment required after 3 doses

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for chronic ocular inflammation; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab; or

1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for chronic ocular inflammation; or

2 Both:

2.1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and

2.2 Any of the following:

2.2.1 Patient is 18 years or older and treatment with at least two other immunomodulatory agents has proven ineffective; or

2.2.2 Patient is under 18 years and treatment with methotrexate has proven ineffective or is not tolerated at therapeutic dose; or

2.2.3 Patient is under 8 years and treatment with steroids or methotrexate has proven ineffective or is not tolerated at a therapeutic dose; or disease requires control to prevent irreversible vision loss prior to achieving a therapeutic dose of methotrexate.

Continuation – chronic ocular inflammation
Re-assessment required after 12 months

Any of the following:

1 The patient has had a good clinical response following 3 initial doses; or

2 Following each 12-month treatment period, the patient has had a sustained reduction in inflammation (Standardisation of Uveitis Nomenclature (SUN) criteria < ½+ anterior chamber or vitreous cells, absence of active vitreous or retinal lesions, or resolution of uveitic cystoid macular oedema); or

3 Following each 12-month treatment period, the patient has a sustained steroid sparing effect, allowing reduction in prednisone to < 10mg daily, or steroid drops less than twice daily if under 18 years old.

Note: A trial withdrawal should be considered after every 24 months of stability, unless the patient is deemed to have extremely high risk of irreversible vision loss if infliximab is withdrawn.
continued…

high risk of irreversible vision loss if infliximab is withdrawn.

**Initiation – Pulmonary sarcoidosis**

Both:

1. Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments; and
2. Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis.

**Initiation – Crohn’s disease (adults)**

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

1. Patient has severe active Crohn's disease; and
2. Any of the following:
   1.1 Patient has a Crohn’s Disease Activity Index (CDAI) score of greater than or equal to 300; or
   1.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
   1.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
   2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
3. Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4. Surgery (or further surgery) is considered to be clinically inappropriate; and
5. Patient must be reassessed for continuation after 3 months of therapy.

**Continuation – Crohn’s disease (adults)**

Gastroenterologist

*Re-assessment required after 6 months*

Both:

1. Any of the following:
   1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab; or
   1.2 CDAI score is 150 or less; or
   1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
2. Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

**Initiation – Crohn’s disease (children)**

Gastroenterologist

*Re-assessment required after 3 months*

All of the following:

1. Paediatric patient has severe active Crohn's disease; and
2. Either:
   2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
   2.2 Patient has extensive small intestine disease; and
3. Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4. Surgery (or further surgery) is considered to be clinically inappropriate; and
5. Patient must be reassessed for continuation after 3 months of therapy.

continued…
Continuation – Crohn's disease (children)
Gastroenterologist
Re-assessment required after 6 months
Both:

1. Any of the following:
   1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
   1.2 PCDAI score is 15 or less; or
   1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and

2. Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – fistulising Crohn's disease
Gastroenterologist
Re-assessment required after 4 months
Both:

1. Patient has confirmed Crohn's disease; and
2. Either:
   2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
   2.2 Patient has one or more rectovaginal fistula(e).

Continuation – fistulising Crohn's disease
Gastroenterologist
Re-assessment required after 6 months
Both:

1. Either:
   1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
   1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and

2. Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – acute severe fulminant ulcerative colitis
Gastroenterologist
Limited to 6 weeks treatment
Both:

1. Patient has acute, severe fulminant ulcerative colitis; and
2. Treatment with intravenous or high dose oral corticosteroids has not been successful.

Continuation – severe fulminant ulcerative colitis
Gastroenterologist
Re-assessment required after 6 months
Both:

1. Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
2. Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

continued…
Initiation – severe ulcerative colitis
Gastroenterologist
Re-assessment required after 3 months
All of the following:

1. Patient has histologically confirmed ulcerative colitis; and
2. Either:
   2.1 Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) is greater than or equal to 4; or
   2.2 Patient is under 18 years and the Paediatric Ulcerative Colitis Activity Index (PUCAI) score is greater than or equal to 65; and
3. Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and
4. Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation – severe ulcerative colitis
Gastroenterologist
Re-assessment required after 6 months
All of the following:

1. Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
2. Either:
   2.1 Patient is 18 years or older and the SCCAI score has reduced by 2 points or more from the SCCAI score when the patient was initiated on infliximab; or
   2.2 Patient is under 18 years and the PUCAI score has reduced by 30 points or more from the PUCAI score when the patient was initiated on infliximab; and
3. Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – plaque psoriasis
Dermatologist
Re-assessment required after 3 doses
Either:

1. Both:
   1.1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or
      1.2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis; or
2. All of the following:
   2.1 Either:
      2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
      2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
   2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and

continued…
continued...

2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation – plaque psoriasis

Dermatologist

Re-assessment required after 3 doses

Both:

1 Either:

1.1 Both:

1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and

1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or

1.2 Both:

1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and

1.2.2 Either:

1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or

1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and

2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initiation – neurosarcoïdosis

Neurologist

Re-assessment required after 18 months

All of the following:

1 Biopsy consistent with diagnosis of neurosarcoïdosis; and

2 Patient has CNS involvement; and

3 Patient has steroid-refractory disease; and

4 Either:

4.1 IV cyclophosphamide has been tried; or

4.2 Treatment with IV cyclophosphamide is clinically inappropriate.

Continuation – neurosarcoïdosis

Neurologist

Re-assessment required after 18 months

Either:

1 A withdrawal period has been tried and the patient has relapsed; or

2 All of the following:

2.1 A withdrawal period has been considered but would not be clinically appropriate; and

2.2 There has been a marked reduction in prednisone dose; and

continued...
2.3 Either:
   2.3.1 There has been an improvement in MRI appearances; or
   2.3.2 Marked improvement in other symptomology.

**Initiation – severe Behcet’s disease**

*Re-assessment required after 4 months*

All of the following:

1. The patient has severe Behcet’s disease which is significantly impacting the patient’s quality of life (see Notes); and
2. Either:
   2.1 The patient has severe ocular, neurological and/or vasculitic symptoms and has not responded adequately to one or more treatment(s) appropriate for the particular symptom(s) (see Notes); or
   2.2 The patient has severe gastrointestinal, rheumatologic and/or mucocutaneous symptoms and has not responded adequately to two or more treatment appropriate for the particular symptom(s) (see Notes); and
3. The patient is experiencing significant loss of quality of life.

**Notes:**

2. Treatments appropriate for the particular symptoms are those that are considered standard conventional treatments for these symptoms, for example intravenous/oral steroids and other immunosuppressants for ocular symptoms; azathioprine, steroids, thalidomide, interferon alpha and ciclosporin for mucocutaneous symptoms; and colchicine, steroids and methotrexate for rheumatological symptoms.

**Continuation – severe Behcet’s disease**

*Re-assessment required after 6 months*

Both:

1. Patient has had a good clinical response to initial treatment with measurably improved quality of life; and
2. Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

**OBINUTUZUMAB – Restricted see terms below**

$ Inj 25 mg per ml, 40 ml vial.................................................. 5,910.00 1 Gazyva

**Initiation**

Haematologist

*Limited to 6 months* treatment

All of the following:

1. The patient has progressive Binet stage A, B or C CD20+ chronic lymphocytic leukaemia requiring treatment; and
2. The patient is obinutuzumab treatment naive; and
3. The patient is not eligible for full dose FCR due to comorbidities with a score > 6 on the Cumulative Illness Rating Scale (CIRS) or reduced renal function (creatinine clearance < 70mL/min); and
4. Patient has adequate neutrophil and platelet counts* unless the cytopenias are a consequence of marrow infiltration by CLL; and
5. Patient has good performance status; and
6. Obinutuzumab to be administered at a maximum cumulative dose of 8,000 mg and in combination with chlorambucil for a maximum of 6 cycles.

**Notes:**

Chronic lymphocytic leukaemia includes small lymphocytic lymphoma. Comorbidity refers only to illness/impairment other than CLL induced illness/impairment in the patient. ‘Good performance status’ means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with obinutuzumab is expected to improve symptoms and improve ECOG score to < 2.

* greater than or equal to $1.5 \times 10^9/L and platelets greater than or equal to $75 \times 10^9/L
OMALIZUMAB – Restricted see terms below

• Inj 150 mg prefilled syringe ................................................................. 450.00 1 Xolair
• Inj 150 mg vial ................................................................................... 450.00 1 Xolair

Initiation – severe asthma
Clinical immunologist or respiratory specialist
Re-assessment required after 6 months

All of the following:
1. Patient must be aged 6 years or older; and
2. Patient has a diagnosis of severe asthma; and
3. Past or current evidence of atopy, documented by skin prick testing or RAST; and
4. Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
5. Proven adherence with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1,600 mcg per day or fluticasone propionate 1,000 mcg per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 mcg bd or eformoterol 12 mcg bd) for at least 12 months, unless contraindicated or not tolerated; and
6. Either:
   6.1 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; or
   6.2 Patient has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, where an exacerbation is defined as either documented use of oral corticosteroids for at least 3 days or parenteral steroids; and
7. Patient has an Asthma Control Test (ACT) score of 10 or less; and
8. Baseline measurements of the patient’s asthma control using the ACT and oral corticosteroid dose must be made at the time of application, and again at around 26 weeks after the first dose to assess response to treatment.

Continuation – severe asthma
Respiratory specialist
Re-assessment required after 6 months

Both:
1. An increase in the Asthma Control Test (ACT) score of at least 5 from baseline; and
2. A reduction in the maintenance oral corticosteroid dose or number of exacerbations of at least 50% from baseline.

Initiation – severe chronic spontaneous urticaria
Clinical immunologist or dermatologist
Re-assessment required after 6 months

All of the following:
1. Patient must be aged 12 years or older; and
2. Either:
   2.1 Both:
      2.1.1 Patient is symptomatic with Urticaria Activity Score 7 (UAS7) of 20 or above; and
      2.1.2 Patient has a Dermatology life quality index (DLQI) of 10 or greater; and
3. Any of the following:
   3.1 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and ciclosporin (> 3 mg/kg day) for at least 6 weeks; or
   3.2 Patient has been taking high dose antihistamines (e.g. 4 times standard dose) and at least 3 courses of systemic corticosteroids (> 20 mg prednisone per day for at least 5 days) in the previous 6 months; or
   3.3 Patient has developed significant adverse effects whilst on corticosteroids or ciclosporin; and
4. Either:
   4.1 Treatment to be stopped if inadequate response* following 4 doses; or
   4.2 Complete response* to 6 doses of omalizumab.
Continuation – severe chronic spontaneous urticaria
Clinical immunologist or dermatologist
Re-assessment required after 6 months
Either:
1. Patient has previously had a complete response* to 6 doses of omalizumab; or
2. Both:
   2.1 Patient has previously had a complete response* to 6 doses of omalizumab; and
   2.2 Patient has relapsed after cessation of omalizumab therapy.

Note: *Inadequate response defined as less than 50% reduction in baseline UAS7 and DLQI score, or an increase in Urticaria Control Test (UCT) score of less than 4 from baseline. Patient is to be reassessed for response after 4 doses of omalizumab. Complete response is defined as UAS7 less than or equal to 6 and DLQI less than or equal to 5; or UCT of 16. Relapse of chronic urticaria on stopping prednisone/ciclosporin does not justify the funding of omalizumab.

PERTUZUMAB – Restricted see terms below
Inj 30 mg per ml, 14 ml vial..............................................................3,927.00 1 Perjeta
Initiation
Re-assessment required after 12 months
All of the following:
1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. Either:
   2.1 Patient is chemotherapy treatment naive; or
   2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
3. The patient has good performance status (ECOG grade 0-1); and
4. Pertuzumab to be administered in combination with trastuzumab; and
5. Pertuzumab maximum first dose of 840 mg, followed by maximum of 420 mg every 3 weeks; and
6. Pertuzumab to be discontinued at disease progression.

Continuation
Re-assessment required after 12 months
Both:
1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. The cancer has not progressed at any time point during the previous 12 months whilst on pertuzumab and trastuzumab.

RANIBIZUMAB – Restricted see terms below
Inj 10 mg per ml, 0.23 ml vial
Inj 10 mg per ml, 0.3 ml vial
Initiation – Wet Age Related Macular Degeneration
Ophthalmologist
Re-assessment required after 3 months
Either:
1. All of the following:
   1.1 Any of the following:
      1.1.1 Wet age-related macular degeneration (wet AMD); or
      1.1.2 Polypoidal choroidal vasculopathy; or

continued…
continued…

1.1.3 Choroidal neovascular membrane from causes other than wet AMD; and

1.2 Either:

1.2.1 The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab; or

1.2.2 There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart; and

1.3 There is no structural damage to the central fovea of the treated eye; and

1.4 Patient has not previously been treated with aflibercept for longer than 3 months; or

2 Patient has current approval to use aflibercept for treatment of wAMD and was found to be intolerant to aflibercept within 3 months.

Continuation – Wet Age Related Macular Degeneration

Ophthalmologist

Re-assessment required after 12 months

All of the following:

1 Documented benefit must be demonstrated to continue; and

2 Patient’s vision is 6/36 or better on the Snellen visual acuity score; and

3 There is no structural damage to the central fovea of the treated eye.

RITUXIMAB – Restricted see terms below

Injection 10 mg per ml, 10 ml vial.................................................................1,075.50 2 Mabthera

Injection 10 mg per ml, 50 ml vial..............................................................2,688.30 1 Mabthera

Initiation – haemophilia with inhibitors

Haematologist

Any of the following:

1 Patient has mild congenital haemophilia complicated by inhibitors; or

2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or

3 Patient has acquired haemophilia.

Continuation – haemophilia with inhibitors

Haematologist

All of the following:

1 Patient was previously treated with rituximab for haemophilia with inhibitors; and

2 An initial response lasting at least 12 months was demonstrated; and

3 Patient now requires repeat treatment.

Initiation – post-transplant

Both:

1 The patient has B-cell post-transplant lymphoproliferative disorder*; and

2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are unapproved indications.

Continuation – post-transplant

All of the following:

1 The patient has had a rituximab treatment-free interval of 12 months or more; and

2 The patient has B-cell post-transplant lymphoproliferative disorder*; and

3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are unapproved indications.
continued...

**Initiation – indolent, low-grade lymphomas or hairy cell leukaemia***

*Re-assessment required after 9 months*

Either:

1. Both:
   1.1 The patient has indolent low grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
   1.2 To be used for a maximum of 6 treatment cycles; or

2. Both:
   2.1 The patient has indolent, low grade lymphoma or hairy cell leukaemia* requiring first-line systemic chemotherapy; and
   2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

**Continuation – indolent, low-grade lymphomas or hairy cell leukaemia***

*Re-assessment required after 9 months*

All of the following:

1. The patient has had a rituximab treatment-free interval of 12 months or more; and
2. The patient has indolent, low-grade NHL or hairy cell leukaemia* with relapsed disease following prior chemotherapy; and
3. To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. *Unapproved indication. 'Hairy cell leukaemia' also includes hairy cell leukaemia variant.

**Initiation – aggressive CD20 positive NHL**

Either:

1. All of the following:
   1.1 The patient has treatment naive aggressive CD20 positive NHL; and
   1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
   1.3 To be used for a maximum of 8 treatment cycles; or

2. Both:
   2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
   2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

**Continuation – aggressive CD20 positive NHL**

All of the following:

1. The patient has had a rituximab treatment-free interval of 12 months or more; and
2. The patient has relapsed refractory/aggressive CD20 positive NHL; and
3. To be used with a multi-agent chemotherapy regimen given with curative intent; and
4. To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

**Initiation – Chronic lymphocytic leukaemia**

*Re-assessment required after 12 months*

All of the following:

1. The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
2. The patient is rituximab treatment naive; and
3. Either:
   3.1 The patient is chemotherapy treatment naive; or
   3.2 Both:
      3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and

continued…
continued…

3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and

4 The patient has good performance status; and
5 The patient does not have chromosome 17p deletion CLL; and
6 Rituximab to be administered in combination with fludarabine and cyclophosphamide or bendamustine for a maximum of 6 treatment cycles; and
7 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to < 2.

**Continuation – Chronic lymphocytic leukaemia**

**Re-assessment required after 12 months**

All of the following:

1 The patient's disease has relapsed following no more than one prior line of treatment with rituximab for CLL; and
2 The patient has had an interval of 36 months or more since the commencement of initial rituximab treatment; and
3 The patient does not have chromosome 17p deletion CLL; and
4 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration) or bendamustine; and
5 Rituximab to be administered in combination with fludarabine and cyclophosphamide or bendamustine for a maximum of 6 treatment cycles.

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments.

**Initiation – rheumatoid arthritis - prior TNF inhibitor use**

Rheumatologist

**Limited to 4 months treatment**

All of the following:

1 Both:
   1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
      1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and
2 Either:
   2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
   2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

**Initiation – rheumatoid arthritis - TNF inhibitors contraindicated**

Rheumatologist

**Limited to 4 months treatment**

All of the following:

1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
2 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and

continued…
continued…

3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and

5 Any of the following:
   5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
   5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
   5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

6 Either:
   6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
   6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

7 Either:
   7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and

8 Either:
   8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
   8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation – rheumatoid arthritis - re-treatment in 'partial responders' to rituximab

Rheumatologist

Re-assessment required after 4 months

All of the following:

1 Any of the following:
   1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
   1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:
   3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
   3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation – rheumatoid arthritis - re-treatment in 'responders' to rituximab

Rheumatologist

Re-assessment required after 4 months

All of the following:

1 Either:

continued…
continued...

1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and

3 Either:

3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or

3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and

4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation – severe cold haemagglutinin disease (CHAD)

Haematologist

Re-assessment required after 4 weeks

Both:

1 Patient has cold haemagglutinin disease*; and

2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms.

Note: Indications marked with * are unapproved indications.

Continuation – severe cold haemagglutinin disease (CHAD)

Haematologist

Re-assessment required after 4 weeks

Either:

1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or

2 All of the following:

2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and

2.2 An initial response lasting at least 12 months was demonstrated; and

2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

Initiation – warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Re-assessment required after 4 weeks

Both:

1 Patient has warm autoimmune haemolytic anaemia*; and

2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to > 5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin.

Note: Indications marked with * are unapproved indications.

Continuation – warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Re-assessment required after 4 weeks

Either:

1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or

2 All of the following:

2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and

2.2 An initial response lasting at least 12 months was demonstrated; and

continued...
2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

**Initiation – immune thrombocytopenic purpura (ITP)**

Haematologist

*Re-assessment required after 4 weeks*

**Both:**

1. Either:
   1.1 Patient has immune thrombocytopenic purpura* with a platelet count of less than or equal to 20,000 platelets per microlitre; or
   1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and

2. Any of the following:
   2.1 Treatment with steroids and splenectomy have been ineffective; or
   2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
   2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy).

Note: Indications marked with * are unapproved indications.

**Continuation – immune thrombocytopenic purpura (ITP)**

Haematologist

*Re-assessment required after 4 weeks*

**Either:**

1. Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or

2. All of the following:
   2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
   2.2 An initial response lasting at least 12 months was demonstrated; and
   2.3 Patient now requires repeat treatment.

Note: Indications marked with * are unapproved indications.

**Initiation – thrombotic thrombocytopenic purpura (TTP)**

Haematologist

*Re-assessment required after 4 weeks*

**Either:**

1. Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or

2. Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology.

Note: Indications marked with * are unapproved indications.

**Continuation – thrombotic thrombocytopenic purpura (TTP)**

Haematologist

*Re-assessment required after 4 weeks*

**All of the following:**

1. Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and

2. An initial response lasting at least 12 months was demonstrated; and


Note: Indications marked with * are unapproved indications.
continued...

**Initiation – pure red cell aplasia (PRCA)**

Haematologist

*Re-assessment required after 6 weeks*

Patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with * are unapproved indications.

**Continuation – pure red cell aplasia (PRCA)**

Haematologist

*Re-assessment required after 6 weeks*

Patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are unapproved indications.

**Initiation – ANCA associated vasculitis**

*Re-assessment required after 4 weeks*

All of the following:

1. Patient has been diagnosed with ANCA associated vasculitis*; and
2. The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks; and
3. Any of the following:
   3.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve significant improvement of disease after at least 3 months; or
   3.2 Patient has previously had a cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g; or
   3.3 Cyclophosphamide and methotrexate are contraindicated; or
   3.4 Patient is a female of child-bearing potential; or
   3.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with * are unapproved indications.

**Continuation – ANCA associated vasculitis**

*Re-assessment required after 4 weeks*

All of the following:

1. Patient has been diagnosed with ANCA associated vasculitis*; and
2. Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
3. The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are unapproved indications.

**Initiation – treatment refractory systemic lupus erythematosus (SLE)**

Rheumatologist or nephrologist

All of the following:

1. The patient has severe, immediately life- or organ-threatening SLE*; and
2. The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
3. The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
4. Maximum of four 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

**Continuation – treatment refractory systemic lupus erythematosus (SLE)**

Rheumatologist or nephrologist

All of the following:

1. Patient’s SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
2. The disease has subsequently relapsed; and

continued…
continued…

3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are unapproved indications.

**Initiation – Antibody-mediated renal transplant rejection**

Nephrologist

Patient has been diagnosed with antibody-mediated renal transplant rejection*.

Note: Indications marked with * are unapproved indications.

**Initiation – ABO-incompatible renal transplant**

Nephrologist

Patient is to undergo an ABO-incompatible renal transplant*.

Note: Indications marked with * are unapproved indications.

**Initiation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)**

Nephrologist

*Re-assessment required after 4 weeks*

All of the following:

1. Patient is a child with SDNS* or FRNS*; and
2. Treatment with steroids for at least a period of 3 months has been ineffective or associated with evidence of steroid toxicity; and
3. Treatment with ciclosporin for at least a period of 3 months has been ineffective and/or discontinued due to unacceptable side effects; and
4. Treatment with mycophenolate for at least a period of 3 months with no reduction in disease relapses; and
5. The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

**Continuation – Steroid dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS)**

Nephrologist

*Re-assessment required after 4 weeks*

All of the following:

1. Patient who was previously treated with rituximab for nephrotic syndrome*; and
2. Treatment with rituximab was previously successful and has demonstrated sustained response for > 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
3. The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

**Initiation – Steroid resistant nephrotic syndrome (SRNS)**

Nephrologist

*Re-assessment required after 4 weeks*

All of the following:

1. Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and
2. Treatment with tacrolimus for at least 3 months has been ineffective; and
3. Genetic causes of nephrotic syndrome have been excluded; and
4. The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

**Continuation – Steroid resistant nephrotic syndrome (SRNS)**

Nephrologist

*Re-assessment required after 4 weeks*

All of the following:

1. Patient is a child with SRNS* where treatment with steroids and ciclosporin for at least 3 months have been ineffective; and
2. Treatment with tacrolimus for at least 3 months has been ineffective; and
3. Genetic causes of nephrotic syndrome have been excluded; and
4. The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

continued…
continued...

1 Patient who was previously treated with rituximab for nephrotic syndrome*; and
2 Treatment with rituximab was previously successful and has demonstrated sustained response for greater than 6 months, but the condition has relapsed and the patient now requires repeat treatment; and
3 The total rituximab dose used would not exceed the equivalent of 375 mg/m² of body surface area per week for a total of 4 weeks.

Note: Indications marked with a * are unapproved indications.

**Initiation – Neuromyelitis Optica Spectrum Disorder (NMOSD)**
Relevant specialist or medical practitioner on the recommendation of a Relevant specialist
Re-assessment required after 6 months

Both:

1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks; and

2 Either:
   2.1 The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD); or
   2.2 All of the following:
      2.2.1 The patient has experienced a breakthrough attack of NMOSD; and
      2.2.2 The patient is receiving treatment with mycophenolate; and
      2.2.3 The patient is receiving treatment with corticosteroids.

**Continuation – Neuromyelitis Optica Spectrum Disorder (NMOSD)**
Relevant specialist or medical practitioner on the recommendation of a Relevant specialist
Re-assessment required after 2 years

All of the following:

1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks; and

2 The patient has responded to the most recent course of rituximab; and

3 The patient has not received rituximab in the previous 6 months.

**Initiation – Severe Refractory Myasthenia Gravis**
Neurologist or medical practitioner on the recommendation of a Neurologist
Re-assessment required after 2 years

Both:

1 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and

2 Either:
   2.1 Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective; or
   2.2 Both:
      2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and
      2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

**Continuation – Severe Refractory Myasthenia Gravis**
Neurologist or medical practitioner on the recommendation of a Neurologist
Re-assessment required after 2 years

All of the following:

1 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and

2 An initial response lasting at least 12 months was demonstrated; and

continued...
3 Either:
   3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or
   3.2 Both:
      3.2.1 The patient’s myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and
      3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

SECUKINUMAB – Restricted see terms below

Either:
   Inj 150 mg per ml, 1 ml prefilled syringe.....................................................1,599.00 2 Cosentyx

Initiation – severe chronic plaque psoriasis, second-line biologic
Dermatologist
Re-assessment required after 4 months

All of the following:
1 The patient has had an initial Special Authority approval for adalimumab or etanercept, or has trialled infliximab in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule, for severe chronic plaque psoriasis; and
2 Either:
   2.1 The patient has experienced intolerable side effects from adalimumab, etanercept or infliximab; or
   2.2 The patient has received insufficient benefit from adalimumab, etanercept or infliximab; and
3 A Psoriasis Area and Severity Index (PASI) assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Continuation – severe chronic plaque psoriasis, second-line biologic
Dermatologist
Re-assessment required after 6 months

Both:
1 Either:
   1.1 Patient’s PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
   1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and
2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

Initiation – severe chronic plaque psoriasis, first-line biologic
Dermatologist
Re-assessment required after 4 months

All of the following:
1 Either:
   1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or
   1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
3 A PASI assessment or Dermatology Quality of Life Index (DLQI) assessment has been completed for at least the most

continued…
continued...

recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and

4 The most recent PASI or DQLI assessment is no more than 1 month old at the time of application.

Note: A treatment course is defined as a minimum of 12 weeks of treatment. “Inadequate response” is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 10, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom sub scores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

**Continuation – severe chronic plaque psoriasis, first-line biologic**

Dermatologist

*Re-assessment required after 6 months*

Both:

1 Either:
   1.1 Patient’s PASI score has reduced by 75% or more (PASI 75) as compared to baseline PASI prior to commencing secukinumab; or
   1.2 Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing secukinumab; and

2 Secukinumab to be administered at a maximum dose of 300 mg monthly.

**SILTUXIMAB – Restricted** see terms below

- Inj 100 mg vial ................................................................. 770.57 1 Sylvant
- Inj 400 mg vial ................................................................. 3,082.33 1 Sylvant

**Initiation**

Haematologist or rheumatologist

*Re-assessment required after 6 months*

All of the following:

1 Patient has severe HHV-8 negative idiopathic multicentric Castleman’s Disease; and
2 Treatment with an adequate trial of corticosteroids has proven ineffective; and
3 Siltuximab is to be administered at doses no greater than 11 mg/kg every 3 weeks.

**Continuation**

Haematologist or rheumatologist

*Re-assessment required after 12 months*

The treatment remains appropriate and the patient has sustained improvement in inflammatory markers and functional status.

**TOCILIZUMAB – Restricted** see terms below

- Inj 20 mg per ml, 4 ml vial ................................................................. 220.00 1 Actemra
- Inj 20 mg per ml, 10 ml vial ............................................................... 550.00 1 Actemra
- Inj 20 mg per ml, 20 ml vial ............................................................... 1,100.00 1 Actemra

**Initiation – cytokine release syndrome**

*Therapy limited to 3 doses*

Either:

1 All of the following:
   1.1 The patient is enrolled in the Children's Oncology Group AALL1731 trial; and
   1.2 The patient has developed grade 3 or 4 cytokine release syndrome associated with the administration of blinatumomab for the treatment of acute lymphoblastic leukaemia; and

continued…
continued…

1.3 Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of 3 doses (if less than 30kg, maximum of 12 mg/kg); or

2 All of the following:
   2.1 The patient is enrolled in the Malaghan Institute of Medical Research Phase I ENABLE trial; and
   2.2 The patient has developed CRS or CAR T-Cell Related Encephalopathy Syndrome (CRES) associated with the administration of CAR T-cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma; and
   2.3 Tocilizumab is to be administered according to the consensus guidelines for CRS and CRES for CAR T-cell therapy (Neelapu et al. Nat Rev Clin Oncol 2018;15:47-62) at doses no greater than 8 mg/kg IV for a maximum of 3 doses.

Initiation – previous use

Any relevant practitioner

Limited to 6 months treatment

Both:

1 Patient was being treated with tocilizumab prior to 1 February 2019; and

2 Any of the following:
   2.1 rheumatoid arthritis; or
   2.2 systemic juvenile idiopathic arthritis; or
   2.3 adult-onset Still’s disease; or
   2.4 polyarticular juvenile idiopathic arthritis; or
   2.5 idiopathic multicentric Castleman’s disease.

Initiation – Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Limited to 6 months treatment

All of the following:

1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and

2 Either:
   2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
   2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and

3 Either:
   3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or
   3.2 Both:
      3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the Section H rules; and
      3.2.2 Either:
         3.2.2.1 The patient has experienced intolerable side effects from rituximab; or
         3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.

Initiation – Rheumatoid Arthritis

Rheumatologist or Practitioner on the recommendation of a rheumatologist

Re-assessment required after 6 months

All of the following:

1 Patient has had severe and active erosive rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and

2 Tocilizumab is to be used as monotherapy; and

3 Either:
   3.1 Treatment with methotrexate is contraindicated; or
   3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and

continued…
continued...

4 Either:
   4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent; or
   4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and

5 Either:
   5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
   5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

6 Either:
   6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
   6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

**Initiation – systemic juvenile idiopathic arthritis**
Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

Both:
1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

**Initiation – adult-onset Still’s disease**
Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

Either:
1 Both:
   1.1 Either:
      1.1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for adult-onset Still’s disease (AOSD); or
      1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the General Rules of the Pharmaceutical Schedule; and
   1.2 Either:
      1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
      1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
2 All of the following:
   2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
   2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids at a dose of at least 0.5 mg/kg, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
   2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

**Initiation – polyarticular juvenile idiopathic arthritis**
Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 4 months*

Either:
1 Both:
continued...

1.1 The patient has had an initial Special Authority approval for both etanercept and adalimumab for juvenile idiopathic arthritis (JIA); and

1.2 The patient has experienced intolerable side effects, or has received insufficient benefit from, both etanercept and adalimumab; or

2 All of the following:

2.1 Treatment with a tumour necrosis factor alpha inhibitor is contraindicated; and

2.2 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and

2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

2.4 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.5 Both:

2.5.1 Either:

2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or

2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

2.5.2 Physician's global assessment indicating severe disease.

**Initiation – idiopathic multicentric Castleman's disease**

Haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist

*Re-assessment required after 6 months*

All of the following:

1 Patient has severe HHV-8 negative idiopathic multicentric Castleman's disease; and

2 Treatment with an adequate trial of corticosteroids has proven ineffective; and

3 Tocilizumab to be administered at doses no greater than 8 mg/kg IV every 3-4 weeks.

**Continuation – Rheumatoid Arthritis**

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

Either:

1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

**Continuation – systemic juvenile idiopathic arthritis**

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

Either:

1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or

2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

**Continuation – adult-onset Still's disease**

Rheumatologist or Practitioner on the recommendation of a rheumatologist

*Re-assessment required after 6 months*

the patient has a sustained improvement in inflammatory markers and functional status.

continued…
Continuation – polyarticular juvenile idiopathic arthritis
Rheumatologist or Practitioner on the recommendation of a rheumatologist
*Re-assessment required after 6 months*

Both:
1. Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2. Either:
   2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
   2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Continuation – idiopathic multicentric Castleman's disease
Haematologist, rheumatologist or Practitioner on the recommendation of a haematologist or rheumatologist
*Re-assessment required after 12 months*

the treatment remains appropriate and the patient has a sustained improvement in inflammatory markers and functional status.

TRASTUZUMAB – Restricted see terms below

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inj 150 mg vial</td>
<td>1,350.00</td>
</tr>
<tr>
<td>Inj 440 mg vial</td>
<td>3,875.00</td>
</tr>
</tbody>
</table>

Restricted (RS1554)

Initiation – Early breast cancer
*Limited to 12 months treatment*

All of the following:
1. The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
3. Any of the following:
   3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
   3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
   3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
   3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned; or
   3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Initiation – metastatic breast cancer (trastuzumab-naive patients)
*Limited to 12 months treatment*

All of the following:
1. The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
2. Either:
   2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
   2.2 Both:
      2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
      2.2.2 The cancer did not progress whilst on lapatinib; and
3. Either:
   3.1 Trastuzumab will not be given in combination with pertuzumab; or
   3.2 All of the following:
      3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
      3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast...
continued…

3.2.3 The patient has good performance status (ECOG grade 0-1); and

4 Trastuzumab not to be given in combination with lapatinib; and

5 Trastuzumab to be discontinued at disease progression.

**Initiation – metastatic breast cancer (patients previously treated with trastuzumab)**

*Limited to 12 months* treatment

All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2 Either:
   2.1 The patient has not previously received lapatinib treatment for HER-2 positive metastatic breast cancer; or
   2.2 Both:
   2.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
   2.2.2 The cancer did not progress whilst on lapatinib; and

3 Either:
   3.1 Trastuzumab will not be given in combination with pertuzumab; or
   3.2 All of the following:
   3.2.1 Trastuzumab to be administered in combination with pertuzumab; and
   3.2.2 Patient has not received prior treatment for their metastatic disease and has had a treatment-free interval of at least 12 months between prior (neo)adjuvant chemotherapy treatment and diagnosis of metastatic breast cancer; and
   3.2.3 The patient has good performance status (ECOG grade 0-1); and

4 Trastuzumab not to be given in combination with lapatinib; and

5 Trastuzumab to be discontinued at disease progression.

**Continuation – metastatic breast cancer**

*Re-assessment required after 12 months*

All of the following:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and

3 Trastuzumab not to be given in combination with lapatinib; and

4 Trastuzumab to be discontinued at disease progression.

**Programmed Cell Death-1 (PD-1) Inhibitors**

**NIVOLUMAB – Restricted** see terms below

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Price (ex man. excl. GST) Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>☑</td>
<td>Inj 10 mg per ml, 4 ml vial.........................................................</td>
<td>1,051.98 1 Opdivo</td>
</tr>
<tr>
<td>☑</td>
<td>Inj 10 mg per ml, 10 ml vial.....................................................</td>
<td>2,629.96 1 Opdivo</td>
</tr>
</tbody>
</table>

**Initiation**

Medical oncologist

*Re-assessment required after 4 months*

All of the following:

1 Patient has metastatic or unresectable melanoma stage III or IV; and

2 Patient has measurable disease as defined by the presence of at least one CT or MRI measurable lesion; and

3 The patient has ECOG performance score of 0-2; and

continued…
continued...

4 Either:
   4.1 Patient has not received funded pembrolizumab; or
   4.2 Both:
      4.2.1 Patient has received an initial Special Authority approval for pembrolizumab and has discontinued pembrolizumab within 12 weeks of starting treatment due to intolerance; and
      4.2.2 The cancer did not progress while the patient was on pembrolizumab; and

5 Nivolumab is to be used at a maximum dose of 3 mg/kg every 2 weeks for a maximum of 12 weeks (6 cycles); and
6 Baseline measurement of overall tumour burden is documented (see Note); and
7 Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of nivolumab will not be continued beyond 12 weeks (6 cycles) if their disease progresses during this time.

Continuation
Medical oncologist
Re-assessment required after 4 months
All of the following:

1 Any of the following:
   1.1 Patient’s disease has had a complete response to treatment according to RECIST criteria (see Note); or
   1.2 Patient’s disease has had a partial response to treatment according to RECIST criteria (see Note); or
   1.3 Patient has stable disease according to RECIST criteria (see Note); and

2 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the most recent treatment period; and

3 No evidence of progressive disease according to RECIST criteria (see Note); and

4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; and

5 Nivolumab will be used at a maximum dose of 3 mg/kg every 2 weeks for a maximum of 12 weeks (6 cycles).

Notes: Disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (Eisenhauer EA, et al. Eur J Cancer 2009;45:228-47). Assessments of overall tumour burden and measurable disease to be undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and suitable for reproducible repeated measurements. Target lesion measurements should be assessed using CT or MRI imaging with the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline and every 12 weeks.

Response definitions as follows:
- Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

PEMBROLIZUMAB – Restricted see terms below

$ Inj 25 mg per ml, 4 ml vial.................................................................4,680.00 1 Keytruda

⇒ Restricted (RS1584)

Initiation
Medical oncologist
Re-assessment required after 4 months
All of the following:

continued…
190

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Price
(ex man. excl. GST) $ Per Brand or Generic Manufacturer

continued...

1 Patient has metastatic or unresectable melanoma stage III or IV; and
2 Patient has measurable disease as defined by the presence of at least one CT or MRI measurable lesion; and
3 The patient has ECOG performance score of 0-2; and
4 Either:
   4.1 Patient has not received funded nivolumab; or
   4.2 Both:
      4.2.1 Patient has received an initial Special Authority approval for nivolumab and has discontinued nivolumab
      within 12 weeks of starting treatment due to intolerance; and
      4.2.2 The cancer did not progress while the patient was on nivolumab; and
5 Pembrolizumab is to be used at a maximum dose of 2 mg/kg every 3 weeks for a maximum of 12 weeks (4 cycles); and
6 Baseline measurement of overall tumour burden is documented (see Note); and
7 Documentation confirming that the patient has been informed and acknowledges that the initial funded treatment period of
   pembrolizumab will not be continued beyond 12 weeks (4 cycles) if their disease progresses during this time.

Continuation

Medical oncologist

Re-assessment required after 4 months

All of the following:

1 Any of the following:
   1.1 Patient's disease has had a complete response to treatment according to RECIST criteria (see Note); or
   1.2 Patient's disease has had a partial response to treatment according to RECIST criteria (see Note); or
   1.3 Patient has stable disease according to RECIST criteria (see Note); and
2 Response to treatment in target lesions has been determined by radiologic assessment (CT or MRI scan) following the
   most recent treatment period; and
3 No evidence of progressive disease according to RECIST criteria (see Note); and
4 The treatment remains clinically appropriate and the patient is benefitting from the treatment; and
5 Pembrolizumab will be used at a maximum dose of 2 mg/kg every 3 weeks for a maximum of 12 weeks (4 cycles).

Notes:

Disease responses to be assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) version
undertaken on a minimum of one lesion and maximum of 5 target lesions (maximum two lesions per organ). Target lesions
should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, and
suitable for reproducible repeated measurements. Target lesion measurements should be assessed using CT or MRI imaging
with the same method of assessment and the same technique used to characterise each identified and reported lesion at baseline
and every 12 weeks.

Response definitions as follows:

● Complete Response: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target)
  must have reduction in short axis to < 10 mm.
● Partial Response: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum
  diameters.
● Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest
  sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%,
  the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new
  lesions is also considered progression).
● Stable Disease: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive
  disease.

Other Immunosuppressants

ANTITHYMOCYTE GLOBULIN (EQUINE)
Inj 50 mg per ml, 5 ml ampoule .................................................................2,351.25 5 ATGAM
ANTITHYMOCYTE GLOBULIN (RABBIT)
Inj 25 mg vial

AZATHIOPRINE
Tab 25 mg – 1% DV Jan-20 to 2022.................................................................7.35 60 Azamun
         9.66 100 Imuran
Tab 50 mg – 1% DV Jan-20 to 2022.................................................................7.60 100 Azamun
         10.58 Imuran
Inj 50 mg vial – 1% DV Nov-19 to 2022............................................................199.00 1 Imuran

(Imuran Tab 25 mg to be delisted 1 January 2020)
(Imuran Tab 50 mg to be delisted 1 January 2020)

BACILLUS CALMETTE-GUERIN (BCG) – Restricted see terms below
  • Inj 2-8 × 10⁸ CFU vial ..................................................................................149.37 1 OncoTICE
  ➤ Restricted (RS1206)
Initiation
For use in bladder cancer.

EVEROLIMUS – Restricted see terms below
  • Tab 5 mg ....................................................................................................4,555.76 30 Afinitor
  • Tab 10 mg ..................................................................................................6,512.29 30 Afinitor
  ➤ Restricted (RS1440)
Initiation
Neurologist or oncologist
Re-assessment required after 3 months
Both:
1. Patient has tuberous sclerosis; and
2. Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.

Continuation
Neurologist or oncologist
Re-assessment required after 12 months
All of the following:
1. Documented evidence of SEGAs reduction or stabilisation by MRI within the last 3 months; and
2. The treatment remains appropriate and the patient is benefiting from treatment; and
3. Everolimus to be discontinued at progression of SEGAs.

Note: MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.

MYCOPHENOLATE MOFETIL
Tab 500 mg.....................................................................................................25.00 50 CellCept
Cap 250 mg.....................................................................................................25.00 100 CellCept
Powder for oral liq 1 g per 5 ml......................................................................187.25 165 ml CellCept
Inj 500 mg vial ...............................................................................................133.33 4 CellCept

PICIBANIL
Inj 100 mg vial

SIROLIMUS – Restricted see terms below
  • Tab 1 mg ....................................................................................................749.99 100 Rapamune
  • Tab 2 mg ..................................................................................................1,499.99 100 Rapamune
  • Oral liq 1 mg per ml ...............................................................................449.99 60 ml Rapamune
  ➤ Restricted (RS1208)
Initiation
For rescue therapy for an organ transplant recipient.
continued…

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR < 30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease
**Respiratory System and Allergies**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

## Antiallergy Preparations

### Allergic Emergencies

**ICATIBANT** – *Restricted* see terms below

- Inj 10 mg per ml, 3 ml prefilled syringe.......................... 2,668.00 1 Firazyr
  - *Restricted (RS1501)*

**Initiation**

Clinical immunologist or relevant specialist

**Re-assessment required after 12 months**

**Both:**

1. Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency; and
2. The patient has undergone product training and has agreed upon an action plan for self-administration.

**Continuation**

**Re-assessment required after 12 months**

The treatment remains appropriate and the patient is benefiting from treatment.

### Allergy Desensitisation

**BEE VENOM** – *Restricted* see terms below

- Maintenance kit - 6 vials 120 mcg freeze dried venom, with diluent
- Inj 550 mcg vial with diluent
  - *Restricted (RS1117)*

**Initiation**

**Both:**

1. RAST or skin test positive; and
2. Patient has had severe generalised reaction to the sensitising agent.

**PAPER WASP VENOM** – *Restricted* see terms below

- Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent
- Inj 550 mcg vial with diluent
  - *Restricted (RS1118)*

**Initiation**

**Both:**

1. RAST or skin test positive; and
2. Patient has had severe generalised reaction to the sensitising agent.

**YELLOW JACKET WASP VENOM** – *Restricted* see terms below

- Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent
- Inj 550 mcg vial with diluent
  - *Restricted (RS1119)*

**Initiation**

**Both:**

1. RAST or skin test positive; and
2. Patient has had severe generalised reaction to the sensitising agent.

### Allergy Prophylactics

**BECLOMETHASONE DIPROPIONATE**

- Nasal spray 50 mcg per dose......................................................... 5.26 200 dose Alanase
- Nasal spray 100 mcg per dose......................................................... 6.00 200 dose Alanase

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
# RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Brand or Generic Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

## BUDESONIDE
- Nasal spray 50 mcg per dose – 1% DV Oct-18 to 2020 .................................. 2.59 200 dose SteroClear
- Nasal spray 100 mcg per dose – 1% DV Oct-18 to 2020 .................. 2.87 200 dose SteroClear

## FLUTICASONE PROPIONATE
- Nasal spray 50 mcg per dose – 1% DV Nov-18 to 2021 .................. 1.98 120 dose Flixonase Hayfever & Allergy

## IPRATROPIUM BROMIDE
- Aqueous nasal spray 0.03% – 1% DV Oct-17 to 2020 .................. 4.61 15 ml Univent

## SODIUM CROMOGLICATE
- Nasal spray 4%

### Antihistamines

#### CETIRIZINE HYDROCHLORIDE
- Tab 10 mg – 1% DV Nov-19 to 2022 .......................................................... 1.12 100 Zista
- Oral liq 1 mg per ml ........................................................................ 2.99 200 ml Histaclear

#### CHLORPHENIRAMINE MALEATE
- Oral liq 0.4 mg per ml
- Inj 10 mg per ml, 1 ml ampoule

#### CYPROHEPTADINE HYDROCHLORIDE
- Tab 4 mg

#### FEXOFENADINE HYDROCHLORIDE
- Tab 60 mg
- Tab 120 mg
- Tab 180 mg

#### LORATADINE
- Tab 10 mg – 1% DV Feb-20 to 2022 .......................................................... 1.69 100 Lorafix
- Oral liq 1 mg per ml ........................................................................ 2.15 120 ml Lorfast

#### PROMETHAZINE HYDROCHLORIDE
- Tab 10 mg – 1% DV Sep-18 to 2021 .......................................................... 1.68 50 Allersoothe
- Tab 25 mg – 1% DV Sep-18 to 2021 .......................................................... 1.89 50 Allersoothe
- Oral liq 1 mg per ml – 1% DV Sep-18 to 2021 .................................................. 2.69 100 ml Allersoothe
- Inj 25 mg per ml, 2 ml ampoule .......................................................... 15.54 5 Hospira

### Anticholinergic Agents

#### IPRATROPIUM BROMIDE
- Aerosol inhaler 20 mcg per dose
- Nebuliser soln 250 mcg per ml, 1 ml ampoule ........................................... 3.35 20 Univent
- Nebuliser soln 250 mcg per ml, 2 ml ampoule – 1% DV Jan-20 to 2022 .... 11.73 20 Univent

### Anticholinergic Agents with Beta-Adrenoceptor Agonists

#### SALBUTAMOL WITH IPRATROPIUM BROMIDE
- Aerosol inhaler 100 mcg with ipratropium bromide 20 mcg per dose
- Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule – 1% DV Oct-18 to 2021 .................................................. 5.20 20 Duolin
# RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST) Per</th>
</tr>
</thead>
</table>

## Long-Acting Muscarinic Agents

### GLYCOPYRRONIUM
- **Note:** inhaled glycopyrronium treatment must not be used if the patient is also receiving treatment with subsidised tiotropium or umeclidinium.
- Powder for inhalation 50 mcg per dose
  - 61.00 $ 30 dose Seebri Breezhaler

### TIOTROPIUM BROMIDE
- **Note:** tiotropium treatment must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or umeclidinium.
- Soln for inhalation 2.5 mcg per dose
  - 50.37 $ 60 dose Spiriva Respimat
- Powder for inhalation 18 mcg per dose
  - 50.37 $ 30 dose Spiriva

### UMECLIDINIUM
- **Note:** Umeclidinium must not be used if the patient is also receiving treatment with subsidised inhaled glycopyrronium or tiotropium bromide.
- Powder for inhalation 62.5 mcg per dose
  - 61.50 $ 30 dose Incruse Ellipta

## Long-Acting Muscarinic Antagonists with Long-Acting Beta-Adrenoceptor Agonists

- **Restricted (RS1518)**

### Initiation
- **Re-assessment required after 2 years**

#### Both:
1. Patient has been stabilised on a long acting muscarinic antagonist; and
2. The prescriber considers that the patient would receive additional benefit from switching to a combination product.

### Continuation
- **Re-assessment required after 2 years**

#### Both:
1. Patient is compliant with the medication; and
2. Patient has experienced improved COPD symptom control (prescriber determined).

**Note:** Combination long acting muscarinic antagonist and long acting beta-2 agonist must not be used if the patient is also receiving treatment with a combination inhaled corticosteroid and long acting beta-2 agonist.

### GLYCOPYRRONIUM WITH INDACATEROL – **Restricted** see terms above
- Powder for Inhalation 50 mcg with indacaterol 110 mcg
  - 81.00 $ 30 dose Ultibro Breezhaler

### TIOTROPIUM BROMIDE WITH OLODATEROL – **Restricted** see terms above
- Soln for inhalation 2.5 mcg with olodaterol 2.5 mcg
  - 81.00 $ 60 dose Spiolto Respimat

### UMECLIDINIUM WITH VILANTEROL – **Restricted** see terms above
- Powder for inhalation 62.5 mcg with vilanterol 25 mcg
  - 77.00 $ 30 dose Anoro Ellipta

## Antifibrotics

- **NINTEDANIB – **Restricted** see terms below

### Initiation – idiopathic pulmonary fibrosis
- Respiratory specialist
- **Re-assessment required after 12 months**

All of the following:

---

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
RESPIRATORY SYSTEM AND ALLERGIES

Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer

continued…

1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
2 Forced vital capacity is between 50% and 90% predicted; and
3 Nintedanib is to be discontinued at disease progression (See Note); and
4 Nintedanib is not to be used in combination with subsidised pirfenidone; and
5 Any of the following:
   5.1 The patient has not previously received treatment with pirfenidone; or
   5.2 Patient has previously received pirfenidone, but discontinued pirfenidone within 12 weeks due to intolerance; or
   5.3 Patient has previously received pirfenidone, but the patient’s disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with pirfenidone).

Continuation – idiopathic pulmonary fibrosis
Respiratory specialist
Re-assessment required after 12 months
All of the following:
1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
2 Nintedanib is not to be used in combination with subsidised pirfenidone; and
3 Nintedanib is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.

PIRFENIDONE – Restricted see terms below

Cap 267 mg................................................................................................3,645.00 270 Esbriet

Initiation – idiopathic pulmonary fibrosis
Respiratory specialist
Re-assessment required after 12 months
All of the following:
1 Patient has been diagnosed with idiopathic pulmonary fibrosis by a multidisciplinary team including a radiologist; and
2 Forced vital capacity is between 50% and 80% predicted; and
3 Pirfenidone is to be discontinued at disease progression (See Notes); and
4 Pirfenidone is not to be used in combination with subsidised nintedanib; and
5 Any of the following:
   5.1 The patient has not previously received treatment with nintedanib; or
   5.2 Patient has previously received nintedanib, but discontinued nintedanib within 12 weeks due to intolerance; or
   5.3 Patient has previously received nintedanib, but the patient’s disease has not progressed (disease progression defined as 10% or more decline in predicted FVC within any 12 month period since starting treatment with nintedanib).

Continuation – idiopathic pulmonary fibrosis
Respiratory specialist
Re-assessment required after 12 months
All of the following:
1 Treatment remains clinically appropriate and patient is benefitting from and tolerating treatment; and
2 Pirfenidone is not to be used in combination with subsidised nintedanib; and
3 Pirfenidone is to be discontinued at disease progression (See Note).

Note: disease progression is defined as a decline in percent predicted FVC of 10% or more within any 12 month period.
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
<th>Expiry Date</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>SALBUTAMOL</td>
<td>Oral liq 400 mcg per ml – 1% DV</td>
<td>Nov-18 to 2021</td>
<td>20.00</td>
<td>Ventolin</td>
</tr>
<tr>
<td></td>
<td>Inj 500 mcg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 1 mg per ml, 5 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aerosol inhaler, 100 mcg per dose</td>
<td></td>
<td>3.80</td>
<td>SalAir</td>
</tr>
<tr>
<td></td>
<td>Nebuliser soln 1 mg per ml, 2.5 ml ampoule – 1% DV</td>
<td>Oct-18 to 2021</td>
<td>3.93</td>
<td>Asthalin</td>
</tr>
<tr>
<td></td>
<td>Nebuliser soln 2 mg per ml, 2.5 ml ampoule – 1% DV</td>
<td>Oct-18 to 2021</td>
<td>4.03</td>
<td>Asthalin</td>
</tr>
<tr>
<td>TERBUTALINE SULPHATE</td>
<td>Powder for inhalation 250 mcg per dose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inj 0.5 mg per ml, 1 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHOLCODINE</td>
<td>Oral liq 1 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OXYMETAZOLINE HYDROCHLORIDE</td>
<td>Aqueous nasal spray 0.25 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aqueous nasal spray 0.5 mg per ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSEUDOEPHEDRINE HYDROCHLORIDE</td>
<td>Tab 60 mg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM CHLORIDE</td>
<td>Aqueous nasal spray isotonic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM CHLORIDE WITH SODIUM BICARBONATE</td>
<td>Soln for nasal irrigation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XYLOMETAZOLINE HYDROCHLORIDE</td>
<td>Aqueous nasal spray 0.05%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aqueous nasal spray 0.1%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nasal drops 0.05%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nasal drops 0.1%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BECLOMETHASONE DIPROPIONATE</td>
<td>Aerosol inhaler 50 mcg per dose</td>
<td></td>
<td>8.54</td>
<td>Beclazone 50</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>9.30</td>
<td>Qvar</td>
</tr>
<tr>
<td></td>
<td>Aerosol inhaler 100 mcg per dose</td>
<td></td>
<td>12.50</td>
<td>Beclazone 100</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>15.50</td>
<td>Qvar</td>
</tr>
<tr>
<td></td>
<td>Aerosol inhaler 250 mcg per dose</td>
<td></td>
<td>22.67</td>
<td>Beclazone 250</td>
</tr>
<tr>
<td>BUDESONIDE</td>
<td>Nebuliser soln 250 mcg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nebuliser soln 500 mcg per ml, 2 ml ampoule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Powder for inhalation 100 mcg per dose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Powder for inhalation 200 mcg per dose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Powder for inhalation 400 mcg per dose</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FLUTICASONE</strong></td>
</tr>
<tr>
<td>Aerosol inhaler 50 mcg per dose .................................... 7.50 120 dose Flixotide</td>
</tr>
<tr>
<td>Powder for inhalation 50 mcg per dose ................................ 4.68 60 dose Floair</td>
</tr>
<tr>
<td>Powder for inhalation 100 mcg per dose ................................ 8.67 60 dose Flixotide Accuhaler</td>
</tr>
<tr>
<td>Aerosol inhaler 125 mcg per dose .................................... 13.87 60 dose Flixotide Accuhaler</td>
</tr>
<tr>
<td>Aerosol inhaler 125 mcg per dose .................................... 13.60 120 dose Flixotide</td>
</tr>
<tr>
<td>Powder for inhalation 250 mcg per dose .............................. 27.20 120 dose Flixotide</td>
</tr>
<tr>
<td>Powder for inhalation 250 mcg per dose .............................. 24.51 60 dose Flixotide Accuhaler</td>
</tr>
</tbody>
</table>

### Leukotriene Receptor Antagonists

**MONTELUKAST**

Tab 4 mg – 1% DV Jan-20 to 2022 ........................................... 5.25 28 Apo-Montelukast

Tab 5 mg – 1% DV Jan-20 to 2022 ........................................... 5.50 28 Apo-Montelukast

Tab 10 mg – 1% DV Jan-20 to 2022 ........................................ 5.65 28 Apo-Montelukast

(Apo-Montelukast Tab 4 mg to be delisted 1 January 2020)

(Apo-Montelukast Tab 5 mg to be delisted 1 January 2020)

(Apo-Montelukast Tab 10 mg to be delisted 1 January 2020)

### Long-Acting Beta-Adrenoceptor Agonists

**EFORMOTEROL FUMARATE**

Powder for inhalation 12 mcg per dose

**EFORMOTEROL FUMARATE DIHYDRATE**

Powder for inhalation 4.5 mcg per dose, breath activated (equivalent to eformoterol fumarate 6 mcg metered dose)

**INDACATEROL**

Powder for inhalation 150 mcg per dose .................................. 61.00 30 dose Onbrez Breezhaler

Powder for inhalation 300 mcg per dose .................................. 61.00 30 dose Onbrez Breezhaler

**SALMETEROL**

Aerosol inhaler 25 mcg per dose .......................................... 9.90 120 dose Meterol

25.00 Serevent

Powder for inhalation 50 mcg per dose .................................. 25.00 60 dose Serevent Accuhaler

### Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

**BUDESONIDE WITH EFORMOTEROL**

Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg

Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg

Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg

Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg

Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg

**FLUTICASONE FURATE WITH VILANTEROL**

Powder for inhalation 100 mcg with vilanterol 25 mcg .................. 44.08 30 dose Breo Ellipta

---

*Item restricted (see ➔ above); Item restricted (see ➔ below)*

*e.g. Brand indicates brand example only. It is not a contracted product.*
FLUTICASONE WITH SALMETEROL
Aerosol inhaler 50 mcg with salmeterol 25 mcg .............................................. 14.58 120 dose RexAir
Powder for inhalation 100 mcg with salmeterol 50 mcg .................................... 33.74 60 dose Seretide Accuhaler
Aerosol inhaler 125 mcg with salmeterol 25 mcg ............................................ 16.83 120 dose RexAir
Powder for inhalation 250 mcg with salmeterol 50 mcg .................................... 44.08 60 dose Seretide Accuhaler

Mast Cell Stabilisers

NEDOCROMIL
Aerosol inhaler 2 mg per dose

SODIUM CROMOGLICATE
Aerosol inhaler 5 mg per dose

Methylxanthines

AMINOPHYLLINE
Inj 25 mg per ml, 10 ml ampoule – 1% DV Nov-17 to 2020 ......................... 124.37 5 DBL Aminophylline

CAFFEINE CITRATE
Oral liq 20 mg per ml (caffeine 10 mg per ml) – 1% DV Nov-19 to 2022 ............ 15.10 25 ml Biomed
Oral liq 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule – 1% DV Nov-19 to 2022 ........................................... 63.25 5 Biomed

THEOPHYLLINE
Tab long-acting 250 mg – 1% DV Jan-20 to 2022 ........................................... 23.02 100 Nuelin-SR
Oral liq 80 mg per 15 ml – 1% DV Jan-20 to 2022 ........................................ 16.60 500 ml Nuelin

Mucolytics and Expectorants

DORNASE ALFA – Restricted see terms below
Nebuliser soln 2.5 mg per 2.5 ml ampoule ..................................................... 250.00 6 Pulmozyme

Restricted (RS1352)

Initiation – cystic fibrosis
The patient has cystic fibrosis and has been approved by the Cystic Fibrosis Panel.

Initiation – significant mucus production
Limited to 4 weeks treatment
Both:
1 Patient is an in-patient; and
2 The mucus production cannot be cleared by first line chest techniques.

Initiation – pleural emphyema
Limited to 3 days treatment
Both:
1 Patient is an in-patient; and
2 Patient diagnoses with pleural emphyema.

SODIUM CHLORIDE
Nebuliser soln 7%, 90 ml bottle – 1% DV Nov-19 to 2022 ......................... 24.50 90 ml Biomed

Pulmonary Surfactants

BERACTANT
Soln 200 mg per 8 ml vial
RESPIRATORY SYSTEM AND ALLERGIES

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
<tbody>
<tr>
<td>$200</td>
<td></td>
</tr>
</tbody>
</table>

### Respiratory Stimulants

DOXAPRAM

Inj 20 mg per ml, 5 ml vial

### Sclerosing Agents

TALC

Powder

Soln (slurry) 100 mg per ml, 50 ml
## Anti-Infective Preparations

### Antibacterials

**CHLORAMPHENICOL**
- Eye oint 1% ................................................................. 2.48 4 g Chlorsig
- Ear drops 0.5% ........................................................... 1.54 10 ml Chlorafast
- Eye drops 0.5% – 1% DV Nov-19 to 2022........................................ 1.54 10 ml Chlorafast
- Eye drops 0.5%, single dose ........................................... 1.54 10 ml Chlorafast

**CIPROFLOXACIN**
- Eye drops 0.3% – 1% DV Jun-18 to 2020 ..................................... 9.99 5 ml Ciprofloxacin Teva

**FRAMYCETIN SULPHATE**
- Ear/eye drops 0.5% .....................................................

**GENTAMICIN SULPHATE**
- Eye drops 0.3% ........................................................... 11.40 5 ml Genoptic

**PROPAMIDINE ISETHIONATE**
- Eye drops 0.1% .................................

**SODIUM FUSIDATE [FUSIDIC ACID]**
- Eye drops 1% .......................................................... 5.29 5 g Fucithalmic

**SULPHACETAMIDE SODIUM**
- Eye drops 10% .................................

**TOBRAMYCIN**
- Eye oint 0.3% .......................................................... 10.45 3.5 g Tobrex
- Eye drops 0.3% .......................................................... 11.48 5 ml Tobrex

### Antifungals

**NATAMYCIN**
- Eye drops 5% ...........................................................

### Antivirals

**ACICLOVIR**
- Eye oint 3% ............................................................. 14.92 4.5 g ViruPOS

### Combination Preparations

**CIPROFLOXACIN WITH HYDROCORTISONE**
- Ear drops ciprofloxacin 0.2% with 1% hydrocortisone .................. 16.30 10 ml Ciproxin HC Otic

**DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN**
- Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml

**DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMIXIN B SULPHATE**
- Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per g .................. 5.39 3.5 g Maxitrol
- Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per ml .................. 4.50 5 ml Maxitrol

**DEXAMETHASONE WITH TOBRAMYCIN**
- Eye drops 0.1% with tobramycin 0.3% .................................. 12.64 5 ml Tobradex
ANTI-INFLAMMATORY PREPARATIONS

Corticosteroids

**DEXAMETHASONE**
- Eye oint 0.1% ................................................................. 5.86 3.5 g Maxidex
- Eye drops 0.1% .............................................................. 4.50 5 ml Maxidex
- Ocular implant 700 mcg................................................. 1,444.50 1 Ozurdex

*Restricted (RS1606)*

**Initiation – Diabetic macular oedema**
Ophthalmologist
*Re-assessment required after 12 months*
All of the following:
1. Patients have diabetic macular oedema with pseudophakic lens; and
2. Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision; and
3. Either:
   3.1 Patient’s disease has progressed despite 3 injections with bevacizumab; or
   3.2 Patient is unsuitable or contraindicated to treatment with anti-VEGF agents; and
4. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

**Continuation – Diabetic macular oedema**
Ophthalmologist
*Re-assessment required after 12 months*
Both:
1. Patient’s vision is stable or has improved (prescriber determined); and
2. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

**Initiation – Women of child bearing age with diabetic macular oedema**
Ophthalmologist
*Re-assessment required after 12 months*
All of the following:
1. Patients have diabetic macular oedema; and
2. Patient has reduced visual acuity of between 6/9 – 6/48 with functional awareness of reduction in vision; and
3. Patient is of child bearing potential and has not yet completed a family; and
4. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.

**Continuation – Women of child bearing age with diabetic macular oedema**
Ophthalmologist
*Re-assessment required after 12 months*
All of the following:
1. Patient’s vision is stable or has improved (prescriber determined); and
2. Patient is of child bearing potential and has not yet completed a family; and
3. Dexamethasone implants are to be administered not more frequently than once every 4 months into each eye, and up to a maximum of 3 implants per eye per year.
SENSORY ORGANS

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLUOROMETHOLONE Eye drops 0.1%</td>
<td>$3.09</td>
<td>FML</td>
</tr>
<tr>
<td>PREDNISOLONE ACETATE Eye drops 0.12%</td>
<td>$7.00</td>
<td>Pred Forte</td>
</tr>
<tr>
<td></td>
<td>Eye drops 1%</td>
<td>$3.93</td>
</tr>
<tr>
<td>PREDNISOLONE SODIUM PHOSPHATE Eye drops 0.5%, single dose (preservative free)</td>
<td>$38.50</td>
<td>Minims Prednisolone</td>
</tr>
</tbody>
</table>

Non-Steroidal Anti-Inflammatory Drugs

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>DICLOFENAC SODIUM Eye drops 0.1%</td>
<td>$13.80</td>
<td>Voltaren Ophtha</td>
</tr>
<tr>
<td>KETOROLAC TROMETAMOL Eye drops 0.5%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Decongestants and Antiallergics

Antiallergic Preparations

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>LEVOCABASTINE Eye drops 0.05%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LODOXAMIDE Eye drops 0.1%</td>
<td>$8.71</td>
<td>Lomide</td>
</tr>
<tr>
<td>OLOPATADINE Eye drops 0.1%</td>
<td>$10.00</td>
<td>Patanol</td>
</tr>
<tr>
<td>SODIUM CROMOGlicate Eye drops 2% – 1% DV Jan-20 to 2022</td>
<td>$1.79</td>
<td>Rexacrom</td>
</tr>
</tbody>
</table>

Decongestants

NAPHAZOLINE HYDROCHLORIDE Eye drops 0.1% | $4.15 | Naphcon Forte |

Diagnostic and Surgical Preparations

Diagnostic Dyes

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLUORESCEIN SODIUM Eye drops 2%, single dose</td>
<td>$125.00</td>
<td>Fluorescite</td>
</tr>
<tr>
<td></td>
<td>Inj 10%, 5 ml vial</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Ophthamlic strips 1 mg</td>
<td></td>
</tr>
<tr>
<td>FLUORESCEIN SODIUM WITH LIGNOCaine HYDROCHLORIDE Eye drops 0.25% with lignocaine hydrochloride 4%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LISSAMINE GREEN Ophthamlmic strips 1.5 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROSE BENGAL SODIUM Ophthamlmic strips 1%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
## SENSORY ORGANS

### Irrigation Solutions

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MIXED SALT SOLUTION FOR EYE IRRIGATION</strong></td>
<td></td>
</tr>
<tr>
<td>Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 15 ml dropper bottle</td>
<td>5.00 15 ml Balanced Salt Solution</td>
</tr>
<tr>
<td>Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 250 ml</td>
<td>e.g. Balanced Salt Solution</td>
</tr>
<tr>
<td>Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 500 ml bottle</td>
<td>10.50 500 ml Balanced Salt Solution</td>
</tr>
</tbody>
</table>

### Ocular Anaesthetics

- **OXYBUPROCAINE HYDROCHLORIDE**
  - Eye drops 0.4%, single dose
- **PROXYMETACAINE HYDROCHLORIDE**
  - Eye drops 0.5%
- **TETRACAINE [AMETHOCAINE] HYDROCHLORIDE**
  - Eye drops 0.5%, single dose
  - Eye drops 1%, single dose

### Viscoelastic Substances

- **HYPROMELLOSE**
  - Inj 2%, 1 ml syringe
  - Inj 2%, 2 ml syringe
- **SODIUM HYALURONATE [HYALURONIC ACID]**
  - Inj 14 mg per ml, 0.85 ml syringe – 1% DV Oct-19 to 2022 | 50.00 1 Healon GV
  - Inj 14 mg per ml, 0.55 ml syringe – 1% DV Oct-19 to 2022 | 50.00 1 Healon GV
  - Inj 23 mg per ml, 0.6 ml syringe – 1% DV Oct-19 to 2022 | 60.00 1 Healon 5
  - Inj 10 mg per ml, 0.85 ml syringe – 1% DV Oct-19 to 2022 | 28.50 1 Healon
- **SODIUM HYALURONATE [HYALURONIC ACID] WITH CHONDROITIN SULPHATE**
  - Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe
  - and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.4 ml syringe | 64.00 1 Duovisc
  - Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe
  - and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.55 ml syringe | 74.00 1 Duovisc
  - Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.75 ml syringe | 67.00 1 Viscoat

### Other

- **DISODIUM EDETATE**
  - Inj 150 mg per ml, 20 ml ampoule
  - Inj 150 mg per ml, 20 ml vial
  - Inj 150 mg per ml, 100 ml vial
RIBOFLAVIN 5-PHOSPHATE
Soln trans epithelial riboflavin
Inj 0.1%
Inj 0.1% plus 20% dextran T500

Gluacoma Preparations

Beta Blockers

BETAXOLOL
Eye drops 0.25% .................................................................11.80 5 ml Betoptic S
Eye drops 0.5% .................................................................7.50 5 ml Betoptic

TIMOLOL
Eye drops 0.25% – 1% DV Sep-17 to 2020 ................................1.43 5 ml Arrow-Timolol
Eye drops 0.25%, gel forming .............................................3.30 2.5 ml Timoptol XE
Eye drops 0.5% – 1% DV Sep-17 to 2020 ................................1.43 5 ml Arrow-Timolol
Eye drops 0.5%, gel forming .............................................3.78 2.5 ml Timoptol XE
(Timoptol XE Eye drops 0.25%, gel forming to be delisted 1 January 2020)

Carbonic Anhydrase Inhibitors

ACETAZOLAMIDE
Tab 250 mg – 1% DV Sep-17 to 2020 .................................17.03 100 Diamox
Inj 500 mg

BRINZOLAMIDE
Eye drops 1%

DORZOLAMIDE
Eye drops 2%

DORZOLAMIDE WITH TIMOLOL
Eye drops 2% with timolol 0.5% – 1% DV Jan-19 to 2021 ..........2.87 5 ml Dortimopt

Miotics

ACETYLCHOLINE CHLORIDE
Inj 20 mg vial with diluent

CARBACHOL
Inj 150 mcg vial

PILOCARPINE HYDROCHLORIDE
Eye drops 1%........................................................................4.26 15 ml Isopto Carpine
Eye drops 2%........................................................................5.35 15 ml Isopto Carpine
Eye drops 2%, single dose
Eye drops 4%........................................................................7.99 15 ml Isopto Carpine

Prostaglandin Analogues

BIMATOPROST
Eye drops 0.03% – 1% DV Feb-19 to 2021 ...........................3.30 3 ml Bimatoprost Multichem

LATANOPROST
Eye drops 0.005% – 1% DV Apr-19 to 2021 ..........................1.57 2.5 ml Teva

TRAVOPROST
Eye drops 0.004% – 1% DV Jan-18 to 2020 ..........................7.30 5 ml Travopt

Products with Hospital Supply Status (HSS) are in bold
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
### Sympathomimetics

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Formulation</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>APRACONIDINE</td>
<td>Eye drops 0.5%</td>
<td>19.77</td>
<td>Iopidine</td>
</tr>
<tr>
<td>BRIMONIDINE TARTRATE</td>
<td>Eye drops 0.2% – 1% DV Feb-18 to 2020</td>
<td>4.29</td>
<td>Arrow-Brimonidine</td>
</tr>
<tr>
<td>BRIMONIDINE TARTRATE WITH TIMOLOL</td>
<td>Eye drops 0.2% with timolol 0.5%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Mydriatics and Cycloplegics

#### Anticholinergic Agents

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Formulation</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATROPINE SULPHATE</td>
<td>Eye drops 0.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eye drops 1%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eye drops 1% – 1% DV Sep-17 to 2020</td>
<td>17.36</td>
<td>Atropt</td>
</tr>
<tr>
<td>CYCLOPENTolate HYdrochloride</td>
<td>Eye drops 0.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eye drops 1%</td>
<td>8.76</td>
<td>Cyclogyl</td>
</tr>
<tr>
<td></td>
<td>Eye drops 1%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TROPICAMIDE</td>
<td>Eye drops 0.5%</td>
<td>7.15</td>
<td>Mydriacyl</td>
</tr>
<tr>
<td></td>
<td>Eye drops 0.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eye drops 1%</td>
<td>8.66</td>
<td>Mydriacyl</td>
</tr>
<tr>
<td></td>
<td>Eye drops 1%, single dose</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Sympathomimetics

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Formulation</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHENYLEPHRINE HYDROCHLORIDE</td>
<td>Eye drops 2.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eye drops 10%, single dose</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Ocular Lubricants

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Formulation</th>
<th>Price (excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARBOMER</td>
<td>Ophthalmic gel 0.3%, single dose</td>
<td>8.25</td>
<td>Poly Gel</td>
</tr>
<tr>
<td></td>
<td>Ophthalmic gel 0.2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARMELLOSE SODIUM WITH PECTIN AND GELATINE</td>
<td>Eye drops 0.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eye drops 0.5%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eye drops 1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eye drops 1%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYPROMELLOSE</td>
<td>Eye drops 0.5%</td>
<td>3.92</td>
<td>Methopt</td>
</tr>
<tr>
<td>HYPROMELLOSE WITH DEXTRAN</td>
<td>Eye drops 0.3% with dextran 0.1%</td>
<td>2.30</td>
<td>Poly-Tears</td>
</tr>
<tr>
<td></td>
<td>Eye drops 0.3% with dextran 0.1%, single dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MACROGOL 400 AND PROPYLENE GLYCOL</td>
<td>Eye drops 0.4% with propylene glycol 0.3% preservative free, single dose</td>
<td>4.30</td>
<td>Systane Unit Dose</td>
</tr>
</tbody>
</table>

---

*Item restricted (see ➥ above); Item restricted (see ➥ below)

*E.g. *Brand* indicates brand example only. It is not a contracted product.*
## PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN
- Eye oint 42.5% with soft white paraffin 57.3%

## PARAFFIN LIQUID WITH WOOL FAT
- Eye oint 3% with wool fat 3%

## POLYVINYL ALCOHOL
- Eye drops 3%

(Vistil Forte Eye drops 3% to be delisted 1 January 2020)

## POLYVINYL ALCOHOL WITH POVIDONE
- Eye drops 1.4% with povidone 0.6%, single dose

## RETINOL PALMITATE
- Oint 138 mcg per g

## SODIUM HYALURONATE [HYALURONIC ACID]
- Eye drops 1 mg per ml

### Other Otological Preparations

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price Per Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACETIC ACID WITH PROPYLENE GLYCOL</td>
<td></td>
</tr>
<tr>
<td>Eye drops 2.3% with propylene glycol 2.8%</td>
<td></td>
</tr>
<tr>
<td>DOCUSATE SODIUM</td>
<td></td>
</tr>
<tr>
<td>Eye drops 0.5%</td>
<td></td>
</tr>
</tbody>
</table>
## Agents Used in the Treatment of Poisonings

### Antidotes

**ACETYLCYSTEINE**
- Tab eff 200 mg
- Inj 200 mg per ml, 10 ml ampoule – **1% DV Sep-18 to 2021**..........................58.76 10 **DBL Acetylcysteine**

**AMYL NITRITE**
- Liq 98% in 3 ml capsule

**DIGOXIN IMMUNE FAB**
- Inj 38 mg vial
- Inj 40 mg vial

**ETHANOL**
- Liq 96%

**ETHANOL WITH GLUCOSE**
- Inj 10% with glucose 5%, 500 ml bottle

**ETHANOL, DEHYDRATED**
- Inj 100%, 5 ml ampoule
- Inj 96%

**FLUMAZENIL**
- Inj 0.1 mg per ml, 5 ml ampoule – **1% DV Dec-18 to 2021**..........................132.68 10 **Hameln**

**HYDROXOCOBALAMIN**
- Inj 5 g vial
- Inj 2.5 g vial

**NALOXONE HYDROCHLORIDE**
- Inj 400 mcg per ml, 1 ml ampoule – **1% DV Aug-18 to 2021**..........................22.60 5 **DBL Naloxone Hydrochloride**

**PRALIDOXIME IODIDE**
- Inj 25 mg per ml, 20 ml ampoule

**SODIUM NITRITE**
- Inj 30 mg per ml, 10 ml ampoule

**SODIUM THIOSULFATE**
- Inj 250 mg per ml, 10 ml vial
- Inj 250 mg per ml, 50 ml vial
- Inj 500 mg per ml, 10 ml vial
- Inj 500 mg per ml, 20 ml ampoule

**SOYA OIL**
- Inj 20%, 500 ml bag
- Inj 20%, 500 ml bottle

### Antitoxins

**BOTULISM ANTITOXIN**
- Inj 250 ml vial

**DIPHTHERIA ANTITOXIN**
- Inj 10,000 iu vial
Antivenoms

RED BACK SPIDER ANTIVENOM
Inj 500 u vial

SNAKE ANTIVENOM
Inj 50 ml vial

Removal and Elimination

CHARCOAL
Oral liq 200 mg per ml ................................................................. 43.50 250 ml Carbosorb-X

DEFERASIROX – Restricted see terms below
- Tab 125 mg dispersible ............................................................... 276.00 28 Exjade
- Tab 250 mg dispersible ............................................................... 552.00 28 Exjade
- Tab 500 mg dispersible ............................................................... 1,105.00 28 Exjade

- Restricted (RS1444)

Initiation
Haematologist
Re-assessment required after 2 years
All of the following:
1. The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and
2. Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and
3. Any of the following:
   3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*; or
   3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or
   3.3 Treatment with deferiprone has resulted in arthritis; or
   3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per µL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per µL).

Continuation
Haematologist
Re-assessment required after 2 years
Either:
1. For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or
2. For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.

DEFERIPRONE – Restricted see terms below
- Tab 500 mg .................................................................................. 533.17 100 Ferriprox
- Oral liq 100 mg per ml ................................................................. 266.59 250 ml Ferriprox

- Restricted (RS1445)

Initiation
Patient has been diagnosed with chronic iron overload due to congenital inherited anaemia or acquired red cell aplasia.

DESFERROXAMINE MESILATE
Inj 500 mg vial – 1% DV Mar-19 to 2021 .............................................. 84.53 10 DBL Desferrioxamine Mesylate for Inj BP

DICOBALT EDETATE
Inj 15 mg per ml, 20 ml ampoule
<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

| DIMERCAPROL | Inj 50 mg per ml, 2 ml ampoule |
| DIMERCAPTOSUCCINIC ACID | Cap 100 mg |
| | Cap 200 mg |
| SODIUM CALCIUM EDETA | Inj 200 mg per ml, 2.5 ml ampoule |
| | Inj 200 mg per ml, 5 ml ampoule |

### Antiseptics and Disinfectants

#### CHLORHEXIDINE
- Soln 4% ................................................................. 1.86 50 ml healthE
- Soln 5% ................................................................. 15.50 500 ml healthE

#### CHLORHEXIDINE WITH CETRIMIDE
- Crm 0.1% with cetrimide 0.5%
- Foaming soln 0.5% with cetrimide 0.5%

#### CHLORHEXIDINE WITH ETHANOL
- Soln 0.5% with ethanol 70%, non-staining (pink) 100 ml .......................... 2.65 1 healthE
- Soln 2% with ethanol 70%, non-staining (pink) 100 ml .......................... 3.54 1 healthE
- Soln 0.5% with ethanol 70%, non-staining (pink) 25 ml .......................... 1.55 1 healthE
- Soln 0.5% with ethanol 70%, staining (red) 100 ml .......................... 2.90 1 healthE
- Soln 2% with ethanol 70%, staining (red) 100 ml .......................... 3.86 1 healthE
- Soln 0.5% with ethanol 70%, non-staining (pink) 500 ml .......................... 4.54 1 healthE
- Soln 0.5% with ethanol 70%, staining (red) 500 ml .......................... 5.90 1 healthE
- Soln 2% with ethanol 70%, staining (red) 500 ml .......................... 9.56 1 healthE

#### IODINE WITH ETHANOL
- Soln 1% with ethanol 70%, 100 ml ........................................... 9.30 1 healthE

#### ISOPROPYL ALCOHOL
- Soln 70%, 500 ml ........................................... 5.65 1 healthE

#### POVIDONE-IODINE
- Vaginal tab 200 mg
- Restricted (RS1354)

<table>
<thead>
<tr>
<th>Initiation</th>
<th>Rectal administration pre-prostate biopsy.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oint 10%</td>
<td>3.27 25 g Betadine</td>
</tr>
<tr>
<td>Soln 10% – 1% DV Nov-19 to 2021</td>
<td>6.20 500 ml Betadine</td>
</tr>
<tr>
<td>Soln 5%</td>
<td>2.55 100 ml Riodine</td>
</tr>
<tr>
<td>Soln 7.5%</td>
<td>Riodine</td>
</tr>
<tr>
<td>Soln 10%, – 1% DV Dec-19 to 2022</td>
<td>3.83 15 ml Riodine</td>
</tr>
<tr>
<td>Pad 10%</td>
<td>5.40 500 ml Riodine</td>
</tr>
</tbody>
</table>

(Betadine Soln 10% to be delisted 1 December 2019)

---

Item restricted (see above); Item restricted (see below)
e.g. Brand indicates brand example only. It is not a contracted product.
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>POVIDONE-IODINE WITH ETHANOL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln 10% with ethanol 30%</td>
<td>10.00</td>
<td>500 ml</td>
<td>Betadine Skin Prep</td>
</tr>
<tr>
<td>Soln 10% with ethanol 70%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SODIUM HYPOCHLORITE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soln</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Contrast Media</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Iodinated X-ray Contrast Media</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle</td>
<td>22.50</td>
<td>100 ml</td>
<td>Gastrografin</td>
</tr>
<tr>
<td>Inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle</td>
<td>80.00</td>
<td>1</td>
<td>Urografin</td>
</tr>
<tr>
<td><strong>DIATRIZOATE SODIUM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral liq 370 mg per ml, 10 ml sachet</td>
<td>156.12</td>
<td>50</td>
<td>Ioscan</td>
</tr>
<tr>
<td><strong>IODISED OIL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 38% w/w (480 mg per ml), 10 ml ampoule</td>
<td>410.00</td>
<td>1</td>
<td>Lipiodol Ultra Fluid</td>
</tr>
<tr>
<td><strong>IODIXANOL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 270 mg per ml (iodine equivalent), 50 ml bottle</td>
<td>220.00</td>
<td>10</td>
<td>Visipaque</td>
</tr>
<tr>
<td>Inj 270 mg per ml (iodine equivalent), 100 ml bottle</td>
<td>430.00</td>
<td>10</td>
<td>Visipaque</td>
</tr>
<tr>
<td>Inj 320 mg per ml (iodine equivalent), 50 ml bottle</td>
<td>220.00</td>
<td>10</td>
<td>Visipaque</td>
</tr>
<tr>
<td>Inj 320 mg per ml (iodine equivalent), 100 ml bottle</td>
<td>430.00</td>
<td>10</td>
<td>Visipaque</td>
</tr>
<tr>
<td>Inj 320 mg per ml (iodine equivalent), 200 ml bottle</td>
<td>850.00</td>
<td>10</td>
<td>Visipaque</td>
</tr>
<tr>
<td><strong>IOHEXOL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj 240 mg per ml (iodine equivalent), 50 ml bottle</td>
<td>75.00</td>
<td>10</td>
<td>Omnipaque</td>
</tr>
<tr>
<td>Inj 300 mg per ml (iodine equivalent), 20 ml bottle</td>
<td>57.00</td>
<td>10</td>
<td>Omnipaque</td>
</tr>
<tr>
<td>Inj 300 mg per ml (iodine equivalent), 50 ml bottle</td>
<td>75.00</td>
<td>10</td>
<td>Omnipaque</td>
</tr>
<tr>
<td>Inj 300 mg per ml (iodine equivalent), 100 ml bottle</td>
<td>150.00</td>
<td>10</td>
<td>Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 20 ml bottle</td>
<td>59.00</td>
<td>10</td>
<td>Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 50 ml bottle</td>
<td>75.00</td>
<td>10</td>
<td>Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 75 ml bottle</td>
<td>114.00</td>
<td>10</td>
<td>Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 100 ml bottle</td>
<td>150.00</td>
<td>10</td>
<td>Omnipaque</td>
</tr>
<tr>
<td>Inj 350 mg per ml (iodine equivalent), 200 ml bottle</td>
<td>290.00</td>
<td>10</td>
<td>Omnipaque</td>
</tr>
<tr>
<td><strong>Non-iodinated X-ray Contrast Media</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BARIUM SULPHATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Powder for oral liq 20 mg per g (2% w/w), 22.1 g sachet</td>
<td>507.50</td>
<td>50</td>
<td>E-Z-Cat Dry</td>
</tr>
<tr>
<td>Oral liq 400 mg per ml (40% w/v, 30% w/w), bottle</td>
<td>17.39</td>
<td>148 g</td>
<td>Varibar - Thin Liquid</td>
</tr>
<tr>
<td>Oral liq 600 mg per g (60% w/w), tube</td>
<td>36.51</td>
<td>454 g</td>
<td>E-Z-Paste</td>
</tr>
<tr>
<td>Oral liq 400 mg per ml (40% w/v), bottle</td>
<td>155.35</td>
<td>250 ml</td>
<td>Varibar - Honey</td>
</tr>
<tr>
<td>Enema 1,250 mg per ml (125% w/v), 500 ml bag</td>
<td>282.30</td>
<td>12</td>
<td>Liquibar</td>
</tr>
<tr>
<td>Oral liq 22 mg per g (2.2% w/w), 250 ml bottle</td>
<td>175.00</td>
<td>24</td>
<td>CT Plus+</td>
</tr>
<tr>
<td>Oral liq 22 mg per g (2.2% w/w), 450 ml bottle</td>
<td>220.00</td>
<td>24</td>
<td>CT Plus+</td>
</tr>
<tr>
<td>Oral liq 1 mg per ml (0.1% w/v, 0.1% w/w), 450 ml bottle</td>
<td>441.12</td>
<td>24</td>
<td>VoLumen</td>
</tr>
<tr>
<td>Oral liq 20.9 mg per ml (2.1% w/v, 2% w/w), 250 ml bottle</td>
<td>140.94</td>
<td>24</td>
<td>Readi-CAT 2</td>
</tr>
<tr>
<td>Powder for oral soln 97.65% w/w, 300 g bottle</td>
<td>237.76</td>
<td>24</td>
<td>X-Opaque-HD</td>
</tr>
<tr>
<td>Oral liq 400 mg per ml (40% w/v, 30% w/w), 20 ml bottle</td>
<td>52.35</td>
<td>3</td>
<td>Tagitol V</td>
</tr>
<tr>
<td>Oral liq 1,250 mg per ml (125% w/v), 2,000 ml bottle</td>
<td>91.77</td>
<td>1</td>
<td>Liquibar</td>
</tr>
<tr>
<td>VARIOUS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Price</strong></td>
<td><strong>Brand or Generic Manufacturer</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>(ex man. excl. GST)</em></td>
<td>$</td>
<td>Per</td>
<td></td>
</tr>
</tbody>
</table>

**BARIUM SULPHATE WITH SODIUM BICARBONATE**
Grans eff 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet.....................................................................................................102.93 50 E-Z-Gas II

**CITRIC ACID WITH SODIUM BICARBONATE**
Powder 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet

**Paramagnetic Contrast Media**

**GADOBENIC ACID**
- Inj 334 mg per ml, 10 ml vial.................................................................324.74 10 Multihance
- Inj 334 mg per ml, 20 ml vial.................................................................636.28 10 Multihance

**GADOBUTROL**
- Inj 1 mmol per ml, 15 ml vial
- Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 5 ml prefilled syringe..................................................................................120.00 5 Gadovist 1.0
- Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 7.5 ml prefilled syringe...........................................................................180.00 5 Gadovist 1.0
- Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 15 ml prefilled syringe.......................................................................700.00 10 Gadovist 1.0

**GADODIAMIDE**
- Inj 287 mg per ml, 10 ml prefilled syringe...........................................200.00 10 Omniscan
- Inj 287 mg per ml, 10 ml vial.................................................................170.00 10 Omniscan
- Inj 287 mg per ml, 5 ml vial.................................................................120.00 10 Omniscan
- Inj 287 mg per ml, 15 ml prefilled syringe...........................................320.00 10 Omniscan

**GADOTERIC ACID**
- Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe...............24.50 1 Dotarem
- Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml bottle..............................34.50 1 Dotarem
- Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml prefilled syringe...............41.00 1 Dotarem
- Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml prefilled syringe...............55.00 1 Dotarem
- Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml bottle..............................23.20 1 Dotarem
- Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml bottle..............................46.30 1 Dotarem
- Inj 279.32 mg per ml (0.5 mmol per ml), 5 ml bottle..............................12.30 1 Dotarem

**GADOXETATE DISODIUM**
- Inj 181.43 mg per ml (equivalent to 0.25 mmol per ml), 10 ml prefilled syringe........................................................................300.00 1 Primovist

**MEGLUMINE GADOPENTETATE**
- Inj 469 mg per ml, 10 ml prefilled syringe...............................................95.00 5 Magnevist
- Inj 469 mg per ml, 10 ml vial.................................................................185.00 10 Magnevist

**MEGLUMINE IOTROXATE**
- Inj 105 mg per ml, 100 ml bottle...........................................................150.00 100 ml Biliscopin

**Ultrasound Contrast Media**

**PERFLUTREN**
- Inj 1.1 mg per ml, 1.5 ml vial.................................................................180.00 1 Definity
- 720.00 4 Definity

---

*Item restricted (see above); Item restricted (see below)*
*e.g. Brand indicates brand example only. It is not a contracted product.*
### Diagnostic Agents

**ARGININE**
- Inj 50 mg per ml, 500 ml bottle
- Inj 100 mg per ml, 300 ml bottle

**HISTAMINE ACID PHOSPHATE**
- Nebuliser soln 0.6%, 10 ml vial
- Nebuliser soln 2.5%, 10 ml vial
- Nebuliser soln 5%, 10 ml vial

**MANNITOL**
- Powder for inhalation
  - e.g. Aridol

**METHACHOLINE CHLORIDE**
- Powder 100 mg

**SECRETIN PENTAHYDROCHLORIDE**
- Inj 100 u ampoule

**SINCALIDE**
- Inj 5 mcg per vial

### Diagnostic Dyes

**BONNEY’S BLUE DYE**
- Soln

**INDIGO CARMIN**
- Inj 4 mg per ml, 5 ml ampoule
- Inj 8 mg per ml, 5 ml ampoule

**INDOCYANINE GREEN**
- Inj 25 mg vial

**METHYLTHIONINIUM CHLORIDE [METHYLENE BLUE]**
- Inj 5 mg per ml, 10 ml ampoule — 240.35 5 Proveblue

**PATENT BLUE V**
- Inj 2.5%, 2 ml ampoule — 440.00 5 Obex Medical

### Irrigation Solutions

**CHLORHEXIDINE WITH CETRIMIDE**
- Irrigation soln 0.015% with cetrimide 0.15%, 500 ml bottle

- **Restricted (RS1683)**

**Initiation**

*Re-assessment required after 3 months*

All of the following:
1. Patient has burns that are greater than 30% of total body surface area (BSA); and
2. For use in the perioperative preparation and cleansing of large burn areas requiring debridement/skin grafting; and
3. The use of 30 ml ampoules is impractical due to the size of the area to be covered.

**Continuation**

*Re-assessment required after 3 months*

The treatment remains appropriate for the patient and the patient is benefiting from the treatment.

Irrigation soln 0.015% with cetrimide 0.15%, 30 ml ampoule — 1% DV

- **Aug-18 to 2021** — 29.76 30 Pfizer

*Products with Hospital Supply Status (HSS) are in bold*

*Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.*
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>
| GLYCINE
  Irrigation soln 1.5%, 3,000 ml bag – 1% DV Sep-18 to 2021 | 31.20                     | 4   | B Braun                        |
| SODIUM CHLORIDE
  Irrigation soln 0.9%, 3,000 ml bag – 1% DV Sep-18 to 2021 | 26.80                     | 4   | B Braun                        |
  Irrigation soln 0.9%, 30 ml ampoule – 1% DV Sep-18 to 2021 | 7.00                      | 20  | Interpharma                    |
  Irrigation soln 0.9%, 1,000 ml bottle – 1% DV Jun-18 to 2021 | 14.90                     | 10  | Baxter Sodium Chloride 0.9%    |
  Irrigation soln 0.9%, 250 ml bottle – 1% DV Aug-18 to 2021  | 17.64                     | 12  | Fresenius Kabi                 |
| WATER
  Irrigation soln, 3,000 ml bag – 1% DV Sep-18 to 2021        | 28.80                     | 4   | B Braun                        |
  Irrigation soln, 1,000 ml bottle – 1% DV Jun-18 to 2021      | 17.30                     | 10  | Baxter Water for Irrigation    |
  Irrigation soln, 250 ml bottle – 1% DV Aug-18 to 2021        | 17.64                     | 12  | Fresenius Kabi                 |

**Surgical Preparations**

BISMUTH SUBNITRATE AND IODOFORM PARAFFIN
- Paste

DIMETHYL SULFOXIDE
- Soln 50%
- Soln 99%

PHENOL
- Inj 6%, 10 ml ampoule

PHENOL WITH IOXAGLIC ACID
- Inj 12%, 10 ml ampoule

TROMETAMOL
- Inj 36 mg per ml, 500 ml bottle
**Cardioplegia Solutions**

**ELECTROLYTES**

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per Manufacturer</td>
<td></td>
</tr>
</tbody>
</table>

**Inj 15 mmol/l sodium chloride, 9 mmol/l potassium chloride, 1 mmol/l potassium hydrogen 2-ketoglutarate, 4 mmol/l magnesium chloride, 18 mmol/l histidine hydrochloride, 180 mmol/l histidine, 2 mmol/l tryptophan, 30 mmol/l mannitol, 0.015 mmol/l calcium chloride, 1,000 ml bag**

Inj aspartic acid 10.43 mg per ml, citric acid 0.22476 mg per ml, glutamic acid 11.53 mg per ml, sodium phosphate 0.1725 mg per ml, potassium chloride 2.15211 mg per ml, sodium citrate 1.80768 mg per ml, sodium hydroxide 6.31 mg per ml and trometamol 11.2369 mg per ml, 364 ml bag

**Inj aspartic acid 8.481 mg per ml, citric acid 0.8188 mg per ml, glutamic acid 9.375 mg per ml, sodium phosphate 0.6285 mg per ml, potassium chloride 2.5 mg per ml, sodium citrate 6.585 mg per ml, sodium hydroxide 5.133 mg per ml and trometamol 9.097 mg per ml, 527 ml bag**

**Inj citric acid 0.07973 mg per ml, sodium phosphate 0.06119 mg per ml, potassium chloride 2.181 mg per ml, sodium chloride 1.788 mg ml, sodium citrate 0.6412 mg per ml and trometamol 5.9 mg per ml, 523 ml bag**

**Inj 110 mmol/l sodium, 16 mmol/l potassium, 1.2 mmol/l calcium, 16 mmol/l magnesium and 160 mmol/l chloride, 1,000 ml bag**

**Inj 143 mmol/l sodium, 16 mmol/l potassium, 16 mmol/l magnesium and 1.2 mmol/l calcium, 1,000 ml bag**

**MONOSODIUM GLUTAMATE WITH SODIUM ASPARTATE**

**Inj 42.68 mg with sodium aspartate 39.48 mg per ml, 250 ml bottle**

**MONOSODIUM L-ASPARTATE**

**Inj 14 mmol per 10 ml, 10 ml**

**Cold Storage Solutions**

**SODIUM WITH POTASSIUM**

**Inj 29 mmol/l with potassium 125 mmol/l, 1,000 ml bag**

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
<table>
<thead>
<tr>
<th>Extemporaneously Compounded Preparations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACETIC ACID</strong></td>
</tr>
<tr>
<td>Liq</td>
</tr>
<tr>
<td><strong>ALUM</strong></td>
</tr>
<tr>
<td>Powder BP</td>
</tr>
<tr>
<td><strong>ARACHIS OIL [PEANUT OIL]</strong></td>
</tr>
<tr>
<td>Liq</td>
</tr>
<tr>
<td><strong>ASCORBIC ACID</strong></td>
</tr>
<tr>
<td>Powder</td>
</tr>
<tr>
<td><strong>BENZoin</strong></td>
</tr>
<tr>
<td>Tincture compound BP</td>
</tr>
<tr>
<td><strong>BISMUTH SUBGALLATE</strong></td>
</tr>
<tr>
<td>Powder</td>
</tr>
<tr>
<td><strong>BORIC ACID</strong></td>
</tr>
<tr>
<td>Powder</td>
</tr>
<tr>
<td><strong>CARBOXYMETHYLCELLULOSE</strong></td>
</tr>
<tr>
<td>Soln 1.5%</td>
</tr>
<tr>
<td><strong>CETRIMIDE</strong></td>
</tr>
<tr>
<td>Soln 40%</td>
</tr>
<tr>
<td><strong>CHLORHEXIDINE GLUCONATE</strong></td>
</tr>
<tr>
<td>Soln 20%</td>
</tr>
<tr>
<td><strong>CHLOROFORM</strong></td>
</tr>
<tr>
<td>Liq BP</td>
</tr>
<tr>
<td><strong>CITRIC ACID</strong></td>
</tr>
<tr>
<td>Powder BP</td>
</tr>
<tr>
<td><strong>CLOVE OIL</strong></td>
</tr>
<tr>
<td>Liq</td>
</tr>
<tr>
<td><strong>COAL TAR</strong></td>
</tr>
<tr>
<td>Soln BP – <strong>1% DV Nov-19 to 2022</strong> ................................................................. 36.25 200 ml Midwest</td>
</tr>
<tr>
<td><strong>CODEINE PHOSPHATE</strong></td>
</tr>
<tr>
<td>Powder</td>
</tr>
<tr>
<td><strong>COLLODION FLEXIBLE</strong></td>
</tr>
<tr>
<td>Liq</td>
</tr>
<tr>
<td><strong>COMPOUND HYDROXYBENZOATE</strong></td>
</tr>
<tr>
<td>Soln – <strong>1% DV Aug-19 to 2022</strong> ................................................................. 30.00 100 ml Midwest</td>
</tr>
<tr>
<td><strong>CYSTEAMINE HYDROCHLORIDE</strong></td>
</tr>
<tr>
<td>Powder</td>
</tr>
<tr>
<td><strong>DISODIUM HYDROGEN PHOSPHATE WITH SODIUM DIHYDROGEN PHOSPHATE</strong></td>
</tr>
<tr>
<td>Inj 37.46 mg with sodium dihydrogen phosphate 47.7 mg in 1.5 ml ampoule</td>
</tr>
<tr>
<td><strong>DITHRANOL</strong></td>
</tr>
<tr>
<td>Powder</td>
</tr>
<tr>
<td><strong>GLUCOSE [DEXTROSE]</strong></td>
</tr>
<tr>
<td>Powder</td>
</tr>
<tr>
<td>Product Description</td>
</tr>
<tr>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>GLYCERIN WITH SODIUM SACCHARIN Suspension – 1% DV Jul-19 to 2022</td>
</tr>
<tr>
<td>GLYCERIN WITH SUCROSE Suspension – 1% DV Jul-19 to 2022</td>
</tr>
<tr>
<td>GLYCEROL Liq – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td>HYDROCORTISONE Powder – 1% DV Sep-17 to 2020</td>
</tr>
<tr>
<td>LACTOSE Powder</td>
</tr>
<tr>
<td>MAGNESIUM HYDROXIDE Paste</td>
</tr>
<tr>
<td>MENTHOL Crystals</td>
</tr>
<tr>
<td>METHADONE HYDROCHLORIDE Powder</td>
</tr>
<tr>
<td>METHYL HYDROXYBENZOATE Powder – 1% DV Jul-19 to 2022</td>
</tr>
<tr>
<td>METHYLCELLULOSE Powder – 1% DV Jul-19 to 2022</td>
</tr>
<tr>
<td>METHYLCELLULOSE Suspension – 1% DV Jul-19 to 2022</td>
</tr>
<tr>
<td>METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN Suspension – 1% DV Jul-19 to 2022</td>
</tr>
<tr>
<td>METHYLCELLULOSE WITH GLYCERIN AND SUCROSE Suspension – 1% DV Jul-19 to 2022</td>
</tr>
<tr>
<td>OLIVE OIL Liq</td>
</tr>
<tr>
<td>PARAFFIN Liq</td>
</tr>
<tr>
<td>PHENOBARBITONE SODIUM Powder</td>
</tr>
<tr>
<td>PHENOL Liq</td>
</tr>
<tr>
<td>PILOCARPINE NITRATE Powder</td>
</tr>
<tr>
<td>POLYHEXAMETHYLENE BIGUANIDE Liq</td>
</tr>
<tr>
<td>Povidone K30 Powder</td>
</tr>
<tr>
<td>SALICYLIC ACID Powder</td>
</tr>
<tr>
<td>SILVER NITRATE Crystals</td>
</tr>
<tr>
<td>SODIUM BICARBONATE Powder BP – 1% DV Jan-20 to 2022</td>
</tr>
</tbody>
</table>
### Extemporaneously Compounded Preparations

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Item</th>
<th>Powder</th>
<th>Powder</th>
<th>Powder</th>
<th>Powder</th>
<th>Powder</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM CITRATE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM METABISULFITE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STARCH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SULPHUR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SYRUP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>THEOBROMA OIL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRISODIUM CITRATE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRICHLORACETIC ACID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UREA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WOOL FAT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XANTHAN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZINC OXIDE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note: e.g. Brand indicates brand example only. It is not a contracted product.*
## Food Modules

### Carbohydrate

**→ Restricted (RS1467)**

**Initiation – Use as an additive**

Any of the following:

1. Cystic fibrosis; or
2. Chronic kidney disease; or
3. Cancer in children; or
4. Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
5. Faltering growth in an infant/child; or
6. Bronchopulmonary dysplasia; or
7. Premature and post premature infant; or
8. Inborn errors of metabolism.

**Initiation – Use as a module**

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

**CARBOHYDRATE SUPPLEMENT – Restricted see terms above**

- Powder 95 g carbohydrate per 100 g, 368 g can
- Powder 96 g carbohydrate per 100 g, 400 g can  
  e.g. Polycal

### Fat

**→ Restricted (RS1468)**

**Initiation – Use as an additive**

Any of the following:

1. Patient has inborn errors of metabolism; or
2. Faltering growth in an infant/child; or
3. Bronchopulmonary dysplasia; or
4. Fat malabsorption; or
5. Lymphangiectasia; or
6. Short bowel syndrome; or
7. Infants with necrotising enterocolitis; or
8. Biliary atresia; or
9. For use in a ketogenic diet; or
10. Chyle leak; or
11. Ascites; or
12. Patient has increased energy requirements, and for whom dietary measures have not been successful.

**Initiation – Use as a module**

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

**LONG-CHAIN TRIGLYCERIDE SUPPLEMENT – Restricted see terms above**

- Liquid 50 g fat per 100 ml, 200 ml bottle  
  e.g. Calogen
- Liquid 50 g fat per 100 ml, 500 ml bottle  
  e.g. Calogen
MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT – Restricted see terms on the previous page

- Liquid 50 g fat per 100 ml, 250 ml bottle
- Liquid 95 g fat per 100 ml, 500 ml bottle

WALNUT OIL – Restricted see terms on the previous page

- Liq

Protein

- Restricted (RS1469)

Initiation – Use as an additive

Either:

1. Protein losing enteropathy; or
2. High protein needs.

Initiation – Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Note: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Protein SUPPLEMENT – Restricted see terms above

- Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can
- Powder 6 g protein per 7 g, can
- Powder 89 g protein, < 1.5 g carbohydrate and 2 g fat per 100 g, 225 g can

Other Supplements

BREAST MILK FORTIFIER

- Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 g sachet
- Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 g sachet
- Powder 0.6 g protein and 1.4 g carbohydrate per 2.2 g sachet

CARBOHYDRATE AND FAT SUPPLEMENT – Restricted see terms below

- Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g can

- Restricted (RS1212)

Initiation

Both:

1. Infant or child aged four years or under; and
2. Any of the following:
   2.1 Cystic fibrosis; or
   2.2 Cancer in children; or
   2.3 Falttering growth; or
   2.4 Bronchopulmonary dysplasia; or
   2.5 Premature and post premature infants.
### Food/Fluid Thickeners

**NOTE:**
While pre-thickened drinks and supplements have not been included in Section H, DHB hospitals may continue to use such products for patients with dysphagia, provided that:
- use was established prior to 1 July 2013; and
- the product has not been specifically considered and excluded by PHARMAC; and
- use of the product conforms to any applicable indication restrictions for similar products that are listed in Section H (for example, use of thickened high protein products should be in line with the restriction for high protein oral feed in Section H).

PHARMAC intends to make a further decision in relation to pre-thickened drinks and supplements in the future, and will notify of any change to this situation.

**CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN**
- Powder
  - e.g. Feed Thickener
    - Karicare Aptamil

**GUAR GUM**
- Powder
  - e.g. Guarcol

**MAIZE STARCH**
- Powder
  - e.g. Resource Thicken
    - Up; Nutilis

**MALTODEXTRIN WITH XANTHAN GUM**
- Powder
  - e.g. Instant Thick

**MALTODEXTRIN WITH XANTHAN GUM AND ASCORBIC ACID**
- Powder
  - e.g. Easy Thick

### Metabolic Products

- **Restricted (RS1232)**

**Initiation**

Any of the following:
1. For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria, isovaleric acidemia, propionic acidemia, methylmalonic acidemia, tyrosinaemia or urea cycle disorders; or
2. Patient has adrenoleukodystrophy; or
3. For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

### Glutaric Aciduria Type 1 Products

**AMINO ACID FORMULA (WITHOUT LYSINE AND LOW TRYPTOPHAN)** – **Restricted** see terms above

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
  - e.g. GA1 Anamix Infant

- Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can
  - e.g. XLYS Low TRY
    - Maxamaid
## SPECIAL FOODS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

### Homocystinuria Products

AMINO ACID FORMULA (WITHOUT METHIONINE) – **Restricted** see terms on the previous page

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
  - e.g. HCU Anamix Infant
- Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can
  - e.g. XMET Maxamaid
- Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can
  - e.g. XMET Maxamum
- Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle
  - e.g. HCU Anamix Junior LQ

### Isovaleric Acidaemia Products

AMINO ACID FORMULA (WITHOUT LEUCINE) – **Restricted** see terms on the previous page

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
  - e.g. IVA Anamix Infant
- Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can
  - e.g. XLEU Maxamaid
- Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can
  - e.g. XLEU Maxamum

### Maple Syrup Urine Disease Products

AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) – **Restricted** see terms on the previous page

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
  - e.g. MSUD Anamix Infant
- Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can
  - e.g. MSUD Maxamum
- Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle
  - e.g. MSUD Anamix Junior LQ

---

Item restricted (see ⬇️ above); Item restricted (see ⬇️ below)
e.g. Brand indicates brand example only. It is not a contracted product.
### Phenylketonuria Products

<table>
<thead>
<tr>
<th>AMINO ACID FORMULA (WITHOUT PHENYLALANINE) – Restricted see terms on page 221</th>
<th>Price (ex man. excl. GST) $ Per</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tab 8.33 mg</td>
<td>1.30 100 g</td>
<td>e.g. Phlexy-10</td>
</tr>
<tr>
<td>Powder 20 g protein, 2.5 g carbohydrate and 0.22 g fibre per 27.8 g sachet</td>
<td>1.30 100 g</td>
<td>e.g. PKU Lophlex Powder (unflavoured)</td>
</tr>
<tr>
<td>Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet</td>
<td>1.30 100 g</td>
<td>e.g. PKU Anamix Junior (van/choc/unfl)</td>
</tr>
<tr>
<td>Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can</td>
<td>1.30 100 g</td>
<td>e.g. PKU Anamix Infant</td>
</tr>
<tr>
<td>Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can</td>
<td>1.30 100 g</td>
<td>e.g. XP Maxamum</td>
</tr>
<tr>
<td>Powder 8.33 g protein and 8.8 g carbohydrate per 20 g sachet</td>
<td>1.30 100 g</td>
<td>e.g. Phlexy-10</td>
</tr>
<tr>
<td>Liquid 10 g protein, 4.4 g carbohydrate and 0.25 g fibre per 100 ml, 62.5 ml bottle</td>
<td>1.30 100 g</td>
<td>e.g. PKU Lophlex LQ 10</td>
</tr>
<tr>
<td>Liquid 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle</td>
<td>1.30 100 g</td>
<td>e.g. PKU Lophlex LQ 20</td>
</tr>
<tr>
<td>Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, bottle</td>
<td>1.30 100 g</td>
<td>PKU Anamix Junior LQ (Berry)</td>
</tr>
<tr>
<td>Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 125 ml bottle</td>
<td>1.30 100 g</td>
<td>PKU Anamix Junior LQ (Orange)</td>
</tr>
<tr>
<td>Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 62.5 ml bottle</td>
<td>1.30 100 g</td>
<td>PKU Anamix Junior LQ (Unflavoured)</td>
</tr>
<tr>
<td>Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 125 ml bottle</td>
<td>1.30 100 g</td>
<td>e.g. PKU Lophlex LQ 20</td>
</tr>
<tr>
<td>Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 62.5 ml bottle</td>
<td>1.30 100 g</td>
<td>e.g. PKU Lophlex LQ 10</td>
</tr>
<tr>
<td>Liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton</td>
<td>1.30 100 g</td>
<td>e.g. Easiphen</td>
</tr>
<tr>
<td>Semi-solid 18.3 g protein, 18.5 g carbohydrate and 0.92 g fibre per 100 g, 109 g pot</td>
<td>1.30 100 g</td>
<td>e.g. PKU Lophlex Sensations 20 (berries)</td>
</tr>
</tbody>
</table>

### Propionic Acidaemia and Methylmalonic Acidaemia Products

<table>
<thead>
<tr>
<th>AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE) – Restricted see terms on page 221</th>
<th>Price (ex man. excl. GST) $ Per</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can</td>
<td>1.30 100 g</td>
<td>e.g. MMA/PA Anamix Infant</td>
</tr>
<tr>
<td>Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can</td>
<td>1.30 100 g</td>
<td>e.g. XMTVI Maxamaid</td>
</tr>
<tr>
<td>Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can</td>
<td>1.30 100 g</td>
<td>e.g. XMTVI Maxamum</td>
</tr>
</tbody>
</table>
Protein Free Supplements

PROTEIN FREE SUPPLEMENT – **Restricted** see terms on page 221

- Powder nil added protein and 67 g carbohydrate per 100 g, 400 g can
  - **e.g.** Energivit

Tyrosinaemia Products

AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE) – **Restricted** see terms on page 221

- Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet
  - **e.g.** TYR Anamix Junior

- Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can
  - **e.g.** TYR Anamix Infant

- Powder 25 g protein and 51 g carbohydrate per 100 g, 400 g can
  - **e.g.** XPHEN, TYR Maxamaid

- Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle
  - **e.g.** TYR Anamix Junior LQ

Urea Cycle Disorders Products

AMINO ACID SUPPLEMENT – **Restricted** see terms on page 221

- Powder 25 g protein and 65 g carbohydrate per 100 g, 200 g can
  - **e.g.** Dialamine

- Powder 79 g protein per 100 g, 200 g can
  - **e.g.** Essential Amino Acid Mix

X-Linked Adrenoleukodystrophy Products

GLYCEROL TRIERUCATE – **Restricted** see terms on page 221

- Liquid, 1,000 ml bottle

GLYCEROL TRIOLEATE – **Restricted** see terms on page 221

- Liquid, 500 ml bottle

Specialised Formulas

Diabetic Products

**⇒ Restricted (RS1215)**

Initiation

Any of the following:

1. For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support; or
2. For patients with pancreatic insufficiency; or
3. For patients who have, or are expected to, eat little or nothing for 5 days; or
4. For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
5. For use pre- and post-surgery; or
6. For patients being tube-fed; or
7. For tube-feeding as a transition from intravenous nutrition.
<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Price</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 1,000 ml bottle</td>
<td>$7.50</td>
<td>Glucerna Select RTH (Vanilla)</td>
</tr>
<tr>
<td>Liquid 5 g protein, 9.6 g carbohydrate and 4.2 g fat per 100 ml, 1,000 ml bag</td>
<td></td>
<td>e.g. Nutrison Advanced Diason</td>
</tr>
</tbody>
</table>

### Elemental and Semi-Elemental Products

**Restricted (RS1216)**

**Initiation**

Any of the following:

1. Malabsorption; or
2. Short bowel syndrome; or
3. Enterocutaneous fistulas; or
4. Eosinophilic enteritis (including oesophagitis); or
5. Inflammatory bowel disease; or
6. Acute pancreatitis where standard feeds are not tolerated; or
7. Patients with multiple food allergies requiring enteral feeding.

### Amino Acid Oral Feed – Restricted see terms above

- Powder 11 g protein, 62 g carbohydrate and 1 g fat per sachet | $4.50 | 80 g Vivonex TEN |

### Amino Acid Oral Feed 0.8 KCAL/ML – Restricted see terms above

- Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton | | e.g. Elemental 028 Extra |

### Peptide-Based Enteral Feed 1 KCAL/ML – Restricted see terms above

- Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag | | e.g. Nutrison Advanced Peptisorb |

### Peptide-Based Enteral Feed 1.5 KCAL/ML – Restricted see terms above

- Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle | $18.06 | 1,000 ml Vital |

### Peptide-Based Oral Feed – Restricted see terms above

- Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 100 g, 400 g can | e.g. Peptamen Junior |
- Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 400 g can | e.g. MCT Pepdite; MCT Pepdite 1+ |
SPECIAL FOODS

<table>
<thead>
<tr>
<th>SPECIAL FOODS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price</td>
</tr>
<tr>
<td>$</td>
</tr>
<tr>
<td>ex man. excl. GST</td>
</tr>
<tr>
<td>Brand or Generic</td>
</tr>
</tbody>
</table>

PEPTIDE-BASED ORAL FEED 1 KCAL/ML – **Restricted** see terms on the previous page

- Liquid 5 g protein, 16 g carbohydrate and 1.69 g fat per 100 ml, carton...........4.95 237 ml Peptamen OS 1.0 (Vanilla)

**Fat Modified Products**

FAT-MODIFIED FEED – **Restricted** see terms below

- Powder 12.9 g protein, 69.1 g carbohydrate and 12.9 g fat per 100 g, 400 g can
  - **Restricted (RS1470)**
  - e.g. Monogen

**Hepatic Products**

HEPATIC ORAL FEED – **Restricted** see terms above

- Powder 11 g protein, 64 g carbohydrate and 20 g fat per 100 g, can ............78.97 400 g Heparon Junior

**High Calorie Products**

ENTERAL FEED 2 KCAL/ML – **Restricted** see terms above

- Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, bottle ........5.50 500 ml Nutrison Concentrated
- Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle.................................................................11.00 1,000 ml TwoCal HN RTH (Vanilla)

ORAL FEED 2 KCAL/ML – **Restricted** see terms above

- Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, bottle.................................................................1.90 200 ml Two Cal HN
High Protein Products

HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML – Restricted see terms below

Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml,
1,000 ml bottle

→ Restricted (RS1327)
Initiation
Both:
1 The patient has a high protein requirement; and
2 Any of the following:
   2.1 Patient has liver disease; or
   2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
   2.3 Patient is fluid restricted; or
   2.4 Patient's needs cannot be more appropriately met using high calorie product.

HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML – Restricted see terms below

Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per
100 ml, 1,000 ml bag

→ Restricted (RS1327)
Initiation
Both:
1 The patient has a high protein requirement; and
2 Any of the following:
   2.1 Patient has liver disease; or
   2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
   2.3 Patient is fluid restricted; or
   2.4 Patient's needs cannot be more appropriately met using high calorie product.

Infant Formulas

AMINO ACID FORMULA – Restricted see terms on the next page

Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml,
400 g can

Powder 13 g protein, 49 g carbohydrate and 23 g fat per 100 g, 400 g can

Powder 13.3 g protein, 56 g carbohydrate and 22 g fat per 100 g, 400 g can

Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can ...........53.00 400 g Neocate

Powder 14.8 g protein, 51.4 g carbohydrate and 23 g fat per 100 g, can ...........53.00 400 g Neocate Gold
(Unflavoured)

Powder 15 g protein, 56 g carbohydrate and 20 g fat per 100 g, can ..........43.60 400 g Neocate Junior Vanilla

Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can ............43.00 400 g Neocate Junior Vanilla

Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can .......53.00 400 g Elecare LCP
(Unflavoured)

Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can ...........53.00 400 g Elecare (Unflavoured)

(Neocate Junior Vanilla Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can to be delisted 1 April 2020)
SPECIAL FOODS

<table>
<thead>
<tr>
<th>Brand or Generic Manufacturer</th>
<th>Price (ex man. excl. GST)</th>
<th>Per</th>
</tr>
</thead>
</table>

**Restricted (RS1471)**

**Initiation**

Any of the following:

1. Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
2. History of anaphylaxis to cows' milk protein formula or dairy products; or
3. Eosinophilic oesphagitis.

Note: A reasonable trial is defined as a 2-4 week trial.

**Continuation**

Both:

1. An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
2. The outcome of the assessment is that the infant continues to require an amino acid infant formula.

**EXTENSIVELY HYDROLYSED FORMULA – Restricted** see terms below

- Powder 1.6 g protein, 7.5 g carbohydrate and 3.1 g fat per 100 ml, 900 g can
- Powder 1.6 g protein, 7.8 g carbohydrate and 3.2 g fat per 100 ml, 900 g can
- Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can

**Restricted (RS1502)**

**Initiation**

Any of the following:

1. Both:
   1.1 Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
   1.2 Either:
      1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
      1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
2. Severe malabsorption; or
3. Short bowel syndrome; or
4. Intractable diarrhoea; or
5. Biliary atresia; or
6. Cholestatic liver diseases causing malabsorption; or
7. Cystic fibrosis; or
8. Proven fat malabsorption; or
9. Severe intestinal motility disorders causing significant malabsorption; or
10. Intestinal failure; or
11. For step down from Amino Acid Formula.

Note: A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.

**Continuation**

Both:

1. An assessment as to whether the infant can be transitioned to a cows' milk protein or soy infant formula has been undertaken; and
2. The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula.

**FRUCTOSE-BASED FORMULA**

- Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat per 100 g, 400 g can

*Item restricted (see ➡ above); Item restricted (see ➡ below)*

*E.g. Brand* indicates brand example only. It is not a contracted product.
### LACTOSE-FREE FORMULA

Powder 1.3 g protein, 7.3 g carbohydrate and 3.5 g fat per 100 ml, 900 g can

- **Brand or Generic Manufacturer**: e.g. Karicare Aptamil Gold De-Lact

Powder 1.5 g protein, 7.2 g carbohydrate and 3.6 g fat per 100 ml, 900 g can

- **Brand or Generic Manufacturer**: e.g. S26 Lactose Free

### LOW-CALCIUM FORMULA

Powder 14.6 g protein, 53.7 g carbohydrate and 26.1 g fat per 100 g, 400 g can

- **Brand or Generic Manufacturer**: e.g. Locasol

### PAEDIATRIC ORAL/ENTERAL FEED 1 KCAL/ML – Restricted see terms below

- **Liquid**:
  - 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre per 100 ml, bottle...
  - **Price**: $2.35
  - **Volume**: 125 ml
  - **Brand or Generic Manufacturer**: Infatrini

- **Initiation** – Fluid restricted or volume intolerance with faltering growth
  - **Both**:
    - 1 Either:
      - 1.1 The patient is fluid restricted or volume intolerant; or
      - 1.2 The patient has increased nutritional requirements due to faltering growth; and
    - 2 Patient is under 18 months old and weighs less than 8kg.
  - **Note**: 'Volume intolerant' patients are those who are unable to tolerate an adequate volume of infant formula to achieve expected growth rate. These patients should have first trialled appropriate clinical alternative treatments, such as concentrating, fortifying and adjusting the frequency of feeding.

### PRETERM FORMULA – Restricted see terms below

- **Liquid**:
  - 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 ml, bottle...
  - **Price**: $0.75
  - **Volume**: 100 ml
  - **Brand or Generic Manufacturer**: S26 LBW Gold RTF

- **Liquid**:
  - 2.3 g protein, 8.6 g carbohydrate and 4.2 g fat per 100 ml, 90 ml bottle
  - **Price**: $e.g. Pre Nan Gold RTF

- **Liquid**:
  - 2.6 g protein, 8.4 g carbohydrate and 3.9 g fat per 100 ml, 70 ml bottle
  - **Price**: $e.g. Karicare Aptamil Gold+Preterm

### THICKENED FORMULA

Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100 ml, 900 g can

- **Brand or Generic Manufacturer**: e.g. Karicare Aptamil Thickened AR

### Ketogenic Diet Products

### HIGH FAT FORMULA – Restricted see terms below

- **Powder**:
  - 14.4 g protein, 2.9 g carbohydrate and 69.2 g fat per 100 g, can...
  - **Volume**: 300 g
  - **Price**: $35.50
  - **Brand or Generic Manufacturer**: Ketocal 4:1 (Unflavoured)

- **Powder**:
  - 15.3 g protein, 7.2 g carbohydrate and 67.7 g fat per 100 g, can...
  - **Volume**: 300 g
  - **Brand or Generic Manufacturer**: Ketocal 3:1 (Unflavoured)
## Paediatric Products

**→ Restricted (RS1473)**

**Initiation**

Both:

1. Child is aged one to ten years; and
2. Any of the following:
   2.1 The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
   2.2 Any condition causing malabsorption; or
   2.3 Faltering growth in an infant/child; or
   2.4 Increased nutritional requirements; or
   2.5 The child is being transitioned from TPN or tube feeding to oral feeding; or
   2.6 The child has eaten, or is expected to eat, little or nothing for 3 days.

**PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML – Restricted** see terms above

- Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, bag.................................................................4.00 500 ml Nutrini Low Energy Multifibre RTH

**PAEDIATRIC ENTERAL FEED 1 KCAL/ML – Restricted** see terms above

- Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag..........2.68 500 ml Pediasure RTH

- Liquid 2.8 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bag e.g. Nutrini RTH

**PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML – Restricted** see terms above

- Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, bag.................................................................6.00 500 ml Nutrini Energy Multi Fibre

- Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bag e.g. Nutrini Energy RTH

**PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted** see terms above

- Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, bottle ..........1.07 200 ml Pediasure (Chocolate) Pediasure (Strawberry) Pediasure (Vanilla)

- Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, can ..........1.34 250 ml Pediasure (Vanilla)

**PAEDIATRIC ORAL FEED 1.5 KCAL/ML – Restricted** see terms above

- Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle e.g. Fortini

- Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, 200 ml bottle e.g. Fortini Multifibre

## Renal Products

**LOW ELECTROLYTE ENTERAL FEED 1.8 KCAL/ML – Restricted** see terms below

- Liquid 8.1 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, bottle.................................................................6.08 500 ml Nepro HP RTH

**→ Restricted (RS1229)**

**Initiation**

For patients with acute or chronic kidney disease.

**LOW ELECTROLYTE ORAL FEED – Restricted** see terms on the next page

- Powder 7.5 g protein, 59 g carbohydrate and 26.3 g fat per 100 g, 400 g can e.g. Kindergen

---

1. Item restricted (see ➥ above);
2. Item restricted (see ➥ below)

*e.g. Brand* indicates brand example only. It is not a contracted product.
SPECIAL FOODS

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST) $ Per</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**Restricted (RS1227)**

Initiation

For children (up to 18 years) with acute or chronic kidney disease.

LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML

- Liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, carton...2.67 220 ml Nepro HP (Strawberry)
- Liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, Nepro HP (Vanilla)

**Restricted (RS1228)**

Initiation

For patients with acute or chronic kidney disease.

LOW ELECTROLYTE ORAL FEED 2 KCAL/ML – Restricted see terms below

- Liquid 9.1 g protein, 19 g carbohydrate and 10 g fat per 100 ml, carton........2.31 237 ml Novasource Renal (Vanilla)
- Liquid 3 g protein, 25.5 g carbohydrate and 9.6 g fat per 100 ml, 237 ml bottle
- Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton e.g. Renilon 7.5

**Restricted (RS1228)**

Initiation

For patients with acute or chronic kidney disease.

**Respiratory Products**

LOW CARBOHYDRATE ORAL FEED 1.5 KCAL/ML – Restricted see terms below

- Liquid 6.2 g protein, 10.5 g carbohydrate and 9.32 g fat per 100 ml, bottle......1.66 237 ml Pulmocare (Vanilla)

**Restricted (RS1230)**

Initiation

For patients with CORD and hypercapnia, defined as a CO2 value exceeding 55 mmHg.

**Surgical Products**

HIGH ARGININE ORAL FEED 1.4 KCAL/ML – Restricted see terms below

- Liquid 10.1 g protein, 15 g carbohydrate, 4.5 g fat and 0 g fibre per 100 ml, carton...4.00 178 ml Impact Advanced Recovery

**Restricted (RS1231)**

Initiation

Three packs per day for 5 to 7 days prior to major gastrointestinal, head or neck surgery.

PREOPERATIVE CARBOHYDRATE FEED 0.5 KCAL/ML – Restricted see terms below

- Oral liq 0 g protein, 12.6 g carbohydrate and 0 g fat per 100 ml, 200 ml bottle...6.80 4 preOp

**Restricted (RS1415)**

Initiation

Maximum of 400 ml as part of an Enhanced Recovery After Surgery (ERAS) protocol 2 to 3 hours before major abdominal surgery.

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
Standard Feeds

**Restricted (RS1214)**

**Initiation**

Any of the following:

1. Any of the following:
   1.1 BMI < 18.5; or
   1.2 Greater than 10% weight loss in the last 3-6 months; or
   1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or
2. For patients who have, or are expected to, eat little or nothing for 5 days; or
3. For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
4. For use pre- and post-surgery; or
5. For patients being tube-fed; or
6. For tube-feeding as a transition from intravenous nutrition; or
7. For any other condition that meets the community Special Authority criteria.

**ENTERAL FEED 1.5 KCAL/ML – Restricted** see terms above

| Liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, bag | 7.00 | 1,000 ml | e.g. Nutrison Energy |
| Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag | e.g. Nutrison Energy Multi Fibre |
| Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, can | 1.75 | 250 ml | Ensure Plus HN |
| Liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, bag | 7.00 | 1,000 ml | Ensure Plus HN RTH |
| Liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, bag | 7.00 | 1,000 ml | Jevity HiCal RTH |

**ENTERAL FEED 1 KCAL/ML – Restricted** see terms above

| Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle | 5.29 | 1,000 ml | e.g. NutrisonStdRTH; NutrisonLowSodium |
| Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, bottle | 5.29 | 1,000 ml | Jevity RTH |
| Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1,000 ml bag | e.g. Nutrison Multi Fibre |

**ENTERAL FEED 1.2 KCAL/ML – Restricted** see terms above

| Liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bag |

**ENTERAL FEED WITH FIBRE 0.83 KCAL/ML – Restricted** see terms above

<p>| Liquid 5.5 g protein, 8.8 g carbohydrate, 2.5 g fat and 1.5 g fibre per 100 ml, bag | 5.29 | 1,000 ml | Nutrison 800 Complete Multi Fibre |</p>
<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price Per 850 g/237 ml</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure (Chocolate)</td>
<td>26.00</td>
<td>Sustagen Hospital</td>
</tr>
<tr>
<td>Ensure (Vanilla)</td>
<td>8.54</td>
<td>Fortisip (Vanilla)</td>
</tr>
<tr>
<td>Sustagen Hospital</td>
<td>26.00</td>
<td>Fortisip (Vanilla)</td>
</tr>
<tr>
<td>Formula Active (Choc)</td>
<td></td>
<td>Fortisip (Vanilla)</td>
</tr>
<tr>
<td>Formula Active (Van)</td>
<td></td>
<td>Fortisip (Vanilla)</td>
</tr>
</tbody>
</table>

Note: Community subsidy of Sustagen Hospital Formula is subject to both Special Authority criteria and a manufacturer's surcharge. Higher subsidy by endorsement is available for patients meeting the following endorsement criteria; fat malabsorption, fat intolerance or chyle leak.

**ORAL FEED 1 KCAL/ML** – Restricted see terms on the previous page

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price Per 237 ml</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>e.g. Resource Fruit Beverage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ensure Plus (Vanilla)</td>
<td>1.33</td>
<td></td>
</tr>
<tr>
<td>Ensure Plus (Banana)</td>
<td>1.26</td>
<td></td>
</tr>
<tr>
<td>Ensure Plus (Chocolate)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ensure Plus (Vanilla)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ORAL FEED 1.5 KCAL/ML** – Restricted see terms on the previous page

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Price Per 200 ml</th>
<th>Brand or Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>e.g. Fortisip</td>
<td></td>
<td></td>
</tr>
<tr>
<td>e.g. Fortisip Multi Fibre</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.**
### Bacterial and Viral Vaccines

#### DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE — **Restricted** see terms below

- Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5 ml syringe

  - 0% DV Sep-17 to 2020

- **Infanrix IPV**

  - 0.00 10

**Initiation**

Any of the following:

1. A single dose for children up to the age of 7 who have completed primary immunisation; or
2. A course of up to four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
3. An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
4. Five doses will be funded for children requiring solid organ transplantation.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes

#### DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE — **Restricted** see terms below

- Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe (1) and inj 10 mcg haemophilus influenzae type B vaccine vial

  - 0% DV Sep-17 to 2020

- **Infanrix-hexa**

  - 0.00 10

**Initiation**

Any of the following:

1. Up to four doses for children up to and under the age of 10 for primary immunisation; or
2. An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
3. Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

#### Bacterial Vaccines

#### ADULT DIPHTHERIA AND TETANUS VACCINE

- Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml syringe

  - 0% DV Jul-17 to 2020

- **ADT Booster**

  - 0.00 5

**Initiation**

Any of the following:

1. For vaccination of patients aged 45 and 65 years old; or
2. For vaccination of previously unimmunised or partially immunised patients; or
continued...

3 For revaccination following immunosuppression; or
4 For boosting of patients with tetanus-prone wounds; or
5 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

**BACILLUS CALMETTE-GUERIN VACCINE** – Restricted see terms below

- Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial Danish strain 1331, live attenuated, vial with diluent

    
    ![Image](image.png) 0.00 10 BCG Vaccine

**Initiation**

All of the following:

1. Living in a house or family with a person with current or past history of TB; and
2. Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB ≥ 40 per 100,000 for 6 months or longer; and
3. During their first 5 years will be living 3 months or longer in a country with a rate of TB ≥ 40 per 100,000.


**DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE** – Restricted see terms below

- Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe – 0% DV Sep-17 to 2020

    
    ![Image](image.png) 0.00 1 Boostrix

**Initiation**

Any of the following:

1. A single dose for pregnant women in the second or third trimester of each pregnancy; or; or
2. A single dose for parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days, who had not been exposed to maternal vaccination at least 14 days prior to birth; or; or
3. A course of up to four doses is funded for children from age 7 up the age of 18 years inclusive to complete full primary immunisation; or
4. An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens.

Note: Tdap is not registered for patients aged less than 10 years. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

**HAEMOPHILUS INFLUENZAE TYPE B VACCINE** – Restricted see terms below

- Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus vial 0.5 ml – 0% DV Sep-17 to 2020

    
    ![Image](image.png) 0.00 1 Hiberix

**Initiation**

Therapy limited to 1 dose

Any of the following:

1. For primary vaccination in children; or

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.
continued…

2 An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or

3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE – Restricted see terms below

- Inj 4 mcg or each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial –

0% DV Jul-17 to 2020 .................................................. 0.00 1 Menactra

Initiation

Any of the following:

1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or

2 One dose for close contacts of meningococcal cases; or

3 A maximum of two doses for bone marrow transplant patients; or

4 A maximum of two doses for patients following immunosuppression*.

Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

MENINGOCOCCAL C CONJUGATE VACCINE – Restricted see terms below

- Inj 10 mcg in 0.5 ml syringe – 0% DV Jul-17 to 2020 ................................. 0.00 1 Neisvac-C

Initiation

Any of the following:

1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with HIV, complement deficiency (acquired or inherited), functional or anatomic asplenia or pre or post solid organ transplant; or

2 One dose for close contacts of meningococcal cases; or

3 A maximum of two doses for bone marrow transplant patients; or

4 A maximum of two doses for patients following immunosuppression*.

Notes: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

PNEUMOCOCCAL (PCV10) CONJUGATE VACCINE – Restricted see terms below

- mcg of pneumococcal polysaccharide serotypes 1, 5, 6B, 7F, 9V, 14 and 23F; 3 mcg of pneumococcal polysaccharide serotypes 4, 18C and 19F in 0.5 ml prefilled syringe – 0% DV Sep-17 to 2020 .......................... 0.00 10 Synflorix

Initiation

Either:

1 A primary course of four doses for previously unvaccinated individuals up to the age of 59 months inclusive; or

2 Up to three doses as appropriate to complete the primary course of immunisation for individuals under the age of 59 months who have received one to three doses of PCV13.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE – Restricted see terms on the next page

- Inj 30.8 mcg of pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in 0.5 ml syringe ........................................ 0.00 1 Prevenar 13

10 Prevenar 13
**PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE** – **Restricted** see terms below

- Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype) – 0% DV Jul-17 to 2020.................................................................0.00 1 Pneumovax 23

**Initiation – High risk patients**

*Therapy limited to 3 doses*

For patients with HIV, for patients post haematopoietic stem cell transplant, or chemotherapy; pre- or post-splenectomy; or with functional asplenia, pre- or post-solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency.
Initiation – High risk children

**Therapy limited to 2 doses**

Both:

1. Patient is a child under 18 years for (re-)immunisation; and
2. Any of the following:
   1. On immunosuppressive therapy or radiation therapy, vaccinate when there is expected to be a sufficient immune response; or
   2. With primary immune deficiencies; or
   3. With HIV infection; or
   4. With renal failure, or nephrotic syndrome; or
   5. Who are immune-suppressed following organ transplantation (including haematopoietic stem cell transplant); or
   6. With cochlear implants or intracranial shunts; or
   7. With cerebrospinal fluid leaks; or
   8. Receiving corticosteroid therapy for more than two weeks, and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; or
   9. With chronic pulmonary disease (including asthma treated with high-dose corticosteroid therapy); or
   10. Pre term infants, born before 28 weeks gestation; or
   11. With cardiac disease, with cyanosis or failure; or
   12. With diabetes; or
   13. With Down syndrome; or
   14. Who are pre-or post-splenectomy, or with functional asplenia.

Initiation – Testing for primary immunodeficiency diseases

For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

**SALMONELLA TYPHI VACCINE – Restricted see terms below**

† Inj 25 mcg in 0.5 ml syringe

→ Restricted (RS1243)

Initiation

For use during typhoid fever outbreaks.

**Viral Vaccines**

**HEPATITIS A VACCINE – Restricted see terms below**

† Inj 720 ELISA units in 0.5 ml syringe – 0% DV Sep-17 to 2020 ......................0.00 1 Havrix Junior

† Inj 1440 ELISA units in 1 ml syringe – 0% DV Sep-17 to 2020 ......................0.00 1 Havrix

→ Restricted (RS1638)

Initiation

Any of the following:

1. Two vaccinations for use in transplant patients; or
2. Two vaccinations for use in children with chronic liver disease; or
3. One dose of vaccine for close contacts of known hepatitis A cases.

**HEPATITIS B RECOMBINANT VACCINE**

† Inj 5 mcg in 0.5 ml vial – 0% DV Jul-17 to 2020 ......................0.00 1 HBvaxPRO

→ Restricted (RS1588)

Initiation

Any of the following:

continued...
continued...

1. For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
2. For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3. For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
4. For HIV positive patients; or
5. For hepatitis C positive patients; or
6. for patients following non-consensual sexual intercourse; or
7. For patients following immunosuppression; or
8. For solid organ transplant patients; or
9. For post-haematopoietic stem cell transplant (HSCT) patients; or
10. Following needle stick injury.

\[\text{Inj} 10 \text{ mcg in 1 ml vial} \] .................................................................$0.00 1 HBvaxPRO

\[\text{Initiation:} \text{Restricted (RS1588)}\]

Any of the following:
1. For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
2. For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3. For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
4. For HIV positive patients; or
5. For hepatitis C positive patients; or
6. for patients following non-consensual sexual intercourse; or
7. For patients following immunosuppression; or
8. For solid organ transplant patients; or
9. For post-haematopoietic stem cell transplant (HSCT) patients; or
10. Following needle stick injury.

\[\text{Inj} 20 \text{ mcg per 1 ml prefilled syringe} \] .................................................................$0.00 1 Engerix-B

\[\text{Initiation:} \text{Restricted (RS1671)}\]

Any of the following:
1. For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
2. For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3. For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination or require a primary course of vaccination; or
4. For HIV positive patients; or
5. For hepatitis C positive patients; or
6. for patients following non-consensual sexual intercourse; or
7. For patients following immunosuppression; or
8. For solid organ transplant patients; or
9. For post-haematopoietic stem cell transplant (HSCT) patients; or
10. Following needle stick injury; or
11. For dialysis patients; or
12. For liver or kidney transplant patients.

\[\text{Inj} 40 \text{ mcg per 1 ml vial} \] – 0% DV Jul-17 to 2020 .................................................................$0.00 1 HBvaxPRO

\[\text{Initiation:} \text{Restricted (RS1413)}\]

Both:
1. For dialysis patients; and
2. For liver or kidney transplant patient.
<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV]** – **Restricted** see terms below

- **Gardasil 9**
  - **Inj 270 mcg in 0.5 ml syringe** – **0% DV Jun-17 to 2020**
  - **Price**: $0.00
  - **Quantity**: 10

**Influenza Vaccine**

- **Fluarix Tetra**
  - **Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine)**
  - **Price**: $9.00
  - **Quantity**: 1

**Initiation – Children aged 14 years and under**

*Therapy limited to 2 doses*

Children aged 14 years and under.

**Initiation – Other conditions**

Either:

1. Up to 3 doses for people aged 15 to 26 years inclusive; or
2. Both:
   - 2.1 People aged 9 to 26 years inclusive; and
   - 2.2 Any of the following:
     - 2.2.1 Up to 3 doses for confirmed HIV infection; or
     - 2.2.2 Up to 3 doses for transplant (including stem cell) patients; or
     - 2.2.3 Up to 4 doses for Post chemotherapy.

**Initiation – Recurrent Respiratory Papillomatosis**

All of the following:

- Either:
  - 1.1 Maximum of two doses for children aged 14 years and under; or
  - 1.2 Maximum of three doses for people aged 15 years and over; and
- 2. The patient has recurrent respiratory papillomatosis; and
- 3. The patient has not previously had an HPV vaccine.

**Influenza Vaccine**

- **Fluarix Tetra**
  - **Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine)**
  - **Price**: $9.00
  - **Quantity**: 1

**Initiation – Cardiovascular disease for patients aged 6 months to 35 months**

Any of the following:

- 1. Ischaemic heart disease; or
- 2. Congestive heart failure; or
- 3. Rheumatic heart disease; or
- 4. Congenital heart disease; or
- 5. Cerebro-vascular disease.

Note: Hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.

**Initiation – Chronic respiratory disease for patients aged 6 months to 35 months**

Either:

- 1. Asthma, if on a regular preventative therapy; or
- 2. Other chronic respiratory disease with impaired lung function.

Note: Asthma not requiring regular preventative therapy is excluded from funding.

**Initiation – Other conditions for patients aged 6 months to 35 months**

Any of the following:

- 1. Diabetes; or
- 2. Chronic renal disease; or
- 3. Any cancer, excluding basal and squamous skin cancers if not invasive; or
- 4. Autoimmune disease; or
- 5. Immune suppression or immune deficiency; or
- 6. HIV; or

continued…
### Price

<table>
<thead>
<tr>
<th>Price (ex man. excl. GST)</th>
<th>Brand or Generic Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>$ Per</td>
<td></td>
</tr>
</tbody>
</table>

**VACCINES**

continued...

7 Transplant recipient; or
8 Neuromuscular and CNS diseases/ disorders; or
9 Haemoglobinopathies; or
10 Is a child on long term aspirin; or
11 Has a cochlear implant; or
12 Errors of metabolism at risk of major metabolic decompensation; or
13 Pre and post splenectomy; or
14 Down syndrome; or
15 Child who has been hospitalised for respiratory illness or has a history of significant respiratory illness.

<table>
<thead>
<tr>
<th>Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)</th>
<th>$90.00</th>
</tr>
</thead>
</table>

**Initiation – People over 65**
The patient is 65 years of age or over.

**Initiation – cardiovascular disease for patients 3 years and over**

Any of the following:

1. Ischaemic heart disease; or
2. Congestive heart failure; or
3. Rheumatic heart disease; or
4. Congenital heart disease; or
5. Cerebro-vascular disease.

Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.

**Initiation – chronic respiratory disease for patients 3 years and over**

Either:

1. Asthma, if on a regular preventative therapy; or
2. Other chronic respiratory disease with impaired lung function.

Note: asthma not requiring regular preventative therapy is excluded from funding.

**Initiation – Other conditions for patients 3 years and over**

Either:

1. Any of the following:
   1.1 Diabetes; or
   1.2 chronic renal disease; or
   1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
   1.4 Autoimmune disease; or
   1.5 Immune suppression or immune deficiency; or
   1.6 HIV; or
   1.7 Transplant recipient; or
   1.8 Neuromuscular and CNS diseases/ disorders; or
   1.9 Haemoglobinopathies; or
   1.10 Is a child on long term aspirin; or
   1.11 Has a cochlear implant; or
   1.12 Errors of metabolism at risk of major metabolic decompensation; or
   1.13 Pre and post splenectomy; or
   1.14 Down syndrome; or
   1.15 Is pregnant; or
   1.16 Is a child aged four and under who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or

2. Patients in a long-stay inpatient mental health care unit or who are compulsorily detained long-term in a forensic unit within a DHB hospital.
<table>
<thead>
<tr>
<th>VACCINES</th>
<th>Price (ex man. excl. GST) $</th>
<th>Per Brand or Generic Manufacturer</th>
</tr>
</thead>
</table>

**MEASLES, MUMPS AND RUBELLA VACCINE** – Restricted see terms below

- Injection, measles virus 1,000 CCID50, mumps virus 5,012 CCID50,
  - Rubella virus 1,000 CCID50; prefilled syringe/ampoule of diluent
  
  0.5 ml – 0% DV Sep-17 to 2020

- **Priorix**

**Initiation** – first dose prior to 12 months

*Therapy limited to 3 doses*

Any of the following:

1. For primary vaccination in children; or
2. For revaccination following immunosuppression; or
3. For any individual susceptible to measles, mumps or rubella.

**Initiation** – first dose after 12 months

*Therapy limited to 2 doses*

Any of the following:

1. For primary vaccination in children; or
2. For revaccination following immunosuppression; or
3. For any individual susceptible to measles, mumps or rubella.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

**POLIOMYELITIS VACCINE** – Restricted see terms below

- Inj 80 D-antigen units in 0.5 ml syringe – 0% DV Jul-17 to 2020

- **IPOL**

**Initiation**

*Therapy limited to 3 doses*

Either:

1. For partially vaccinated or previously unvaccinated individuals; or
2. For revaccination following immunosuppression.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

**RABIES VACCINE**

- Inj 2.5 IU vial with diluent

**ROTAVIRUS ORAL VACCINE** – Restricted see terms below

- Oral susp live attenuated human rotavirus 1,000,000 CCID50 per dose,
  - prefilled oral applicator – 0% DV Sep-17 to 2020

- **Rotarix**

**Initiation**

*Therapy limited to 2 doses*

Both:

1. First dose to be administered in infants aged under 14 weeks of age; and
2. No vaccination being administered to children aged 24 weeks or over.

**VARICELLA VACCINE [CHICKENPOX VACCINE]** – Restricted see terms below

- Inj 2000 PFU prefilled syringe plus vial – 0% DV Sep-17 to 2020

- **Varilrix**

**Initiation** – primary vaccinations

*Therapy limited to 1 dose*

Either:

1. Any infant born on or after 1 April 2016; or
2. For previously unvaccinated children turning 11 years old on or after 1 July 2017, who have not previously had a varicella

... continued
continued…

infection (chickenpox).

Initiation – other conditions

Therapy limited to 2 doses

Any of the following:

1 Any of the following:
    for non-immune patients:
    1.1 With chronic liver disease who may in future be candidates for transplantation; or
    1.2 With deteriorating renal function before transplantation; or
    1.3 Prior to solid organ transplant; or
    1.4 Prior to any elective immunosuppression*; or
    1.5 For post exposure prophylaxis who are immune competent inpatients; or

2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist; or

3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist; or

4 For HIV positive patients non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist; or

5 For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella; or

6 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to
    immune compromise where the household contact has no clinical history of varicella; or

7 For household contacts of adult patients who have no clinical history of varicella and who are severely
    immunocompromised or undergoing a procedure leading to immune compromise where the household contact has no
    clinical history of varicella.

Note: * immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than
28 days

VARICELLA ZOSTER VACCINE [SHINGLES VACCINE] – Restricted see terms below

Varicella zoster virus (Oka strain) live attenuated vaccine [shingles
vaccine] ................................................................. 0.00 1 Zostavax

Reactions

Restricted (RS1619)

Initiation – people aged 65 years

Therapy limited to 1 dose

One dose for all people aged 65 years.

Initiation – people aged between 66 and 80 years

Therapy limited to 1 dose

One dose for all people aged between 66 and 80 years inclusive from 1 April 2018 and 31 March 2020.

Diagnostic Agents

TUBERCULIN PPD [MANTOUX] TEST

Inj 5 TU per 0.1 ml, 1 ml vial – 0% DV Jul-17 to 2020 ..................................................... 0.00 1 Tubersol
## Optional Pharmaceuticals

**NOTE:**
In addition to the products expressly listed here in Part III: Optional Pharmaceuticals, a range of hospital medical devices are listed in an addendum to Part III which is available at www.pharmac.govt.nz. The Optional Pharmaceuticals listed in the addendum are deemed to be listed in Part III, and the Rules of the Pharmaceutical Schedule applying to products listed in Part III apply to them.

### BLOOD GLUCOSE DIAGNOSTIC TEST METER
- 1 meter with 50 lancets, a lancing device, and 10 diagnostic test strips $20.00
  - Brand or Generic Manufacturer
  - CareSens N Premier

### BLOOD GLUCOSE DIAGNOSTIC TEST STRIP
- Blood glucose test strips $10.56
  - 50 test CareSens N
- Test strips $10.56
  - 50 test CareSens PRO

### BLOOD KETONE DIAGNOSTIC TEST STRIP
- Test strips $15.50
  - 10 strip KetoSens

### DUAL BLOOD GLUCOSE AND BLOOD KETONE DIAGNOSTIC TEST METER
- Meter with 50 lancets, a lancing device, and 10 blood glucose diagnostic test strips $20.00
  - 1 CareSens Dual

### MASK FOR SPACER DEVICE
- Small $2.20
  - 1 e-chamber Mask

### PEAK FLOW METER
- Low Range $9.54
  - 1 Mini-Wright AFS Low Range
- Normal Range $9.54
  - 1 Mini-Wright Standard

### PREGNANCY TEST - HCG URINE
- Cassette $12.00
  - 40 test Smith BioMed Rapid Pregnancy Test

### SODIUM NITROPRUSSIDE
- Test strip $22.00
  - 50 strip Ketostix

### SPACER DEVICE
- 220 ml (single patient) $2.95
  - 1 e-chamber Turbo
- 510 ml (single patient) $5.12
  - 1 e-chamber La Grande
- 800 ml $6.50
  - 1 Volumatic
INDEX: Generic Chemicals and Brands

- Symbols -

8-methoxypsoralen .................................. 56

- A -

A-Scabies ............................................53
Abacavir sulphate .................................. 86
Abacavir sulphate with lamivudine ........... 86
Abiciximab ........................................ 151
Abiraterone acetate ................................ 143
Acarbose ........................................... 8
Accretic 10 ........................................ 38
Accretic 20 ......................................... 38
Acetazolamide ..................................... 205
Acetic acid .......................................... 208
Extemporaneously Compounded Preparations 216
Genito-Urinary ........................................ 58
Acetic acid with hydroxyquinoline, glycerol and ricinoleic acid .... 58
Acetic acid with propylene glycol ............... 207
Acetyltocopheryl chloride ......................... 205
Acetylcysteine .................................... 208
Aciclovir
Infections ............................................ 89
Sensory ............................................... 201
Aciclovir-Claris .................................... 89
Acid Citrate Dextrose A ............................. 30
Acidex ............................................... 5
Acipimox ............................................ 46
Acitretin ............................................ 56
Aclasta ................................................ 94
Actemra .............................................. 183
Actinomycin D ....................................... 129
Adalat 10 ............................................ 43
Adalat Oros ......................................... 43
Adalimumab ........................................ 151
Adapalene .......................................... 53
Adefovir dipivoxil ................................ 88
Adenocor ............................................ 40
Adenosine ........................................... 40
Adenuric ............................................ 99
Adrenaline ......................................... 47
ADT Booster ...................................... 234
Adult diphtheria and tetanus vaccine ........... 234
Advantan ............................................ 55
Advate .............................................. 29
Adynovate .......................................... 29
Aerrane ............................................. 104
Afinitor ............................................. 191
Afiblercept ......................................... 161
Agents Affecting the Renin-Angiotensin System ................................ 38
Agents for Parkinsonism and Related Disorders .................................. 103
Agents Used in the Treatment of Poisonings ....................................... 208
Ajmaline ............................................ 40
Amitraz .............................................. 193
Albendazole ........................................ 83
Aldurazyme ......................................... 15
Aldosterone sodium ................................ 94
Alendronate sodium with colecaciferol .......... 94
Alopecia ............................................. 21
Alfamino Junior .................................... 227
Alfentanil ........................................... 108
Aplisol ................................................ 13
Alimastat .......................................... 108
Alimencil ............................................ 22
Allmercap .......................................... 40
Allerpro 1 .......................................... 39
Allerpro 2 .......................................... 228
Allersothe ......................................... 194
Allmercap ......................................... 131
Alloporpinol ........................................ 98
Alpha tocopherol .................................. 22
Alpha tocopherol acetate ......................... 22
Alpha-Adrenoceptor Blockers ..................... 39
Alphamox .......................................... 76
Alphamox 125 ..................................... 76
Alphamox 250 ..................................... 76
Alprolix ............................................. 28
Alprostadil hydrochloride ......................... 48
Alteplase ........................................... 32
Alum .................................................. 216
Aluminium chloride ................................ 26
Aluminium hydroxide .............................. 5
Aluminium hydroxide with magnesium hydroxide and simeticone ...... 5
Amantadine hydrochloride ......................... 103
AmBisome ......................................... 80
Ambrisentan ....................................... 49
Amethocaine
Nervous .............................................. 107
Sensory .............................................. 204
Amikacin ........................................... 72
Amiloride hydrochloride ............................ 45
Amiloride hydrochloride with furosemide ...... 44
Amiloride hydrochloride with hydrochlorothiazide .................. 44
Aminolevulinic acid hydrochloride ............... 145
Aminophylline ..................................... 199
Amiodarone hydrochloride ......................... 40
Amisulpride ........................................ 117
Amorig .............................................. 110
Amodipine ........................................ 43
Amorolfine ......................................... 52
Amoxicillin ........................................ 76
Amoxicillin with clavulanic acid ................. 76
Amphotericin B
Nutritional ........................................... 19
Infections .......................................... 80
Amsacrine ......................................... 132
Ampicillin .......................................... 208
Anabolics .......................................... 62
Anastomosis ........................................ 104
Anagrelide hydrochloride ......................... 132
Analgesics ......................................... 107
Anastrozole ........................................ 145
Andriol Testocaps ................................ 62
Androderm .......................................... 62
Androjen Agonists and Antagonists ............... 62
Anterior Capsular Prosthesis ................. 195
Antabuse ........................................... 126
Antacids and Antiflatulents ....................... 5
Anti-Infective Preparations ......................... 58
Anti-Infective Preparations
Dermatological ................................... 52
Sensory .............................................. 201
Anti-Inflammatory Preparations ................. 202
Antiacne Preparations ............................ 53
Antiallergy Preparations ......................... 193
Antianetamics ..................................... 24
Antiarrhythmics ................................... 40
Antibacterials ..................................... 72
Anticholinergic Agents ............................ 194
Anticholinesterases ............................... 94
Antidepressants ................................... 110
Antidiarrhoeals and Intestinal
Anti-Inflammatory Agents ......................... 5
Antiepilepsy Drugs ............................... 112
Antifibrinolytics, Haemostatics and
Local Sclerosants ................................ 26
Antibiotics .......................................... 195
Antifungals ........................................ 80
Antihypotensives ................................ 41
Antimigraine Preparations ....................... 115
Antimycobacterials ................................. 82
Antinausea and Vertigo Agents ................. 116
Antiparasitics ...................................... 83
Antipruritic Preparations ......................... 53
Antipsychotic Agents ............................. 117
Antiretrovirals .................................... 85
Antirheumatoid Agents ........................... 94
Antiseptics and Disinfectants .................... 210
Antispasmodics and Other Agents
Alterting Gut Motility ............................. 7
Antithrombotics ................................... 29
INDEX: Generic Chemicals and Brands

Antithymocyte globulin (equine) .................. 190
Antithymocyte globulin (rabbit) ................. 191
Antilucreants ......................................... 7
Antivirals .................................................. 88
Anxiolytics ................................................. 120
Apida .......................................................... 10
Apida Solostar ............................................. 10
Apo-Amloidine ........................................... 43
Apo-Amoxi .................................................. 76
Apo-Azithromycin ....................................... 74
Apo-Ciclopirox ........................................... 52
Apo-Cilazapril ............................................ 38
Apo-Cilazapril/Hydrochlorothiazide .............. 38
Apo-Clarithromycin ..................................... 75
Apo-Clomipramine ....................................... 110
Apo-Diclo SR ............................................... 101
Apo-Diltiazem CD ....................................... 43
Apo-Doxazosin .......................................... 39
Apo-Folic Acid ............................................. 25
Apo-Furosemide ......................................... 44
Apo-Gabapentin .......................................... 113
Apo-Leflunomide ......................................... 94
Apo-Megestrol ............................................. 143
Apo-Metoprolol .......................................... 42
Apo-Mirtazapine ......................................... 111
Apo-Montelukast ......................................... 198
Apo-Nadolol ............................................... 42
Apo-Nicotinic Acid ....................................... 46
Apo-Ondansetron ........................................ 117
Apo-Oxybutynin .......................................... 61
Apo-Paroxetine ........................................... 112
Apo-Perindopril ........................................... 38
Apo-Pindolol ............................................... 42
Apo-Pravastatin .......................................... 46
Apo-Prazosin .............................................. 40
Apo-Prednisone ......................................... 64
Apo-Propranolol .......................................... 42
Apo-Pyridoxine .......................................... 21
Apo-Ropinrole ............................................. 104
Apo-Sumatriptan ......................................... 115
Apo-Terazosin ............................................. 40
Apoporphine hydrochloride ......................... 103
Apaclodine .................................................. 206
Aprepitant ................................................. 116
Apresoline .................................................. 48
Aprotin ....................................................... 26
Aqueous cream ........................................... 54
Arachis oil [Peanut oil] ................................. 216
Ararat .......................................................... 40
Arginine ....................................................... 14
Arginine Alimentary .................................... 14
Arginine Various ......................................... 213
Argirepressin [Vasopressin] ......................... 71
Aripiprazole ............................................... 117
Aripiprazole Sandoz .................................... 117
Aristocort ..................................................... 56
Arrow - Clopid ............................................ 31
Arrow - Amitriptyline ................................ 110
Arrow-Bendrofluazide .................................. 45
Arrow-Brimonidine ..................................... 206
Arrow - Calcium .......................................... 17
Arrow-Diazepam ......................................... 120
Arrow-Fluoxetine ........................................ 112
Arrow-Lamotrigin ....................................... 113
Arrow-Losartan & Hydrochlorothiazide .......... 39
Arrow-Morphine LA ..................................... 109
Arrow-Norfloxacin ...................................... 77
Arrow - Ornidazole ...................................... 84
Arrow - Quinapril 10 .................................. 38
Arrow - Quinapril 20 .................................. 38
Arrow - Quinapril 5 .................................... 38
Arrow-Roxithromycin .................................. 75
Arrow-Sertraline ......................................... 112
Arrow-Tolterodine ....................................... 61
Arrow-Topiramate ....................................... 114
Arrow - Tramadol ........................................ 110
Arsenic trioxide .......................................... 132
Asam ......... 6
Asapam ....................................................... 6
Ascorbic acid .............................................. 21
Alimentary .................................................. 21
Extemporaneously Compounded Preparations .... 216
Aspen Adrenaline ......................................... 47
Aspirin ....................................................... 31
Blood .......................................................... 107
Nervous ....................................................... 107
Asthalin ....................................................... 197
Atazanavir sulphate .................................... 87
Ateolol ....................................................... 41
Ateolol-AFT ................................................. 41
ATGAM ....................................................... 190
Ativan .......................................................... 121
Atomoxetine ............................................... 123
Atovastatin ............................................... 45
Atovaquone with proguanil hydrochloride ...... 84
Atracurium besylate ................................... 100
Atropine sulphate .........................................
Cardiovascular ........................................... 40
Sensory ...................................................... 206
Atropine ..................................................... 206
Aubagio ...................................................... 121
Augmentin .................................................... 76
Aurorix ....................................................... 111
Avelox ....................................................... 77
Avelox IV 400 ............................................. 77
Avonex ....................................................... 122
Avonex Pen .................................................. 122
Azaciclidine ............................................... 130
Azaciclidine Dr Reddy's ............................... 130
Azactam ...................................................... 78
Azamun ....................................................... 191
Azathoprine ............................................... 191
Azithromycin .............................................. 74
Azol ............................................................. 65
AZT ............................................................... 86
Aztrenon ...................................................... 78

- B -
Bacillus calmette-guerin (BCG) .................... 191
Bacillus calmette-guerin vaccine .................. 235
Baclofen ...................................................... 100
Bacterial and Viral Vaccines ....................... 234
Bacterial Vaccines ....................................... 234
Balanced Salt Solution ................................ 204
Barium sulphate ......................................... 211
Barium sulphate with sodium bicarbonate ...... 212
Barrier Creams and Emollients ..................... 53
Basiliximab ............................................... 162
BCC Vaccine ............................................... 235
BD PosiFlush .............................................. 36
Beclazone 100 ............................................. 197
Beclazone 250 ............................................. 197
Beclazone 50 ............................................... 197
Beclomethasone dipropionate ....................... 193, 197
Bee venom ................................................... 193
Bendamustine hydrochloride ....................... 128
Bendrofluazide ............................................ 45
Bendroflumethiazide [Bendrofluazide] .......... 45
Benzathine benzypenicillin ......................... 76
Benzatropine mesylate ................................ 103
Benzbromaron AL 100 ................................... 99
Benzbromaron ............................................ 99
Benzoic acid .............................................. 105
Benzocaine ............................................... 105
Benzocaine with tetracaine hydrochloride ...... 105
Benzoin ...................................................... 216
Benzoyl peroxide ......................................... 53
Benztrop .................................................... 103
Benzydamine hydrochloride ................. 19
Benzydamine hydrochloride with cetylpyridinium chloride .......... 19
Benzylenicillin sodium [Penicillin G] ................ 76
Beractant .................................................. 199
INDEX: Generic Chemicals and Brands

Beta Cream ..................................55
Beta Ointment.............................55
Beta Scalp ..................................56
Beta-Adrenoceptor Agonists ...........197
Beta-Adrenoceptor Blockers ...........41
Betadine ....................................210
Betadine Skin Prep.......................211
Betahistine dihydrochloride ..........116
Betaine ......................................14
Betaloc CR ..................................42
Betamethasone ............................63
Betamethasone dipropionate ..........55
Betamethasone dipropionate with calcioprotili.................56
Betamethasone sodium phosphate with betamethasone acetate ....63
Betamethasone valerate .................55-56
Betamethasone valerate with clioquinol .........................56
Betamethasone valerate with sodium fusidate [Fusidic acid] ...56
Betaxolol ....................................205
Betnovate ....................................55
Betoptic ......................................205
Betoptic S ....................................205
Bevacizumab ...............................162
Bezafibrate .................................45
Bezalip .......................................45
Bezalip Retard ..............................45
Bicalutamide ...............................143
Bicillin LA ..................................76
BICNU .......................................129
Bicnu Heritage ............................129
Bile and Liver Therapy .................8
Biliscopin ...................................212
Bimatoprost ................................205
Bimatoprost Multichem .................205
Binarex ......................................143
Binocrit ......................................24
Biodone .....................................109
Biodone Extra Forte .......................109
Biodone Forte .............................109
Biin ...........................................14
Bisacodyl ...................................13
Bismuth subgallate .......................216
Bismuth subnitrate and iodoform paraffin .................214
Bisoprolol fumarate .......................41
Bivalirudin ...................................29
Bleomycin sulphate .......................129
Blood glucose diagnostic test meter ..........244
Blood glucose diagnostic test strip .......244
Blood ketone diagnostic test strip ........244
Bonney's blue dye .........................213
Boostrix .....................................235
Boric acid ...................................216
Bortezomib .................................132
Bosantan ....................................49
Bosantan Dr Reddy's .................49
Bosvate .....................................41
Botulism antitoxin .........................208
Bplox ..........................................21
Breo Ellipta ..................................198
Brevinor 1/28 ...............................58
Bridion .......................................101
Brilinta .......................................32
Brimonidine tartrate ......................206
Brimonidine tartrate with timolol ..........206
Bristov .......................................130
Bromizolamide .............................205
Bromocriptine .............................103
Brufen SR .....................................101
Budesonide ................................ 5
Budesonide with eftomerol ..........198
Bumetanide ..................................44
Bupafen ......................................106
Bupivacaine hydrochloride ........105
Bupivacaine hydrochloride adrenalina ..........105
Bupivacaine hydrochloride with fentanyl ..........106
Bupivacaine hydrochloride with glucose ..........106
Buprenorphine Naloxone BN ........126
Buprenorphine with naloxone ....126
Bupropion hydrochloride ............126
Burinex ......................................44
Buscopan .................................... 7
Buserelin ....................................66
Buspinone hydrochloride ..........120
Busulfan ....................................129
Cabergoline ...................................65
Caffeine .....................................123
Caffeine citrate ............................199
Calamine .....................................53
Calcipotriol .................................56
Calcitonin ...................................62
Calcirol .......................................22
Calcirol-AFT ...............................22
Calcium carbonate .......................5, 17
Calcium Channel Blockers ..........43
Calcium chloride ..........................34
Calcium folinate ...........................142
Calcium Folinate Ebewe .............142
Calcium Gluconate ........................43
Calcium gluconate .......................43
Calcium Homeostasis ................. 62
Calcium polystyrene sulphonate ....36
Calcium Resonium .......................36
Cancidas .....................................82
Candesartan cilexetil ...............39
Candesartan ................................39
Capecitabine ...............................130
Capoten ......................................38
Capsaicin ..................................129
Musculoskeletal ..........................102
Nervous .....................................107
Captopril .....................................205
Carbamazepine ............................112
Carbasorb-X ...............................209
Carbimazole ............................... 70
Carboner ....................................206
Carboplatin .................................136
Carboplatin Ebewe .......................136
Carboprost trometamol ...............59
Carboxymethylcellulose ..........19
Alimentary ..................................19
Extemporaneously Compounded Preparations ..............216
Cardinol LA ..................................42
CareSens Dual .............................244
CareSens N .................................244
CareSens N POP .........................244
CareSens N Premier .................244
CareSens PRO .........................244
Carmellose sodium with pectin and gelatine ...........
Alimentary ..................................19
Sensory ....................................206
Carmustine .................................129
Carvedilol ...................................42
Carvedilol Sandoz .......................42
Caspofungin ....................82
Catapres .....................................44
Cathejell .................................106
Ceenu .........................................129
Cefaclor .................................... 73
Cefalexin ....................................73
Cefalexin Sandoz ..........................73
Cefazolin ....................................73
Cefepime .................................73
Cefepime-AFT .............................73
Cefotaxime .................................73
Cefotaxime Sandoz ....................73
Cefoxitin .....................................73
Cefoxitin Actavis .........................73
Ceftarolone fosamil ....................74
INDEX: Generic Chemicals and Brands

<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefazidime</td>
<td>73</td>
</tr>
<tr>
<td>Cefazidime Mylan</td>
<td>73</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>73</td>
</tr>
<tr>
<td>Ceftriaxone-AFT</td>
<td>73</td>
</tr>
<tr>
<td>Cefuroxime</td>
<td>73</td>
</tr>
<tr>
<td>Cefuroxime Actavis</td>
<td>73</td>
</tr>
<tr>
<td>Celecoxib</td>
<td>101</td>
</tr>
<tr>
<td>Celecoxib Pfizer</td>
<td>101</td>
</tr>
<tr>
<td>Cephalixin ABM</td>
<td>73</td>
</tr>
<tr>
<td>Cetirizine hydrochloride</td>
<td>194</td>
</tr>
<tr>
<td>Cetomacrogol</td>
<td>54</td>
</tr>
<tr>
<td>Cetomacrogol with glycerol</td>
<td>54</td>
</tr>
<tr>
<td>Cetriamide</td>
<td>216</td>
</tr>
<tr>
<td>Cetuximab</td>
<td>163</td>
</tr>
<tr>
<td>Charcoal</td>
<td>209</td>
</tr>
<tr>
<td>Chemotherapeutic Agents</td>
<td>128</td>
</tr>
<tr>
<td>Chickenpox vaccine</td>
<td>242</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>129</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>129</td>
</tr>
<tr>
<td>Chlorphenacel</td>
<td>194</td>
</tr>
<tr>
<td>Chlorhexitide</td>
<td>210</td>
</tr>
<tr>
<td>Chlorhexidine gluconate</td>
<td>19</td>
</tr>
<tr>
<td>Chlorhexidine with cetrimide</td>
<td>210, 213</td>
</tr>
<tr>
<td>Chlorhexidine with ethanol</td>
<td>210</td>
</tr>
<tr>
<td>Chlorhormone</td>
<td>216</td>
</tr>
<tr>
<td>Chloroquine phosphate</td>
<td>84</td>
</tr>
<tr>
<td>Chlorothiazide</td>
<td>45</td>
</tr>
<tr>
<td>Chlorophrinamaleate</td>
<td>194</td>
</tr>
<tr>
<td>Chlorpromazine hydrochloride</td>
<td>117</td>
</tr>
<tr>
<td>Chlorsig</td>
<td>201</td>
</tr>
<tr>
<td>Chloraldehyde [Chlortalidone]</td>
<td>45</td>
</tr>
<tr>
<td>Chlorothalidone</td>
<td>45</td>
</tr>
<tr>
<td>Choice Load 375</td>
<td>59</td>
</tr>
<tr>
<td>Choice TT380 Short</td>
<td>59</td>
</tr>
<tr>
<td>Choice TT380 Standard</td>
<td>59</td>
</tr>
<tr>
<td>Cholestyramine</td>
<td>46</td>
</tr>
<tr>
<td>Choline salicylate with cetalkonium chloride</td>
<td>19</td>
</tr>
<tr>
<td>Choriogonadotropin alfa</td>
<td>66</td>
</tr>
<tr>
<td>Ciclopirox olamine</td>
<td>52</td>
</tr>
<tr>
<td>Ciclosporin</td>
<td>145</td>
</tr>
<tr>
<td>Cidofovir</td>
<td>89</td>
</tr>
<tr>
<td>Cilazapril</td>
<td>38</td>
</tr>
<tr>
<td>Cilazapril with hydrochlorothiazide</td>
<td>38</td>
</tr>
<tr>
<td>Cilicaine</td>
<td>76</td>
</tr>
<tr>
<td>Cilicaine VK</td>
<td>76</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>7</td>
</tr>
<tr>
<td>Cinacalcet</td>
<td>62</td>
</tr>
<tr>
<td>Cinchocaine hydrochloride with hydrocortisone</td>
<td>6</td>
</tr>
<tr>
<td>Ciplox</td>
<td>77</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>77</td>
</tr>
<tr>
<td>Ciprofloxacin Teva</td>
<td>201</td>
</tr>
<tr>
<td>Ciprofloxacin with hydrocortisone</td>
<td>201</td>
</tr>
<tr>
<td>Ciprox HC Otic</td>
<td>201</td>
</tr>
<tr>
<td>Circadin</td>
<td>122</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>136</td>
</tr>
<tr>
<td>Citalopram hydrobromide</td>
<td>111</td>
</tr>
<tr>
<td>Citranest</td>
<td>107</td>
</tr>
<tr>
<td>Citrate sodium</td>
<td>30</td>
</tr>
<tr>
<td>Citric acid</td>
<td>216</td>
</tr>
<tr>
<td>Citric acid with magnesium oxide and sodium picosulphate</td>
<td>11</td>
</tr>
<tr>
<td>Citric acid with sodium bicarbonate</td>
<td>212</td>
</tr>
<tr>
<td>Cladribine</td>
<td>130</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>75</td>
</tr>
<tr>
<td>Clexane</td>
<td>30</td>
</tr>
<tr>
<td>Cincinnati</td>
<td>78</td>
</tr>
<tr>
<td>Ciandamycin</td>
<td>78</td>
</tr>
<tr>
<td>Ciandamycin ABM</td>
<td>78</td>
</tr>
<tr>
<td>Clinitect</td>
<td>51</td>
</tr>
<tr>
<td>Clinicians Multivit &amp; Mineral Boost</td>
<td>20</td>
</tr>
<tr>
<td>Clinicians Renal Vit</td>
<td>20</td>
</tr>
<tr>
<td>Clobazam</td>
<td>112</td>
</tr>
<tr>
<td>Clobetasol propionate</td>
<td>55, 57</td>
</tr>
<tr>
<td>Clobetasone butyrate</td>
<td>55</td>
</tr>
<tr>
<td>Clofazimine</td>
<td>82</td>
</tr>
<tr>
<td>Clomazol</td>
<td>52</td>
</tr>
<tr>
<td>Dermatological</td>
<td>52</td>
</tr>
<tr>
<td>Genito-Urinary</td>
<td>58</td>
</tr>
<tr>
<td>Clomifene citrate</td>
<td>65</td>
</tr>
<tr>
<td>Clomipramine hydrochloride</td>
<td>110</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>112–113, 120</td>
</tr>
<tr>
<td>Clonidine</td>
<td>44</td>
</tr>
<tr>
<td>Clonidine BNM</td>
<td>44</td>
</tr>
<tr>
<td>Clonidine hydrochloride</td>
<td>44</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>31</td>
</tr>
<tr>
<td>Clopene</td>
<td>118</td>
</tr>
<tr>
<td>Clopixol</td>
<td>119–120</td>
</tr>
<tr>
<td>Clostridium botulinum type A toxin</td>
<td>100</td>
</tr>
<tr>
<td>Cotrimazole</td>
<td>52</td>
</tr>
<tr>
<td>Dermatological</td>
<td>52</td>
</tr>
<tr>
<td>Genito-Urinary</td>
<td>58</td>
</tr>
<tr>
<td>Clove oil</td>
<td>216</td>
</tr>
<tr>
<td>Clozapine</td>
<td>118</td>
</tr>
<tr>
<td>Clozaril</td>
<td>118</td>
</tr>
<tr>
<td>Clustran</td>
<td>115</td>
</tr>
<tr>
<td>Co-trimoxazole</td>
<td>79</td>
</tr>
<tr>
<td>Coal tar</td>
<td>216</td>
</tr>
<tr>
<td>Coal tar with salicylic acid and sulphur</td>
<td>56</td>
</tr>
<tr>
<td>Cocaine hydrochloride</td>
<td>106</td>
</tr>
<tr>
<td>Cocaine hydrochloride with adrenaline</td>
<td>106</td>
</tr>
<tr>
<td>Codeine phosphate</td>
<td>120</td>
</tr>
<tr>
<td>Extemporaneously Compounded Preparations</td>
<td>216</td>
</tr>
<tr>
<td>Nervous</td>
<td>108</td>
</tr>
<tr>
<td>Cogentin</td>
<td>103</td>
</tr>
<tr>
<td>Colaspase [L-asparaginase]</td>
<td>133</td>
</tr>
<tr>
<td>Colchicine</td>
<td>99</td>
</tr>
<tr>
<td>Colecalciferol</td>
<td>22</td>
</tr>
<tr>
<td>Colestimethate</td>
<td>78</td>
</tr>
<tr>
<td>Colestipol hydrochloride</td>
<td>46</td>
</tr>
<tr>
<td>Colgout</td>
<td>99</td>
</tr>
<tr>
<td>Colifoam</td>
<td>6</td>
</tr>
<tr>
<td>Colistin sulphomethate</td>
<td>[Colestimethate]</td>
</tr>
<tr>
<td>Colistin-Link</td>
<td>78</td>
</tr>
<tr>
<td>Collodion flexible</td>
<td>216</td>
</tr>
<tr>
<td>Colloidal bismuth subcitrate</td>
<td>8</td>
</tr>
<tr>
<td>Colofac</td>
<td>7</td>
</tr>
<tr>
<td>Colony-Stimulating Factors</td>
<td>33</td>
</tr>
<tr>
<td>Coloxyl</td>
<td>12</td>
</tr>
<tr>
<td>Compound electrolytes with glucose [Dextrose]</td>
<td>34, 37</td>
</tr>
<tr>
<td>Compound electrolytes</td>
<td>34, 37</td>
</tr>
<tr>
<td>Compound hydroxybenzoate</td>
<td>216</td>
</tr>
<tr>
<td>Compound sodium lactate [Hartmann's solution]</td>
<td>34</td>
</tr>
<tr>
<td>Concerta</td>
<td>124</td>
</tr>
<tr>
<td>Condylene</td>
<td>57</td>
</tr>
<tr>
<td>Contraceptives</td>
<td>58</td>
</tr>
<tr>
<td>Contrast Media</td>
<td>211</td>
</tr>
<tr>
<td>Copaxone</td>
<td>121</td>
</tr>
<tr>
<td>Cordarone-X</td>
<td>40</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>55</td>
</tr>
<tr>
<td>Dermatological</td>
<td>55</td>
</tr>
<tr>
<td>Hormone Preparations</td>
<td>63</td>
</tr>
<tr>
<td>Corticosterone (ovine)</td>
<td>66</td>
</tr>
<tr>
<td>Cosentixy</td>
<td>182</td>
</tr>
<tr>
<td>Cosmegen</td>
<td>129</td>
</tr>
<tr>
<td>Cough Suppressants</td>
<td>197</td>
</tr>
<tr>
<td>Creon 10000</td>
<td>11</td>
</tr>
<tr>
<td>Creon 25000</td>
<td>11</td>
</tr>
<tr>
<td>Crotamiton</td>
<td>53</td>
</tr>
<tr>
<td>Crystaderm</td>
<td>52</td>
</tr>
<tr>
<td>CT Plus+</td>
<td>211</td>
</tr>
<tr>
<td>Cubicin</td>
<td>78</td>
</tr>
<tr>
<td>Curam</td>
<td>76</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Index Number</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------</td>
</tr>
<tr>
<td>Curosurf</td>
<td>200</td>
</tr>
<tr>
<td>Cvite</td>
<td>21</td>
</tr>
<tr>
<td>Cyclazine hydrochloride</td>
<td>116</td>
</tr>
<tr>
<td>Cyclazine lactate</td>
<td>116</td>
</tr>
<tr>
<td>Cyclogyl</td>
<td>206</td>
</tr>
<tr>
<td>Cyclopenotolacte hydrochloride</td>
<td>206</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>129</td>
</tr>
<tr>
<td>Cycloserine</td>
<td>82</td>
</tr>
<tr>
<td>Cyklokapron</td>
<td>27</td>
</tr>
<tr>
<td>Cymeve</td>
<td>89</td>
</tr>
<tr>
<td>Cyproheptadine hydrochloride</td>
<td>194</td>
</tr>
<tr>
<td>Cyproterone acetate</td>
<td>62</td>
</tr>
<tr>
<td>Cyproterone acetate with ethinylstradiol</td>
<td>58</td>
</tr>
<tr>
<td>Cystadane</td>
<td>14</td>
</tr>
<tr>
<td>Cysteamine hydrochloride</td>
<td>216</td>
</tr>
<tr>
<td>Cytarabine</td>
<td>130</td>
</tr>
<tr>
<td>Cytotec</td>
<td>7</td>
</tr>
<tr>
<td>D-Penamine</td>
<td>94</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>30</td>
</tr>
<tr>
<td>Dacarbazine</td>
<td>133</td>
</tr>
<tr>
<td>Daclinafine [Actinomycin D]</td>
<td>129</td>
</tr>
<tr>
<td>Daivobet</td>
<td>56</td>
</tr>
<tr>
<td>Daivonex</td>
<td>56</td>
</tr>
<tr>
<td>Dalacin C</td>
<td>78</td>
</tr>
<tr>
<td>Dalteparin</td>
<td>30</td>
</tr>
<tr>
<td>Danaparoid</td>
<td>30</td>
</tr>
<tr>
<td>Danazol</td>
<td>65</td>
</tr>
<tr>
<td>Dantum</td>
<td>100</td>
</tr>
<tr>
<td>Danterium</td>
<td>100</td>
</tr>
<tr>
<td>Dantrolene</td>
<td>100</td>
</tr>
<tr>
<td>Daonil</td>
<td>10</td>
</tr>
<tr>
<td>Dapa-Tab</td>
<td>45</td>
</tr>
<tr>
<td>Dapson</td>
<td>82</td>
</tr>
<tr>
<td>Daptomycin</td>
<td>78</td>
</tr>
<tr>
<td>Darunavir</td>
<td>87</td>
</tr>
<tr>
<td>Dasatinib</td>
<td>136</td>
</tr>
<tr>
<td>Daunorubicin</td>
<td>129</td>
</tr>
<tr>
<td>DBL Acetycline</td>
<td>208</td>
</tr>
<tr>
<td>DBL Adrenaline</td>
<td>47</td>
</tr>
<tr>
<td>DBL Amikacin</td>
<td>72</td>
</tr>
<tr>
<td>DBL Aminophylline</td>
<td>199</td>
</tr>
<tr>
<td>DBL Bleomycin Sulfate</td>
<td>129</td>
</tr>
<tr>
<td>DBL Cefotaxime</td>
<td>73</td>
</tr>
<tr>
<td>DBL Cisplatin</td>
<td>136</td>
</tr>
<tr>
<td>DBL Dacarbazine</td>
<td>133</td>
</tr>
<tr>
<td>DBL Desferrioxamine Mesylate for Inf</td>
<td>100</td>
</tr>
<tr>
<td>DBL Diurin 40</td>
<td>65</td>
</tr>
<tr>
<td>DBL Diclofenac</td>
<td>37</td>
</tr>
<tr>
<td>DBL Diamox</td>
<td>110</td>
</tr>
<tr>
<td>DBL Diclofenac sodium</td>
<td>115</td>
</tr>
<tr>
<td>DBL Dicypramine</td>
<td>71</td>
</tr>
<tr>
<td>DBL Diclofenac sodium</td>
<td>108</td>
</tr>
<tr>
<td>DBL Diclofenac sodium</td>
<td>43</td>
</tr>
<tr>
<td>DBL Diclofenac sodium</td>
<td>59</td>
</tr>
<tr>
<td>DBL Diclofenac sodium</td>
<td>210</td>
</tr>
<tr>
<td>DBL Diclofenac sodium</td>
<td>200</td>
</tr>
<tr>
<td>DBL Diclofenac sodium</td>
<td>57</td>
</tr>
<tr>
<td>DBL Diclofenac sodium</td>
<td>235</td>
</tr>
<tr>
<td>DBL Diclofenac sodium</td>
<td>234</td>
</tr>
<tr>
<td>DBL Diclofenac sodium</td>
<td>31</td>
</tr>
<tr>
<td>DBL Diclofenac sodium</td>
<td>204</td>
</tr>
<tr>
<td>DBL Diclofenac sodium</td>
<td>216</td>
</tr>
<tr>
<td>DBL Diclofenac sodium</td>
<td>216</td>
</tr>
<tr>
<td>DBL Diclofenac sodium</td>
<td>216</td>
</tr>
<tr>
<td>DBL Diclofenac sodium</td>
<td>216</td>
</tr>
<tr>
<td>INDEX: Generic Chemicals and Brands</td>
<td></td>
</tr>
<tr>
<td>-------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Dobutamine ..................................</td>
<td>47</td>
</tr>
<tr>
<td>Dobutamine-hemeln ........................</td>
<td>47</td>
</tr>
<tr>
<td>Docetaxel ....................................</td>
<td>142</td>
</tr>
<tr>
<td>Docusate sodium ................................</td>
<td>12</td>
</tr>
<tr>
<td>Docusate sodium with sennosides ..........</td>
<td>12</td>
</tr>
<tr>
<td>Dolutegravir ..................................</td>
<td>88</td>
</tr>
<tr>
<td>Domperidone ..................................</td>
<td>116</td>
</tr>
<tr>
<td>Donepezil hydrochloride ....................</td>
<td>125</td>
</tr>
<tr>
<td>Donepezil-Rex ................................</td>
<td>125</td>
</tr>
<tr>
<td>Dopamine hydrochloride .....................</td>
<td>47</td>
</tr>
<tr>
<td>Dopress .........................................</td>
<td>111</td>
</tr>
<tr>
<td>Dornase alfa ..................................</td>
<td>199</td>
</tr>
<tr>
<td>Dortimopl ........................................</td>
<td>205</td>
</tr>
<tr>
<td>Dorzolamide ....................................</td>
<td>205</td>
</tr>
<tr>
<td>Dorzolamide with timolol ....................</td>
<td>205</td>
</tr>
<tr>
<td>Dostinex .........................................</td>
<td>65</td>
</tr>
<tr>
<td>Dosulepin [Dothiepin] hydrochloride ........</td>
<td>111</td>
</tr>
<tr>
<td>Dotarem ..........................................</td>
<td>212</td>
</tr>
<tr>
<td>Dothiepin .......................................</td>
<td>111</td>
</tr>
<tr>
<td>Doxapram ........................................</td>
<td>200</td>
</tr>
<tr>
<td>Doxazosin .......................................</td>
<td>39</td>
</tr>
<tr>
<td>Doxepin hydrochloride ......................</td>
<td>111</td>
</tr>
<tr>
<td>Doxine ...........................................</td>
<td>78</td>
</tr>
<tr>
<td>Doxorubicin Ebewe ............................</td>
<td>129</td>
</tr>
<tr>
<td>Doxorubicin hydrochloride .................</td>
<td>129</td>
</tr>
<tr>
<td>Doxycycline .....................................</td>
<td>78</td>
</tr>
<tr>
<td>DP Lotn HC .......................................</td>
<td>55</td>
</tr>
<tr>
<td>DP-Allopurinol ..................................</td>
<td>98</td>
</tr>
<tr>
<td>Dr Reddy’s Omeprazole ......................</td>
<td>8</td>
</tr>
<tr>
<td>Droperidol .......................................</td>
<td>116</td>
</tr>
<tr>
<td>Droperidol Panpharma .......................</td>
<td>116</td>
</tr>
<tr>
<td>Drugs Affecting Bone Metabolism ..........</td>
<td>94</td>
</tr>
<tr>
<td>Dual blood glucose and blood ketone diagnostic test meter</td>
<td>244</td>
</tr>
<tr>
<td>Duolin ...........................................</td>
<td>194</td>
</tr>
<tr>
<td>Duvoisc ..........................................</td>
<td>204</td>
</tr>
<tr>
<td>Duride ...........................................</td>
<td>47</td>
</tr>
<tr>
<td>Dynastat .........................................</td>
<td>102</td>
</tr>
<tr>
<td>Dysport ..........................................</td>
<td>100</td>
</tr>
<tr>
<td>e-chamber La Grande .........................</td>
<td>244</td>
</tr>
<tr>
<td>e-chamber Mask ..................................</td>
<td>244</td>
</tr>
<tr>
<td>e-chamber Turbo ................................</td>
<td>244</td>
</tr>
<tr>
<td>E-Mycin .........................................</td>
<td>75</td>
</tr>
<tr>
<td>E-Z-Cat Dry .....................................</td>
<td>211</td>
</tr>
<tr>
<td>E-Z-Gas II .....................................</td>
<td>212</td>
</tr>
<tr>
<td>E-Z-Paste ........................................</td>
<td>211</td>
</tr>
<tr>
<td>Econazole nitrate .............................</td>
<td>52</td>
</tr>
<tr>
<td>Edrophonium chloride .......................</td>
<td>94</td>
</tr>
<tr>
<td>Elavirenz ........................................</td>
<td>85</td>
</tr>
<tr>
<td>Elavirenz with emtricitabine and tenofovir disoproxil</td>
<td>86</td>
</tr>
<tr>
<td>Effient .........................................</td>
<td>32</td>
</tr>
<tr>
<td>Efomoterol fumarate .........................</td>
<td>198</td>
</tr>
<tr>
<td>Efomoterol fumarate dihydrate ..........</td>
<td>198</td>
</tr>
<tr>
<td>Eftrenonacog alfa [Recombinant factor IX]</td>
<td>28</td>
</tr>
<tr>
<td>Efudix ...........................................</td>
<td>57</td>
</tr>
<tr>
<td>Elaprase .........................................</td>
<td>15</td>
</tr>
<tr>
<td>Elecare (Unflavoured) .......................</td>
<td>227</td>
</tr>
<tr>
<td>Elecare (Vanilla) ............................</td>
<td>227</td>
</tr>
<tr>
<td>Elecare LCP (Unflavoured) ..................</td>
<td>227</td>
</tr>
<tr>
<td>Electral .........................................</td>
<td>37</td>
</tr>
<tr>
<td>Electrolites ....................................</td>
<td>215</td>
</tr>
<tr>
<td>Eleyso ...........................................</td>
<td>17</td>
</tr>
<tr>
<td>Elocon ..........................................</td>
<td>55</td>
</tr>
<tr>
<td>Elocon Alcohol Free ..........................</td>
<td>55</td>
</tr>
<tr>
<td>Ettrombopag ...................................</td>
<td>26</td>
</tr>
<tr>
<td>Emend Tri-Pack ................................</td>
<td>116</td>
</tr>
<tr>
<td>EMLA ..............................................</td>
<td>107</td>
</tr>
<tr>
<td>Emtricitabine ..................................</td>
<td>86</td>
</tr>
<tr>
<td>Emtricitabine with tenofovir disoproxil</td>
<td>90</td>
</tr>
<tr>
<td>Emtriva .........................................</td>
<td>86</td>
</tr>
<tr>
<td>Emulsifying ointment .......................</td>
<td>54</td>
</tr>
<tr>
<td>Enalapril maleate ............................</td>
<td>38</td>
</tr>
<tr>
<td>Enbrel ..........................................</td>
<td>146</td>
</tr>
<tr>
<td>Endocrine Therapy ............................</td>
<td>143</td>
</tr>
<tr>
<td>Endoxan .........................................</td>
<td>129</td>
</tr>
<tr>
<td>Enerlyte .........................................</td>
<td>37</td>
</tr>
<tr>
<td>Engerix-B .......................................</td>
<td>239</td>
</tr>
<tr>
<td>Enfak XR .........................................</td>
<td>111</td>
</tr>
<tr>
<td>Enoxaparin sodium .........................</td>
<td>30</td>
</tr>
<tr>
<td>Ensure (Chocolate) ...........................</td>
<td>233</td>
</tr>
<tr>
<td>Ensure (Vanilla) .............................</td>
<td>233</td>
</tr>
<tr>
<td>Ensure Plus (Banana) .......................</td>
<td>233</td>
</tr>
<tr>
<td>Ensure Plus (Chocolate) ....................</td>
<td>233</td>
</tr>
<tr>
<td>Ethosuximide ...................................</td>
<td>113</td>
</tr>
<tr>
<td>Ethyl chloride ..................................</td>
<td>106</td>
</tr>
<tr>
<td>Etoposide .......................................</td>
<td>104</td>
</tr>
<tr>
<td>Etoposide (as phosphate) ...................</td>
<td>133</td>
</tr>
<tr>
<td>Etoposide (as phosphate) ...................</td>
<td>133</td>
</tr>
<tr>
<td>Etoposide (as phosphate) ...................</td>
<td>133</td>
</tr>
<tr>
<td>Etoposide (as phosphate) ...................</td>
<td>133</td>
</tr>
<tr>
<td>Etoposide (as phosphate) ...................</td>
<td>133</td>
</tr>
<tr>
<td>Etoximet ........................................</td>
<td>85</td>
</tr>
<tr>
<td>Everet ..........................................</td>
<td>113</td>
</tr>
<tr>
<td>Everolimus ......................................</td>
<td>191</td>
</tr>
<tr>
<td>Evoke ............................................</td>
<td>97</td>
</tr>
<tr>
<td>Exelon ..........................................</td>
<td>125</td>
</tr>
<tr>
<td>Exemestane .....................................</td>
<td>145</td>
</tr>
<tr>
<td>Exjade ..........................................</td>
<td>209</td>
</tr>
<tr>
<td>Extemporaneously Compounded Preparations</td>
<td>216</td>
</tr>
<tr>
<td>Eylea ............................................</td>
<td>161</td>
</tr>
<tr>
<td>Ezetimibe .......................................</td>
<td>46</td>
</tr>
<tr>
<td>Ezetimibe Sandoz .............................</td>
<td>46</td>
</tr>
<tr>
<td>Ezetimibe with simvastatin ...............</td>
<td>46</td>
</tr>
<tr>
<td>Epoprostenol ...................................</td>
<td>51</td>
</tr>
<tr>
<td>Eptacog alfa [Recombinant factor VIII] ...</td>
<td>28</td>
</tr>
<tr>
<td>Epifibatide .....................................</td>
<td>32</td>
</tr>
<tr>
<td>Erbitux .........................................</td>
<td>163</td>
</tr>
<tr>
<td>Ergometrine maleate .......................</td>
<td>59</td>
</tr>
<tr>
<td>Ergotamine tartrate with caffeine ........</td>
<td>115</td>
</tr>
<tr>
<td>Ertolinib .......................................</td>
<td>137</td>
</tr>
<tr>
<td>Erthropin .......................................</td>
<td>72</td>
</tr>
<tr>
<td>Erythromycin IV ...............................</td>
<td>75</td>
</tr>
<tr>
<td>Erythromycin (as ethylsuccinate) ..........</td>
<td>75</td>
</tr>
<tr>
<td>Erythromycin (as lactobionate) ...........</td>
<td>75</td>
</tr>
<tr>
<td>Erythromycin (as stearate) ...............</td>
<td>75</td>
</tr>
<tr>
<td>Esbrel ..........................................</td>
<td>196</td>
</tr>
<tr>
<td>Escitalopram ....................................</td>
<td>112</td>
</tr>
<tr>
<td>Escitalopram-Apoxet .......................</td>
<td>112</td>
</tr>
<tr>
<td>Esmolol hydrochloride .......................</td>
<td>42</td>
</tr>
<tr>
<td>Estradot ........................................</td>
<td>64</td>
</tr>
<tr>
<td>Etanercept ......................................</td>
<td>146</td>
</tr>
<tr>
<td>Ethambutol hydrochloride ...................</td>
<td>82</td>
</tr>
<tr>
<td>Ethanol .........................................</td>
<td>208</td>
</tr>
<tr>
<td>Ethanol with glucose .......................</td>
<td>208</td>
</tr>
<tr>
<td>Ethanol, dehydrated .......................</td>
<td>208</td>
</tr>
<tr>
<td>Ethics Aspirin ..................................</td>
<td>107</td>
</tr>
<tr>
<td>Ethics Aspirin EC ............................</td>
<td>31</td>
</tr>
<tr>
<td>Ethics Enalapril ................................</td>
<td>38</td>
</tr>
<tr>
<td>Ethics Lisinopril ................................</td>
<td>38</td>
</tr>
<tr>
<td>Ethinylestradiol ................................</td>
<td>65</td>
</tr>
<tr>
<td>Ethinylestradiol with desogestrel ........</td>
<td>58</td>
</tr>
<tr>
<td>Ethinylestradiol with levonorgestrel .....</td>
<td>58</td>
</tr>
<tr>
<td>Ethinylestradiol with norethisterone ......</td>
<td>58</td>
</tr>
<tr>
<td>ethosuximide ..................................</td>
<td>113</td>
</tr>
<tr>
<td>Etoposide (as phosphate) ...............</td>
<td>133</td>
</tr>
<tr>
<td>Etoposide (as phosphate) ...............</td>
<td>133</td>
</tr>
<tr>
<td>Emerin ..........................................</td>
<td>101</td>
</tr>
<tr>
<td>Etravirine ......................................</td>
<td>85</td>
</tr>
<tr>
<td>EVI .............................................</td>
<td>97</td>
</tr>
<tr>
<td>Exelon ..........................................</td>
<td>125</td>
</tr>
<tr>
<td>Exemestane .....................................</td>
<td>145</td>
</tr>
<tr>
<td>Exjade ..........................................</td>
<td>209</td>
</tr>
<tr>
<td>Extemporaneously Compounded Preparations</td>
<td>216</td>
</tr>
<tr>
<td>Eylea ............................................</td>
<td>161</td>
</tr>
<tr>
<td>Ezetimibe .......................................</td>
<td>46</td>
</tr>
<tr>
<td>Ezetimibe Sandoz .............................</td>
<td>46</td>
</tr>
<tr>
<td>Ezetimibe with simvastatin ...............</td>
<td>46</td>
</tr>
<tr>
<td>generic_name</td>
<td>page_number</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Fludarabine Ebewe</td>
<td>130</td>
</tr>
<tr>
<td>Fludarabine phosphate</td>
<td>130</td>
</tr>
<tr>
<td>Fludrocortisone acetate</td>
<td>63</td>
</tr>
<tr>
<td>Fludroxyprednizone</td>
<td>89</td>
</tr>
<tr>
<td>Flumazenil</td>
<td>208</td>
</tr>
<tr>
<td>Flumetasone pivalate with clobetasol propionate</td>
<td>202</td>
</tr>
<tr>
<td>Fluocortolone caproate with fluocortolone pivalate and dexamethasone</td>
<td>7</td>
</tr>
<tr>
<td>Fluorescein sodium</td>
<td>203</td>
</tr>
<tr>
<td>Fluorescein sodium with lignocaine</td>
<td>203</td>
</tr>
<tr>
<td>Fluoxetine hydrochloride</td>
<td>198</td>
</tr>
<tr>
<td>Fluticasone furoate with vilanterol</td>
<td>198</td>
</tr>
<tr>
<td>Fluticasone propionate</td>
<td>194</td>
</tr>
<tr>
<td>Fluticasone with salmeterol</td>
<td>199</td>
</tr>
<tr>
<td>FML</td>
<td>203</td>
</tr>
<tr>
<td>Fobin</td>
<td>52</td>
</tr>
<tr>
<td>Folic acid</td>
<td>25</td>
</tr>
<tr>
<td>Fondaparinux sodium</td>
<td>31</td>
</tr>
<tr>
<td>Food Modules</td>
<td>219</td>
</tr>
<tr>
<td>Food/Fluid Thickener</td>
<td>221</td>
</tr>
<tr>
<td>Forteo</td>
<td>98</td>
</tr>
<tr>
<td>Fortisip (Vanilla)</td>
<td>233</td>
</tr>
<tr>
<td>Fosamax</td>
<td>94</td>
</tr>
<tr>
<td>Fosamax Plus</td>
<td>94</td>
</tr>
<tr>
<td>Foscarnet sodium</td>
<td>89</td>
</tr>
<tr>
<td>Fosfomycin</td>
<td>78</td>
</tr>
<tr>
<td>Fragnin</td>
<td>30</td>
</tr>
<tr>
<td>Framycetin sulphate</td>
<td>201</td>
</tr>
<tr>
<td>Fresenius Kabi Blood</td>
<td>34, 36</td>
</tr>
<tr>
<td>Fresenius Kabi Various</td>
<td>214</td>
</tr>
<tr>
<td>Fresol 1% MCT/LCT</td>
<td>105</td>
</tr>
<tr>
<td>Frusemide</td>
<td>44</td>
</tr>
<tr>
<td>Frusemide-Claris</td>
<td>44</td>
</tr>
<tr>
<td>Fuadin</td>
<td>79</td>
</tr>
<tr>
<td>Fucithalmic</td>
<td>201</td>
</tr>
<tr>
<td>Fungil</td>
<td>19</td>
</tr>
<tr>
<td>Furosemide [Frusemide]</td>
<td>44</td>
</tr>
<tr>
<td>Fusidic acid</td>
<td>90</td>
</tr>
<tr>
<td>Dermatological</td>
<td>52, 56</td>
</tr>
<tr>
<td>Infections</td>
<td>79</td>
</tr>
<tr>
<td>Sensory</td>
<td>201</td>
</tr>
</tbody>
</table>

**INDEX: Generic Chemicals and Brands**

F - G

Factor eight inhibitor bypassing fraction ........................................ 28
Famotidine ................................................................................. 7
Febuxostat ................................................................................. 99
FEIBA NF .................................................................................. 28
Felo 10 ER ............................................................................... 43
Felo 5 ER .................................................................................. 43
Felodipine .................................................................................. 52
Fentanyl ...................................................................................... 108
Fentanyl Sandoz ......................................................................... 108
Ferinject ...................................................................................... 18
Ferodoran .................................................................................... 18
Fircarboxymaltose ................................................................. 18
Fircresubsaltate ......................................................................... 27
Ferriprox .................................................................................... 209
Ferro-F-Tabs ............................................................................... 18
Ferro-tab ...................................................................................... 18
Ferrograd .................................................................................... 18
Ferrosig ...................................................................................... 18
Ferrous fumarate ........................................................................ 18
Ferrous gluconate with ascorbic acid ........................................ 18
Ferrous sulfate .......................................................................... 18
Ferrous sulphate ........................................................................ 18
Ferrous sulphate with ascorbic acid ......................................... 18
Ferrum H ..................................................................................... 18
Fexofenadine hydrochloride .................................................... 194
Filgrastim .................................................................................. 33
Finasteride .................................................................................. 60
Fingolimod ............................................................................... 121
Firazyr ...................................................................................... 193
Flagyl ......................................................................................... 84
Flagyl-S ...................................................................................... 84
Flamazine .................................................................................. 52
Flecaainide acetate .................................................................... 41
Flecaainide BNM ...................................................................... 41
Flecaainide Controlled Release
  Teva ....................................................................................... 41
Fleet Phosphate Enema ........................................................... 13
Flitsenase Hayfever & Allergy .................................................. 194
Flitoxide ...................................................................................... 198
Flitoxide Accuhaler .................................................................. 198
Floair ......................................................................................... 198
Floirenef ..................................................................................... 63
Fluanxol .................................................................................... 119
Fluara Tetra .............................................................................. 240
Flucil .......................................................................................... 76
Flucloxacillin ............................................................................ 76
Flucloxicin .................................................................................. 76
Fluconazole .............................................................................. 80
Fluconazole-Claris .................................................................... 80
Flucytosine ............................................................................... 82
Fludara Oral .............................................................................. 130

- G -

Gabapentin .................................................................................. 133
Gacet .......................................................................................... 108
Gadobenic acid ......................................................................... 212
Gadobutrol ................................................................................ 212
Gadodiamide ............................................................................. 212
Gadoteric acid ........................................................................... 212
Gadovist 1.0 .............................................................................. 212
Gadoxetate disodium .................................................................. 212
Galsulfase .................................................................................. 14
Galvumet .................................................................................... 10
Galvus ........................................................................................ 10
Ganciclovir ............................................................................... 89
Gardasil 9 .................................................................................. 240
Gastrodenol ................................................................................ 8
Gastrografin ............................................................................... 211
Gazvy ......................................................................................... 170
Gefitinib ..................................................................................... 137
Gelatine, succinylated .............................................................. 37
Gelifusine ................................................................................... 37
Gemcitabine ............................................................................ 131
Gemcitabine Ebewe .................................................................. 131
Gemfibrozil ............................................................................... 45
Genoptic ..................................................................................... 201
Gentamicin sulphate ................................................................. 72
Gastrointestinal ....................................................................... 201
Gestrinone .................................................................................. 65
Gilenya ....................................................................................... 121
Ginest ......................................................................................... 58
Glatiramer acetate ...................................................................... 121
Glaucoma Preparations ............................................................ 205
Glecaprevir with pibrentasvir .................................................... 89
Glibenclamide .......................................................................... 10
Gliclazide ................................................................................... 10
Gliolan ....................................................................................... 145
Glipizide .................................................................................... 10
Glicer ......................................................................................... 138
Glizeid ....................................................................................... 10
Glucagen Hypokit ....................................................................... 9
Glucagon hydrochloride ............................................................ 9
Glucerna Select (Vanilla) .......................................................... 225
Glucerna Select RTH (Vanilla) ................................................... 225
Glucobay ................................................................................... 8
Glucose [Dextrose] ................................................................. 9
Alimentary ................................................................................ 34
Blood ......................................................................................... 34
Extemporaneously Compound Preparations ................................ 216
Glucose with potassium chloride .............................................. 34
Glucose with potassium chloride and sodium chloride ............. 35
Glucose with sodium chloride .................................................. 35
Glucose with sucrose and fructose ............................................ 9
Glycerin with sodium saccharin .............................................. 217
INDEX: Generic Chemicals and Brands

Glycerin with sucrose .......................... 217
Glycerol ............................................ 12
Alimentary ......................................... 12
Extemporaneously Compounded
Preparations ..................................... 217
Glycerol with paraffin ......................... 54
Glycerol trinitrate ............................... 7
Alimentary ......................................... 7
Cardiovascular ................................... 47
Glycine .............................................. 214
Glycopyrronium................................. 195
Glycopyrronium bromide ................. 7
Glycopyrronium with indacaterol ........... 195
Glycpressin .................................... 71
Glytrin ............................................. 47
Gonadorelin ..................................... 66
Goserelin ......................................... 66
Granisetron .................................... 116

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>204</td>
</tr>
<tr>
<td>207</td>
</tr>
<tr>
<td>19</td>
</tr>
<tr>
<td>79</td>
</tr>
<tr>
<td>54</td>
</tr>
<tr>
<td>15</td>
</tr>
<tr>
<td>71</td>
</tr>
<tr>
<td>7</td>
</tr>
<tr>
<td>9</td>
</tr>
<tr>
<td>45</td>
</tr>
<tr>
<td>52</td>
</tr>
<tr>
<td>58</td>
</tr>
<tr>
<td>98</td>
</tr>
<tr>
<td>231</td>
</tr>
<tr>
<td>92</td>
</tr>
<tr>
<td>9</td>
</tr>
<tr>
<td>92</td>
</tr>
<tr>
<td>32</td>
</tr>
<tr>
<td>85</td>
</tr>
<tr>
<td>9</td>
</tr>
<tr>
<td>9</td>
</tr>
<tr>
<td>85</td>
</tr>
<tr>
<td>116</td>
</tr>
<tr>
<td>133</td>
</tr>
<tr>
<td>129</td>
</tr>
<tr>
<td>240</td>
</tr>
<tr>
<td>195</td>
</tr>
<tr>
<td>91</td>
</tr>
<tr>
<td>198</td>
</tr>
<tr>
<td>197</td>
</tr>
<tr>
<td>234</td>
</tr>
<tr>
<td>241</td>
</tr>
<tr>
<td>197</td>
</tr>
<tr>
<td>45</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>10</td>
</tr>
</tbody>
</table>

Hydrocortisone
Dermatological ................................ 55
Extemporaneously Compounded
Preparations .................................. 217
Hormone Preparations ................. 63
Hydrocortisone acetate
Alimentary ..................................... 6
Dermatological ............................... 55
Hydrocortisone acetate with pramoxine hydrochloride 6
Hydrocortisone and paraffin liquid and lanolin 55
Hydrocortisone butyrate ........... 55, 57
Hydrocortisone with miconazole 56
Hydrocortisone with natamycin and neomycin 56
Hydrogen peroxide .................. 52
Hydroxycobalamin
Alimentary ..................................... 21
Various ........................................... 208
Hydroxychloroquine .................... 94
Hydroxyurea ................................ 133
Hygroton ...................................... 45
Hylo-Fresh ................................ 207
Hyoscine butylbromide ............... 7
Hyoscine hydrobromide .............. 116
Hyperuricaemia and Antigout ....... 98
Hypermellose .......................... 204, 206
Hypermellose with dextran ....... 206

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>194</td>
</tr>
<tr>
<td>213</td>
</tr>
<tr>
<td>129</td>
</tr>
<tr>
<td>64</td>
</tr>
<tr>
<td>240</td>
</tr>
<tr>
<td>9</td>
</tr>
<tr>
<td>9</td>
</tr>
<tr>
<td>240</td>
</tr>
<tr>
<td>95</td>
</tr>
<tr>
<td>102</td>
</tr>
<tr>
<td>234</td>
</tr>
<tr>
<td>240</td>
</tr>
<tr>
<td>91</td>
</tr>
<tr>
<td>198</td>
</tr>
<tr>
<td>197</td>
</tr>
<tr>
<td>197</td>
</tr>
<tr>
<td>116</td>
</tr>
<tr>
<td>98</td>
</tr>
<tr>
<td>138</td>
</tr>
<tr>
<td>198</td>
</tr>
<tr>
<td>234</td>
</tr>
<tr>
<td>197</td>
</tr>
<tr>
<td>45</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>10</td>
</tr>
</tbody>
</table>

Ibiamox ....................................... 76
Ibuprofen .................................... 101
Icatibant .................................... 193
Idarubicin hydrochloride ............ 130

Idarubicumab ................................. 27
Idursulfumab ................................. 15
Ifofareotide ................................. 129
Ikorem ........................................ 48
Iomedin ....................................... 51
Iloprost ....................................... 51
Imaging Agents .............................. 145
Imatinib dislolate ......................... 138
Imatinib-AFT ................................. 138
Imipenem with cilastatin ............ 72
Imipenem+Cilastatin RBX .......... 72
Imipramine hydrochloride .......... 111
Imiquimod ................................... 57
Immune Modulators ..................... 92
Immunosuppressants ................. 145
Impact Advanced Recovery ....... 231
Imuran ........................................ 191
Incuress ellipta ........................... 195
Indacaterol .................................. 198
Indapamide ................................... 45
Indigo carmine ............................. 213
Indinavir ..................................... 87
Indocyanine green ..................... 213
Indomethacin ............................... 102
Infanrix IPV ................................ 234
Infanrix-hexa ............................... 234
Influenza vaccine ....................... 240
Influvac Tetra ................................ 241
Inhaled Corticosteroids ............. 197
Inspra ........................................ 45
Insulin aspart .............................. 10
Insulin aspart with insulin aspart
protamine ..................................... 9
Insulin glargine ......................... 9
Insulin glulisine ..................... 10
Insulin isophane ...................... 9
Insulin lispro ............................ 10
Insulin lispro with insulin lispro
protamine ..................................... 9
Insulin neutral ......................... 10
Insulin neutral with insulin
isophane ..................................... 9
Integrelin .................................. 32
Intolerance .................................. 85
Interferon alfa-2a ...................... 92
Interferon alfa-2b ...................... 92
Interferon beta-1-alpha .......... 122
Interferon beta-1-beta .......... 122
Interferon gamma .................... 92
Intra-uterine device .................. 59
Invanz ....................................... 72
Invega Sustenna ....................... 119
Iodine ....................................... 70
Iodine with ethanol .............. 210
<table>
<thead>
<tr>
<th>Chemical/Brand</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iodised oil</td>
<td>211</td>
</tr>
<tr>
<td>Iodixanol</td>
<td>211</td>
</tr>
<tr>
<td>Iohexol</td>
<td>211</td>
</tr>
<tr>
<td>Iopidine</td>
<td>206</td>
</tr>
<tr>
<td>Isocan</td>
<td>211</td>
</tr>
<tr>
<td>IPOL</td>
<td>242</td>
</tr>
<tr>
<td>Ipratropium bromide</td>
<td>194</td>
</tr>
<tr>
<td>Iressa</td>
<td>137</td>
</tr>
<tr>
<td>Irinotecan Actavis 100</td>
<td>133</td>
</tr>
<tr>
<td>Irinotecan hydrochloride</td>
<td>133</td>
</tr>
<tr>
<td>Iron polymaltose</td>
<td>10</td>
</tr>
<tr>
<td>Iron sucrose</td>
<td>18</td>
</tr>
<tr>
<td>Irrigation Solutions</td>
<td>213</td>
</tr>
<tr>
<td>Isentress</td>
<td>88</td>
</tr>
<tr>
<td>Isentress HD</td>
<td>88</td>
</tr>
<tr>
<td>Ismo 40 Retard</td>
<td>47</td>
</tr>
<tr>
<td>Ismo-20</td>
<td>47</td>
</tr>
<tr>
<td>Isoflurane</td>
<td>104</td>
</tr>
<tr>
<td>Isoniazid</td>
<td>83</td>
</tr>
<tr>
<td>Isoniazid with rifampicin</td>
<td>83</td>
</tr>
<tr>
<td>Isoprenaline [Isoproterenol]</td>
<td>47</td>
</tr>
<tr>
<td>Isopropyl alcohol</td>
<td>210</td>
</tr>
<tr>
<td>Isopropenol alcohol</td>
<td>47</td>
</tr>
<tr>
<td>Isoptin</td>
<td>44</td>
</tr>
<tr>
<td>Isopropyl alcohol</td>
<td>44</td>
</tr>
<tr>
<td>Isopto Carpine</td>
<td>205</td>
</tr>
<tr>
<td>Isoisorbide mononitrate</td>
<td>47</td>
</tr>
<tr>
<td>Isotretinoin</td>
<td>53</td>
</tr>
<tr>
<td>Ispaghula (psyllium) husk</td>
<td>12</td>
</tr>
<tr>
<td>Isradipine</td>
<td>43</td>
</tr>
<tr>
<td>Itch-Soothe</td>
<td>53</td>
</tr>
<tr>
<td>Itaconazole</td>
<td>80</td>
</tr>
<tr>
<td>Itrazol</td>
<td>80</td>
</tr>
<tr>
<td>Ivabradine</td>
<td>41</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>83</td>
</tr>
<tr>
<td>Ivermectin SR</td>
<td>44</td>
</tr>
<tr>
<td>J -</td>
<td></td>
</tr>
<tr>
<td>Jadelle</td>
<td>59</td>
</tr>
<tr>
<td>Jakavi</td>
<td>140</td>
</tr>
<tr>
<td>Jaydess</td>
<td>59</td>
</tr>
<tr>
<td>Jevelry HiCal RTH</td>
<td>232</td>
</tr>
<tr>
<td>Jevelry RTH</td>
<td>232</td>
</tr>
<tr>
<td>Juno Pemetrexed</td>
<td>131</td>
</tr>
<tr>
<td>Kaletra</td>
<td>87</td>
</tr>
<tr>
<td>Kenacomb</td>
<td>202</td>
</tr>
<tr>
<td>Kenacort-A 10</td>
<td>64</td>
</tr>
<tr>
<td>Kenacort-A 40</td>
<td>64</td>
</tr>
<tr>
<td>Kenalog in Orabase</td>
<td>19</td>
</tr>
<tr>
<td>Ketalar</td>
<td>104</td>
</tr>
<tr>
<td>Ketamine</td>
<td>104</td>
</tr>
<tr>
<td>Ketamine-Claris</td>
<td>104</td>
</tr>
<tr>
<td>Ketocar 3:1 (Unflavoured)</td>
<td>229</td>
</tr>
<tr>
<td>Ketocar 4:1 (Unflavoured)</td>
<td>229</td>
</tr>
<tr>
<td>Ketocal 4:1 (Vanilla)</td>
<td>229</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>52</td>
</tr>
<tr>
<td>infections</td>
<td>80</td>
</tr>
<tr>
<td>Infusions</td>
<td></td>
</tr>
<tr>
<td>Infections</td>
<td></td>
</tr>
<tr>
<td>Ivermectin</td>
<td>59</td>
</tr>
<tr>
<td>Ivermectin SR</td>
<td>44</td>
</tr>
<tr>
<td>Ivermectin SR</td>
<td>44</td>
</tr>
<tr>
<td>J -</td>
<td></td>
</tr>
<tr>
<td>Jadelle</td>
<td>59</td>
</tr>
<tr>
<td>Jakavi</td>
<td>140</td>
</tr>
<tr>
<td>Jaydess</td>
<td>59</td>
</tr>
<tr>
<td>Jevelry HiCal RTH</td>
<td>232</td>
</tr>
<tr>
<td>Jevelry RTH</td>
<td>232</td>
</tr>
<tr>
<td>Juno Pemetrexed</td>
<td>131</td>
</tr>
<tr>
<td>Kaletra</td>
<td>87</td>
</tr>
<tr>
<td>Kenacomb</td>
<td>202</td>
</tr>
<tr>
<td>Kenacort-A 10</td>
<td>64</td>
</tr>
<tr>
<td>Kenacort-A 40</td>
<td>64</td>
</tr>
<tr>
<td>Kenalog in Orabase</td>
<td>19</td>
</tr>
<tr>
<td>Ketalar</td>
<td>104</td>
</tr>
<tr>
<td>Ketamine</td>
<td>104</td>
</tr>
<tr>
<td>Ketamine-Claris</td>
<td>104</td>
</tr>
<tr>
<td>Ketocar 3:1 (Unflavoured)</td>
<td>229</td>
</tr>
<tr>
<td>Ketocar 4:1 (Unflavoured)</td>
<td>229</td>
</tr>
<tr>
<td>Ketocal 4:1 (Vanilla)</td>
<td>229</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>52</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>59</td>
</tr>
<tr>
<td>Ivermectin SR</td>
<td>44</td>
</tr>
<tr>
<td>Ivermectin SR</td>
<td>44</td>
</tr>
<tr>
<td>J -</td>
<td></td>
</tr>
<tr>
<td>Jadelle</td>
<td>59</td>
</tr>
<tr>
<td>Jakavi</td>
<td>140</td>
</tr>
<tr>
<td>Jaydess</td>
<td>59</td>
</tr>
<tr>
<td>Jevelry HiCal RTH</td>
<td>232</td>
</tr>
<tr>
<td>Jevelry RTH</td>
<td>232</td>
</tr>
<tr>
<td>Juno Pemetrexed</td>
<td>131</td>
</tr>
<tr>
<td>Kaletra</td>
<td>87</td>
</tr>
<tr>
<td>Kenacomb</td>
<td>202</td>
</tr>
<tr>
<td>Kenacort-A 10</td>
<td>64</td>
</tr>
<tr>
<td>Kenacort-A 40</td>
<td>64</td>
</tr>
<tr>
<td>Kenalog in Orabase</td>
<td>19</td>
</tr>
<tr>
<td>Ketalar</td>
<td>104</td>
</tr>
<tr>
<td>Ketamine</td>
<td>104</td>
</tr>
<tr>
<td>Ketamine-Claris</td>
<td>104</td>
</tr>
<tr>
<td>Ketocar 3:1 (Unflavoured)</td>
<td>229</td>
</tr>
<tr>
<td>Ketocar 4:1 (Unflavoured)</td>
<td>229</td>
</tr>
<tr>
<td>Ketocal 4:1 (Vanilla)</td>
<td>229</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>52</td>
</tr>
<tr>
<td>L- asparaginase</td>
<td>133</td>
</tr>
<tr>
<td>L-ornithine L-aspartate</td>
<td>8</td>
</tr>
<tr>
<td>Labetalol</td>
<td>42</td>
</tr>
<tr>
<td>Lacosamide</td>
<td>113</td>
</tr>
<tr>
<td>Lactose</td>
<td>217</td>
</tr>
<tr>
<td>Lactulose</td>
<td>13</td>
</tr>
<tr>
<td>Laevolac</td>
<td>13</td>
</tr>
<tr>
<td>Lamicalt</td>
<td>113</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>86, 88</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>113</td>
</tr>
<tr>
<td>Lanoxin</td>
<td>40</td>
</tr>
<tr>
<td>Lanoxin PG</td>
<td>40</td>
</tr>
<tr>
<td>Lansoprazole</td>
<td>8</td>
</tr>
<tr>
<td>Lantus</td>
<td>9</td>
</tr>
<tr>
<td>Lantus SoloStar</td>
<td>9</td>
</tr>
<tr>
<td>Lanzol Relief</td>
<td>8</td>
</tr>
<tr>
<td>Lapatinib</td>
<td>138</td>
</tr>
<tr>
<td>Largecil</td>
<td>117</td>
</tr>
<tr>
<td>Laronidase</td>
<td>15</td>
</tr>
<tr>
<td>Lasix</td>
<td>44</td>
</tr>
<tr>
<td>Latanoprost</td>
<td>205</td>
</tr>
<tr>
<td>Lax-Suppositories</td>
<td>13</td>
</tr>
<tr>
<td>Lax-Tabs</td>
<td>13</td>
</tr>
<tr>
<td>Laxatives</td>
<td>11</td>
</tr>
<tr>
<td>Laxsol</td>
<td>12</td>
</tr>
<tr>
<td>Ledipasvir with sofosbuvir</td>
<td>89</td>
</tr>
<tr>
<td>Leflunomide</td>
<td>94</td>
</tr>
<tr>
<td>Lenalidomide</td>
<td>133</td>
</tr>
<tr>
<td>Letrolole</td>
<td>145</td>
</tr>
<tr>
<td>Letrozole</td>
<td>145</td>
</tr>
<tr>
<td>Leukotriene Receptor Antagonists</td>
<td>198</td>
</tr>
<tr>
<td>Leunase</td>
<td>133</td>
</tr>
<tr>
<td>Leupreolrin acetate</td>
<td>66</td>
</tr>
<tr>
<td>Leustatin</td>
<td>130</td>
</tr>
<tr>
<td>Levetiracetam</td>
<td>113</td>
</tr>
<tr>
<td>Levetiracetam-AFT</td>
<td>113</td>
</tr>
<tr>
<td>Levrin ED</td>
<td>58</td>
</tr>
<tr>
<td>Levocabastine</td>
<td>203</td>
</tr>
<tr>
<td>Levocarnitine</td>
<td>16</td>
</tr>
<tr>
<td>Levodopa with benserazide</td>
<td>104</td>
</tr>
<tr>
<td>Levodopa with carbidopa</td>
<td>104</td>
</tr>
<tr>
<td>Levomepromazine</td>
<td>118</td>
</tr>
<tr>
<td>Levomepromazine hydrochloride</td>
<td>118</td>
</tr>
<tr>
<td>Levonorgestrel</td>
<td>59</td>
</tr>
<tr>
<td>Levosimendan</td>
<td>47</td>
</tr>
<tr>
<td>Levothyroxine</td>
<td>70</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine]</td>
<td>106</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] with adrenaline</td>
<td>106</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] hydrochloride</td>
<td>106</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] hydrochloride with adrenaline and tetracaine</td>
<td>106</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] hydrochloride with phenylephrine</td>
<td>107</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] hydrochloride with chlorhexidine</td>
<td>107</td>
</tr>
<tr>
<td>Lidocaine [Lignocaine] with prilocaine</td>
<td>107</td>
</tr>
<tr>
<td>Lidocaine-Claris</td>
<td>106</td>
</tr>
<tr>
<td>Lignocaine</td>
<td></td>
</tr>
<tr>
<td>Lignocaine</td>
<td></td>
</tr>
<tr>
<td>Lincomycin</td>
<td>79</td>
</tr>
<tr>
<td>Linezolid</td>
<td>79</td>
</tr>
<tr>
<td>Linezolid Kabi</td>
<td>79</td>
</tr>
<tr>
<td>Lioresal Intrathecal</td>
<td>100</td>
</tr>
<tr>
<td>Lithothryonite sodium</td>
<td>70</td>
</tr>
<tr>
<td>Lipazil</td>
<td>45</td>
</tr>
<tr>
<td>Lipid-Modifying Agents</td>
<td>45</td>
</tr>
<tr>
<td>Lipiodol Ultra Fluid</td>
<td>211</td>
</tr>
<tr>
<td>Liquibar</td>
<td>211</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>38</td>
</tr>
<tr>
<td>Lissamine green</td>
<td>203</td>
</tr>
<tr>
<td>Lithicarb FC</td>
<td>118</td>
</tr>
<tr>
<td>Lithium carbonate</td>
<td>118</td>
</tr>
<tr>
<td>LMX4</td>
<td>106</td>
</tr>
<tr>
<td>Local Preparations for Anal and Rectal Disorders</td>
<td>6</td>
</tr>
<tr>
<td>Locoid</td>
<td>55, 57</td>
</tr>
<tr>
<td>Locoid Crelyo</td>
<td>55</td>
</tr>
<tr>
<td>Locoid Lipocream</td>
<td>55</td>
</tr>
<tr>
<td>Lodi</td>
<td>40</td>
</tr>
<tr>
<td>Lodoxamide</td>
<td>203</td>
</tr>
<tr>
<td>Logem</td>
<td>113</td>
</tr>
<tr>
<td>Lornide</td>
<td>203</td>
</tr>
<tr>
<td>Lornustine</td>
<td>129</td>
</tr>
<tr>
<td>Long-Acting Beta-Ardenoceptor Agonists</td>
<td>198</td>
</tr>
<tr>
<td>Loniten</td>
<td>48</td>
</tr>
<tr>
<td>Loperamide hydrochloride</td>
<td>5</td>
</tr>
<tr>
<td>Lopinavir with ritonavir</td>
<td>87</td>
</tr>
<tr>
<td>Lorainx</td>
<td>194</td>
</tr>
<tr>
<td>Loratadine</td>
<td>194</td>
</tr>
<tr>
<td>Generic Chemicals and Brands</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td></td>
</tr>
<tr>
<td>Lorazepam..........................112, 121</td>
<td></td>
</tr>
<tr>
<td>Lorfast................................194</td>
<td></td>
</tr>
<tr>
<td>Lormetazepam..........................122</td>
<td></td>
</tr>
<tr>
<td>Lorstat..................................45</td>
<td></td>
</tr>
<tr>
<td>Losartan Actavis.........................39</td>
<td></td>
</tr>
<tr>
<td>Losartan potassium.........................39</td>
<td></td>
</tr>
<tr>
<td>Losartan potassium with hydrochlorothiazide.........................39</td>
<td></td>
</tr>
<tr>
<td>Lovir........................................89</td>
<td></td>
</tr>
<tr>
<td>Loxamine..................................112</td>
<td></td>
</tr>
<tr>
<td>Lucrin Depot 1-month......................66</td>
<td></td>
</tr>
<tr>
<td>Lucrin Depot 3-month......................66</td>
<td></td>
</tr>
<tr>
<td>Lyderm..................................53</td>
<td></td>
</tr>
<tr>
<td>Lysine acetylsalicylate ['Lysine asprin']..........................32</td>
<td></td>
</tr>
<tr>
<td>Lysine asprin................................32</td>
<td></td>
</tr>
<tr>
<td>m-Amoxiclav................................76</td>
<td></td>
</tr>
<tr>
<td>m-Esilon................................109</td>
<td></td>
</tr>
<tr>
<td>Matbera..................................173</td>
<td></td>
</tr>
<tr>
<td>Macrogol 3550 with ascorbic acid, potassium chloride and sodium chloride..........................12</td>
<td></td>
</tr>
<tr>
<td>Macrogol 3550 with potassium chloride, sodium bicarbonate and sodium chloride..........................13</td>
<td></td>
</tr>
<tr>
<td>Macrogol 3550 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate..........................12</td>
<td></td>
</tr>
<tr>
<td>Macrogol 400 and propylene glycol..........................206</td>
<td></td>
</tr>
<tr>
<td>Madopar 125..............................104</td>
<td></td>
</tr>
<tr>
<td>Madopar 250..............................104</td>
<td></td>
</tr>
<tr>
<td>Madopar 62.5..............................104</td>
<td></td>
</tr>
<tr>
<td>Madopar HBS..............................104</td>
<td></td>
</tr>
<tr>
<td>Madopar Rapid.............................104</td>
<td></td>
</tr>
<tr>
<td>Mafenide acetate..........................52</td>
<td></td>
</tr>
<tr>
<td>Magnesium amino acid chelate.................18</td>
<td></td>
</tr>
<tr>
<td>Magnesium chloride.........................18</td>
<td></td>
</tr>
<tr>
<td>Magnesium hydroxide.........................18</td>
<td></td>
</tr>
<tr>
<td>Alimentary.................................18</td>
<td></td>
</tr>
<tr>
<td>Extemporaneously Compounded Preparations..........................217</td>
<td></td>
</tr>
<tr>
<td>Magnesium oxide.........................18</td>
<td></td>
</tr>
<tr>
<td>Magnesium oxide with magnesium aspartate, magnesium amino acid chelate and magnesium citrate..........................18</td>
<td></td>
</tr>
<tr>
<td>Magnesium sulphate.........................18</td>
<td></td>
</tr>
<tr>
<td>Magnevist..................................212</td>
<td></td>
</tr>
<tr>
<td>Malarone..................................84</td>
<td></td>
</tr>
<tr>
<td>Malarone Junior............................84</td>
<td></td>
</tr>
<tr>
<td>Malathion [Maldison]..........................53</td>
<td></td>
</tr>
<tr>
<td>Malidson..................................53</td>
<td></td>
</tr>
<tr>
<td>Mannitol.................................Cardiovascular 44</td>
<td></td>
</tr>
<tr>
<td>Various..................................213</td>
<td></td>
</tr>
<tr>
<td>Mantoux..................................243</td>
<td></td>
</tr>
<tr>
<td>Meprobamate...............................111</td>
<td></td>
</tr>
<tr>
<td>Marcain..................................105</td>
<td></td>
</tr>
<tr>
<td>Marcan Heavy.............................106</td>
<td></td>
</tr>
<tr>
<td>Marcin Isobaric............................105</td>
<td></td>
</tr>
<tr>
<td>Marcin with Adrenaline......................105</td>
<td></td>
</tr>
<tr>
<td>Marevan..................................31</td>
<td></td>
</tr>
<tr>
<td>Marine Blue Lotion SPF 50+..................57</td>
<td></td>
</tr>
<tr>
<td>Mask for spacer device........................244</td>
<td></td>
</tr>
<tr>
<td>Mast Cell Stabilisers........................199</td>
<td></td>
</tr>
<tr>
<td>Maviret..................................89</td>
<td></td>
</tr>
<tr>
<td>Maxidex..................................202</td>
<td></td>
</tr>
<tr>
<td>Maxitrol..................................201</td>
<td></td>
</tr>
<tr>
<td>Measles, mumps and rubella vaccine..........................242</td>
<td></td>
</tr>
<tr>
<td>Mebendazole...............................83</td>
<td></td>
</tr>
<tr>
<td>Mebeverine hydrochloride......................7</td>
<td></td>
</tr>
<tr>
<td>Medrol..................................64</td>
<td></td>
</tr>
<tr>
<td>Medroxyprogesterone.........................65</td>
<td></td>
</tr>
<tr>
<td>Medroxyprogesterone acetate Genito-Urinary..........................59</td>
<td></td>
</tr>
<tr>
<td>Hormone Preparations........................65</td>
<td></td>
</tr>
<tr>
<td>Mefenamic acid............................102</td>
<td></td>
</tr>
<tr>
<td>Meloxicam.................................84</td>
<td></td>
</tr>
<tr>
<td>Megestrol acetate..........................143</td>
<td></td>
</tr>
<tr>
<td>Meglumine gadodobenate........................212</td>
<td></td>
</tr>
<tr>
<td>Meglumine ioxoacte..........................212</td>
<td></td>
</tr>
<tr>
<td>Melatonin..................................122</td>
<td></td>
</tr>
<tr>
<td>Melphalan.................................129</td>
<td></td>
</tr>
<tr>
<td>Menactra..................................236</td>
<td></td>
</tr>
<tr>
<td>Meningococal A, C, Y and W-135 conjugate vaccine..........................236</td>
<td></td>
</tr>
<tr>
<td>Meningococal C conjugate vaccine..........................236</td>
<td></td>
</tr>
<tr>
<td>Menthol..................................217</td>
<td></td>
</tr>
<tr>
<td>Mepivacaine hydrochloride...............107</td>
<td></td>
</tr>
<tr>
<td>Mercapturic acid.........................131</td>
<td></td>
</tr>
<tr>
<td>Meropenem.................................73</td>
<td></td>
</tr>
<tr>
<td>Meropenem Ranbaxy.........................73</td>
<td></td>
</tr>
<tr>
<td>Mesalazine.................................6</td>
<td></td>
</tr>
<tr>
<td>Mesna..................................142</td>
<td></td>
</tr>
<tr>
<td>Mestinon.................................94</td>
<td></td>
</tr>
<tr>
<td>Metabolic Disorder Agents...............13</td>
<td></td>
</tr>
<tr>
<td>Metabolic Products..........................221</td>
<td></td>
</tr>
<tr>
<td>Metaraminol...............................48</td>
<td></td>
</tr>
<tr>
<td>Metaxylolate...............................198</td>
<td></td>
</tr>
<tr>
<td>Metformin hydrochloride....................10</td>
<td></td>
</tr>
<tr>
<td>Methacholine chloride......................213</td>
<td></td>
</tr>
<tr>
<td>Methadone hydrochloride Extemporaneously Compounded Preparations..........................217</td>
<td></td>
</tr>
<tr>
<td>Nervous..................................109</td>
<td></td>
</tr>
<tr>
<td>Methotrexate..............................131</td>
<td></td>
</tr>
<tr>
<td>Methotrexate Ebewe.........................131</td>
<td></td>
</tr>
<tr>
<td>Methotrexate Sandoz.........................131</td>
<td></td>
</tr>
<tr>
<td>Methoxalam..................................217</td>
<td></td>
</tr>
<tr>
<td>Methoxymeparal....................[8-methoxypsoralen] 56</td>
<td></td>
</tr>
<tr>
<td>Methoxyflurane.............................107</td>
<td></td>
</tr>
<tr>
<td>Methyl aminovleulinate hydrochloride.....................57</td>
<td></td>
</tr>
<tr>
<td>Methyl hydroxybenzoate......................217</td>
<td></td>
</tr>
<tr>
<td>Methylcellulose............................217</td>
<td></td>
</tr>
<tr>
<td>Methylcellulose with glycerin and sodium saccharin.....................217</td>
<td></td>
</tr>
<tr>
<td>Methylcellulose with glycerin and sucrose..........................217</td>
<td></td>
</tr>
<tr>
<td>Methyldopa................................44</td>
<td></td>
</tr>
<tr>
<td>Methyldopa Mylan..........................44</td>
<td></td>
</tr>
<tr>
<td>Methylene blue.............................213</td>
<td></td>
</tr>
<tr>
<td>Methylnaltrexone bromide.....................12</td>
<td></td>
</tr>
<tr>
<td>Methyphenidate ER - Teva...................124</td>
<td></td>
</tr>
<tr>
<td>Methyphenidate hydrochloride..................124</td>
<td></td>
</tr>
<tr>
<td>Methylnitrosole sulphone........................64</td>
<td></td>
</tr>
<tr>
<td>Metoprolol succinate........................42</td>
<td></td>
</tr>
<tr>
<td>Metoprolol tartrate........................42</td>
<td></td>
</tr>
<tr>
<td>Metronidazol....................................</td>
<td></td>
</tr>
<tr>
<td>Dermatological............................52</td>
<td></td>
</tr>
<tr>
<td>Metoclopramide Actavis....................116</td>
<td></td>
</tr>
<tr>
<td>Metoclopramide hydrochloride...............116</td>
<td></td>
</tr>
<tr>
<td>Metoclopramide hydrochloride with paracetamol.....................115</td>
<td></td>
</tr>
<tr>
<td>Metolazone................................45</td>
<td></td>
</tr>
<tr>
<td>Metoprolol succinate........................42</td>
<td></td>
</tr>
<tr>
<td>Metoprolol tartrate........................42</td>
<td></td>
</tr>
<tr>
<td>Miconazole..................................19</td>
<td></td>
</tr>
<tr>
<td>Miconazole nitrate..........................19</td>
<td></td>
</tr>
<tr>
<td>Dermatological............................52</td>
<td></td>
</tr>
<tr>
<td>Genito-Urinary............................58</td>
<td></td>
</tr>
<tr>
<td>Micremit....................................58</td>
<td></td>
</tr>
<tr>
<td>Micreme H.................................56</td>
<td></td>
</tr>
<tr>
<td>Microgynon 20 ED...........................58</td>
<td></td>
</tr>
<tr>
<td>Microgynon 50 ED...........................58</td>
<td></td>
</tr>
<tr>
<td>Midazolam.................................122</td>
<td></td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

Infections..............................................80
- O -
O/W Fatty Emulsion Cream..................54
Obinutuzumab........................................170
Obsetric Preparations..........................59
Octocog alfa [Recombinant factor VIII] (Advate)......29
Octocog alfa [Recombinant factor VIII] (Kogenate FS)......29
Octreotide...........................................144
Ocular Lubricants.................................206
Oestradiol...........................................64–65
Oestradiol valerate..............................64
Oestradiol with norethisterone acetate..............64
Oestradiol
Genito-Urinary.....................................60
Hormone Preparations..........................65
Oestrone...............................................60
Oestrone (conjugated equine)..................64
Oestrone with medroxyprogesterone acetate..........65
Ofev......................................................195
Oil in water emulsion............................54
Oil phenol [Phenol oil].............................7
Olanzapine..........................................118–119
Olive oil...............................................217
Olopatadine..........................................203
Olsalazine............................................6
Omalizumab..........................................171
Omeprazole..........................................8
Omeprazole actis..................................8
Omeprazole actis 20..............................8
Omeprazole actis 40..............................8
Omeprazole IV.......................................8
Omnipaque...........................................211
Omnsican............................................212
Omitrope.............................................66
Onbrez Brezhaler.................................198
Oncospar.............................................134
OncoTICE...........................................191
Ondansetron.........................................117
Ondansetron Kabi.................................117
Ondansetron ODT-DRLA..........................117
Ondansetron-Claris................................117
One-Alpha...........................................21
Onrex...................................................117
Opendo...............................................188
Optional Pharmaceuticals......................244
Ora-Blend............................................217
Ora-Blend SF.......................................217
Ora-Plus.............................................217
Ora-Sweet...........................................217
Ora-Sweet SF.......................................217
Oratane...............................................53
Orion Temozolomide..............................134
Ornidazole..........................................84
Orphenadrine citrate.............................100
Oruvail SR............................................102
Oseltamivir..........................................91
Osmolite RTH.......................................232
Other Cardiac Agents............................47
Other Endocrine Agents........................65
Other Oestrogen Preparations..................65
Other Otological Preparations.................207
Other Progestogen Preparations................65
Other Skin Preparations.........................57
Ovastin..............................................60
Ox-Pam...............................................121
Oxalacid.............................................136
Oxalipatin...........................................136
Oxalipatin Accord................................136
Oxandrolone.........................................62
Oxazeepam..........................................121
Oxpentifyline.......................................48
Oxybuprocaine hydrochloride..................204
Oxybutynin..........................................61
Oxycodeone hydrochloride.....................110
Oxycodo Sandoz..................................110
Oxymethazoline hydrochloride.................197
OxyNorm.............................................110
Oxycodone.........................................59
Oxycodone BMP....................................59
Oxycodone with ergometrine maleate...........59
Ozurdex...............................................202
- P -
Pacifen...............................................100
Pacitaxel............................................142
Pacitaxel Ebewe..................................142
Paliperidone........................................119
Pamidronate disodium............................
Pamidronate.........................................94
Pamisol..............................................94
Pan-Penicillin G Sodium........................76
Pancreatic enzyme..............................11
Pancuronium bromide...........................100
Pantoprazole........................................8
Panzap Relief.......................................8
Paper wasp venom...............................193
Para-aminosalicylic Acid.........................83
Paracare............................................108
Paracare Double Strength.......................108
Paracetamol........................................108
Paracetamol Kabi.................................108
Paracetamol with codeine.......................110
Parafin
Alimentary..........................................12
Dermatological....................................54
Extemporaneously Compounded
- Preparations.......................................217
Paraffin liquid with soft white paraffin..........207
Paraffin liquid with wool fat...............207
Paraffin with wool fat...........................55
Paraldehyde........................................112
Parcoxib.............................................102
Paromomycin......................................72
Paroxetine..........................................112
Paser..................................................83
Patanol..............................................203
Patent blue V......................................213
Paxam...............................................120
Pazopanib.........................................139
Peak flow meter..................................244
Peanut oil..........................................216
Pedialyte - Bubblegum.........................37
Pediasure (Chocolate)............................230
Pediasure (Strawberry)..........................230
Pediasure (Vanilla)...............................230
Pediasure RTH.....................................230
Pegasparge..........................................134
Pegasys...............................................92
Pegfilgrastim.......................................33
Pegylated interferon alfa-2a..................92
Pembrolizumab....................................189
Pemetrexed..........................................131
Penicillamine......................................94
Penicillin G.........................................76
Penicillin V.........................................76
Pentacrinat.........................................84
Pentagastrin........................................65
Pentamidine isethionate.........................84
Pentasa...............................................6
Pentostatin [Deoxycoformycin]................134
Pentoxifylline [Oxpentifylline]..................48
Peptamine OS 1.0 (Vanilla)......................226
Peptisoothe..........................................7
Perfluorocarbon.................................212
Perhexiline maleate..............................43
Pericyazine.........................................118
Peridopril............................................38
Perjeta...............................................172
Permethrin..........................................53
Perrigo...............................................57
Pertuzumab.........................................172
Pethina..............................................83
Pethidine hydrochloride.......................110
Pexig...................................................43
Pilzer Exemestane..............................145
Pharmacy Health SLS-free......................54
Pharmacy Health Sorbolene with
Glycerin.............................................54
Pheburane..........................................17
Phenaseth..........................................132
Phenelzine sulphate............................111
INDEX: Generic Chemicals and Brands

Phenindione............................................31
Phenobarbinate ........................................113, 122
Phenobarbinate sodium..............................217
Phenol
Extemporaneously Compounded
Preparations ...........................................217
Various ..................................................214
Phenol oily ..............................................7
Phenol with ioxaglic acid .........................214
Phenothrin ..................................................53
Phenoxybenzamine hydrochloride ...............39
Phenoxymethylenicillin [Penicillin V] .........76
Phentolamine mesylate ................................40
Phenylenephrine hydrochloride
Cardiovascular ...........................................48
Sensory ..................................................206
Phenytoin...................................................114
Phenytoin sodium ......................................112, 114
Pholcodine .................................................197
Phosphorus ..................................................37
Phytomenadione .........................................29
Picibanil ....................................................191
Pilocarpine hydrochloride .........................205
Pilocarpine nitrate .......................................217
Pimafucort ..................................................56
Pindolol ......................................................42
Pine tar with trolamine laurilsulfate
and fluorescein ...........................................56
Pinetarsol ....................................................56
Pioglitazone ................................................10
Piperacillin with tazobactam ......................76
Pipithiazine palmitate ................................120
PipTaz Sandoz .............................................76
Pirfenidone ..................................................96
Pituitary and Hypothalamic
Hormones and Analogues .........................66
Pivmecillinam ............................................79
Pizotifen .....................................................79
PKU Anamix Junior LQ (Berry).....................223
PKU Anamix Junior LQ (Orange)....................223
PKU Anamix Junior LQ
(Unflavoured) ............................................223
Plaquetin ...................................................94
Plasma-Lyte 148 ...........................................34
Plasma-Lyte 148 & 5% Glucose .................34
Plendid ER ....................................................43
Plexixafor ...................................................33
Pneumococcal (PCV10) conjugate
vaccine ......................................................236
Pneumococcal (PCV13) conjugate
vaccine ......................................................236
Pneumococcal (PPV23) polysaccharide vaccine 237
Pneumovax 23 .............................................237
Podophyllotoxin .........................................07
Polidocanol ..................................................27
Polyimmelitis vaccine .................................242
Poloxamer .....................................................12
Poly Gel .....................................................206
Poly-Tears ....................................................206
Poly-Visc .....................................................207
Polyhexamethylene biguanide .................217
Polivinyl alcohol .........................................207
Polivinyl alcohol with povidone ..............207
Poractant alfa .............................................200
Posaconazole ..............................................80
Postinor-1 ...................................................59
Potassium chloride ......................................35, 37
Potassium chloride with sodium
chloride ...................................................35
Potassium citrate ..........................................61
Potassium dihydrogen phosphate ..............35
Potassium iodate ...........................................17
Potassium iodate
Alimentary ..................................................17
Hormone Preparations ................................70
Potassium iodate with iodine ......................18
Potassium perchorlate ................................70
Potassium permanganate ............................56
Povidone K30 ..............................................217
Povidone-iodine ..........................................210
Povidone-iodine with ethanol ....................211
Pradaxa ......................................................30
Pralidoxime iodide .....................................208
Pramipexole hydrochloride .......................104
Prasugrel .....................................................32
Pravastatin ...................................................46
Praxbind .....................................................27
Praziquantel .................................................84
Prazosin .....................................................40
Precedex .....................................................104
Pres Forte .....................................................203
Prednisolone ..............................................64
Prednisolone acetate ..................................203
Prednisolone sodium phosphate ...............203
Prednisolone- AFT .......................................203
Prednisone ...................................................64
Pregabalin ...................................................114
Pegabalin Pfizer ..........................................114
Pregnancy test - hCG urine ......................244
preOp .........................................................231
Presol .........................................................42
Prevenar 13 .................................................236
Prezista .......................................................87
Prlacaine hydrochloride .............................107
Prlacaine hydrochloride with
felypressin .............................................107
Primacor .....................................................48
Primacrine phosphate ..................................84
Primidone ...................................................114
Primolut N ...................................................65
Primovist ....................................................212
Priorix .......................................................242
Probencid ....................................................100
Procaine penicillin ....................................76
Procarbazine hydrochloride ......................134
Prochloperazine .........................................117
Proctosedyl ...................................................6
Procyclidine hydrochloride .......................103
Procytox .....................................................129
Progerone ...................................................59
Proglucem ....................................................9
Prolia .........................................................96
Prolia .........................................................96
Promethazine hydrochloride ......................194
Propafenone hydrochloride .......................41
Propamidine isethionate .............................201
Propofol .....................................................105
Propranolol ...................................................42
Propylthiouracil .........................................70
Prostin E2 .....................................................59
Prostin VR ....................................................48
Protamine sulphate ......................................31
Protamine sulphate
Protonamide ..............................................83
Protirelin .....................................................71
Proveblue ....................................................213
Provera .......................................................65
Provera HD ...................................................65
Proxymetacaine hydrochloride .................204
Pseudoephedrine hydrochloride ..............197
PSM Citalopram ..........................................111
Psoriasis and Eczema
Preparations ...............................................56
PTU ..........................................................70
Pulmocare (Vanilla) ....................................231
Pulmonary Surfactants ...............................199
Pulmozyme ..................................................199
Puri-nethol ..................................................131
Puria ..........................................................22
Pyraclinamid .................................................83
Pyridostigmine bromide .........................94
Pyridoxal-5-phosphate ................................65
Pyridoxine hydrochloride .........................21
Pyrimethamine ............................................85
Pytazen SR ....................................................31
Q .............................................................85
Quetapep ....................................................118
Quetiapine ...................................................118
Quinapril .....................................................38
Quinapril with
<table>
<thead>
<tr>
<th>INDEX: Generic Chemicals and Brands</th>
</tr>
</thead>
<tbody>
<tr>
<td>hydrochlorothiazide</td>
</tr>
<tr>
<td>Quinine dihydrochloride</td>
</tr>
<tr>
<td>Quinine sulphate</td>
</tr>
<tr>
<td>Qvar</td>
</tr>
<tr>
<td>RA-Morph</td>
</tr>
<tr>
<td>Rabies vaccine</td>
</tr>
<tr>
<td>Raloxifene</td>
</tr>
<tr>
<td>Raltegravir potassium</td>
</tr>
<tr>
<td>Ramipex</td>
</tr>
<tr>
<td>Ranbaxy-Cefaclor</td>
</tr>
<tr>
<td>Ranibizumab</td>
</tr>
<tr>
<td>Rantidline</td>
</tr>
<tr>
<td>Rantidline Relief</td>
</tr>
<tr>
<td>Rapamune</td>
</tr>
<tr>
<td>Rasburicase</td>
</tr>
<tr>
<td>Readi-CAT 2</td>
</tr>
<tr>
<td>Reandron 1000</td>
</tr>
<tr>
<td>Recombinant factor IX</td>
</tr>
<tr>
<td>Recombinant factor VIII</td>
</tr>
<tr>
<td>Recombinant factor VIII</td>
</tr>
<tr>
<td>Rectogesic</td>
</tr>
<tr>
<td>Red back spider antivenom</td>
</tr>
<tr>
<td>Redipred</td>
</tr>
<tr>
<td>Relenza</td>
</tr>
<tr>
<td>Relist</td>
</tr>
<tr>
<td>Remicade</td>
</tr>
<tr>
<td>Remifentanil</td>
</tr>
<tr>
<td>Remifentanil-AFT</td>
</tr>
<tr>
<td>RePro</td>
</tr>
<tr>
<td>Resonium A</td>
</tr>
<tr>
<td>Resource Beneprotein</td>
</tr>
<tr>
<td>Resource Diabetic (Vanilla)</td>
</tr>
<tr>
<td>Respiratory Stimulants</td>
</tr>
<tr>
<td>Retinol</td>
</tr>
<tr>
<td>Retinol Palmitate</td>
</tr>
<tr>
<td>ReTrieve</td>
</tr>
<tr>
<td>Retrovir</td>
</tr>
<tr>
<td>Retrovir IV</td>
</tr>
<tr>
<td>Revimid</td>
</tr>
<tr>
<td>Revolade</td>
</tr>
<tr>
<td>Rexacrom</td>
</tr>
<tr>
<td>RexAir</td>
</tr>
<tr>
<td>Riboflavin 5-phosphate</td>
</tr>
<tr>
<td>Ribomustin</td>
</tr>
<tr>
<td>Ricit</td>
</tr>
<tr>
<td>Rifabutin</td>
</tr>
<tr>
<td>Rifadin</td>
</tr>
<tr>
<td>Rifampicin</td>
</tr>
<tr>
<td>Rifaximin</td>
</tr>
<tr>
<td>Rifinah</td>
</tr>
<tr>
<td>Rilutek</td>
</tr>
<tr>
<td>Riluzole</td>
</tr>
<tr>
<td>Ringer’s solution</td>
</tr>
<tr>
<td>Riodine</td>
</tr>
<tr>
<td>Risedronate Sandoz</td>
</tr>
<tr>
<td>Secukinumab</td>
</tr>
<tr>
<td>Sedatives and Hypnotics</td>
</tr>
<tr>
<td>Seebri Breezhaler</td>
</tr>
<tr>
<td>Selegeline hydrochloride</td>
</tr>
<tr>
<td>Senonoside</td>
</tr>
<tr>
<td>Seroquel</td>
</tr>
<tr>
<td>Sertaline</td>
</tr>
<tr>
<td>Setrona</td>
</tr>
<tr>
<td>Sildenafil</td>
</tr>
<tr>
<td>Silver nitrate</td>
</tr>
<tr>
<td>Dermatological</td>
</tr>
<tr>
<td>Extemporaneously Compounded</td>
</tr>
<tr>
<td>Preparations</td>
</tr>
<tr>
<td>Preparations</td>
</tr>
<tr>
<td>Sincalide</td>
</tr>
<tr>
<td>Sinemet CR</td>
</tr>
<tr>
<td>Siterone</td>
</tr>
<tr>
<td>Smith BioMed Rapid Pregnancy Test</td>
</tr>
<tr>
<td>Snake antivenom</td>
</tr>
<tr>
<td>Sodium bicarbonate</td>
</tr>
<tr>
<td>Sodium alginate with magnesium alginate</td>
</tr>
<tr>
<td>Sodium bicarbonate with sodium bicarbonate and calcium bicarbonate</td>
</tr>
<tr>
<td>Sodium carbonate</td>
</tr>
<tr>
<td>Sodium benzoate</td>
</tr>
<tr>
<td>Sodium bicarbonate</td>
</tr>
<tr>
<td>Blood</td>
</tr>
<tr>
<td>Sodium chloride</td>
</tr>
<tr>
<td>Sodium chloride</td>
</tr>
<tr>
<td>Respiratory</td>
</tr>
<tr>
<td>Sodium chloride with sodium bicarbonate</td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

Sodium citrate
Alimentary ...................................... 5

Extemporaneously Compounded
Preparations .................................. 218

Sodium citrate with sodium chloride
and potassium chloride ....................... 31

Sodium citrate with sodium laurel
sulphoacetate .................................. 13

Sodium citrate with sodium lauryl
tartrate ........................................... 61

Sodium cromoglicate
Alimentary ........................................ 6

Respiratory ..................................... 194, 199

Sensory .......................................... 203

Sodium dihydrogen phosphate
[ Sodium acid phosphate ] ..................... 36

Sodium fluoride .................................. 17

Sodium fusidate [ Fusidic acid ]
Dermatological .................................. 52

Infections ....................................... 79

Sensory .......................................... 201

Sodium hyaluronate [ Hyaluronic acid ]
Alimentary ....................................... 19

Sensory .......................................... 204, 207

Sodium hyaluronate [ Hyaluronic acid ]
with chondroitin sulphate .................... 204

Sodium hypochlorite ........................... 211

Sodium metabisulphite ....................... 218

Sodium nitrile .................................. 208

Sodium nitroprusside
Cardiovascular .................................. 48

Optional Pharmaceuticals ..................... 244

Sodium phenylbutyrate ....................... 17

Sodium phosphate with phoshoric
acid ................................................ 13

Sodium polystyrene sulphonate ............. 37

Sodium stibogluconate ....................... 85

Sodium tetradecyl sulphate .................. 27

Sodium thiosulphate ......................... 208

Sodium valproate .............................. 114

Sodium with potassium ....................... 215

Solan ............................................ 117

Solifenacin Mylan ................................ 61

Solifenacin succinate ......................... 61

Solu-Cortef ..................................... 63

Solu-Medrol ..................................... 64

Solu-Medrol Act-O-Vial ....................... 64

Somatropin ..................................... 66

Sotalol .......................................... 42

Soya oil .......................................... 208

Spacer device ................................... 244

Span-K .............................................. 37

Specialised Formulas ........................ 224

Spiolo Respimat .................................. 195

Spiractin ........................................ 45

Spiramycin ...................................... 85

Spiriva ........................................... 195

Spiriva Respimat ............................... 195

Spirolactone .................................... 45

Sprycl ............................................. 136

Standard Feeds ................................. 232

Staphlex ......................................... 76

Starch .............................................. 218

Stavudine ....................................... 86

Sterculia with frangula ....................... 12

SteroClear ....................................... 194

Stesolid .......................................... 112

Stimulants / ADHD Treatments ............. 123

Stripentol ....................................... 114

Stocrin ............................................ 85

Strattera ......................................... 123

Streptomycin sulphate ........................ 72

Stromectol ...................................... 83

Suboxone ........................................ 126

Sucrafate ........................................ 8

Sucrose .......................................... 108

Sugammadex ..................................... 101

Sulfadiazine silver ......................... 52

Sulfasalazine .................................. 6

Sulindac ......................................... 102

Sulphacetamide sodium ..................... 201

Sulphadiazine .................................. 79

Sulphur .......................................... 218

Sulpirid .......................................... 117

Sumatriptan ..................................... 115

Sunitinib ........................................ 140

Sunscreen, proprietary ....................... 57

Suprate .......................................... 104

Surgical Preparations ....................... 214

Sustagen Diabetic (Vanilla) ................. 225

Sustagen Hospital Formula Active
(Choc) ............................................ 233

Sustagen Hospital Formula Active
(Van) ............................................. 233

Sutent ............................................ 140

Suxamethonium chloride .................... 100

Sylvant .......................................... 183

Symmetrel ....................................... 103

Sympathomimetics ............................ 47

Synachten ........................................ 66

Synacthen Depot ............................... 66

Synflexor ........................................ 236

Syntometrine ................................... 59

Syrup .............................................. 218

Systane Unit Dose ............................. 206

- T -

Tacrolimus ...................................... 145

Tacrolimus Sandoz ............................ 145

Tagiot V ......................................... 211

Talc ............................................... 200

Taliglucerase alfa ............................ 17

Tambocor ........................................ 41

Tambocor CR .................................... 41

Tamtrocin ...................................... 145

Tamoxifen citrate ............................. 145

Tamoxifen Sandoz ............................ 145

Tamsulosin hydrochloride ................. 60

Tamsulosin-Rex ............................... 60

Tarceva ......................................... 137

Tasinia .......................................... 139

Tasmir ............................................ 104

Tecfidera ....................................... 121

Telegretol ....................................... 112

Tegretol ......................................... 112

Teriflunomide .................................. 121

Teriparid ........................................ 98

Terlipressin .................................... 71

Testosterone .................................... 62

Testosterone cipionate ...................... 62

Testosterone esters .......................... 62

Testosterone undecanoate ................... 62

Tetrahydrocannabinol ....................... 103

Tetracaine [ Amethocaine ] hydrochloride
Nervous ......................................... 107

Sensory .......................................... 204

Tetracosactide [ Tetracosactrin ] .......... 66

Tetracosactrin .................................. 66

Tetracycline .................................... 78

Tetracyclин Wolff ............................. 78

Thalidomide ..................................... 135

Thalomid ........................................ 135

Theobroma oil ................................... 218

Theophylline .................................... 199

Thiamine hydrochloride ..................... 21

Thioguanine .................................... 132

Thioguanine sodium .......................... 105

Thiopenal [ Thiopenente ] sodium ......... 105

Thiopental ...................................... 105

Thiotepa ......................................... 129

Thrombin ........................................ 27

Thymol glycerin ................................ 20

Thyroid and Antithyroid
Preparations .................................... 70

Thyrotropin alfa ............................... 66

Tictac ............................................ 32

Ticaricillin with clavulanic acid .......... 76

Ticlopidine .................................... 32

Tigecycline ..................................... 78
### INDEX: Generic Chemicals and Brands

<table>
<thead>
<tr>
<th>Chemical</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triamcinolone acetonide with nystatin</td>
<td>56</td>
</tr>
<tr>
<td>Triamcinolone hexacetonide</td>
<td>64</td>
</tr>
<tr>
<td>Triazolam</td>
<td>123</td>
</tr>
<tr>
<td>Trichloroacetic acid</td>
<td>218</td>
</tr>
<tr>
<td>Trichloracetic acid</td>
<td>218</td>
</tr>
<tr>
<td>Trichlozoide</td>
<td>84</td>
</tr>
<tr>
<td>Trientine dihydrochloride</td>
<td>17</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>79</td>
</tr>
<tr>
<td>Trimethoprim with sulphamethoxazole</td>
<td>79</td>
</tr>
<tr>
<td>Trolamol</td>
<td>214</td>
</tr>
<tr>
<td>Trompamide</td>
<td>206</td>
</tr>
<tr>
<td>Tropicetron</td>
<td>117</td>
</tr>
<tr>
<td>Tropisetron-AFT</td>
<td>117</td>
</tr>
<tr>
<td>Tuberculin PPD [Mantoux] test</td>
<td>243</td>
</tr>
<tr>
<td>Tubersol</td>
<td>243</td>
</tr>
<tr>
<td>Two Cal HN</td>
<td>226</td>
</tr>
<tr>
<td>TwoCal HN RTH (Vanilla)</td>
<td>226</td>
</tr>
<tr>
<td>Tykerb</td>
<td>138</td>
</tr>
<tr>
<td>Tysabri</td>
<td>121</td>
</tr>
<tr>
<td>- U - Ultra Breezhaler</td>
<td>195</td>
</tr>
<tr>
<td>Ultraproduct</td>
<td>7</td>
</tr>
<tr>
<td>Umeclidinium</td>
<td>195</td>
</tr>
<tr>
<td>Umeclidinium with vilanterol</td>
<td>195</td>
</tr>
<tr>
<td>Uniset</td>
<td>194</td>
</tr>
<tr>
<td>Ural</td>
<td>61</td>
</tr>
<tr>
<td>Urea</td>
<td>55</td>
</tr>
<tr>
<td>Dermatological</td>
<td></td>
</tr>
<tr>
<td>Extemporaneously Compounded Preparations</td>
<td>218</td>
</tr>
<tr>
<td>Urex Forte</td>
<td>44</td>
</tr>
<tr>
<td>Urograin</td>
<td>211</td>
</tr>
<tr>
<td>Urokinase</td>
<td>33</td>
</tr>
<tr>
<td>Urologicals</td>
<td>60</td>
</tr>
<tr>
<td>Uromitexan</td>
<td>142</td>
</tr>
<tr>
<td>Ursodeoxycholic acid</td>
<td>11</td>
</tr>
<tr>
<td>Ursosan</td>
<td>11</td>
</tr>
<tr>
<td>Utrogestan</td>
<td>59</td>
</tr>
<tr>
<td>- V - Varcloriv</td>
<td>89</td>
</tr>
<tr>
<td>Valaciclovir</td>
<td>89</td>
</tr>
<tr>
<td>Valgalniclovir</td>
<td>89</td>
</tr>
<tr>
<td>Valgalniclovir Mylan</td>
<td>89</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>79</td>
</tr>
<tr>
<td>Varenicline</td>
<td>127</td>
</tr>
<tr>
<td>Varenicline Pfizer</td>
<td>127</td>
</tr>
<tr>
<td>Varenicline Pfizer</td>
<td>127</td>
</tr>
<tr>
<td>Varibar - Honey</td>
<td>211</td>
</tr>
<tr>
<td>Varibar - Nectar</td>
<td>211</td>
</tr>
<tr>
<td>Varibar - Pudding</td>
<td>211</td>
</tr>
<tr>
<td>Varibar - Thin Liquid</td>
<td>211</td>
</tr>
<tr>
<td>Varicella vaccine [Chickenpox vaccine]</td>
<td>242</td>
</tr>
<tr>
<td>Varicella zoster vaccine [Shingles vaccine]</td>
<td>243</td>
</tr>
<tr>
<td>Varilrix</td>
<td>242</td>
</tr>
<tr>
<td>Vasodilators</td>
<td>48</td>
</tr>
<tr>
<td>Vasopressin</td>
<td>71</td>
</tr>
<tr>
<td>Vasopressin agents</td>
<td>71</td>
</tr>
<tr>
<td>Vecuronium bromide</td>
<td>100</td>
</tr>
<tr>
<td>Vedafild</td>
<td>50</td>
</tr>
<tr>
<td>Velcade</td>
<td>132</td>
</tr>
<tr>
<td>Velleti</td>
<td>51</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>111</td>
</tr>
<tr>
<td>Venoven</td>
<td>18</td>
</tr>
<tr>
<td>Venovis</td>
<td>51</td>
</tr>
<tr>
<td>Venolin</td>
<td>197</td>
</tr>
<tr>
<td>Vepesid</td>
<td>133</td>
</tr>
<tr>
<td>Verapamil hydrochloride</td>
<td>44</td>
</tr>
<tr>
<td>Verto 16</td>
<td>116</td>
</tr>
<tr>
<td>Vepamil SR</td>
<td>44</td>
</tr>
<tr>
<td>Vesamoid</td>
<td>136</td>
</tr>
<tr>
<td>Vexazole</td>
<td>10</td>
</tr>
<tr>
<td>Vfend</td>
<td>81</td>
</tr>
<tr>
<td>Vgbatrin</td>
<td>115</td>
</tr>
<tr>
<td>Vildagliptin</td>
<td>10</td>
</tr>
<tr>
<td>Vildagliptin with metformin hydrochloride</td>
<td>10</td>
</tr>
<tr>
<td>Vipmulin</td>
<td>113</td>
</tr>
<tr>
<td>Vinblamine sulphate</td>
<td>143</td>
</tr>
<tr>
<td>Vincristine sulphate</td>
<td>143</td>
</tr>
<tr>
<td>Vinoreline</td>
<td>143</td>
</tr>
<tr>
<td>Viral Vaccines</td>
<td>238</td>
</tr>
<tr>
<td>Virumune Suspension</td>
<td>86</td>
</tr>
<tr>
<td>ViruPOS</td>
<td>201</td>
</tr>
<tr>
<td>Viscoat</td>
<td>204</td>
</tr>
<tr>
<td>Vispaque</td>
<td>211</td>
</tr>
<tr>
<td>Vistil Forte</td>
<td>207</td>
</tr>
<tr>
<td>Vit D3</td>
<td>22</td>
</tr>
<tr>
<td>Vit A-POS</td>
<td>207</td>
</tr>
<tr>
<td>Vital</td>
<td>225</td>
</tr>
<tr>
<td>Vitamin A with vitamins D and C</td>
<td>21</td>
</tr>
<tr>
<td>Vitamin B complex</td>
<td>21</td>
</tr>
<tr>
<td>Vitamin B6 25</td>
<td>21</td>
</tr>
<tr>
<td>Vitamins</td>
<td>20</td>
</tr>
<tr>
<td>Vixonen TEN</td>
<td>225</td>
</tr>
<tr>
<td>Volbris</td>
<td>49</td>
</tr>
<tr>
<td>Voltaren</td>
<td>101</td>
</tr>
<tr>
<td>Voltaren D</td>
<td>101</td>
</tr>
<tr>
<td>Voltaren Ophtha</td>
<td>203</td>
</tr>
<tr>
<td>Volumatic</td>
<td>244</td>
</tr>
<tr>
<td>Volumen</td>
<td>211</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>81</td>
</tr>
<tr>
<td>Votient</td>
<td>139</td>
</tr>
<tr>
<td>Vtack</td>
<td>81</td>
</tr>
<tr>
<td>- W - Warfarin sodium</td>
<td>31</td>
</tr>
<tr>
<td>Wart Preparations</td>
<td>57</td>
</tr>
<tr>
<td>Water</td>
<td></td>
</tr>
<tr>
<td>Blood</td>
<td>36</td>
</tr>
<tr>
<td>Various</td>
<td>214</td>
</tr>
</tbody>
</table>
INDEX: Generic Chemicals and Brands

Wool fat
- Dermatological ......................... 55
- Extemporaneously Compounded
  Preparations .............................. 218

- X -
  X-Opaque-HD ............................ 211
  Xanthan .................................. 218
  Xarelto .................................... 31
  Xifaxan .................................. 8
  Xolair .................................... 171
  Xylocaine ................................. 106
  Xylometazoline hydrochloride ........ 197
  Xyntha .................................... 28

- Y -
  Yellow jacket wasp venom ............ 193

- Z -
  Zanamivir .................................. 92
  Zantac ....................................... 7
  Zapril ........................................ 38
  Zarfatin .................................... 113
  Zavedos .................................... 130
  Zeffix ....................................... 88
  Zetlam ....................................... 88
  Zigen ......................................... 86
  Zidovudine [AZT] ......................... 86
  Zidovudine [AZT] with
    lamivudine ................................ 86
  Zimybe ...................................... 46
  Zinc
    - Alimentary ............................. 19
    - Dermatological ....................... 53
    Zinc and castor oil ..................... 54
    Zinc chloride ........................... 19
    Zinc oxide ................................ 218
    Zinc sulphate ........................... 19
    Zinc with wool fat ...................... 54
    Zincaps .................................... 19
    Zinforo .................................... 74
    Zinnat ..................................... 73
    Ziprasidone ................................ 119
    Zista ........................................ 194
    Zithromax .................................. 74
    Zoladex ..................................... 66
  Zoledronic acid
    - Hormone Preparations .................. 63
    - Musculoskeletal ....................... 94
  Zoledronic acid Mylan .................. 63
  Zopiclone .................................. 123
  Zopiclone Actavis ......................... 123
  Zostavax .................................... 243
  Zostrix ...................................... 102
  Zostrix HP .................................. 107
  Zuclopenthixol acetate .................. 119
  Zuclopenthixol decanoate .............. 120
  Zuclopenthixol hydrochloride .......... 119
  Zuddone ..................................... 119
  Zypine ....................................... 118
  Zypine ODT .................................. 118
  Zyprexa Relprevv ......................... 119
  Zytag ......................................... 143
  Zyvox ........................................ 79
  Zyban ........................................ 126